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Metazoan DNA replication is a finely controlled event. The driving force promoting cell 
division is increasing kinase levels as cells progress from G1 to Mitosis. Phosphorylation of 
cell cycle driving targets is driven though motifs surrounding phosphorylation sites in 
proteins. Dysregulation of these events results in an alteration of the DNA replication 
programme inducing DNA replication stress. This can result in an erosion of genome stability, 
driving cancer progression. Mutation in multiple oncogenes has the effect of altering CDK 
networks, and replication timing. 
CIZ1 is a DNA replication factor. It plays a role in co-ordinating the spatiotemporal 
localisation of Cyclin A and Cyclin E surrounding the G1/S transition. CIZ1’s activity is 
controlled by CDK mediated phosphorylations, when hypo-phosphorylated, CIZ1 promotes 
nuclear matrix localisation of Cyclin A. Evidence suggests that CIZ1 has both oncogenic and 
tumour suppressor functions. However, the mechanisms that link CIZ1 to cancer remain 
unclear. CIZ1 may act as a kinase sensor modifying how cells respond to CDK networks. 
Here, to determine the role of CIZ1 in cell cycle progression, and DNA replication two 
independent CIZ1 KO cell lines were produced. There were no detectable differences in cell 
cycle profiles using EdU and flow cytometry. However, analysis of cell cycle re-entry kinetics 
after release from quiescence showed that CIZ1 KO cells bypass restriction point earlier than 
parental cell lines. In addition, CIZ1 KO cells express cyclin A earlier than parental cell lines, 
consistent with the earlier timing of restriction point.  
Significantly, cell free DNA replication analysis of CIZ1 KO cell lines and parental cell lines 
revealed CIZ1 KO cells showed a defect in cyclin A chromatin loading that could be reversed 
by titration of CIZ1. This suggests that CIZ1 aids localisation of cyclin A to chromatin. 
Furthermore, CIZ1 KO cell lines require 2-fold higher cyclin A-CDK2 levels to initiate DNA 
replication in vitro, and this effect is reversed by addition of CIZ1 which reduces this level to 
xi 
 
the optimal level for the parental cells. In addition, analysis of the interplay between CIZ1 
and cyclin A-CDK2 showed that the threshold CDK activity to promote DNA replication is 
modulated by the levels of CIZ1.  
Analysis of the DNA replication kinetics of CIZ1 KO cell lines by DNA combing identified a 
DNA replication stress phenotype, characterised by a change in DNA replication dynamics, 
including a reduced fork rate and increased origin firing. The DRS phenotype was reversed by 
CIZ1 addback (CIZ1AB). In addition, CIZ1 KO cells showed defects in recovery from DRS 
inducing agent hydroxyurea and this defect was reversed in CIZ1AB cell lines. Together this 
data indicates that CIZ1 is involved in regulating cellular responses to CDK activity, that CIZ1 
KO induces altered replication timing and replication stress. These observations provide 
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Cancers result from a deregulation of the pathways that control the cell cycle. Arguably, the 
major pathways involved in this are the Cyclin/Cyclin dependent kinase (CDK) networks. As 
cells progress through the cell division cycle each stage is governed by phosphorylation from 
CDKs (Stern & Nurse, 1996; Ulhmann et al., 2011). Dysregulation of CDK networks results in 
aberrant DNA replication, mitotic defects, DNA damage, and increased mutation rate. These 
pathways, or regulators of these pathways, are frequently mutated early in cancers providing 
the growth advantage that allows tumorigenesis (Mol et al., 2013). This is followed by a 
prolonged erosion of cell cycle control, promoting genome instability as further mutations 
are acquired that underpin the development of cancer.  
A major barrier to cancer occurs at the G1/S phase transition, the point where cells commit 
to the cell cycle, and begin replicating their DNA. This is governed through phosphorylation 
of key replication licensing proteins by CDKs, further into the cell cycle further 
phosphorylation of these same proteins by CDKs promote their inhibition preventing re-
replication of the genome, ensuring that the cell cycle is unidirectional (Pauzaite et al., 2017). 
This process is also accompanied by a switch between the primary Cyclin activating CDK2, 
from Cyclin E to Cyclin A. Cyclin A has roles in regulating both DNA replication, and mitosis 
(Hégarat et al., 2020). This switch is thought to be governed by a localisation change 
promoted by nuclear matrix anchoring protein Cip1 interacting zinc finger protein 1 (CIZ1) 
(Copeland et al., 2015).  
There is increasing evidence that CIZ1 can perform oncogenic like functions. CIZ1 is 
frequently overexpressed or alternatively spliced in numerous common cancers, including 
lung, bladder, and prostate cancers (Higgins et al., 2012; Liu et al., 2015; Chen et al., 2019). 
Loss of CIZ1 has also been shown in vitro to possess a tumour suppressor function, increasing 
tumorigenesis, and promoting lymphoproliferative disorders in mice (Nishibe et al., 2013; 
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Ridings-Figueroa et al., 2017). This dual, yet contrasting, phenotype is one shared by other 
proteins, notably, p21 a CDK inhibitor, and interacting partner of CIZ1 (Mitsui et al., 1999; 
Abbas & Dutta, 2009; Ohkoshi et al., 2016; Georgakillas et al., 2017). The exact function of 
CIZ1 is unclear, although it is clear that CIZ1 functions around the G1/S phase checkpoint and 
can promote the activation of a number of pathways that contribute to cell cycle 
progression: CDK signalling, and YAP signalling. (Coverley et al., 2005; Copeland et al., 2010, 
Copeland et al., 2015; Lei et al., 2016). Additionally, CIZ1 may play a role in DNA damage 
responses (DDR), as CIZ1 ablation results in increased sensitivity to DNA damage and over-
expression of CIZ1 is associated with tumorigenesis (Coverley et al., 2005; Higgins et al., 
2012; Nishibe et al., 2013; Lei et al., 2015; Wang et al., 2018). The focus of this project is to 
understand the role that CIZ1 plays in DNA replication initiation process, and how it 
contributes to DNA replication stress.  
This chapter will introduce the main concepts crucial to this report: Cyclin/CDK signalling, 
CIZ1 biology, DNA Replication Stress, tumorigenesis, the DNA damage response, and the 
quantitative model of cell cycle progression. These will provide the basis for understanding 
the results that will follow. Results in this thesis demonstrate that loss of CIZ1 induces 
changes to cell cycle re-entry timing, altered responses to CDK signalling in vitro, an aberrant 
DNA damage response to replication stress, and a change in DNA replication dynamics 
consistent with DNA replication stress. Together these phenotypes link CIZ1 with cell cycle 
regulation, critically during the G1/S transition. These results have implication for 
mechanisms that underpin the link between CIZ1 and tumorigenesis.  
1.2. The DNA replication programme across the Domains of Life 
Licensing of replication origins by replication factors has to occur at thousands of putative 
origins across the metazoan genome. The DNA replication programme describes the 
organisation of DNA replication initiation, elongation, and termination that is required for 
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accurate, timely, replication of a genome (Ganier et al., 2019). The replication programme 
varies widely across the domains of life, with evolution needing to solve different problems 
as genome size increased, chromosomes became separated, and the need to respond to 
replication challenges became more important for the survival of a species, or individual. 
This section will summarise the adaptations that occurred throughout the evolution of the 
three domains of life (Table 1.1).  
Each kingdom has specific mechanisms to ensure the timely and accurate copying of DNA. 
Different organisms have different problems that need to be solved when replicating DNA. 
Proteobacteria, such as E. coli, have small genomes encoded on a circular chromosome of 
4.6 Mbp. This is orders of magnitude smaller than those of higher eukaryotes. The E. coli 
replication origin (OriC) lies proximal to genes encoding DNA replication proteins, such as 
DnaA and DnaN, the bacterial orthologues of the origin recognition complex (ORC) and 
proliferating cell nuclear antigen (PCNA) respectively (Section 1.5) (Mackiewicz et al., 2004). 
Small circular chromosomes enable timely and efficient duplication that facilitates a doubling 
time of approximately 20 minutes (Gibson et al., 2018). 
It is worth noting that other species of bacteria, although a minority, utilize multiple 
replication origins during DNA synthesis (Gao et al., 2015). Bacterial origins are sequence 
dependent, DnaA binds at conserved 9-mer repeats (TTA/TTNCACA) (Speck & Messer, 2001). 
DNA melting occurs at adjacent AT rich sequences. The minimum sequence for OriC 
recognition has been determined to be 163 bp, although this does display deficiencies in 
initiating multiple simultaneous rounds of replication per cell division (Stepankiw et al., 
2009). After initiation, DNA replication occurs rapidly (relative to eukaryotes) with replication 
forks traveling bidirectionally at velocity of 60 kb/min (Mechali, 2010). This rapid speed is 
required to ensure duplication of the 4.6 Mbp within the 20-minute cell division cycle 
(Gibson et al., 2018).  
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In evolutionary history, Archae branched from eukaryotes more recently than bacteria. At 
first appearances, archaeal genomes resemble closely those of Bacteria: DNA is arranged on 
a single, circular gene rich chromosome. Counter-intuitively, Archaea DNA replication 
proteins appear more similar to eukaryotes. Many replication proteins sequence shares 
more homology with eukaryotes than Bacteria, including ORC, the DNA polymerases and 
PCNA (Edgell & Doolittle, 1997; Robinson & Bell, 2005; Wu et al., 2014). Computational 
analysis of numerous archaeal genomes identified OriC like regions in some, but not all of 
test archaea species (Lopez et al., 2002). As in bacteria, these origins were located closely 
within the genome to the genes of replication proteins including CDC6 (Luo & Gao, 2019). 
However, multiple species, such as Sulfolobus acidocaldarius, and Sulfolobus solfataricus, 
have been identified which contain multiple putative origins. Furthermore, deletion of 
origins in certain strains does not prevent replication initiation, indicating that in some 
species a conserved origin sequence is not required. Following initiation from a single, 
multiple or, a non-canonical origin of replication in archaea proceeds at an intermediate rate 
between Bacteria, and Eukaryota, at approximately 20 kbp/min. This is slower than Bacteria 
yet remains an order of magnitude more rapid than eukaryotes (Kelman & Kelman, 2018).  
Eukaryotes use conserved mechanisms for origin specification, loading and activation of the 
DNA replication machinery. Eukaryotes differ from their prokaryotic counterparts through 
the use of multiple linear chromosomes. Typically, the chromosomes are much larger and 
less gene dense in eukaryotes than archaea or prokaryotes, and eukaryote genome length 
varies widely (Coelho et al., 2013). Fungal species range from 9 Mbp in the methylotrophic 
yeast Hansenula polymorpha to 180 Mbp in the ectomycorrhizal fungus: Cenococcum 
geophilum. Typically, genome size is roughly 40 Mbp (Mohanta & Bae, 2015) that compares 
to gigabase genomes of higher Eukaryotes. The increased genome size, and the presence of 
multiple linear chromosomes requires multiple replication origins to facilitate efficient and 
timely duplication of the genome. The DNA replication process begins with the specification 
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of putative DNA replication origins. In Fungi this process is facilitated by specific DNA 
sequences called autonomously replicating sequences (ARS), that are conserved AT rich 
regions (Dhar et al., 2012).  
The yeast Saccharomyces cerevisiae, like E. coli replicates its DNA in half an hour, it has a 12 
Mbp genome (3-fold higher than E. coli), this genome is organised into 16 discreet 
chromosomes (Engel et al., 2014). S. cerevisiae genomes contain an estimated 520 ARSs. The 
ARS of S. cerevisiae include sites adjacent to genes encoding replication proteins including 
members of the minichromosome maintenance (MCM) 2-7 complex (Wang & Gao, 2019). 
Deep sequencing of S. cerevisiae revealed that DNA replication origins are activated at 
different times during S phase, some early, some mid and some late suggesting a temporally 
controlled DNA replication program (Muller et al., 2014). In addition, there are preferred 
replication origins and cryptic replication origins that are activated under times of replication 
stress to complete duplication of the genome before cell division (Santocanale et al., 1999; 
Brambati et al., 2018). This flexibility in origin usage is characteristic of eukaryotic replication 
programmes. The S. cerevisiae replication forks proceed at a median rate between 1.5 - 2.5 
kbp/min (Rivin & Fangman, 1980; Yousefi & Rowicki, 2019). This rate is far below that 
observed in prokaryotes, when compounded with multiple chromosomes, and a larger 
genome this explains the need for multiple simultaneously replication origins to ensure DNA 
replication is completed within half an hour.  
Unsurprisingly, the DNA replication programme in Animalia is increasingly complicated. 
Animalia replication origins are not sequence specific, and initially, it was thought that DNA 
replication origins occurred at random, yet transcriptionally inactive sequences within the 
genome. ORC bind DNA in a manner more dependent on the structure of the supercoiled 
DNA than the sequence itself, driven more by epigenetics than genetic sequence (Hyrien et 
al., 2015).  
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The Homo sapien genome is approximately 3 Gbp, orders of magnitude longer than either 
fungi or prokaryota encoded in 23 pairs of chromosomes that are less gene rich than bacteria 
or fungi (Piovesan et al., 2019). Due to the lack of sequence specificity the number of 
replication origins in the human genome is unknown, it is thought to be between 7000, and 
10000 (Prioleau & MacAlpine, 2016). Analogous to the replication programme in yeast, DNA 
replication origin usage changes during S phase. This results in distinct temporally regulated 
activation of early, mid and late S phase replication origins. Similarly, there are dormant 
origins that are fired in response to replication challenge. The replication fork speed is 
between 1 – 3 kbp/min (Mechali, 2010). Challenges to the replication programmed can 
result in uncompleted replication, re-replication, or increased mutation frequency. All these 
properties can lead to tumorigenesis or cell death highlighting the importance of a correctly 











Bacteria 4.6 Mbp 1 Circular 
Chromosome 
1 60  
Archaea Variable 1+ Circular 
Chromosome 
1 +  20 
Yeast 12 Mbp 16 Linear 
Chromosomes 
520 1.5-2.5 
Human 3 Gbp 23 Linear 
Chromosome 
Pairs 
7000-10000 1-3  
Table 1.1- Comparison of genome sizes, DNA replication fork rates and genome 
architecture across the domains of life.  
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1.3. The Cell Cycle 
The cell cycle is the co-ordinated series of events that occur during cellular division. During 
this process, the genome of the cell must be duplicated, precisely and accurately (Section 
1.2), and the cell must divide into two, with each daughter cell receiving one copy of the 
duplicated genome. The means by which cells achieve these two goals has diverged and 
varies significantly across the domains of life in terms of timing, regulation, and mechanism. 
This process is achieved by binary fission in bacteria. Eukaryotes utilise the mitotic spindle to 
orientate and segregate the genome equally into daughter cells that completes the more 
complex mitotic cell cycle of higher eukaryotes.  
The simplest form of the cell cycle is found in bacteria such as Escherichia coli (E. coli) which 
can rapidly duplicate their cells, with a doubling time of 20 minutes in optimal conditions 
(Fossum et al., 2007). Briefly, E. coli replicate their ~4,600,000 base pair circular genome bi-
directionally from a single origin or replication known as OriC (Blattner et al., 1997). E. coli 
cells elongate and partition into two identical daughter cells (Figure 1.1a). Interestingly, 
insertion of an additional OriC into the E. coli chromosome produces cells that replicate as 
normal and displayed no abnormal growth characteristics showing the capability of even 
basic life forms to select origins (Wang et al., 2011). 
In optimal conditions, E. coli can initiate two rounds of DNA replication from already 
replicated OriC to increase the rate of cellular division (Figure 1.1b). After duplication of the 
genome, each daughter cell receives a copy of the E. coli genome during rolling circle 
replication allowing E. coli to double their cell number in 20 minutes, compared to 40 
minutes if the chromosome was replicated from a single origin (Wawrzyniak et al., 2017).      
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With mammalian cells the control, timing and maintenance of cellular duplication is more 
complex. There are a logistical challenges mammalian cells must overcome for successful 
genome duplication. The large human genome (~3.5 Gbps), would take over 18 days for 
complete duplication if DNA replication initiated from a single origin analogous to E. coli 
(Kapusta et al., 2017), this is also impossible as human DNA is separated into 23 
chromosome pairs. Yet, in human fibroblast cells, DNA replication can be completed in 
 
Figure 1.1-E. coli Replication A) Schematic for the replication of E. coli, one of the 
simplest cell cycles found across the domains of life. Replication proceeds from a single 
origin of replication OriC. The entire chromosome is then replicated from this point. 
After replication sister chromosomes are separated by decatenation. B) A schematic 
showing how E. coli can initiate two rounds of DNA replication during a cell division to 
maximise growth time. A feature not found in eukaryotic cells. This is known as rolling 
circle replication and shows bacteria can utilize multiple replication origins under 





between 6 – 8 hours (Griffiths, 1984). Precise and accurate duplication is achieved through 
separation of the two major events of cellular duplication: DNA replication, which occurs in S 
phase, and Cellular division, which occurs in M phase. These events are separated by two 
gap phases (G1 and G2) where cells prepare for these events, and if needed arrest the cell 
cycle (Figure 1.2).  
Figure 1.2-The metazoan cell cycle A schematic for the eukaryotic mitotic cell cycle. 
Displaying the 4 key cell cycle stages and the unidirectional progression.  DNA replication 
occurs in S phase, and mitosis and cytokinesis occur in M phase. These 2 events are 
separated by the 2 gap phases G1 and G2. 
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In G1, phase cells commit to entering the cell cycle and completing duplication after 
stimulation by extracellular signals. Key events include replication origin licensing, the 
multistep process of loading of replication factors that results in recruitment and activation 
of the DNA helicase and polymerase proteins (Fragkos et al., 2015), and Rb phosphorylation 
a process which activates a positive feedback loop resulting in the commitment to S phase 
(Nishitani & Lygerou, 2002; Narasimha et al., 2014). 
In mammalian S phase, the timing of replication origin firing is essential for cellular function. 
In early S phase, the euchromatin is preferentially replicated, with replication origin 
activation showing a positive correlation with actively transcribed genes in early S-phase 
(Sequeira-Mendes et al., 2009). Euchromatin is less tightly packed than heterochromatin 
making it more accessible to the replication machinery. Conversely, in late S phase DNA 
replication occurs at heterochromatic sites within the nucleus and areas close to the nuclear 
lamina (Rhind & Gilbert, 2013). The ends of chromosomes, the telomeres are replicated 
throughout S phase with different replication times being associated with different 
localizations after replication (Arnoult et al., 2010). 
In G2, cells ensure that DNA replication is completed accurately, enabling an increase in CDK 
activity leading to initiation of the assembly of the mitotic spindle and provide a checkpoint 
to prevent damaged cells entering mitosis (Kousholt et al., 2012). In M phase cells divide and 
segregate their genome equally between 2 daughter cells. Errors in mitosis can result in 
chromosomal translocations and uneven partitioning of chromosome leading to aneuploidy, 
a common feature in cancer, mitotic defects also contribute to tumour resistance to 
immunotherapy (Lengauer, 1998; Levine & Holland, 2018). 
Unidirectional progression through the eukaryotic cell cycle is driven by the activity of cyclin 
dependent kinases (CDKs). CDKs are kinase proteins with remarkable target promiscuity. 
They are expressed at high levels throughout the cell cycle (Arooz et al., 2000) and their 
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activation is tightly controlled. CDK activity requires dimerization with partner proteins, 
known as cyclins, and an activating phosphorylation catalysed by the CDK activating kinase 
(CAK), a ternary complex composed of cyclin H, MAT1, and CDK7 (Lolli & Johnson, 2005). 
There are approximately 20 cyclin and CDK proteins identified that have a diverse range of 
functions including regulation of RNA splicing to spermatogenesis (Peyressatre et al., 2015). 
The best characterised Cyclins and CDKs have roles in cell cycle progression (Table 1.2).   
 
Briefly, as a cell re-enters the cell cycle after exit from mitosis commitment to the cell cycle 
requires activity of growth factors. These mitogens promote the transcription of cyclin D the 
activity of which commits cells to the cell cycle through phosphorylation of the 
retinoblastoma protein (pRB) (Albrecht & Hansen, 1999; Moser et al., 2018). The 
phosphorylation of pRB promotes the transcription of cyclin E, cyclin A, and many other 
proteins through activation of the E2F transcription pathway (Müller & Helin, 2000; Thwaites 
et al., 2019). Cyclin D degradation is required prior to S phase as its activity blocks the activity 
of processivity factor PCNA and CDK2 (Fukami-Kobayashi & Mitsui, 1999; Qie & Diehl, 2020). 
Cyclin E/CDK2 promotes S phase entry, a notable event being phosphorylation events that 
trigger the unwinding of DNA through loading of the CMG complex allowing recruitment of 
the replicative polymerases (Li et al., 2011; Pauzaite et al., 2017). Cyclin A/CDK2 is active 
through S phase, promoting continuation. It is noteworthy that nuclei isolated from post-
CDK Cyclin  Cell Cycle Role 
CDK1 
Cyclin A G2 
Cyclin B Mitosis 
CDK2 
Cyclin A Late G1 + S Phase 
Cyclin E Late G1  
 
CDK4 
Cyclin D Early G1 CDK6 
Table 1.2- The major CDKs, cyclin binding partners, and their role in cell cycle control. 
Adapted from Peyressatre et al. (2015). 
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quiescent mouse fibroblast cells can be initiated to replicate by cyclin A/CDK2 yet cyclin 
E/CDK2 requires further replication factors suggesting a role for cyclin A/CDK2 in DNA 
replication initiation (Coverley et al., 2002).  
This appears to contrast with analyses of cyclin function in cell-based systems, knockout of 
both isoforms of Cyclin E: Cyclin E1 & Cyclin E2 are embryonically lethal. However individual 
knockouts are not cell cycle deficient due to redundancies between targets (Caldon & 
Musgrove, 2010). Cyclin E1/E2 null cells can be generated by growing embryos with WT 
placentas, Cyclin E null cells generated in this manner displayed reduce ability to re-enter the 
cell cycle following quiescence, through disturbed MCM helicase loading onto DNA, this 
behaviour appears independently of CDK2 activity (Geng et al., 2007). Cyclin A2 ablation 
allows normal cell cycle progression in mouse fibroblast cells due to compensation by 
increased Cyclin E activity, concurrent loss of Cyclin A2 and CDK2 however does suppress 
tumorigenesis and cell proliferation (Kalaszczynska et al., 2009; Gopinathan et al., 2014).  
In G2 phase, Cyclin A is paired with CDK1 before being exchanged for cyclin B, which quickly 
promotes its own nuclear import triggering mitosis, there is a level of redundancy between 
CDK1, and CDK2, ablation of CDK2 results in a compensatory increase in CDK1 levels to allow 
cell cycle progression (Gavet & Pines, 2010 Gopinathan et al., 2015). The last act of the cyclin 
B-CDK1 complex is the activation of the anaphase promoting complex (APC/CCdh1). 
APC/CCdh1mediates the metaphase to anaphase transition by proteasome mediated 
destruction of cohesin, resolution of the centromeres and separation of the sister 
chromatids. Finally, APC/CCdh1 results in the destruction of cyclin B by ubiquitylation, 
reducing CDK activity to a low level enabling PP2A to reset the CDK phosphoproteome to a 
basal level as cells enter G1 phase of the cell cycle after mitotic exit (Sivakumar & Gorbsky, 
2015). Deregulation of these regulatory mechanisms results in tumorigenesis.  
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1.4. Deregulation of the cell cycle underpins tumorigenesis 
Deregulation of the cell cycle leads to the uncontrolled proliferation of cells known as 
cancer. Cancer is a significant healthcare problem in the developed world. Public health 
efforts in the developing world over the last century have seen an increase in antiseptic 
techniques, advances in surgery, the development of antibiotics, and increased food and 
water hygiene has increased the life expectancy. In the UK, life expectancy for a person born 
between 1910 – 1912 was 55 years for females and 52 years for males. 100 years later, this 
has risen to 83 years for females and 79 years for males (Office of National Statistics, 2015). 
With increased life expectancy, and increased surveillance, there is increased time to 
develop mutations that underpin, transformation and acquisition of additional 
characteristics associated with over-proliferation and cell survival leading to cancer. Due to 
increased longevity, current estimates suggest that in the UK over half of people born after 
1960 will be diagnosed with cancer during their lifespan (Ahmad et al., 2015). Fortunately, 
research into cancer causes and treatments have caused a decrease in mortality from 
cancer, dropping over a fifth between 1971 and 2012 (Oke et al., 2015).  
Cancer is a genetic disease, primarily caused through mutation of genes arising through 
environmental stress. A number of genes are involved in cancer development that are 
characterised by their activity. For example, mutations in genes that increases their activity 
are known as oncogenes. This increase in activity tends to increase cellular growth and can 
be mediated by duplication of the gene, mutation of the promoter, point mutations causing 
increased activity (Vogelstein et al., 2013). This contrasts with tumour suppressor proteins 
that prevent untimely cellular division. Mutations in tumour suppressors, or changes to their 
transcription regulation, lead to a loss of function and loss of their activity promote 
tumorigenesis (Payne & Kemp, 2005; Botezatu et al., 2019). Tumour suppressors are often 
involved in halting the cell cycle following DNA damage or cellular stress and include the 
classic example of a tumour suppressor gene is p53 a master regulator of the cell cycle (Yan 
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et al., 2011; Marcel et al., 2015). Examples of both these types of genes, and their functions 
will be discussed in the following sections.  
Knowledge of common hereditary mutations that increase cancer incidence allows the 
opportunity for screening, and early intervention.  The most well categorised mutations of 
this class are tumour suppressors BRCA1 and BRCA2. Without intervention women carrying 
hereditary loss of function BRCA1 mutations have a 70 % risk of contracting breast cancer 
(Semmler et al., 2019). Both BRCA1 and BRCA2 play roles in regulating homologous 
recombination to repair DNA in response to DSBs. Identification of genes that pre-dispose 
people to cancer allows for the development of targeted therapeutics. Poly ADP ribose 
polymerase (PARP) inhibition has been effective in treatment BRCA1 and BRCA2 mutated 
tumours (Frampton, 2015).  
There are multiple types of mutations that result in oncogene activation. These include point 
mutations, or insertions/deletions within the coding sequence to the gene. These will 
typically result in a hyperactive or hyper stable version of the gene product. An example of 
this is RAS, a family of membrane coupled G-proteins that transduce signals from tyrosine 
kinases that promote cell division. Multiple mutations in RAS found in cancers block the 
hydrolysis of GTP-GDP ‘locking’ RAS proteins in a permanently activated state; this reduces 
cells dependences on growth signals, and promotes cell proliferation (Miller & Miller, 2012).  
Another class of mutations that cause oncogene activation are mutations within the 
promotor region of the oncogene; typically, these will increase transcription of the 
oncogene, increasing protein levels. An example of this is the gene TERT in malignant pleural 
mesothelioma (MPM). MPM is the cancerous condition commonly associated with the 
inhalation of asbestos; MPM has very low survival rates. TERT is a component of telomerase, 
the enzyme that ‘caps’ DNA, cancer cells dues to increased division rely on this to prevent 
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loss of telomeres and achieve replicative immortality. Mutations in the promoter that 
increase TERT mRNA levels have been identified in MLM cells (Tallet et al., 2014). 
The third common class of mutation that causes oncogene activations is chromosomal re-
arrangements. This can include moving genes to areas in the genome with greater 
transcription levels, or fusion of multiple genes resulting in increased oncogenic activation. 
Examples of this include the BCR-ABL. This is a fusion of chromosome 9 and 22 fusing the 
genes BCR and ABL. BCR-ABL fusions are commonly found within common myeloid 
leukaemia cells. The BCR-ABL gene product results in increased cell signalling, promoting cell 
proliferation and supressing apoptosis. (Quintas-Cardama & Cortes, 2009). Identification of 
mutations that promote cancer such as BCR-ABL allow development of targeted therapies 
(Rossari et al., 2018). 
1.5. Replication Licensing and Initiation  
The accurate and timely duplication of DNA in mammalian cells requires strict regulation. 
Perturbation of this system results in untimely inaccurate replication, resulting in activation 
of cell cycle checkpoints or an increase in DNA mutation rate. Increases in mutation rate can 
accelerate the progression of tumorigenesis.  Multiple redundant regulatory and checkpoint 
pathway exist to safeguard the genome during DNA replication. Before S phase can begin, 
origins of replication must be selected and prepared for replication initiation. This process is 
termed replication licensing. Replication licensing results in the recruitment of proteins to 
putative origins known as pre-replication complexes (PreRCs). 
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Firstly, during the conclusion of mitosis, the origin recognition complex (ORC) forms a ring 
around DNA and marks putative origin sites. This complex is it composed of subunits ORC1-6 
and facilitates recruitment of two further proteins, CDC6 and  Chromatin licensing and DNA 
replication factor 1 (CDT1). CDC6 is a AAA+ ATPase, ATP hydrolysis by CDC6 results in the 
recruitment and loading of two identical heterohexameric complexes. These complexes are 
each formed of six subunits, MCM2-7. These MCM2-7 complexes, upon replication initiation, 
function as the catalytic core of the DNA helicase. One ring is provided to one of the 
replisomes for each origin (Bliechert et al., 2017) (Figure 1.3).  
Replication licensing is controlled through multiple levels of regulation. ORC1, ORC 6 and 
ORC2-5 are recruited to the nucleus through independent mechanisms mediated by 
chaperone proteins and CDK phosphorylation (Ghosh et al., 2011). The ORC is recruited to 
origins through conserved (in eukaryotes) basic residues in ORC1, binding requires ATP 
Figure 1.3 - DNA Replication Licensing During M and G1 phase replication origins are 
licensed. Origins are bound by the origin recognition complex (ORC1-6) in a DNA 
structure dependent manner. CDC6 and CDT1 are recruited to the ORC at putative 
origins. CDT1 and CDC6 promote recruitment of the MCM2-7 heterohexamer. Two 
MCM2-7  heterohexamers are recruited per origin. The ORC, CDC6, CDT1, MCM2-7 
complex is known as a Pre-replication complex. More origins are licensed on the 
genome than are used during S phase.   
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binding of the AAA+ ATPase ORC1 (Kawakami et al., 2015). ORC binding requires subunits 1-
5, whilst ORC 6 is required for efficient S phase entry. In yeast, depletion of ORC 6 in G1 
resulted in loss of MCM2 chromatin association, reduced origin firing rates, and impaired S 
phase progression (Semple et al., 2006).  Expression of ORC subunits is not cell cycle stage 
specific, as it is not the limiting step for replication initiation (Thome et al., 2000). 
Deregulation of ORC activity and expression has not been found to be associated with 
cancer.  
Conversely, CDC6 levels are tightly linked to cell cycle stage. CDC6 is degraded on the onset 
of S phase and accumulates at the beginning of the cell cycle. CDC6 expression is E2F 
regulated, requiring external growth signals to stimulate expression. CDC6 is essential for 
DNA replication, removal of CDC6 in tumour cells blocks initiation of DNA replication and 
impairs tumour growth. (Yan et al., 1998; Chen et al., 2016). Degradation of CDC6 is 
mediated by the activity of CDK2, phosphorylation of the N terminus of CDC6 by CDK2 and 
CDK1 promotes SCF mediated ubiquitination and degradation (Drury et al., 1997; Al Zain et 
al., 2015). The accumulation of CDC6 in G1 and degradation during S phase helps ensure that 
DNA replication is initiated only once per cell cycle. CDC6 expression is increased in breast 
cancers, and higher expression trends with lower survival rates (Mahaevappa et al., 2017).  
CDT1 is regulated through numerous pathways. CDT1 expression is E2F mediated.  CDT1 is 
inhibited by re-replication inhibiting protein geminin. Geminin blocks CDT1 binding both 
CDC6, and interacting with the MCM heterohexamer (Kushwaha et al., 2016). Geminin levels 
drop after mitosis, geminin is degraded by the APC/C ubiquitin ligase, geminin levels rise 
again during S phase as the APC/C is deactivated (Rizzardi & Cook, 2012). This allows CDT1 
activity to be highest during replication licensing. Similarly, to CDC6, CDT1 levels are found 
higher in breast cancers, and higher expression trends with lower survival rates 
(Mahadevappa et al., 2017).  
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MCM2-7 act as the replicative helicase an essential role for replication. Loading of MCM2-7 
at dormant origins is used for completing replication when cells are under replication stress 
(Ge et al., 2007). Loading of MCM2-7 onto chromatin is largely controlled by CDT1, itself 
controlled by the Ubiquitin Proteasome System (UPS) and geminin. Activation of MCM2-7 
requires binding of MCM10, GINS, CDC45 (CMG), and phosphorylation by CDK2 and DDK. 
DNA is unwound upon CMG activation, double stranded DNA enters the hexameric ring at N-
terminal zing finger regions, the strand that is to become the leading strand is pulled down 
through the heterohexameric ring exiting through a C-terminal motor ring. An ‘exit groove’ 
formed by zinc finger regions in MCM3 and MCM5 provides a channel which the strand of 
DNA to become the lagging strand traverses (Yuan et al., 2020). After S Phase, MCM2-7 is 
inhibited by phosphorylation to prevent re-replication of DNA, phosphorylation of MCM4 by 
Cyclin A/CDK2 reduced the DNA binding of MCM2-7 (Moritani & Ishimi, 2013).  
The phosphorylation of MCM2-7 complex is mediated by CDK2, CDK1, Cdc7 (the kinase 
component of DDK), ATM and ATR (Fei & Xu, 2018). Phosphorylation from CDK2 has two 
broad functions, to promote PreIC assembly, and to inhibit re-replication. CDK2 mediated 
phosphorylation of MCM3 at T772 promotes chromatin loading (Yeeles et al., 2015). 
Contrastingly, phosphorylation of MCM4 across numerous phosphorylation sites reduces 
chromatin association of the MCM2-7 complex (Tudzarova et al., 2016). The discrete roles of 
CDK signalling to enforce cell cycle unidirectionality. Phosphorylation of MCM subunits also 
play an important role in checkpoint activation and cell cycle arrest. ATR and ATM 
phosphorylates sites on MCM2 and MCM3 in response to stressed replication, inhibiting 
replication (Fei & Xu, 2018). CDK1 phosphorylation of MCM4 inhibits replication, preventing 
re-replication of DNA. CDC45 phosphorylation have a number of activities including 




Licensed origins do not automatically initiate DNA replication. The activity of CDK and DDK 
are required for the recruitment of factors that are required to activate the replicative 
helicase complexes are required (Mailand & Diffley, 2005; Sheu & Stillman 2016; Rossbach & 
Sclafani, 2016). Site-specific phosphorylation on MCM subunits by CDK2 and DDK causes the 
recruitment of three proteins essential for replication initiation: MCM10, CDC45 and GINS. 
GINS is a multiunit protein complex formed of four subunits: Psf1, Psf2, Psf3 and Sld5. 
Together, MCM2-7, GINS and CDC45 form the CMG complex that forms the replicative 
helicase in mammalian cells, with MCM2-7 acting as the catalytic core (Li & O’Donnell, 2018). 
GINS also activates the polymerase activity of the RNA primase DNA polymerase α (DNA pol 
α), the polymerase responsible for synthesising short RNA primers that enable processive 
DNA synthesis by DNA pol δ and DNA pol ε in the replisome complex (De Falco et al., 2007; 
Zhou et al., 2018). The DNA polymerases are anchored on to DNA through the trimeric ring 
protein proliferating chain nuclear antigen (PCNA). This prevents dissociation of polymerases 
increasing processivity, as well as providing a binding site for cell cycle regulators, and 
regulating signals (Boehm et al., 2016). Replication continues bi-directionally from the 
replication origin through both leading and lagging strand synthesis (Figure 1.4).  
Cyclin E/CDK2 and DDK phosphorylation along with the activity of the Sld3-Dpb11-Sld2 
complex promotes the recruitment and activation of the CDC45, GINS, MCM2-7 (CMG) 
complex that serves as the eukaryotic replicative DNA helicase (Boos et al., 2011). Following 
unwinding of DNA, the replicative machinery is loaded onto the replication bubble to copy 
the DNA template bidirectionally. The replisome includes PCNA, a processivity factor 
analogous to the bacterial sliding clamp protein; DNA polymerase  that produces the RNA 
primers require to initiate DNA synthesis; DNA polymerase , which elongates the leading 
strand, and DNA polymerase , which elongates the lagging strand (Miyabi et al., 2011; Muzi-
Falconi et al., 2003). Although it has been proposed that DNA polymerase  often catalyses 
21 
 
The initial DNA on the leading strand but becomes replaced by DNA polymerase  (Daigaku 
et al., 2015) (Figure 1.4).   
CDC45 has a number of interactions and regulatory mechanisms. Firstly, it is part of the CMG 
complex of the fully activated helicase. CDC45 interacts with MCM5, and 7, as well as the 
main replicative polymerases, topoisomerases, and primases (Broderick & Nasheuer, 2009). 
CDC45 in the CMG interfaces with MCM2, MCM5 and GINS (Simon et al., 2016). In response 
Figure 1.4 - DNA Replication Initiation Pre replication complexes are converted to Pre-
initiation complexes in response to increasing CDK activity. The coordinated activity of 
CDCK2 and DDK promotes recruitment of CDC45, GINS and MCM10 to MCM2-7 activating 
its helicase activity. Further Phosphorylation events facilitate the recruitment of PCNA the 
DNA polymerases delta, alpha and epsilon (replisome). Multiple interfaces between CMG, 





to DNA damage, a CHK1 response promotes dissociation of CDC45, this is not simply due to 
inhibition of the CDK signals that promote CDC45 binding (Liu et al., 2006).   
Activation of pre-RCs and pre-ICs requires numerous phosphorylation events. These are 
mediated through CDK and DDK. DDK activity is supressed in events of replication stress, in 
yeast activation of S phase checkpoint results in activation of RAD53, interactions between 
RAD53 and DDK promote a dissociation from chromatin supressing cell cycle progression 
(Larasati & Duncker et al., 2017).  
PCNA has numerous functions, as well as anchoring the replisome to DNA it provides a 
platform for binding of a number of proteins, this requires multiple mechanisms of 
regulation.  Roles involved include DNA replication, and DNA repair (Mailand et al., 2013). 
PCNA expression is regulated by E2F4 (Ren et al., 2002). Phosphorylation of PCNA at tyrosine 
211 stabilises chromatin bond DNA (Wang et al., 2006). Acetylation of PCNA prevents PCNA 
interacting with protein MutT homolog2 (MTH2), promoting degradation of PCNA (Yu et al., 
2009). Mono-ubiquitination of PCNA is required to promote translesion synthesis across 
replication barriers.  DNA polymerase η is recruited to mono-ubiquitinated PCNA at lysine 
164 by RAD18 (Watanabe et al., 2004). Small ubiquitin-like modification (SUMOsyltaion) of 
PCNA prevents DSB formation through maintenance of DNA repair pathways. In unperturbed 
replication, SUMOsylation of lysine164 prevents TLS by suppression of ubiquitination of the 
same residue as well as recruiting SRS2P, a helicase that supresses homologous 
recombination (HR) (Hoege et al., 2002; Papouli et al., 2005).  
The core polymerase enzymes are also subject to regulation. DNA pol 𝛿 is heterotetramer 
formed of p125, p68, p50 and p12. DNA pol delta remains anchored to the replisome 
through interactions with PCNA via a C-terminal PIP box of the p68 subunit of the 
polymerase (Lee et al., 2017). Replication stress results in the ubiquitination and degradation 
of the p12 subunit in an ATR dependent manner. Additional factors such as protein PDIP46 
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(DNA polymerase delta interacting protein 46) bind and activate DNA pol delta, through the 
P50 subunit.  (Zhang et al., 2007). The eukaryotic DNA primase DNA pol alpha is regulated 
through phosphorylation. Phosphorylation by Cyclin E/CDK2 promotes primase activity in a 
manner not seen by Cyclin A/CDK2, differentiating the needs across G1, S and G2 phase 
(Voitenleitner et al., 1999). 
The importance of the accurate DNA replication licensing, initiation and termination events 
ensure that DNA is replicated accurately and only once per cell cycle. Regulation of DNA 
replication licensing and activation is complex, multifaceted, and adaptable in response to 
damage and stress. Critically, almost every facet of DNA replication licensing and initiation is 
impacted by CDK mediated phosphorylation. Therefore, regulation of CDK activity is essential 
for the correct maintenance of replication initiation (Section 1.8). 
1.6. CIZ1 
Cip1 interacting zinc finger protein (CIZ1) is a protein found in higher mammalian organisms 
and there are regions of homology with the C-terminus in some vertebrates. In humans, CIZ1 
is encoded by the CIZ1 gene located on chromosome 9. CIZ1 was first identified in 1999 
(Mitsui et al., 1999) and there are no high-resolution structures of CIZ1, but it is predicted to 
be natively disordered in the N-terminal region, while the C-terminus is predicted to be more 
structured. The C terminus of CIZ1 contains a matrin type zinc finger domain (Ainscough et 
al., 2007). Matrin motifs are stabilised by a zinc ligand that function in RNA and DNA binding, 
and are commonly found in transcription factors (Klug, 2010; Font & Mackay, 2010). 
Functions of zinc finger containing proteins include regulation of chromatin folding, 
transcriptional regulation, and translation regulation.  
A number of alternatively spliced CIZ1 isoforms have been identified (Coverley et al., 2005; 
Rahman et al., 2010; Higgins et al., 2012, Swarts et al., 2018). The best characterised CIZ1 
isoform is the embryonic CIZ1 (ECIZ1) transcript identified in murine embryos that lacks the 
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N-terminal polyglutamine motif that aids expression (Coverley et al., 2005). Differential CIZ1 
splicing is a common event in tumours and the functional significance of these variants are 
beginning to be determined. A cancer specific splice variant lacking exon 8 has been 
proposed as a biomarker for lung cancer (b-variant). This variant lacks the nuclear matrix 
attachment domain, and its expression was significantly increased in lung tumour samples 
compared to adjacent tissue (Higgins et al., 2012). Interestingly targeted depletion of CIZ1 b-
variant in mouse xenografts caused reduced the growth of tumours suggesting that CIZ1 is 
required for tumour growth in this context and may serve as a viable target in certain 
cancers. 
 Contrastingly, CIZ1 also has been reported to act as a tumour suppressor, loss of CIZ1 in 
mice are sensitive to hydroxyurea mediated replication stress, and sensitive to retroviral 
insertional mutations, developing numerous leukaemias. CIZ1 null mice also develop 
lymphoproliferative disorders (Nishibe et al., 2013 Ridings-Figueroa et al., 2017) A summary 
of published mutations found in CIZ1 in cancers is summarised in Chapter 7. 
Recently, CIZ1 activity has been associated with the inactive X chromosome (Xi) in female 
mouse cells. These findings showed that CIZ1 was recruited to Xi during early embryonic 
development. This interaction is through repeat E anchors in X-inactive specific transcript 
(Xist) RNA (Sunwo et al., 2017). This provides a further potential link to cancer as X 
chromosome inactivation is disrupted in a number of cancers (Ridings-Figueroa et al., 2017; 
Sunwoo et al., 2017). Loss of CIZ1, and long-term cell culture, results in compromised 
relocation of Xi that occurs as cells proliferate. This was accompanied by a change in the 
expression of genes regulated by polycomb repressive complexes (PRC1/2), PRC1/2 are 
transcriptional regulators that suppress transcription by modulating chromatin 
environments, similarly to CIZ1 PRC2 mutations have been observed to function 
contrastingly as both tumour suppressor, and oncogenes (Laugesen et al., 2016, Stewart et 
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al., 2019). Whether or not this change in behaviour is linked to CIZ1’s role in cancer remains 
unclear, however deregulation of PRC1 and PRC2 can result on DNA replication stress in 
cultured cells, something CIZ1 null cells have been shown to be sensitive to (Nishibe et al., 
2013; Piunti et al., 2017). 
1.7. CIZ1 Interactions with Cyclin CDKs During the G1/S Transition 
CIZ1 plays a role in the events of DNA replication initiation. CIZ1 binds to DNA the nuclear 
matrix fraction of chromatin, where it may anchor CDC6 to this site. The nuclear matrix is a 
collection of proteins, and ribonucleotides that aids in the organisation of chromosomes and 
within the nucleus. Organisation of the nuclear matrix differs across cell type and during 
tumorigenesis. The nuclear matrix is made up of lamin proteins which span the nuclear 
envelope linking the chromosomes to the cytoskeleton and composes the scaffold that 
remains after chromatin isolation, crosslinking and DNAse digestion (Nickerson et al., 1997; 
Rynearson et al., 2011; Wasąg et al., 2016; Wilson et al., 2016). DNA attaches to the nuclear 
matrix through loops at matrix attachment regions (MARs) and scaffold attachment regions 
(SARs). The nuclear matrix plays a role in DNA replication, nascent DNA becomes associated 
to the nuclear matrix. Additionally, replication origins have been shown to be recruited to 
the nuclear matrix during late G1, and preRC/IC proteins are recruited to the nuclear matrix 
following mitosis (including ORC proteins, CDC6, CDT1, and MCM3), as well as Cyclin E and 
Cyclin A. Cyclin E NM recruitment is lost in cancers (Wilson et al., 2013).   
 CIZ1 can associate with cyclin A/CDK2 and cyclin E/CDK2 during the events of DNA 
replication potentially contributing to the spatiotemporal regulation of DNA replication firing 
(Pauzaite et al., 2017). CIZ1 can expand and increase the replication initiation activity of 
recombinant cyclin A/CDK2 in vitro (Coverley et al., 2005; Copeland et al., 2010). 
Additionally, in vitro experiments have shown that phosphomimic versions of CIZ1 abolishes 
this effect (Copeland et al, 2015).  
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CIZ1 itself is regulated by the activity of cyclin-CDK mediated phosphorylation and contains 
several phosphorylation sites (Coverley et al., 2005; Copeland et al., 2015). CIZ1 is a 
substrate of cell cycle kinases, which have important functions surround the G1/S phase 
transition: Cyclin E/CDK2, cyclin A/CDK2 (Copeland et al., 2015). When CIZ1 is 
phosphorylated at sites T293 or T192 its replication activity is reduced in vitro. This activity is 
linked to CIZ1’s ability to co-ordinate Cyclin A/CDK2 and Cyclin E/CDK2 during the G1/S 
transition, anchoring these kinases to the nuclear matrix, close in proximity to licenced 
origins  (Coverley et al., 2005, Copeland et al., 2015).  
CIZ1 interacts with G1/S cyclins through cyclin-binding motifs (K/RXL). As cells progress 
through the cell cycle from mitosis Cyclin E levels increase, here CIZ1 interacts with Cyclin E 
at the nuclear matrix. It appears that CIZ1 is recruited to regions of the nuclear matrix with 
high Cyclin E as depletion of CIZ1 by siRNAs does not impact cyclin E nuclear matrix 
localisation.  Later, Cyclin A levels increase as cells reach late G1 and early S phase, this 
increase is accompanied by a switch in Cyclin binding to CIZ1, Cyclin E is displaced at the 
nuclear matrix on CIZ1 by Cyclin A. This localisation change of Cyclin A is CIZ1 dependent, 
depletion of CIZ1 by siRNA results in loss of the nuclear matrix localisation of Cyclin A 
(Copeland et al., 2010). This exchange ensures that Cyclin A/CDK2 becomes localised to sites 
that experience Cyclin E/CDK2 activity (Figure 1.5a).     
Phosphorylation of CIZ1 by CDKs results in a loss of its DNA replication initiation activity, in 
cycling cells, these phosphorylations occur as cells enter S phase when replication initiation is 
no longer required. Phosphomimetic variants of CIZ1 no longer promote DNA replication in 
vitro. These phosphorylations are accompanied by a loss of the ability for CIZ1 to interact 
with Cyclin A. These phosphorylations do not restrict CIZ1’s nuclear localisation, and CIZ1 can 
still interact with replication licensing factor CDC6 as this interaction is at a different binding 
27 
 
site.  This implies that CIZ1 de-activation promotes replication after the onset of S phase 
(Copeland et al., 2015) (Figure 1.5b). 
 
 
A                                         B 
Figure 1.5-CIZ1 Promotes Replication initiation through interactions with Cyclins A) 
CIZ1 recruits Cyclin A/CDK2 to sites with Cyclin E activity. CIZ1 interacts with Cyclin E 
in mid G1 phase, as Cyclin A levels increase Cyclin A/CDK2 displaces Cyclin E, 
promoting a shift in the active Cyclin at CIZ1 enriched sites. Adapted from Copeland 
et al. (2010) B) Cyclin A is recruited to replication origins by CIZ1, Cyclin A/CDK2 
promotes replication initiation, and then phosphorylates CIZ1 promoting release of 
Cyclin A/CDK2 from CIZ1 at the nuclear matrix. Adapted from Copeland et al (2015).  
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Together, these studies inform a model by which CIZ1 is localised to licensed origins through 
interactions with CDC6 and Cyclin E at the nuclear matrix. This promotes the activation of 
these origins through Cyclin E (and later Cyclin A) mediated CDK2 phosphorylation. As cells 
progress towards S phase Cyclin A accumulates and is brought to these ‘selected’ origins by 
CIZ1. Cyclin A mediated phosphorylation then promotes replication origin firing, and then 
later CIZ1 phosphorylation promotes the dissociation of Cyclin A/CDK 2 and CIZ1. Preventing 
replication initiation at fired origins. Therefore, it appears that CIZ1 acts as a ‘kinase sensor’ 
translating levels of Cyclin A, and Cyclin E to their activity (Pauzaite et al., 2017). Disruption 
of this could result in aberrant Cyclin/CDK signalling. Localisation changes of G1/S cyclins are 
sufficient to induce DNA replication stress and result in mitotic defects (Bagheri-Yarmand et 
al., 2010). Correct regulation of CDK activity and the timing of the phosphorylation of CDK 
substrates is important for cell cycle regulation. 
1.8. The quantitative model of cell cycle regulation by CDK and the Permissive Kinase 
Window 
The cell cycle is regulated by the activity of cyclin dependent kinases, which oscillates from 
low in G1 phase to high during mitosis. The organisation of the cell cycle can be recapitulated 
by a single cyclin-CDK fusion protein in fission yeast (Coudreuse & Nurse, 2010; Gutierrez-
Escribano & Nurse, 2015). The thresholds that determine the cell cycle phase transitions 
appears to be governed by the intrinsic CDK activity rather than by a specific activity of any 
cyclin-CDK complex.  The quantitative model, originally proposed by Stern & Nurse (1996), 
provides a molecular basis for the G1/S and G2/M transitions of the cell cycle. The 
hypothesis that this project intends to test relies on the “kinase model of DNA replication”. 
This states that DNA replication initiation is only possible within a tightly controlled window 
of kinase activity. There is a low kinase activity threshold (TS) below which replication cannot 
occur, and a higher inhibitory kinase threshold (iTS) above which replication is blocked. 
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Additionally, there is a third increase kinase threshold at which mitosis can begin (TM) 
(Pauzaite et al., 2016) (Figure 1.6).  
 
The lower kinase activity (Ts) is set primarily through the activity of two kinases: CDK2 
complexed with cyclin A or cyclin E, and Dbf4-dependent kinase (DDK). The activity of these 
two kinases is required to convert preRCs into preICs (Fragkos et al., 2015). CDKs also 
phosphorylate other replication factors such as Sld2 and Sld3 part of the budding yeast 
Figure 1.6 – The Quantitative Model of the Cell Cycle A schematic showing kinase level 
changes across the cell cycle, and the thresholds present throughout the cell cycle. Kinase 
level increase is primarily driven through the temporally controlled expression of cyclins 
which activate cyclin dependent kinase binding partners. 
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PreIC, which promotes the recruitment of further factors such as GINS and pol ε (Araki, 
2010).  Without this activity, licensed origins could not recruit the replicative polymerases 
Pol δ and Pol ε and replication cannot occur.  
The inhibitory higher kinase activity iTS that prevents DNA replication initiation is driven 
through a number of mechanisms. In general, higher kinase levels lead to phosphorylation of 
key replication proteins that targets them for removal from the nucleus or destruction by 
ubiquitination. These include ORC1 and CDT1 (Guarino et al., 2011; Mendez et al., 2002). 
Within the quantitative model lies the ability to control whether cells lie in dormant 
quiescence (G0) or enter the cell cycle into S phase, here there is a kinase threshold, the 
restriction point. Whether cells enter the cell cycle straight away, or enter quiescence is 
governed by p21 levels at mitosis and G1. Cells that divide with high p21, typically have 
hypophosphorylated RB, low CDK activity and will enter G0 or need external signals to 
promote cell cycle entry (Moser et al., 2018). Cells which divide with low intracellular p21 
levels enter G1 with higher CDK activity, leading to hyperphosphorylation of RB, and rapidly 
begin a further round of cell division. (Moser et al., 2018). CDK activity, is key for RB 
phosphorylation, control over cell cycle entry above and below the restriction point 
threshold governs cell division rates. Once the G1/S transition is passed, p21 is degraded by 
the ubiquitin proteasome system through the activity of CRL4Cdt2 and SCFSkp2 E3 ligases. p21 
levels at G2/M are linked to DNA damage within the S phase of the previous cell cycle. DNA 
damage promotes a DDR, which results in the accumulation of p53 through G1, triggering an 
accumulation of p21. These cells will not enter S phase even in high serum conditions due to 
CDK inhibition keeping the kinase level below the threshold (Barr et al., 2017). The cell cycle 
is driven by these two thresholds, the RP, and the G1/S phase transition, both in turn 
governed by kinase levels. The RP is promoted by an increase in kinase activity opposed by 
p21 inhibition of CDKs.  Between the restriction point and the G1/S transition cells can return 
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to their G0 state, however this becomes impossible after the G1/S transition. Degradation of 
p21 by the UPS promotes high CDK levels driving proliferation through the cell cycle. p21 
levels will accumulate through S and G2 allowing DNA repair however cells commit to 
division. This drives the unidirectionality of the cell cycle, driven by a one-way kinase level 
increase protecting against re-replication (Heldt et al., 2018).  
The presence of these precise kinase thresholds coupled with the increasing kinase activity 
throughout the stages of the cell cycle, followed by resetting upon activation of the APC/C 
ensures DNA replication and mitosis occur only at the correct time as well as ensuring origins 
do not fire more than once per cell cycle (Spencer et al., 2013). Consequently, the activity of 
CDKs ensure the unidirectional progression of the cell cycle.   
Recently, the molecular mechanisms that underpin the quantitative model of CDK activity 
have begun to be determined. Swaffer et al. (2016), demonstrated that CDK substrates can 
be roughly grouped into their sensitivity to CDK activity. This can be roughly split into early 
(phosphorylated, G1/S), intermediate, and late (phosphorylated G2/M). In this report, re-
ordering of the cell cycle, DNA synthesis before on set of M phase was achieved through 
dephosphorylation and subsequent re-phosphorylation of the early targets. Additionally, 
cells arrested in G1/S phase exposed to high CDK activity simultaneously phosphorylated 
early and late CDK targets, and concurrently entered S phase and M phase. Intermediate 
kinase targets appeared to be regulated by cyclin specificity, the absence of G1/S cyclins 
resulted in a decrease in the rate of intermediate targets increasing gradually over the cell 
cycle. Swaffer et al. (2016) proposed a model where early and late targets are driven through 
global increases in kinase activity and intermediate targets are regulated by cyclin/CDK 
specificity.  
More recently, Ord et al., (2019) demonstrated that cyclin specific phosphorylation is 
triggered by three major sequence specific factors. Firstly, threonine residues are less 
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efficiently phosphorylated than serine residues, bifurcating targets to late and early 
phosphorylation. Secondly, the distances between CDK phosphorylation sites, and changes in 
combinations of CDK phosphorylation sites could dictate the activity and time required to 
phosphorylate them. This effect could be reduced by addition of cyclin specific docking sites 
this could be how mid targets are more specifically regulated by the specific Cyclin-CDKs. 
Thirdly, through specific cyclin docks, S phase CDK recognised an RxL motif and M phase 
CDKs recognised an LxF motif, the order of phosphorylation can be reversed by altering 
which motif is present. Together these two reports enrich the quantitative model of the cell 
cycle. Early and late targets are defined by being more readily phosphorylated, mediated 
through phosphorylation patterns and serine threonine switching.  This allows cell cycle 
progression using only 1 CDK (Gutierrez-Escribano & Nurse, 2015). However, phosphorylation 
thresholds are fine tuned in mid targets by the presence of cyclin specific binding docks, 
allowing the fine control of 1000s of different targets involved in cell cycle progression. 
A key thing to note is that bringing cyclins into close contact with targets through docking 
ports was key to defining thresholds, a role that CIZ1 plays during the G1/S transition 
(Copeland et al., 2010). CIZ1 also interacts with p21, the protein involved with setting the 
kinase level after mitosis (Moser et al., 2018). In vitro CIZ1 appears to regulate CDK activity at 
the G1/S transition (Coverley et al., 2005), if CIZ1 is altering the S phase threshold this may 
result in deregulated CDK signalling. Deregulation of CDK signalling will result in a 
phenomenon known as DNA replication stress (Jones et al., 2012; Shimura et al., 2013; 
Llobet et al., 2019) which could help uncover the role CIZ1 plays in tumour development.  
1.9. DNA Replication Stress  
DNA Replication stress (DRS) is defined as the stalling and slowing of DNA replication forks, 
this can be caused by oncogenic mutation, external stresses, or collisions with transcription 
events. Replication stress triggers the DDR and activates the S phase checkpoint. This allows 
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cells to repair DNA or in circumstances where repair is not possible to undergo programmed 
cell death. If cells can bypass this ‘tumorigenesis barrier’ during sustained replication stress, 
mutation rates increase resulting in cancer developments (Bartkova et al., 2006). Sustained 
replication stress leads to genome instability, which underlies many of the hallmarks of 
cancer. DRS is characterised by slow replication forks and activation of cryptic origin sites 
(Gaillard et al., 2015). 
DRS can be mediated by a number of factors including oncogene activation (RAS, myc, BCL-
2), overexpression of cyclin D/E or regulators of the DNA replication process (CDC6), or 
reduction of factors that stabilise ssDNA such as RPA (Sideridou et al., 2011; Kotsantis et al., 
2016; Macheret & Halozonetis, 2018; Primo & Teixeira, 2020). There are a number of 
mechanisms by which oncogene activation induces replication stress. These include collisions 
with transcription machinery, collision with abnormal DNA structures (e.g. G quadruplexes), 
abnormal origin licensing, impaired origin firing, or depletion of nucleotide pools, or 
replication when nucleotide pools are low (Primo & Teixeira, 2019). All of these result in a 
slowdown or increased stalling of replication forks resulting in genome instability.  
Prolonged replication stress causes damage to DNA; this is most noticeable at common 
fragile sites (CFS), which are sites that are likely to break during replication stress. These sites 
often share characteristics: CFS are commonly located in late replicating regions of the DNA 
(Beau et al., 1998). CFS commonly are AT rich containing interrupted AT repeat regions 
(Zlotorynski et al., 2003), addition of these AT rich patterns to genes in yeast increases DNA 
fragility (Zhang et al., 2007; Glover et al., 2017). Recently, databases of the ~125 identified 
CFS have been established, identifying over 4000 protein coding regions within them. 
Notably the most common conditions linked to genes within CFS were neoplasia. Functions 
of proteins within CFS included DNA repair, and mitotic spindle checkpoint proteins (Kumar 
et al., 2019). The tumour suppressor gene: fragile histidine triad protein (FHIT) that functions 
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in regulation of nucleotide metabolism lies within a CFS commonly damaged in response to 
carcinogens and mutated in a number of cancers (Limas & Cook, 2019).  
Cells have developed mechanisms to protect from the effects of replication stress. DRS could 
result in under replicated DNA, that could result in cell death through apoptosis, the removal 
of the cell from the cell cycle via senescence, or if allowed to replicate through a mitotic 
catastrophe. The activation of dormant ‘cryptic’ origins within the genome enables complete 
duplication of the genome under DRS conditions. Activation of cryptic origins is observed 
when MCM2-7 proteins are lowered. In ‘normal’ growth conditions, MCM2-7 deficient cells 
replicate at a rate comparable to control. However, when replication is challenged by 
nucleotide synthesis inhibitor hydroxyurea replicate rates were drastically lowered (Ge et al., 
2007).  
There are two major results of DRS: under replicated DNA due to under licensed origins, slow 
DNA replication forks, or reduced origin firing. In the absence of complete duplication of the 
genome under-replicated DNA proceeding through mitosis can cause loss of genomic 
integrity. The second result of DRS is stalled replication forks, failure to replicate through 
stalled forks will result in mitotic catastrophe. Cells have mechanisms to replicate through 
stalled forks, but these mechanisms are error prone and can also result in DNA damage. This 
implicates replication stress as a source for genome instability, explaining why DRS has been 
proposed as a hallmark of cancer (Macheret & Halozonetis, 2015). 
Replication through DNA lesions using trans-lesion synthesis (TLS), which utilizes alternative 
DNA polymerase enzymes to replicate past lesions. These include the Y family of DNA 
polymerases, principally Pol η (Sale, 2013).This polymerase commonly replicates through 
bulky cyclobutane pyrimidine dimers (CPDs) caused by UV damage, utilizing an enlarged 
more open active site than replicative polymerases pol δ and pol ε (Biertümpfel et al., 2010). 
Loss of Pol η in xeroderma pigmentosum v (XP-V) results in an increased photosensitivity 
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(Black, 2016). TLS lack the proofreading ability present in the principal replicative 
polymerases: pol δ and pol ε. S. cerevisiae Pol η has a single base substitution rate of 950 per 
100,000 base pairs, compared with ≤ 1.3 and ≤ 0.2 for pol δ and pol ε respectively. 
Furthermore, S. cerevisiae pol η has a single insertion or deletion rate of 93 per 100,000 bp, 
compared to 1.3 and 0.5 in pol δ and pol ε respectively (McCulloch & Kunkel, 2008).  
Increased TLS has been linked to multiple cancer types; furthermore, it has been implicated 
as a mechanism for tumours to develop resistance to chemotherapy (Zafar & Eoff, 2017).  
Another mechanism by which cells resolve replication stress due to stalled forks is through 
homologous repair (HR). HR relies on a homologous sequence of DNA from sister chromatid 
to repair. If HR is not possible the more error prone non- homologous end joining (NHEJ) 
pathway is used. HR is often disrupted in cancer, notable mutations in HR tumour suppressor 
proteins BRCA1/BRCA2 confer severe cancer risk, woman who carry BRCA1 mutations have a 
70 % chance of developing breast cancer in their lifetimes (Semmler et al., 2019). Failure to 
resolve replication stress can result in genome instability in a multiple ways. This can include 
point mutations due to TLS, large-scale chromosomal re-arrangements, changes in 
chromosome number due to mitotic error, addition, or deletion of DNA (Bishop & Schiestl, 




The second defence against replication stress is the ATR Chk1 checkpoint response. This is 
discussed in detail in Section 1.11. Interestingly, DRS is a feature of many tumour cells and 
this can be targeted by DRS inducing factors to selectively kill cancer cells. In mice, CHK1 
inhibition can kill tumours with high levels of replication stress derived from overexpression 
of MYC transcription factors. This was ineffective in tumours that did not displayed increased 
DRS. These cancer cells rely on the checkpoint response to complete DNA replication without 
catastrophe (Murga et al., 2011). This chronic DRS is a potential avenue to explore for 
personalised anticancer treatments.    
1.10. Targeting the Replication Stress Response in Cancer Therapeutics  
Previous sections described both replication stress, the causes of replication stress, and the 
cellular response to replication stress. Clearly, minimising replication stress and developing 
robust mechanisms to protect against its effect is vital for the long-term survival and health 
Figure 1.7- Oncogene Activation Induces Replication Stress. Oncogene activation can 
result in multiple phenotypes. Many of these phenotypes summarised in this figure result 
in the slowing or stalling of replication forks i.e. replication stress. These lead to increased 
DNA damage at CFS and under replication of DNA. If left unchecked for a prolonged time 
oncogene induced replication stress results in genome instability,  
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of multicellular organisms. Recently, due to weaknesses in tumour cells response to 
replication stress. Replication stress has become a target for cancer therapeutics.  
Many approved cancer therapeutics function by inducing replication stress in the rapidly 
replicating tumour cells. These classes of drugs can function by inhibition of DNA and RNA 
synthesis (5-Fluorouracil), or by inhibition of nucleotide biosynthesis (Hydroxyurea, 
mercaptopurine, or methotrexate). These drugs have no preference between proliferating 
‘healthy’ cells and rapidly proliferating tumour cells. Tumour cells are more sensitive to these 
drugs as they are proliferating more rapidly, therefore DRS is induced in these tumour cells 
promoting apoptosis, additionally, tumour cells often rely on the DRS to prevent catastrophic 
replication defects (O’Niel et al.,2017). Consequently, drugs of this class are associated with 
a number of side effects that would cause discomfort or danger to the patient. Side effects 
include nausea, fatigue, immunosuppression, and diarrhoea (Formen & O’Connor, 2018). 
Clearly, such drugs are not ideal unless no better option is available.   
Conventional chemotherapeutics include drugs that compete with dCTP for DNA 
incorporation, preventing DNA elongation and inducing DRS by stalling replication forks 
(Cytarabine and gemcitabine) (Uhbi et al., 2019). Cytarabine promoted remission of acute 
myeloid leukaemia by 60-80 % in young adults (Wu et al., 2017).  
Another family of conventional drugs that induce DNA damage are DNA alkylating and cross-
linking agents. These drugs block replication through physical linking of DNA bases (both 
neighbouring and disparate). Cisplatin is an example of this class of drug (Uhbi et al., 2019). 
Cisplatin has been used to treat multiple cancer types including lung, testicular, and ovarian 
cancers. Cisplatin promotes apoptosis, inducing both inter-strand and intra-strand cross 
links, this occurs at any point in the cell cycle (Aldossary, 2019). Side effects of cisplatin are 
severe commonly including anaemia, bone marrow failure, and sepsis. In rare occurrences, 
cisplatin treatment causes cardiac arrest, and acute leukaemia (NICE, 20202). 
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Finally, another class of conventional of chemotherapeutic drugs that induce DNA replication 
stress are the topoisomerase inhibitors. These prevent the resolution of DNA supercoiling 
induced by DNA replication, blocking continued replication, and inducing DSB (Ubhi et al., 
2019).  An example of this type of chemotherapeutic is doxorubicin (Nitiss, 2009). 
Doxorubicin is used to treat numerous cancers including leukaemia, lymphoma, and breast 
cancer. The various replication stress inducing cancer therapeutics have responses that vary 
across cancer type, and individual. They all commonly share severe side effects. Clearly, 
more targeted, lower side effect chemotherapeutics need to be developed as cancer 
treatment becomes more personalised.  
More recently, targeted drugs have been developed that exploit weaknesses in tumour cells 
DDR to induce catastrophic damage to the cell. The first of these developed was Olaparib, a 
PARP inhibitor. BRCA1 and 2 are tumour suppressor genes that function within the DNA 
repair programme BRCA1 was first discovered in 1994, around the same time BRCA2 was 
identified (Swensen et al., 1994; Wooster et al., 1995), both genes were discovered due to 
heredity breast cancer cases. Women with BRCA1/2 mutations without intervention have a 
40 – 60 % chance of developing breast cancers. Screening families of those effected by BRCA 
mutations has proved preventative (Chen & Parmigianim, 2007; Bryant et al. 2005). 
Small cell lung cancer, representing 15 % of lung cancers, displays replication stress caused 
by the activation of oncogenes and the loss of TS functions (Bian & Lin, 2019). Therefore, a 
potential mechanism for the treatment of SCLC via targeting replication stress. One potential 
candidate is WEE1, which is a CDK1 inhibitor that regulates the G2/M checkpoint and 
prevents the untimely onset of mitosis. SCLC cells and other cancer cells are under 
constitutive replication stress. Cells under constitutive DRS often fail to complete DNA 
replication before mitosis. WEE1 is a kinase that targets CDK2 and CDK1 through inhibitory 
phosphorylation, preventing the signals that would promote mitosis. WEE1 also inhibits the 
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firing of fully licenced replication origins through inhibition of CDK2 (Moiseeva et al., 
2019).The mechanism by which WEE1 inhibition functions as a cancer treatment is that 
WEE1 inhibition would allow cells to enter mitosis when DNA replication is not finished, this 
would result in a mitotic catastrophe causing the death of daughter cells. In p53 mutant 
cancer cells, WEE1 depletion reduced cell proliferation, as well as sensitising cells to ionising 
radiation (Yin et al., 2017). Furthermore, chemical inhibition of WEE1 in SCLC by AZD1775 
revealed that numerous SCLC cell lines were sensitive to WEE 1 inhibition (Sen et al., 2017). 
AZD1775 is currently undergoing clinical trial.  Modern strategies have been developed to 
increase the potency of AZD1775, repurposing it as a proteolysis targeting chimera 
(PROTAC), to selectively target WEE1 for degradation by the ubiquitin proteasome system 
reducing dose required, and promoting G2/M accumulation (Li et al., 2020). 
A third potential target is ATR inhibition. It is a component of the SSB DNA damage 
checkpoint activated by long stretches of RPA the single strand binding protein. ATRi has 
been shown in vitro to be effective at sensitising cancer cell lines to radiotherapy, by 
preventing the DNA damage response (DDR), in cells damaged by radiation, and allowing the 
cell cycle to progress through to mitosis. This resulted in mitotic catastrophe that induced 
cell death (Dillon et al., 2017). Currently there are multiple ATRi in clinical trial, both as a 
single treatment, and in combinational therapy with other treatments such as Olaparib and 
radiotherapy (Cancer Research UK, 2020; National Institute of Health ,20201, National 
Institute of Health ,20202, National Institute of Health ,20203, El-Maouche et al., 2020).  
Another potential target in the DDR pathway is CHK1. CHK1 lies directly downstream of ATR 
in the DDR. Again, inhibition of this in cells under constitutive DRS (tumour cells) would 
result in erosion of the S phase checkpoint, resulting in mitosis in the presence of under-
replicated DNA, which would result in mitotic catastrophe that would cause cell death (Ubhi 
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& Brown, 2019). A number of CHK1 inhibitors have been trialled, although a number were 
discontinued due to poor tolerability and toxicity (Muageri-Sacca et al., 2013).   
The common theme behind a number of these DRS targeting cancer therapeutics is the 
concept of synthetic lethality. Synthetic lethality is the phenomenon whereby a drug blocks 
or impedes one arm of a redundant pathway. ‘Healthy’ cells, cells can use another arm of the 
pathway to ensure DNA repair (O’Neil et al., 2017) (Figure 1.8), but the exact mechanism by 
which PARPi is synthetically lethal is unclear. One theory is that PARP proteins are 
responsible for SSB repair such as BER, BRCA1/2 negative cells are defective in HR, a major 
mechanism for the repair of DSBs. When PARP is inhibited, SSB become DSBs, which in 
healthy cells can be repaired, but in BRCA1/2 cells cannot resulting in catastrophic DNA 
damage (Morales et al., 2014). PARPi is damaging to healthy cells, but the damage is 
exacerbated in HR deficient cells (Murai et al., 2012; Hopkins et al., 2019). Additionally, PARP 
inhibition traps enzymes PARP1 and PARP2 at damaged DNA foci, which are more 




The development of PARP inhibition was a breakthrough in cancer therapeutics. However, 
common to many targeted therapies there is the issue of resistance. Since clinical use of 
Olaparib became widely available several resistance mechanisms have been identified in  
tumours, the mechanisms by which cells develop resistant to PARPi is unclear. Some 
examples are by restoration of HR pathways, increase egress of drug, stabilization of stalled 






Figure 1.8 - Synthetic Lethality Synthetic lethality is the concept that a cancers mutation 
background results in a drug that is not lethal to ‘healthy’ cells becomes lethal to tumour 
cells. One mechanism by which this occurs is summarised here. DNA repair can be achieved 
by 2 pathways, one involves TS gene, the other involves gene 2. In healthy cells, inhibition of 
gene 2 is not lethal, DNA is repaired through the TS gene pathway. The cancer cells are TS 
gene negative, inhibition of gene 2 here leaves no pathway by which DNA can be repaired. 
Drug X causes the death of the tumour cells but allows survival of healthy cells, hence 
synthetic lethality.  
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1.11. DNA Damage Response 
Mammalian cells face numerous replication challenges. These can be from external sources, 
such as UV light, inhaled carcinogens, or, they can be from internal sources, oncogene 
activation, or reactive oxygen species (ROS). The key result of all these challenges is an 
increase in the rate of DNA damage. This damage can exist in multiple ways. UV light results 
in bulk adducts such as CPDs. Oncogene activation can result in an increase in single strand 
breaks, stalled replication forks can lead to an increase in DSBs. Unresolved this damage will 
result in increased mutations, cell death and mitotic catastrophe (Chatterjee & Walker, 
2017). To compete with constant challenges to DNA replication across all the cells in an 
organism, mechanisms have evolved that repair DNA damage to allow replication to occur. A 
key mechanism is the DNA damage response (DDR) of the S phase checkpoint. 
The DDR consists of a network of signals including proteins that sense DDR, these trigger a 
signal transduction pathway that results in the halting of the cell cycle. The major effectors 
of this response is the tumour suppressor ‘guardian of the genome’ p53. These prevent S 
phase progression buying the cell time to either repair DNA damage, remove the cell from 
the cell cycle completely (senescence), or in cases of irreparable damage safely remove the 
cell through apoptosis (Bartkova et al., 2006; Ciccia & Elledge, 2010). Together these 
pathways exist as the tumorigenesis barrier, preventing the accumulation of mutations in 
somatic cells. Bypass of this barrier can be key for cancer development  
Double strand breaks (DSBs( are generated by a number of mechanisms, for example, 
exposure to X-rays. DSBs trigger the phosphorylation of the serine 139 residue of histone 
H2AX (gammaH2AX) by the protein ataxia telangiectasia mutant (ATM). H2AX 
phosphorylation is itself facilitated through a change in chromatin, through release of 
heterochromatin protein 1 ((HP1)-beta) from methylate histone H3 (H3K9me) in response to 
DSBs.  The MRN (MRE 11, RAD50, NBS1) complex is recruited to DSBs independently of H2AX 
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phosphorylation, and can promote DNA repair in the absence of DNA (Yuan & Chen, 2010)  
Together γH2AX and the MRN complex provide the sites to recruit and activate further 
proteins in the DSB response (van den Bosch et al., 2003). The MRN complex recruits and 
activates the ATM kinase, which is largely responsible for the signal transduction in response 
to DSBs. ATM phosphorylates and activates a number of downstream proteins including 
checkpoint kinase 2 (CHK2). Chk2 in turn phosphorylates and activates p53, and CDC25. p53 
phosphorylation results in the halting of the cell cycle, CDC25 phosphorylation results in the 
inactivation of the phosphatase, this prevents the activating phosphorylation of CDK2 
resulting in cell cycle progression inhibition. This is compounded by p53 binding to the 
promoter of p21 and promoting expression and accumulation of p21, p21 directly inhibits 





Figure 1.9 – The DDR to DSBs. Double strand breaks are DNA damage caused by multiple sources 
e.g. ionising radiation. DSBs are labelled by the MRN complex and gammaH2AX. These activate 
ATM promoting H2AX phosphorylation and activation of CHK2. CHK2 promotes inhibition of cell 
cycle progression through activation of p53 and inhibition of cdc25. Together these promote 




Single strand breaks (SSB) and replication stress both trigger the halting of the cell cycle 
through activation of ATM-related (ATR) kinase. ATR is a component of the replisome and 
mediates responses to DNA damage and replication stress, which causes a decoupling of 
replicative polymerase and replicative helicases, resulting in long strands of ssDNA coated in 
single strand binding protein RPA. RPA recruits TOPBP1 to the sites of DNA damage through 
direct binding, via the BRCT2 domain of TOPBP1, ATR binds ATRIP and ATRIP is recruited to 
stall forks by binding RPA, when together at stalled forks, mediated through RPA, TOPBP1 
activates ATR activating its kinase activity allowing downstream effects to occur (Acevedo et 
al., 2016). ATR phosphorylated checkpoint kinase 1 (CHK1). CHK1 phosphorylates p53 and 
CDC25. This has the same effect as CHK2, restraint of the cell cycle and inhibition of CDKs 
(Figure 1.9). SSBs are repaired using multiple mechanisms. One mechanism is the error 
prone trans lesion synthesis (TLS), other involve PARP signalling (Abbots & Wilson, 2017) 
(Section 1.7). RPA increases genome integrity. Inhibition of RPA induces DNA replication 
stress, suppression of RPA results in activation of the Fanconi anaemia pathway, suppression 
of RPA in cells lacking the FA pathway displayed increase rates of DNA damage (Glanzer et 
al., 2014; Jang et al., 2016) The FA pathway coordinates the repair of inter-strand crosslinks 










Figure 1.10 The replication stress response. Replication stress induces formation of long 
stretches of ssDNA that are recognised and coated with RPA. RPA coating recruits ATR, 
ATRIP, and TOPBP1promoting activation of ATR. ATR phosphorylates and activates CHK1 
which restrains the cell cycle through activation of p53, and p21. 
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Activation of cell cycle checkpoints through the DDR, halts cell cycle progression while cells 
respond to genotoxic stress. Initially, cells will attempt to repair DNA damage and if this is 
unsuccessful cells will wither enter senescence or promote cell death.  Responses to DNA 
damage vary across the stages of the cell cycle. Neocarzinostatin (NCZ) induces DSBs 
independently of cell cycle stage. Cells treated with NCZ in G1 rapidly halt the cell cycle at 
the G1/S checkpoint, cells treated during S phase continued through to G2 at low-moderate 
doses arresting at the following G2/M checkpoint, finally cells damaged at G2 or M rapidly 
arrested the cell cycle. The stage of the cell cycle damage occurs effects the repair pathways 
used to resolve it, after S phase DNA has a homologous chromatid which allows higher 
resolution repair (Chao et al., 2017). The major repair pathways from DSBs are HR, and NHEJ. 
NHEJ is more error prone than HR. If DNA cannot be repaired, then senescence is an option. 
p53 is activated upon DNA damage, and sustained p53 activation can result in apoptosis or 
senescence to remove the damaged cell from the cell cycle and prevent tumorigenesis (Qian 
et al., 2013). Constitutive p53 activation ensures that p21 expression is prolonged, leading to 
accumulation of p16ink4a (Abbots & Wilson, 2017). p16Ink4a is an inhibitor of CDK4 and CDK6. 
Coupled with cyclin D these provide the major signal for the phosphorylation of pRB, which 
drives promotion of E2F transcription promoting cell cycle entry. Cells without this signal 
enter senescence, a permanently non-replicative state. Senescence in aging cells is linked to 
the strength of the promoter for p16Ink4a (Liu et al., 2019). The other option is apoptosis, this 
occurs when cells are under greater stress. Increasing doses of Doxorubicin in cells promotes 
a switch of cell fates from senescence to apoptosis (Altieri et al., 2012). This choice is 
partially due to acetylation status of p53. In high levels of stress, acetylation of K117 
upregulates PUMA and NOX promoting apoptosis (Childs et al., 2014). 
Cancers evade the DDR to be able to replicate their genome despite the presence of DNA 
damage and that leads to increased DNA mutation rates. Many of the proteins seen in the 
DDR are tumour suppressor genes. In fact, p53 is the most commonly mutated tumour 
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suppressor gene, mutated in up to 50 % of ovarian cancers (Olivier et al., 2010). Chk2 is a 
tumour suppressor gene (Hiroa et al., 2002). ATM is a tumour suppressor gene, qPCR 
analysis of nasopharyngeal carcinoma cells revealed reduced ATM expression (Bose et al., 
2009). p21 displays different effects based on localization nuclear localised p21 acts as a 
tumour suppressor whereas cytoplasmic p21 has been reported to have oncogenic activity 
(Ohkoshi et al., 2015). CDC25 has been suggested as a therapeutic target for triple negative 
breast cancer (Liu et al., 2018). Collectively, these examples demonstrate the key role that 
the DDR plays in tumour development.  
1.12 Aims: 
In vitro experiments suggest that CIZ1 may be able to perturb the concentrations at which 
cyclin A/CDK2 can promote DNA replication initiation (Coverley et al., 2005; Copeland et al., 
2010; Copeland et al., 2015). Permitting replication firing at both conditions lower and higher 
than when additional CIZ1 is not present. Coupling this with the observed overexpression 
and altered expression of CIZ1 in a number of cancers including breast and lung cancers may 
help to explain these effects (den Hollander et al., 2006; Higgins et al., 2012).  
The overall aim of this project is to assess the role of CIZ1 in regulation of DNA replication. In 
particular, the role of CIZ1 in establishing the threshold of cyclin A-CDK2 that promotes 
initiation of DNA replication. To evaluate the effect of differential cyclin A-CDK2 cell free DNA 
replication approaches will be used. The rate of DNA replication will be determined using 
DNA combing using cell free and cell-based approaches. 
A CIZ1 KO fibroblast cell line will be produced to further investigate the role that CIZ1 plays in 
the initiation of DNA replication and DNA replication fork dynamics. Hoping to identify a link 
between CIZ1 and DNA replication kinetics, to identify if this is a potential mechanism that 
underpins CIZ1’s role in cancers. The principal experimental aims of this project are: 
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• Optimise the DNA combing technique for use in NIH 3T3 cells, and in vitro cell free 
replication assays (Chapter 3) 
• Generate CIZ1 null cells using CRISPR CAS9 (Chapter 4) 
• Identify alterations in cell cycle regulation upon loss of CIZ1 (Chapter 4) 
• Investigate links between CIZ1 and Cyclin A/CDK2 activity at the G1/S transition 
(Chapter 5)  
• Identify any alterations to the replication programme upon loss of CIZ1 (Chapter 6) 








Chapter 2.             




2.1 E. coli 
2.1.1. Bacterial Cell Culture 
To ensure aseptic technique all E. coli culture media was sterilised by autoclaving prior to 
use. All bacterial cell culture was performed in a laminar flow hood. 
E. coli were grown in 10 ml primary culture of LB broth (MELFORD) (10 g/L tryptone, 10 g/L 
sodium chloride, 5 g/L yeast extract) supplemented with appropriate antibiotics and grown 
overnight at 37 °C, 150 rpm. Where required, primary cultures were inoculated into 75 ml 
cultures of LB broth supplemented with appropriate antibiotics. For bacteria transformed 
with pGEX-6P-3 plasmids or its derivatives LB liquid cultures and LB agar plates were 
supplemented with 100 µg/ml ampicillin (Melford). Top10 cells transformed with the 
GeneArt® CRISPR Nuclease Vector were grown on LB agar plates supplemented with 100 
µg/ml ampicillin (Melford).  
E. coli were grown on LB agar (Fisher Scientific, 40 g/l) plates at 37 °C. Bacteria were spread 
or streaked onto LB agar plates supplemented with appropriate antibiotics.  
2.1.2. Preparing Competent Cells 
BL21 (DE3) cells from an existing glycerol stock were grown overnight at 37 °C in a 5 ml LB 
broth culture. The following day, a 75 ml secondary culture was inoculated and grown for 
approximately two hours. The OD600 was measured every half hour until it reached 0.3 – 
0.4. When the OD600 had reached 0.3 the bacterial culture was centrifuged for 10 minutes 
at 3000 rpm at 4 °C in an MSE Harrier 18/80R centrifuge. 
The supernatant was discarded and the bacterial pellet was re-suspended in 30 ml of ice 
cold, filter sterilised CCMB80 buffer (10 mM potassium acetate, 80 mM CaCl2, 20 mM MnCl2, 
10 mM MgCl2, 10% v/v glycerol). The bacteria was incubated on ice for 20 minutes. After 
incubation, the bacteria were centrifuged for 10 minutes at 3000 rpm at 4 °C in an MSE 
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Harrier 18/80R centrifuge. The supernatant was discarded and the bacterial pellet was re-
suspended in 4 ml of ice cold, filter sterilised CCMB80 buffer. Competent cells were stored in 
50 µl aliquots at -80 °C.  
Competent cells were tested by transformation with pGEX-6P-3 relative to a negative control 
plate. After transformation cells were grown on plates containing 100 µg/ml ampicillin 
(Melford) cells were deemed competent if sufficient growth on transformed cells, and no 
growth on control cells. Cells were also tested for ability to express recombinant protein 
using an IPTG induction.  
2.1.3. Bacterial Transformation  
100 ng of plasmid DNA was added to 50 µl of competent cells (prepared as in Section 2.1.3.) 
on ice for half an hour. Following incubation, the transformation mixture was heat shocked 
at 42 °C in a heat block for 2 minutes. Samples were then placed on ice for 5 minutes. 
Samples were mixed with 300 µl of super optimal broth with catabolite repression (SOC) 
media (Invitrogen) and incubated whilst shaking at 37 °C for 1 hour. Following incubation, 
the transformation mixture was spread onto LB agar plates supplemented with appropriate 
antibiotics (100 µg/ml ampicillin or 50 µg/ml kanamycin) as appropriate.  
2.1.4. Inducing Recombinant Protein Expression using IPTG 
BL21 (DE3) cells were transformed with PGEX-6P-3 plasmids with appropriate inserts as. 
After overnight incubation colonies were selected and inoculated into 5 ml of LB broth 
supplemented with appropriate antibiotics and incubated at 37 °C overnight. The bacterial 
culture was transferred to 75 ml of LB broth supplemented with appropriate antibiotics and 
incubated at 37 °C. After 1 hour, 1 ml of bacterial culture was taken and its OD600 measured 
using a spectrophotometer using LB broth as a blank. This was repeated every 30 minutes 
until the OD600 reached between 0.4 – 0.6.  
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When the OD600 was between 0.4 and 0.6, 1 ml of the bacterial culture was removed 
centrifuged and re-suspended in SDS-PAGE loading buffer. IPTG was added to the bacterial 
culture at a concentration of 0.4 µM. Every hour for 3 hours 1 ml of bacteria was removed, 
centrifuged, and prepared for SDS-PAGE.  
2.1.5. Inducing Recombinant Protein Using Auto induction Media 
To ensure that protein was expressed in a correctly folded soluble form, expression of 
recombinant protein is slowed by incubation of bacteria at 20 °C for 20 hours in auto 
induction media (Table 2.1) which slows the rate of protein expression. E. coli transformed 
with a pGEX-6P-3 plasmid with appropriate inserts were grown overnight in 5 ml LB broth. 5 
ml of the primary culture were inoculated into 75 ml of LB broth and grown overnight. The 
75 ml culture was added to 750 ml of autoinduction media and cultured overnight. Bacteria 
were harvested after 16-20 hours. 
Component Concentration 
Ammonium Sulphate  25 mM  
Potassium Phosphate 50 mM  
Sodium Phosphate 50 mM  
Glycerol 5 g/l 
Glucose 2.78 mM  
α Lactose  5.84 mM  
MgSO4 1 mM  
FeCl3 50 µM 
CaCl2 20 µM 
MnCl2 10 µM 
ZnSO4 10 µM 
CoCl2 2 µM 
CuCl2 2 µM 
NiCl2 2 µM 
Na2MoO4 2 µM 
Na2SeO3 2 µM 
H3BO3 2 µM 
Tryptone 10 g/l 
Yeast Extract 5 g/l 
Ampicillin 100 µg/ml 
Table 2.1 – Recipe of auto induction broth 
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2.1.6. Purification of recombinant GST Tagged Proteins 
Bacteria were sub—cultured in 5 ml cultures prior to being grown overnight in auto-
induction media. All steps were performed at 4 °C, or on ice. Bacteria were harvested by 
centrifugation using a JLA 8.1000 rotor (Beckman Coulter) at 4500 RPM for 15 minutes in an 
Avanti J-26 XP centrifuge. If bacteria were to be stored for later purification bacteria pellets 
were resuspended in 25 ml of supernatant, placed into a 50 ml falcon tube, centrifuged at 
4500 RPM for 15 minutes, supernatant discarded and pellets were flash frozen in liquid 
nitrogen then stored at -80 °C.  
Pellets were re-suspended in 25 ml of HEPES buffered saline (HBS) (50 mM HEPES pH 7.8, 
135 mM NaCl, 3 mM EDTA, 1 mM DTT) supplemented with 2 cOmplete™ EDTA-free Protease 
Inhibitor Cocktail tablets (ROCHE), and 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma 
Aldrich). Concurrently, 750 µl of glutathione sepharose beads were re-suspended in 50 ml of 
HBS and incubated on a roller for 1 hour.  
To lyse the E. coli, cells were sonicated four times for 15 seconds with a 1 minute rest 
between each sonication to prevent heating. Lysed bacteria was centrifuged at 40,000 x g for 
30 minutes using a JA-25.50 Rotor (Beckman Coulter) in an Avanti J-26 XP centrifuge and cell 
lysate removed. Glutathione sepharose beads were rehydrated by incubation in buffer for 30 
minutes in HBS. After swelling, beads were harvested by centrifugation at 1000 RPM for 1 
minute, and discarding supernatant. The cell lysate was mixed with glutathione sepharose 
beads an incubated for 1 hour on a vertical rotator. 
Beads were washed 5 times in 10 ml HBS supplemented with 1 mM DTT, and cOmplete™ 
EDTA-free Protease Inhibitor centrifuging bead solution at 1,000 RPM for 1 minute between 
each wash and discarding supernatant. Beads were washed 3 times in 10 ml 3C cleavage 
buffer (50 mM Tris HCl pH 7.0, 150 mM NaCl, 2 mM DTT). Beads were transferred to 1.5 ml 
Eppendorf tubes and filled up to capacity with 3C buffer. After the final wash a 50 µl sample 
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was removed for analysis by SDS-PAGE. 10 µl of PreScission 3C Protease (GE Healthcare Life 
Science) was added and samples were incubated overnight on a vertical rotor.  
Following proteolysis, beads were removed from solution by two 6 second pulse 
centrifugations through Pierce spin columns (Thermo Fisher Scientific). 50 µl Samples of 
beads, and supernatant were removed for analysis using SDS-PAGE. Protein was stored in 20 
µl aliquots in liquid nitrogen.  
2.1.7. Quantifying Protein Concentration  
Protein concentration was calculated using the protocol outlined in the Pierce BCA protein 
assay kit (Thermo Scientific). 
2.1.8. Purifying Plasmid DNA from E. coli 
E. coli were prepared from glycerol stocks or fresh transformations. 10 ml of bacteria was 
grown overnight at 37 °C in LB broth. Bacteria were harvested by centrifugation at 4500 RPM 
for 10 minutes. Plasmid DNA was isolated following the protocol outline in the GeneJET 
plasmid miniprep kit (Thermo Fisher Scientific). When higher concentrations of DNA were 
required plasmids were eluted in 25 µl elution buffer.  
2.1.9 Quantifying DNA Concentration  
DNA concentration was measured using a NanoDrop 2000c spectrophotometer (Thermo 
Fisher Scientific) following manufacturer’s instructions.  
2.1.10 Ethanol Precipitation  
To increase DNA concentrations after miniprep or gel extraction ethanol precipitations were 
used. The volume of the sample was determined and 0.1 volumes of 3 M sodium acetate (pH 
5.2), and 3 volumes of 100% ethanol were added. Samples were incubated at -20 oC 
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overnight, centrifuged at 14,000 x g for 30 minutes. Pelleted DNA was rinsed with 100 µl of 
70 % ethanol. Samples were centrifuged at 14,000 x g for 15 minutes. The supernatant was 
removed, pellets were air dried for 15 minutes on ice to allow remaining ethanol to 
evaporate. DNA was dissolved in tris acetate ESTA (TAE) (40 mM Tris-acetate, 1 mM EDTA, 
pH 8.3)  to produced desired concentration.  
2.1.11. Agarose Gel Electrophoresis 
DNA samples were prepared in 6 x DNA loading buffer (NEB), mixing one part loading buffer 
with 5 parts of DNA sample. Agarose gels were prepared by dissolving agarose in Tris borate 
EDTA solution (TBE) (89 mM Tris borate, 2 mM EDTA, pH 8.3). Agarose was dissolved by 
heating in a microwave, replacing any water lost through boiling. 0.01 % (v/v) gel red, or 
SYBR safe was added when the agarose solution had cooled sufficiently. Agarose was poured 
into a gel tank and left to set, with appropriate comb. Samples were loaded into wells along 
with a DNA ladder (as indicated in figure). Gels were run in TBE buffer at 120 V for 90 
minutes, or until the dye reached the end of the gel. Gels were imaged using the Bio-Rad 
Chemidoc MP imaging system 
2.1.12. Gel Extraction  
DNA from agarose gels was isolated using the protocol outlined in the GeneJET gel extraction 
kit (Thermo Fisher Scientific).  
2.1.13. Restriction Digests 
All restriction enzymes were purchased from New England Biolabs. 1 µg of DNA was digested 




PCR reactions were prepared using the PfuUltra II Fusion HS DNA Polymerase (Agilent) 
following manufacturer’s instructions. PCR conditions were different between primers and 
templates using manufacturer’s optimised program templates.  
2.2. Protein Extraction and SDS-PAGE 
2.2.1. Casting SDS-PAGE gels  
Gels were casted using the Bio-Rad Mini-PROTEAN® tetra handset system. Resolving gels 
were prepared using a specified concentration of polyacrylamide (typically 10 % (v/v)), 0.38 
M Tris pH 8.8, 0.1 % w/v sodium dodecyl sulphate (SDS), 0.06 % w/v ammonium persulphate 
(sigma). 10 µl of Tetramethylethylenediamine (TEMED) was added prior to pouring. Gels 
were poured between spacer plates; a thin layer of isopropanol was added on top to remove 
bubbles. After the resolving gel had set, isopropanol was removed using filter paper. A 
stacking gel was prepared with concentration 5 % v/v polyacrylamide, 83 mM Tris pH 6.8, 
0.07 % w/v SDS, 0.03 % w/v APS. Directly prior to pouring, 5 µl of TEMED was added. A 10 or 
15 well comb was added and the gel was allowed to set. Gels were used immediately or 
stored at 4 °C wrapped in wet blue roll and saran wrap.  
2.2.2. SDS-PAGE 
Samples were run on either a 4–15% Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad) or 
10 % self-cast gels resolving gels with 5 % stacking gels (Section 2.2.1.). Gels were run in a 
Mini-PROTEAN Tetra Cell tank (Bio-Rad). Mini-PROTEAN® TGX™ Precast Protein Gels at 200 V 
for approximately 35 minutes, or until dye front reached the base of the gel. Hand casted 




2.2.3. Staining SDS-PAGE Gels 
Protein on gels were stained with the ThermoFisher Scientific GelCode blue safe protein 
stain, or InstantBlue® Coomassie Protein Stain (Abcam). 
2.2.4. Isolation of Protein from 15 cm and 10 cm Cell Culture Plates  
Media was removed from plates. Cells were rinsed in 10 ml (5 ml for 10 cm plates) PBS 
supplemented with 1 mM DTT and aspirated. Cells were incubated in 10 ml (5 ml for 10 cm 
plates) PBS, 1 mM DTT at 4 °C for 5 minutes. PBS 1 mM DTT was removed, and plates were 
placed at 45 ° and incubated at 4 °C for 5 minutes. Remaining pooled buffer was aspirated, 
cells were scraped using a cell scraper to the bottom of the plate until all cells had been 
visibly removed from the surface. Cells slurry was collected, and the total volume was made 
up to 200 µl (100 µl for 5 cm plates) with buffer. 80 µl (40 µl for 5 cm plates) of 4 x loading 
buffer was added and PMSF to 1 µM. Samples were boiled at 95 °C for 10 minutes and 
stored at -20 °C. 
2.2.5. Isolation of Cytosolic and Chromatin Fractions Through CSK Fractionation  
To isolate cytosolic and chromatin fractions, cells were incubated in cytoskeletal buffer (CSK, 
10 mM PIPES pH 6.8, 100 mM NaCl, 300 mM sucrose, 1 mM EDTA, 1 mM MgCl2, 1 mM DTT, 
ROCHE complete Protease inhibitors) and harvested by scrape harvesting (Section 2.2.4.)  
Cell slurry was split equally into two tubes. One was the total protein sample, and 40 µl (20 
for 10 cm plates) of 4x SDS-PAGE loading buffer and 1 mM PMSF was added, prior to heating 
to 95 °C for 10 minutes. The other tube was used to separate the chromatin and cytosolic 
fractions. Cytosolic and chromatin fractions were isolated by addition of 5 µL 10 % (v/v) 
Triton X-100 for 5 minutes on ice, centrifuged at 14,000 x g for 5 minutes. 40 µl 4X SDS-PAGE 
loading buffer and 1 mM PMSF were added to the supernatant (cytosolic and nucleosolic 
proteins). The pellet (Chromatin) was resuspended directly in 100 µl 4X SDS-PAGE loading 
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buffer and 1 mM PMSF. Samples were heated to 95 °C for 10 minutes. Samples were stored 
at -20 °C. 
2.2.6. Isolating Whole cell extracts from 6 Well Plates 
Media was aspirated from wells; wells were washed with 1 ml PBS and 100 µl of 1 x SDS-
PAGE loading buffer supplemented with 1 mM PMSF and protease inhibitors were added to 
wells. Cells were incubated at room temperature for 10 minutes on a rocker, rotating the 
plate by 90 ° halfway though. Plates were placed at 45 ° for 2 minutes. Whole cell extracts 
(WCE) were collected by pipetting against the surface of the well 3 times to ensure 
separation. Samples were incubated at 95 °C for 10 minutes. Samples were stored at -20 °C.  
2.3. Western Blotting 
2.3.1. Transferring Protein to Membranes  
2.3.1a. Transferring Protein to Nitrocellulose Membrane  
For western blot analysis proteins were run on SDS-PAGE then transferred to an Amersham™ 
Protran™ 0.45 µm nitrocellulose blotting membrane (GE Healthcare Life Sciences) using a 
semi dry transfer system. 8 pieces of filter paper and 1 piece of nitrocellulose membrane was 
cut for each gel (9 cm x 7 cm per gel). Filter paper, membrane, and protein gels were each 
soaked in transfer buffer: 0.75 mM Trizma® base (Sigma Aldrich), 10 µM CAPS (Sigma 
Aldrich), 10 % (v/v) ethanol, 0.01 % (w/v) SDS. 4 layers of filter paper were stacked on the 
base of the transfer system, then the nitrocellulose membrane, SDS-PAGE gel, and the final 4 
filter paper layers. Protein transfers were run at 1 mA/cm2 for 90 minutes. 
2.3.1b. Transferring Protein to a Polyvinylidene Difluoride (PVDF) Membrane   
For western blot analysis proteins were run on SDS-PAGE then transferred to an Amersham 
Hybond P 0.2 PVDF western blotting membrane (GE Healthcare Life Sciences) using a semi 
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dry transfer system. Filter paper and membrane were prepared as in 2.3.1a. Membrane was 
hydrated in 98 % ethanol and soaked in transfer buffer (0.75 mM Trizma® base (Sigma 
Aldrich), 10 µM CAPS (Sigma Aldrich), 10 % (v/v) ethanol, 0.01 % (w/v) SDS) for 5 minutes. 
Components were stacked and transferred as in 2.3.1a.  
2.3.2. Probing Membranes 
Following transfer, membranes were blocked for 1 hour in 50 ml falcon tubes in 10 ml of 
blocking buffer (1 % (w/v) BSA, 0.05 M Tris (Sigma-Aldrich), 0.138 M NaCl (Sigma Aldrich), 
0.0027 M KCl (Sigma Aldrich), 0.1% Tween-20), pH 8.0) on a roller. Following blocking, 
membranes were incubated with primary antibody at appropriate concentration (Table 2.2), 
in 5 ml of blocking buffer overnight at 4 °C. After the primary antibody incubation, 
membranes were washed 4 times for 5 minutes in 5 ml of blocking buffer. 5 ml of blocking 
buffer with an appropriate concentration of HRP conjugated secondary antibody was added 
for 1 hour. Membranes were washed 4 times for 5 minutes in 5 ml of washing buffer (0.05 M 
Tris (Sigma-Aldrich), 0.138 M NaCl (Sigma Aldrich), 0.0027 M KCl (Sigma Aldrich), 0.1% 
Tween-20 (supplier), pH 8.0). 
Western blots were developed with the Bio-Rad Chemidoc MP imaging system. Blots were 
developed using Westar EtaC 2.0 or Westar supernova (Cyanogen) reagents. Developing 
times varied across different antibodies and samples.  
2.3.3. Normalising Loads Across Western Blot Samples 
Protein levels were equalised across western blots by comparing the levels of actin in cellular 
samples, and histone H3 in chromatin bound fractions, and in vitro experiments. Samples 
were loaded on SDS-PAGE gels at equal volumes, typically 10 µl. SDS-PAGE gels were 
prepared and separated protein transferred to a nitrocellulose membrane. Blots were 
probed for actin or histone H3 and developed. Using the image lab software (BIO RAD) the 
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signal intensity was compared. To alter the volume to achieve equal loads values were 
standardising to the highest load and altering volumes loaded inversely proportionally. Gels 
for probing were reloaded with the altered volumes.  
 
2.3.4. Antibodies 
Antigen Raised in  Usable Concentration (v/v) Supplier 
Rabbit IgG (HRP 
conjugated) 
Goat 0.02 % Abcam 
Mouse IgG (HRP 
conjugated)  
Goat 0.02 % Sigma 
MCM2 Mouse 0.2 % BD biosciences 
CIZ1 Rabbit 0.05 % Covalabs – 
generated 2015. 
Cyclin A Mouse 0.2 % Abcam Ab38 
Cyclin E Mouse 0.2 % Santa Cruz 
biotechnology 
(HE12) 
CDC6 Mouse 0.2 % Santa Cruz 
Biotechology 
(sc-9964) 
PCNA Mouse 0.2 % Santa Cruz 
Biotechology 
(sc56) 
Actin Mouse 0.05 %  Sigma 
Histone H3 Rabbit  0.01 %  Abcam 
Table 2.2.-Western blot antibodies, suppliers, targets, and species.  
2.4. Mammalian Cell Culture 
2.4.1. Growing Mammalian Cells 
All passaging of cells was performed in a laminar flow hood using appropriate aseptic 
technique. Both S3 HeLa cells and NIH 3T3 cell were grown in GIBCO Dulbecco’s modified 
eagle medium (DMEM) (1 g/l glucose, with pyruvate and glutaMAX), 10 % (v/v) labtech FBS, 
1 % (v/v) GIBCO 100x penicillin streptomycin glutamine. A ThermoFisher Scientific Heracell 
150i incubator was used. Cells were grown at 37 °C. 
62 
 
2.4.2. Passaging Mammalian Cells 
Cells were passaged every 2 or 3 days unless being synchronised by quiescent release. Media 
was removed by serological pipetting and washing in 10 ml of D-PBS (GIBCO). Cells were then 
incubated in 10 ml of 0.05 % trypsin-EDTA (GIBCO) solution in D-PBS until cells no longer 
adhered to the base of plates (if being release from confluence a 0.1 % trypsin-EDTA solution 
was used for 4-5 minutes). The trypsin cell solution was split across the required number of 
plates containing 30 ml of DMEM.  
2.4.3. Freezing Mammalian Cell Stocks 
Cells were grown to approximately 50 % density in 15 cm dishes for general cell culture, or in 
6 well plates for CRISPR-Cas9 treated cells prior to selection. For 15 cm plates, cells were 
washed in 10 ml of DPBS. Cells were trypsinised as described (Section 2.5.2). Cells were 
added to 10 ml D-MEM, inactivating the trypsin. The cell suspension was centrifuged at 500 x 
g for 5 minutes, the media was removed by pouring, the remaining cells were centrifuged at 
500 x g for 1 minute, the remainder of media was removed by pipetting. The cell pellet was 
re-suspended in 15 ml of a 5 % (v/v) solution of dimethyl sulfoxide (DMSO) (SIGMA-Aldrich) 
in DMEM. Cells were separated into 1 ml aliquots in cryotubes. Cryotubes were added to a 
Mr. Frosty™ freezing container (Thermo Fisher Scientific) and frozen overnight at -80 °C and 
transferred to liquid nitrogen for long-term storage. The procedure for freezing cells from 6 
well plates is identical, excluding PBS washes and trypsinisation were done in 2 ml, the cell 
trypsin solution was quenched in 2 ml of DMEM and only one 1 ml aliquot of each cell type 
was frozen.  
2.4.4. Double Thymidine Arrest of HeLa Cells and S phase Synchrony 
To produce S-phase cytosolic extracts for cell free replication assays the double thymidine 
synchrony method was used. For S phase synchrony of HeLa S3 cells were grown to 70 % 
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density in 15 cm cell culture dishes. Upon reaching the desired density, cells were incubated 
for 24 hours in 30 ml of DMEM and 2.5 mM thymidine (SIGMA ALDRICH). Following 
incubation, cells were washed in 10 ml DPBS, then 30 ml of fresh DMEM was added and cells 
incubated for 8 hours (Section 2.5.1). Following incubation, cells were washed in 10 ml of 
DPBS, buffer aspirated, 30 ml of DMEM + 2.5 mM thymidine was added and cells incubated 
for 16 hours. Following incubation, cells were washed in 10 ml DPBS, then 30 ml of fresh 
DMEM was added, this was treated as the 0 hour time point.  
2.4.5. Quiescence Synchronisation of NIH 3T3 Cells  
To produce a synchronous G1 population of NIH 3T3 cells, they were synchronised in G0 by 
contact inhibition and serum depletion. Cells were cultured in 15 cm plates until they 
reached quiescence. Once confluent, media was replaced and cells incubated for a further 48 
hours. Cells were then passaged either 1 in 4 on 15 cm plates, or 1 in 10 on 9 cm plates. This 
was treated as the 0 hour time point. Cells were harvested at 15 hours for reactions using G1 
extracts or 17.5 hours for the production of late G1 nuclei for use in cell free assays. 
2.4.6. EdU Labelling Fluorescence microscopy 
EdU labelling was performed to measure the proportion of cells in S phase through 
fluorescence microscopy. Cells were grown in plates containing autoclaved coverslips. Cells 
were incubated with 10 µM EdU (Thermo Fisher Scientific) 30 minutes (1 hour for flow 
samples) before harvesting coverslips were removed and placed in 24 well plates. Coverslips 
were removed and washed 3 x 3 minutes in 1 ml PBS. Coverslips were fixed with 0.2 ml 4 % 
PFA in PBS for 15 minutes at room temperature. PFA was removed and coverslips washed 3 x 
3 minutes with 1 ml PBS. 
EdU was fluorescently labelled using the Click-iT™ EdU Cell Proliferation Kit for Imaging 
(Thermo Fisher Scientific). Alexa Fluor 555 azide and Alexa Fluor 488 azide were used as 
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indicated. After labelling and washing coverslips were mounted onto glass slides with 
VECTASHIELD® Antifade Mounting Media with DAPI (Vector Laboratories).  
EdU labelled and GFP fluorescent cells were imaged using a Zeiss Scope A1 fluorescent 
microscope. DAPI, Alexafluor 555, and GFP were imaged using the red, blue, and green filters 
respectively. Multi-channel images were generated using the Zeiss Zen software add channel 
process.   
 2.4.7. Cell cycle analysis with EdU Labelling by Flow Cytometry 
1 hour before harvesting cells EdU was added to the media at a final concentration of 10 µM. 
Cells were harvested by trypsinisation. Cell solution was quenched in 5 ml DMEM. Cells were 
centrifuged at 500 x g for 5 minutes. Pellets were washed 3 times in 1 % BSA PBS 
centrifuging for 5 minutes at 500 x g after each wash. Cells were permeabilised in 0.5 % 
triton X-100 for 20 minutes at 4 °C. Cells were centrifuged and washed 3 times in 1 % BSA 
PBS and centrifuged after each wash. Cells were labelled with 500 µl of EdU labelling cocktail 
(from alexa fluor 488 azide Click-iT™ EdU Cell Proliferation Kit) for 30 minutes at 4 °C. Cells 
were washed 3 times in 0.1 % Triton X-100 in PBS and centrifuged after each wash. 
Propidium Iodide was added to a concentration of 50 µg/ml. Cells were imaged using a 
Beckman Coulter CytoFLEX. 
2.4.8. Mycoplasma Testing 
Quarterly mycoplasma tests were performed as well as tests after generation of each new 
cell line. Tests were performed using the MycoAlert mycoplasma detection kit (Lonza). Upon 




2.5. in vitro DNA Replication Assays 
2.5.1. Preparation of replication competent nuclei 
Five 15 cm plates of NIH 3T3 cells were synchronised in G0. Nuclei were harvested 17.5 hours 
after release from quiescence and cytosolic extracts 15 hours after release from quiescence. 
All steps were performed at 4 °C. Cells were washed in 10 ml of hypotonic buffer (20 mM 
HEPES (pH 7.8), 15 mM potassium acetate, 0.5 mM MgCl2, 1 mM DTT), cells were incubated 
in 10 ml of hypotonic buffer for 5 minutes. Hypotonic buffer was removed and plates were 
left at an angle for a further 5 minutes. Any excess buffer was discarded and cells were 
scraped and harvested. Cells were dounce homogenised 7 times using the tight pestle and 
centrifuged for 5 minutes at 6000 RPM. The cytosolic extract was removed and the nuclei 
pellet was re-suspended in an equal volume (~200 µl) of hypotonic buffer. Nuclei were flash 
frozen and stored in 10 µl aliquots in liquid nitrogen.  
2.5.2. Preparation of G1 Extracts from NIH 3T3 Cells 
G1 extracts were prepared in the same manner as replication competent nuclei. Key 
differences were extracts were isolated at the 15.5 hour time point, cells were dounce 
homogenised 25 times, centrifugation was done at 14000 RPM for 15 minutes, and 
supernatant was stored discarding the pellet. Extracts were flash frozen and stored in 50 µl 
aliquots in liquid nitrogen. 
2.5.3. Preparation of S Phase Extracts from HeLa Cells 
S phase extracts were isolated in the same manner as G1 extracts using double thymidine 
synchronisation (section 2.5.4). Extracts were isolated from 20 plates of S3 HeLa cells 1 hour 
after release from a double thymidine block. Extracts were flash frozen and stored in 50 µl 
aliquots in liquid nitrogen. 
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2.5.4. Preparation of 10x Premix Solution 
10 x premix solutions were prepared to a final concentration of: 40 mM HEPES, pH 7.8, 7 mM 
MgCl2, 1 mM DTT, 40 mM phosphocreatine (CALBIOCHEM/MERCK), 3 mM ATP, 0.1 mM GTP, 
0.1 mM CTP, 0.1 mM UTP, 0.1 mM dATP, 0.1 mM dGTP, 0.1 mM dCTP. All nucleotides were 
added slowly to avoid unresolvable precipitation.  
2.5.5. Preparation of Creatine phosphokinase (CPK) Buffer 
CPK buffer was prepare with the following concentrations: 40 mM HEPES, pH 7.8, 7 mM 
MgCl2, 1 mM DTT.  
2.5.6. In vitro Cell Free DNA Replication Reactions  
The volume of in vitro reactions changed depending on the experiment. Samples for 
counting using epifluorescence microscopy were typically from 10 µl reactions, Samples for 
analysis via western blotting or DNA combing were typically from 50 µl reactions. The ratio 
of each component added to each in vitro reaction are displayed in Table 2.3 Any protein or 
small molecule added to reactions were dissolved in CPK buffer.  
 
Component Ratio to extract 
0.1 M MgCl2 1:50 
10 µg/ml creatine phosphokinase (CPK) 1:50 
Biotin-16-dUTP  1:50 
Premix Solution 1:10 




Reactions were performed at 37 °C for 30 minutes. For analysis by Western blot, one third of 
the volume was removed and prepared for SDS-PAGE this was the total protein. 2 µL of 10 % 
(v/v) Triton X-100 was added to the remaining sample for 2 minutes, sample centrifuged at 
12,000 x g for 5 minutes. The supernatant was removed and 20 µL 4 x SDS-PAGE buffer prior 
to heating to 95 for 10 minutes. The chromatin pellet was re-suspended in 30 µL 4 x SDS-
PAGE buffer mixed with 90 µl of hypotonic buffer prior to heating to 95 °C for 10 minutes 
and samples stored at -20 °C until use. 
2.6 CRISPR/Cas9 
2.6.1. Primer Design 
DNA oligonucleotide primers were designed by identifying protospacer adjacent motif (PAM) 
sequences early in the gene desired to be knocked out. PAM sequences are the target for the 
Cas9 nuclease they have the sequence NGG where N is any nucleotide. 20 nucleotides 
directly 5’ of the chosen PAM sites were used as the template for the CRISPR primers. For 
insertion into the GeneArt® CRISPR nuclease vector (thermofisher) a 3’ overhang was added 
with sequence GTTTT. For the complimentary oligonucleotide the 20 nucleotide target 
sequence was reverse transcribed. For insertion into the GeneArt® CRISPR nuclease vector 
(thermofisher) a 3’ overhang was added with sequence CGGTG. DNA Oligonucleotides were 
synthesised by and purchased from Eurofins genomics. The 4 oligo nucleotides designed for 
generating CIZ1 knockout NIH3T3 cells are displayed in Table 2.4. 
DNA Oligonucleotide 
Name 
DNA Oligonucleotide Sequence  
CIZ1 KO1 for 5’ - TTGCTCCTACAGCAGTTGCAGTTTT- 3’ 
CIZ1 KO1 rev 5’ -TCGAACTGCTGTAGGAGCAACGGTG - 3’ 
CIZ1 KO2 for  5’ - CAAGGTATGGCAGTTCCCCGGTTTT - 3’ 
CIZ1 KO2 rev 5’ - CGGGGAACTGCCATACCTTGCGGTG - 3’ 
Table 2.4 – Primers Used for Generating CIZ1 Cells Using CRISPR Cas9 
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2.6.2. Annealing Complimentary Oligonucleotides 
Oligonucleotides were dissolved in ultrapure DNase free water to yield a concentration of 
200 µM. 5 µl of each primer were mixed with oligonucleotide annealing buffer and made up 
to 10 µl in DNAse/RNase free water. Reaction mixtures were heated for 4 minutes at 95 °C 
then left at room temperature for 10 minutes. Once annealed the double stranded oligo 
nucleotides were serially diluted from 50 µM to 5 nM in oligonucleotide annealing buffer. 
The 5 nM solution was either used or stored at -20 °C. 
2.6.3. Ligating Double Stranded Oligonucleotides into the GeneArt® CRISPR Nuclease 
Vector 
20 µl ligation mixtures were prepared in DNase/RNase free water with concentrations 50 
mM Tris HCl, pH 7.6, 10 mM MgCl2, 1 mM ATP, 1 mM DTT, 5% (w/v) polyethylene glycol-
8000, 1.5 ng/µl linearized CRISPR nuclease vector, 1 mM Tris HCl, pH 8, 100 µM EDTA, pH 8, 
0.5 nM double stranded oligonucleotide. Ligation mixtures were gently mixed, then 
incubated at room temperature for 10 minutes. Ligation mixtures were transformed into 
TOP10 E. coli competent cells using the procedure outlined in Section 2.1.4. 
2.6.4. Purifying Plasmid DNA 
Single colonies were picked from LB agar plates following transformation and inoculated into 
5 ml of LB broth supplemented with 100 µg/ml ampicillin and grown overnight at 37 °C. 
Plasmid DNA was purified from top 10 E. coli using the Thermo Fisher Scientific Gene JET 
plasmid Miniprep kit. Plasmid concentration was quantified using a Thermo Fisher Scientific 
nano drop 2000c spectrophotometer.  
2.6.5. Sequencing GeneArt® CRISPR Nuclease Vector  
Sequences inserted into the linearized GeneArt® CRISPR Nuclease Vector to be sent to be 
sequenced were diluted to 50 – 100 ng/µl. Diluted plasmids were sequenced by eurofins 
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genomics using the U6 forward primer. The sequence of the U6 forward primer (5’ - 
GGACTATCATATGCTTACCG – 3’ ). 
2.6.6. Transfection of NIH3T3 Cells 
NIH 3T3 cell transfection was performed using the Amaxa® Cell Line Nucleofector® Kit R 
(Lonza). NIH 3T3 cells were grown to between 70 – 80 % confluence, cells trypsinised, and 
trypsin quenched with 5 ml of DMEM. Cells were harvested by centrifugation at 500 x g for 5 
minutes, supernatant was removed, and then centrifuged for a further minute at 500 x g, 
and remaining supernatant removed. Cells were re-suspended in 100 µl of Kit R solution with 
2µl DNA and transferred to electro cuvettes. Cells were transfected using the NIH 3T3 
programme (U-030) using the Lonza nucleofector 2b electroporation system. Transfected 
cells were added to 30 ml of DMEM, plated on to 15 cm dishes and incubated. 
2.6.7. Enrichment of Transfected CRISPR Cas9 Cells  
24 hours following transection with the GeneArt® CRISPR Nuclease Vector cells were to be 
selected and enriched. Successfully transfected cells were selected using CD4 expression. 
Cells were harvested by trypsinisation and centrifugation at 500 x g for 5 minutes. Cells were 
suspended in 2 ml of enrichment buffer (PBS, 0.1 % BSA, 2 mM EDTA) and centrifuged, this 
was repeated a further two times. After the final centrifugation cells were resuspended in 50 
µl of enrichment buffer. Concurrently, 25 µl of Dynabeads® CD4 magnetic beads (Thermo 
Fisher Scientfic) were placed on a magnetic separator for 1 minute, the supernatant was 
discarded and beads resuspended in 100 µl of enrichment buffer. The beads were placed on 
a magnetic separator, supernatant removed and resuspended in 25 µl of enrichment buffer. 
The cells and beads were added together and made up to 1 ml with enrichment buffer. The 
bead cell mixture was incubated at 4 °C on a rotator for 30 minutes.  
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Cells were placed on a magnetic separator for 1 minute, the supernatant was discarded and 
cells were re-suspended in 500 µl of enrichment buffer. This process was repeated 6 times. 
Cells were placed on a magnetic separator for 1 minute, beads re-suspended in 100 µl of 
DMEM and 10 µl DETACHaBEAD® CD4 for 45 minutes on a rotator. The supernatant was 
removed and stored; beads were washed in 500 µl of DMEM 3 times recovering the 
supernatant each time. Supernatants were made up to 4 ml and centrifuged at 500 X g for 5 
minutes. Pellets were re-suspended in DMEM, cells were counted and diluted to 
approximately 5 cells/ml. Cells were plated into 96 well plates and incubated at 37 °C.  
24 hours after enrichment, the number of cells in each well was determined by microscopy. 
Wells that contained single cells were selected to be grown further. They were grown up to 9 
cm plates via 24 well plates and 6 well plates. At this stage cells were frozen for storage in 
liquid nitrogen and cells were prepared for SDS-PAGE to determine which cells were CIZ1 
knock outs.  
2.7 DNA Combing 
2.7.1. Pulse Labelling of Cells 
This describes a basic pulse labelling; timings of pulses were typically 20 minutes  for each 
nucleotide. However, incubation may vary and this will be indicated in the figure in the 
experimental design image.  
2.7.1a. Dual labelling with IdU and CldU 
Cells were cultured to 70-80 % confluence. Media replaced with 30 ml media supplemented 
with 25 µM iododeoxyuridine (IdU) and incubated for 20 minutes. Media was removed, cells 
were washed with 10 ml PBS. Cells were incubated in 30 ml of DMEM media + 250 µM 
chlorodeoxyuridine (CldU) for 20 minutes. Cells were then harvested by trypsinisation, and  
quenched in 5 ml DMEM. Cells were centrifuged at 500 x g for 5 minutes. Supernatant was 
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discarded, and cells were centrifuged at 500 x g for 1 minute to remove remaining media. 
Cell pellets were encapsulated in agarose (Section 2.8.4).  
2.7.1b. Single Labelling with EdU  
Cells were prepared for DNA combing as in section2.8.1a, except cells were incubated in 30 
ml of DMEM supplemented with 10 µM EdU for 1 hour at 37 °C to label DNA, all other steps 
were identical.  
2.7.2. Pulse Labelling of Nuclei in cell free DNA replication Assays. 
Nuclei were sequentially pulse labelled in S phase extracts (Section 2.6.3.), nuclei were pulse 
labelled with numerous modified nucleotides specified in experimental design. Between 
pulse labelling nuclei were centrifuged at 500 x g for 5 minutes then resuspended in fresh 
extracts with the second modified nucleotide.  
2.7.3. Producing Silanized Coverslips.  
22 mm by 22 mm by 0.5 mm square coverslips (Agar Scientific) were homogenously coated 
in a hydrophobic layer of trimethoxysilane for DNA combing experiments. All steps were 
performed in a fume hood. Coverslips were placed in Teflon racks in the bottom of 
autoclaved 250 ml heavy duty beakers. Coverslips were moved to clean beakers after every 
wash. Coverslips were rinsed in 120 ml of acetone (Fisher) for 1 minute. Coverslips were 
dried, transferred to a fresh beaker, and washed in 120 ml 50% (v/v) methanol for 20 
minutes in an ultrasonic water bath. Coverslips were air dried, transferred to a fresh beaker 
then washed in 120 ml chloroform (Sigma Aldrich) for 20 minutes in an ultrasonic water 
bath. Coverslips were air dried and transferred to an ultrasonic water bath. Coverslips were 
washed for 20 minutes in 120 ml of piranha solution (70 % (v/v) sulfuric acid 99% (w/v), 30 % 
(v/v) hydrogen peroxide 35 % (w/v) in a 60 °C water bath. Coverslips were removed from 
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piranha solution and left until the majority of viscous acid had run off the coverslips. 
Coverslips were washed in 120 ml of water in an ultrasonic water bath for 5 minutes. 
Coverslips were washed in 120 ml of chloroform in an ultrasonic water bath for 5 minutes, 
followed by a water wash. Chloroform and water washes were repeated until viscous acid 
was visibly removed from the coverslip and air dried.  
Coverslips were submerged in 120 ml of 0.1 % (v/v) (7-octen-1-yl) trimethoxysilane in 
heptane (Sigma Aldrich) overnight in a desiccator. Coverslips were washed in an ultrasonic 
waterbath for all subsequent steps. Coverslips were washed in heptane (Sigma Aldrich) for 5 
minutes, coverslips removed, washed in 120 ml of water for 5 minutes, and washed in 120 
ml of chloroform (Sigma Aldrich) for 5 minutes. Coverslips were air dried and silanized 
coverslips stored individually in 50 ml falcon tubes in the dark in a desiccator.  
2.7.4. Purification of DNA  
Following in vitro replication assays, reactions were centrifuged and suspended in 115 µl of 
PBS and warmed to 42 °C. Concurrently, 1 % (w/v) low melting point agarose in PBS was 
prepared, melted at 65 °C and cooled to 42 °C for 15 minutes. 98 µl of low melting point 
agarose was added to the warmed nuclei solution. The agarose nuclei solution was added to 
agarose plug moulds (BIO-RAD), 100 µl per plug. Agarose was set at 4°C for 30 minutes. Plugs 
were digested overnight in 2 mg/ml proteinase K (Bio-Rad) at 42 °C. 
Plugs were washed for 60 minutes in 10 ml of 0.2 µm filtered TNE 50 buffer (10 mM Tris HCl, 
pH 7.5, 20 mM NaCl, 50 mM EDTA). This was repeated 3 further times, incorporating 1 mM 
PMSF on the penultimate wash. At this stage plugs could either be stored short term in the 
fridge or the DNA purified and combed. After the final wash in TNE 50, plugs were washed 
for half an hour in 2 ml of 0.2 µm filtered MES EDTA buffer (50 mM MES (pH 5.7). Plugs were 
warmed to 65 °C for 15 minutes in 0.2 µm filtered MES EDTA buffer. Agarose plugs were 
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allowed to reach 42 °C, then 100 µl of 2 % (v/v) beta agarose 1 (New England Biolabs) added 
and incubated overnight, releasing the naked genomic DNA. 
2.7.5. DNA Combing 
DNA solution (from section 2.8.2) was slowly poured into a Teflon block with 25 x 25 x 4 mm 
milled well. DNA was combed using the KSV NIMA dip coater system (Biolin Scientific). 
Silanised coverslips were clipped onto the combing apparatus and lowered into the DNA 
solution. Coverslips were incubated in the DNA solution for 10 minutes prior to removal from 
solution at 300 µm/second. Coverslips were glued to slides using cyanoacrylate glue on each 
corner. A second 22 x 22 mm coverslips was mounted on top of the coverslip with DNA 
bound to its surface using Prolong diamond anti-fade mountant (Thermo Scientfic). 
2.7.6 Labelling and Imaging  
2.7.6a. Yoyo1 labelling 
Samples from in vitro replication experiments were labelled using 0.1 µM YOYO - 1 iodide 
(ThermoFisher Scientific) prior to combing. DNA was imaged using a Zeiss LSM 880 confocal 
microscope.  
2.7.6b. Antibody Labelling of IdU, CldU, and ssDNA 
All wash steps were performed in coplin jars. After combing, coverslips were incubated at 60 
°C for 1 hour. DNA was denatured in 0.5 M NaOH for 30 minutes at room temperature. Slides 
were washed 3 x 3 minutes in washing buffer (0.1 % v/v Tween 20, PBS, pH 7.4) slides 
transferred to a humidity chamber and blocked in 200 µl blocking buffer (3% BSA, 0.1 % v/v 
Tween 20, PBS 7.4) at 37 °C for 1 hour. Blocking buffer was removed and 50 µl of primary 
antibody solution 1 was added (Table 2.5). Primary antibody solutions were incubated 
overnight at 4 °C. 
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Slides were washed 3 x 3 minutes in washing buffer, transferred to a humidity chamber, 50 
µl of secondary antibody solution 1 (Table 2.5) added and incubated at 37 °C for 30 minutes. 
Slides were washed 3 x 3 minutes in washing buffer, transferred to a humidity chamber and 
50 µl of primary antibody solution 2 was incubated for 2 hours at room temperature. Slides 
were washed 3 x 3 minutes in washing buffer, 50 µl of secondary antibody solution 2 was 
added and incubated for 30 minutes at 37 °C. Slides were washed 3 x 3 minutes in washing 
buffer and slides mounted on a 22mm by 22mm square coverslip with ProLong™ Gold 
Antifade Mountant (Thermo Fisher Scientific) 
 
 
Solution  Antibody  Species Raised Concentration  Supplier 
Primary 
Antibody 
Solution 1  
IdU Mouse 1/20 BD Biosciences 
347580 




Solution 2  




















Fluor 633  



















solution 3  
Digoxigenin  Mouse 1/50 Abcam (AB420) 
Secondary 
antibody 




Goat 1/50 Thermo Fisher 
Scientific A-
21050 




2.7.6c. EdU Labelling (Denatured DNA)  
All wash steps were performed in coplin jars. After combing, coverslips were incubated at 60 
°C for 1 hour. DNA was denatured in 0.5 M NaOH for 30 minutes at room temperature. Slides 
were washed 3 x 3 minutes in washing buffer (0.1 % v/v Tween 20, PBS, pH 7.4). Slides were 
transferred to a humidity chamber and blocked in 200 µl blocking buffer (3% BSA, 0.1 % v/v 
Tween 20, PBS 7.4) at 37 °C for 1 hour, blocking buffer removed and 50 µl of EdU labelling 
cocktail was added and incubated at 37 °C for 30 minutes. Slides were washed 3 x 3 minutes 
in washing buffer, transferred to a humidity chamber and 50 µl of primary antibody solution 
incubated for 2 hours at room temperature. Slides were washed 3 x 3 minutes in washing 
buffer, 50 µl of secondary antibody solution 2 was added and incubated for 30 minutes at 37 
°C. Slides were washed 3 x 3 minutes in washing buffer. Slides were mounted with 22mm by 
22mm square coverslip with ProLong™ Gold Antifade Mountant (Thermo Fisher Scientific). 
2.7.6d. EdU Labelling (dsDNA)  
DNA was pre-labelled with YOYO-1, After combing DNA was treated exactly as in 2.8.4b. 
omitting the denaturing and antibody labelling steps. Additionally, Alexa fluor 555 azide was 
used rather that Alexa Fluor 488 azide. After the Click-It reaction and washing slides were 
mounted with 22mm by 22mm square coverslip with ProLong™ Gold Antifade Mountant 
(Thermo Fisher Scientific). 
2.7.4e. Digoxigenin labelling 
EdU labelling was performed as in 2.8.4c. After Edu Labelling and washing, cells were 
transferred to a humidity chamber where 50 µl of primary antibody solution 3 was added, 
incubated overnight at 4 °C. Slides were washed 3 x 3 minutes in washing buffer50 µl of 
secondary antibody solution 3 was added and incubated at 37 °C for 30 minutes. Slides were 
washed 3 x 3 minutes in washing buffer, 50 µl of primary antibody solution 2 was added and 
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incubated for 2 hours at room temperature. Slides were washed 3 x 3 minutes in washing 
buffer, 50 µl of secondary antibody solution 2 was added and incubated for 30 minutes at 37 
°C. Slides were washed 3 x 3 minutes in washing buffer. Slides were mounted with 22mm by 
22mm square coverslip with ProLong™ Gold Antifade Mountant (Thermo Fisher Scientific). 
2.7.5a. Imaging of Combed DNA 
DNA combing images were captured using a Zeiss LSM 880 confocal microscope. ssDNA 
labelled with Alexafluor 568, IdU labelled with Alexafluor 633, and CldU labelled with 
alexafluor 488 were excited with the 568, 633, and 488 nm lasers respectively and captured 
using 568-640 nm, 638-747 nm, and 493-598 nm ranges.  dsDNA labelled with YOYO1 and 
EdU labelled with Alexafluor 555 were excited with the 568 and 488 nm lasers respectively. 
For both experimental approaches each fluorophore was captured on a separate track to 
minimise bleed through effects . 
2.7.4b Analysis of Replication Tracks 
Lengths on DNA fibres were calculated with image J using the straight line measure tool. For 
each length the 2 furthest points colocalised to DNA were used to define the replication 
track. 
2.8. Statistical Analysis  
Where only two groups were involved the means were compared using the students T-test, 
p values were calculated with Microsoft excel. When multiple comparisons were required for 
a single factor (e.g. DNA Combing experiments) experimental means were compared using a 
one way analysis of variance (one-way ANOVA) followed by post-hoc pairwise comparisons 
by a Tukey’s honestly significant difference (HSD) test using SPSS. When multiple 
comparisons were required across two factors (e.g. ) a two way analysis of variance (two-
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way ANOVA) was performed using SPSS followed by post-hoc pairwise comparisons using 


















Chapter 3.            
Optimisation of DNA Combing for Cell Based 





3.1. Introduction  
3.1.1 Introduction to DNA Combing 
DNA combing was first described by Bensimon et al. (1994). In this seminal paper, viral & 
bacterial genomes were stretched onto silanised cover slips using the force of a constant 
movement through an air water meniscus. This established the principle that uniformly 
stretched lengths of DNA could be visualised by fluorescence microscopy. This work was 
extended to refine the forces and optimal hydrophobic surfaces required to stretch DNA 
consistently and enabled measurement of the tensile strength of DNA (Bensimon et al., 
1995). DNA combing was used by Michalet et al. (1997) to map deletions in disease genes 
using hybridised fluorescent DNA probes. Direct measurement of differences in distance 
allowed the observation and measurement of disease related genomic deletions. This 
approach was further modified using novel nucleotide analogues that are incorporated into 
nascent DNA during replication and imaged using immunofluorescent techniques (Jackson & 
Pombo, 1998) (Figure 3.1). 
 
Figure 3.1-DNA Combing Schematic. A schematic diagram displaying the process 
of DNA combing. A silanized coverslip is placed into a DNA solution in a Teflon 
well. After a DNA binding step the coverslip is removed at a constant rate to allow 
uniform stretching of DNA.  
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Concurrently the fibre stretching assay was developed by Parra & Windle (1993). The major 
difference between DNA combing and fibre stretching is that fibre stretching uses cells lysed 
on slides tilted allowing the DNA solution to run down the slide, aligning the DNA. The first 
use of fibre stretching mapped fluorescent tags to DNA, a technique that was adapted with 
DNA combing by Michalet et al. (1997). This assay provides less consistent stretching, and 
DNA from single cells, but is less technically difficult, less time consuming, and requires less 
specific technical equipment than DNA combing.  
DNA combing has primarily been used to measure and monitor DNA replication stress 
through high precision measurements of changes in DNA replication dynamics. Fluorescent 
labelling of modified nucleotides on combed DNA was first used by Jackson & Pombe (1998). 
In this paper, the dynamics of replication origin firing within replicons was measured using a 
single pulse labelled BrdU step. By extending the length of pulse labelling, differences in 
replication dynamics over time were observed. Merrick et al. (2004) further developed the 
dual labelled technique to measure DNA replication dynamics. This method remains in 
common use today and is used in Chapter 6 to investigate the effects of CIZ1 knock out on 
DNA replication kinetics. The use of sequential iododeoxyuridine (IdU) and 
chlorodeoxyuridine (CldU) treatments allowed high precision measurements of several 
replication parameters including replication fork velocity, origin firing, and DNA replication 
fork stalling. These parameters are often altered during DRS. For example, DNA damaging 
agents slow replication fork progression, blocking new origin firing, and increase replication 
fork stalling (Gaillard et al., 2015; Macheret et al., 2015; Técher et al., 2017). Together these 
early innovators provided the tools that are used ubiquitously today to monitor DNA 
replication dynamics.  
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3.1.2. Using DNA Combing to Measure DNA Replication Dynamics 
To determine the rate of replication fork progression, it is necessary to differentiate between 
replication origin firing, elongation and termination events. The use of a single label does not 
allow this without the ability to control the simultaneous firing of all origins (possible in 
yeast) (Bianco et al., 2012; Hiraga et al., 2018). A sequential dual labelling approach with 
differentially labelled nucleotides is required to achieve discrimination as this produces 
unique patterns for each initiation, elongation and termination.   
DNA combing typically used to determine replication fork velocity. This is achieved through 
two sequential equal length (typically 20 minutes) pulse-labelling steps with two different 
modified nucleotides (typically IdU, and CldU) (Figure 3.2).  
Figure 3.2.-DNA Replication Event Schematic. A schematic displaying how different 
replication events are visualised using a dual labelled DNA combing approach. A) An actively 
replicating fork is represented by neighbouring replication tracks from each nucleotide, the 
order of colours determines the direction. B) Origin firing is represented by symmetrical 
replication tracks. Timing of origin firing determines the appearance of origins. C) Similarly, 
termination events are represented by symmetrical patterns, however the second nucleotide 











To measure replication fork velocities, origin firing during the second pulse labelling step, 
and termination events are excluded from the dataset, as DNA replication either ended early 
(termination) or started late (origin firing). Both events prevent incorporation of the 
modified nucleotide to occur for the entire duration of the second pulse label and would 
inaccurately reduce fork speeds. For each remaining replication event the length of the 
second pulse labelling track is measured, this value is then converted to kbp/min using the 
known stretching factor (1 µm= 2 kbp) and incubation time. The median value of this 
provides an accurate measure for the replication fork velocity for a specific cell line in 
specific conditions. This is summarised in Figure 3.3.  
Figure 3.3-Measuring Replication Fork Rate. A schematic diagram displaying how to 
measure replication fork rate using DNA combing. Blue represents DNA, Red represents the 
first labelling nucleotide, Green represents the second labelling nucleotide. 
 
Critically, the fork rate changes when cells are under DRS. DNA combing has been used to 
demonstrate DRS induction in pre-senescent and senescent cells is independent of 
replication timing changes. This research revealed that replication fork velocities slowed in 
pre-senescent and senescent cells, however replication timing remained unchanged. This 
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demonstrated the degradation of function of senescent cells over time (Rivera-Mulia et al., 
2018). 
During DRS, cells activate ‘cryptic’ origins to facilitate timely completion of DNA replication 
(Courtot et al., 2018). Activation of cryptic origins can result in a reduction in the intra-origin 
distance (IoD) between replication origins and this value reduces the more cryptic origins 
activated. The activation of cryptic origins depletes replication factors, such as the ssDNA 
binding protein RPA, which can cause aberrant DNA replication and recombination events 
(Toledo et al., 2013). Incomplete replication would result in problems during mitosis, such as 
anaphase bridges.  
IOD is measured using the same pulse labelling technique as used to measure replication 
fork velocity. Cycling cells are sequentially pulse labelled for equal time (typically 20 minutes) 
with two different modified nucleotides (typically IdU and CldU). For IOD measuring, 
termination events and processive replication fork patterns are excluded from analysis and 
adjacent origins on the same fibre of DNA are measured (Figure 3.4).  
Median IOD changes as replication dynamics change. This technique has been used to 
demonstrate that as cells become terminally differentiated, their IOD becomes shorter. It 
Figure 3.4 – Measuring IOD Using DNA Combing A graphical schematic displaying two 
representative images of DNA combing of neighbouring origins.  
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was proposed that this was due to chromatin becoming more tightly packed in more 
differentiated cells (Estefanía et al., 2012). This would cause a decrease in the speed of 
replication forks, so more active origins are required to replicate DNA in a timely manner.  
A third parameter that can be measured through DNA combing is replication fork stalling. 
Cells under replication stress stall forks. Stalled forks activate cell cycle checkpoints and 
trigger the DDR. If stalled forks can be resolved, DNA replication can continue. If resolution is 
not possible, stalled forks are a major signal for the induction of apoptosis. Failure to manage 
stalled forks during S phase can result in incomplete replication of DNA, leading to mitotic 
defects, some of which promote growth defects and tumorigenesis (Pond et al., 2019). 
For the first method  of measuring replication fork stalling rates only the processing 
replication fork patterns are measured (Figure 3.2). If DNA replication is unperturbed, the 
replication forks rate is comparable between the first and the second pulse labelling and this 
would remain true if DNA replication is slowed during DRS. Therefore, unperturbed 
replication should produce dual labelled replication tracks with equal lengths. Whereas, if 
there is an increase in fork stalling rates, the fork rate for the first and second pulse labelling 
events will deviate. The ratio between the observed rates for the first and second pulse 
labels will shift away from 1 where there is extensive fork stalling (Tourrière et al., 2017). 
Any increase in replication fork stalling, increases the probability of fork stalling during pulse 
labelling for both the first and the second modified nucleotide. Stalling events during the first 
pulse labelling cannot be distinguished from termination events during the first pulse 
labelling, both will be resolved as a single labelled replication track of the first nucleotide, as 
DNA replication will stall before the second pulse labelling. However, replication stalling 
events during the second nucleotide are detectable. Unstalled forks should maintain their 
IdU : CldU length ratio (i.e. 1). However, if replication forks are stalled during the second 
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CldU labelling the ratio will shift, as. CldU labelling will be reduced relative to IdU, resulting in 
a ratio shift away from 1 as fork stalling increases (Figure 3.5). 
The second method to measure replication fork stalling rates uses sequential pulse labelling 
reactions of equal length and determines the fork rate for both events.  For this method, 
origins that are fired either before or during the first pulse labelling period are used 
(summarised in Figure 3.2). If fork stalling rates are low, both replication forks from each 
origin (sister replication forks) would progress at a similar rate, yielding sister replication 
tracks will be of comparable length. However, where replication fork stalling occurs, there is 
a deviation in the sister replication forks rate, leading to asymmetric fork rates (Quinet et al., 
2017). This can be observed by plotting a scatter graph of the length of the second 
nucleotide pulse of the left track against the second nucleotide pulse of the right track of 
Figure 3.5 - Measure Replication Fork Stalling Through IdU:CldU Length Ratio – a 
graphical schematic displaying two representative images of DNA combing of processive 
replication tracks for samples where DNA fork stalling rates were not increased (control) 
and samples where replication fork stalling rate was increased (treatment).  
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sister replication tracks. Lower replication fork stalling rates lead to lower fork asymmetry. 
This results in a tight correlation between the left and the right track. Higher fork stalling rate 
reduces fork symmetry and produces a looser correlation between the lengths of the sister  
replication tracks. This can be measured either by the strength of the correlation between 
the track lengths, or an average of the ratio of the length of sister replication tracks (Figure 
3.6). 
This technique has been used to demonstrate that depletion of topoisomerase I increases 
the rate of fork stalling. Topoisomerase I acts at contact points between replication at 
transcription machinery. This experiment showed that siRNA depletion significantly 
increased replication fork asymmetry. Loss of topoisomerase I increased polymerase clashing 
as cells could no longer maintain replication (Tuduri et al., 2009). 
Another parameter that can be measured at high resolution by DNA combing is replication 
fork restart rates. When cells are under replication stress processing replication forks can 
stall. This can be through collisions with transcription machinery or through the activation of 
the DDR. Changes in replication fork restart rates give information as to how well the cell is 
Figure 3.6 – Measuring Replication Fork Stalling Through Replication Fork Asymmetry. A 
graphical schematic displaying two representative images of DNA combing of processive 
replication tracks for samples where DNA fork stalling rates were not increased (control) and 
samples where replication fork stalling rate was increased (treatment).  
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able to respond to stress. Low concentrations of a drug may allow fork restart whereas high 
concentrations may prevent it. Changes in this can result in changes in how cells are able to 
respond to stress. To measure replication fork restart rates, cells are treated with one 
modified nucleotide (typically IdU) for 1 hour, followed by a 2 hour treatment with a drug or 
treatment that is expected to induce replication fork stalling (e.g. hydroxyurea) , followed by 
a 20 minute treatment with a second modified nucleotide (typically CldU). This will reveal 
both stalled and restarted forks, as stalled forks will only be labelled with the first nucleotide, 
whereas restarted forks will be dual labelled (Figure 3.7).  
  
Figure 3.7- Measuring Replication Fork Restart Rate A) Schematic of approach to measure 
replication fork restart rate using DNA combing with representative images.  
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This technique has been used to demonstrate that depletion of the nuclease proteins XPF-
ERCC1 and ARTEMIS results in a decrease in the rates that cells can restart forks stalled by 
hydroxyurea (Betous et al., 2018). It was proposed that these proteins could cleave DNA at 
stalled forks to promote a rapid restart of DNA replication at these sites. Similar to the 
mechanism of MUS81-EME1 after long period under DRS.  This work identified a novel 
pathway for maintaining replicative integrity during DRS.  
3.1.3 Chapter Aims 
Consistent stretching of DNA is primarily dependent on three factors. Quality of isolated 
DNA, quality and consistency of coverslip coating of trimethoxysilane, and the pH of the final 
DNA solution. In this chapter, the basic parameters required for effective DNA combining will 
be determined and include: 
• Validation of coverslip silanisation procedure 
• Optimising of the pH for efficient DNA stretching and binding to a silanised coverslip. 
• Verification of whether antibody labelling of ssDNA results in DNA stretched 
comparably to dsDNA 
• Verification of single and dual nucleotide labelling methods 







3.2. Optimising DNA Combing for Cell Based Experiments 
3.2.1 Combing dsDNA from λ phage DNA 
The method used here utilised trimethoxysilane coated coverslips. Efficient coating requires 
a high level of cleanliness of coverslips and imperfections on the glass surface can disrupt the 
trimethoxysilane layer. A non-uniform silane coating results in non -linear stretched DNA 
preventing data analysis (Labit et al., 2008). In addition, the hydrophobicity of coverslips can 
be verified simply by observations of water droplets on coverslips that form near spherical 
beads on a hydrophobic surface.  However, this gives no information as to whether the 
silanisation is uniform. To verify the silanisation technique and ensure that stretching forces 
are appropriate λ phage DNA was used. λ phage DNA has a known length of 48,000 bp. 
Stretching of DNA at 2 kbp/µm (Lebofsky & Bensimon, 2003) yields an average length of 14 
µm assuming that the combing process is working efficiently. To test the quality of the 
coverslip coating and to ensure that the force applied provides a consistent stretching factor, 
phage DNA was used as a molecular ruler. The Phage DNA was diluted, fluorescently labelled 





Figure 3.8. Analysis and quality control of Yoyo1 Stained Lambda Phage DNA A) A 
schematic of the experimental design. B) Representative images of yoyo1 stained 
combed lambda phage DNA. This figure is a mosaic of 10 randomly picked strands of 
DNA images. C) Straightness of combed DNA fibres. D) Observed lengths of combed DNA 
fibres (N = 150). E) Angle of combed fibres compared to a reference line (N = 150). Red 












Visual inspection revealed that combing of λ DNA was successful, with straight, parallel DNA 
strands. This was confirmed by measuring the length of the DNA (LDNA). The length between 
the start point and end point of each length of DNA was measured (LBF). Straightness was 
measured using the following equation:  𝑆 =  
𝐿𝐵𝐹
𝐿𝐷𝑁𝐴
 . This compared the actual length of DNA, 
to the shortest possible length of DNA. The less straight a line is, the more curves it has, 
therefore the longer it is between 2 points. The closer to 1 the S value the more straight the 
lines and this experiment revealed an S value of 0.987. In addition, the DNA was parallel, 
consistently stretched and perpendicular to the air water meniscus that was used to stretch 
the DNA. The angles were consistent around a median angle of -1.5°. Critically, the range of 
measured angles of the fibres was very low (-10° – 7°) consistent with efficient DNA combing.  
λ phage DNA has a 48 kilobase genome making it a useful tool to determine that observed 
length is close to predicted length after DNA combing. The published DNA stretching factor 
of DNA combing is 2 kbp/µm (Kaykov et al., 2016). The mean observed length was 23.4±4.7 
µm, corresponding to 47.4 kbp, demonstrating that consistent stretching is observed, and 
that this system is able to accurately quantitate the length of DNA fibres (Figure 3.8).  
3.2.2. Optimisation of anti-ssDNA antibodies using Single Stranded λ Phage DNA 
The next step was to optimise the labelling methods of ssDNA, and various modified 
nucleotides. This would allow experiments to measure replication dynamics to be able to be 
performed. The labelling of DNA with modified nucleotides requires fluorescent labelling 
after combing. For antibody-based labelling systems, DNA must be denatured to facilitate 
antibody accessibility and after denaturation the DNA is visualised with an anti-single 
stranded DNA antibody. However, EdU labelled DNA does not require denaturation and is 
double stranded when imaged. Critically, as analysis of both dsDNA and ssDNA would be 
performed, the labelling methods must produce consistent results. The epitopes for IdU, and 
CldU lie within the DNA double helix. DNA would need to be denatured, to expose the 
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epitopes, and allow antibody binding for labelling. This requires denaturation in 0.5 M NaOH 
and pH can affect the stretching of DNA. If the methods produced different results (in terms 
of DNA stretching) comparison between dsDNA and ssDNA approaches would be more 
complex. To verify that results from ssDNA and dsDNA labelling were comparable, the 
combing of λ DNA was performed but with NaOH denaturation, and antibody labelling of 
single stranded DNA (Figure 3.9). 
 
 
Figure 3.9. Analysis of antibody labelled Lambda Phage ssDNA A) Experimental overview. B) 
Representative images of yoyo1 stained combed lambda phage DNA. This figure is a mosaic 
of 10 randomly picked strands of DNA and were digitally aligned for presentation. C) Lengths 
of combed DNA fibres (N = 150). D) Angle of combed fibres  (N = 150). E) Straightness of 















Visual inspection of the DNA indicates that the DNA was successfully stretched (Figure 3.9a). 
The parameters determined for the denatured DNA were similar to those found for dsDNA 
(Figure 3.8). The DNA had an S value (straightness) of 0.926, comparable to yoyo 1 stained λ 
phage DNA, and there was no significant difference between the two values  (T test, p > 
0.05). The median length of DNA strands was 21.5 µm (43 kbp)  ± 4.6 (Figure 3.9c). This data 
was normally distributed. This result is comparable to the expected length of λ phage DNA 
24 µm (48 kbp). The yoyo1 stained double stranded λ phage had a median length of 24 µm, a 
difference of less than 3.5 µm, that was not significantly different (T test: p > 0.05). The data 
suggest that the two methods were compatible for combing efficiency, in terms of 
generating straight, and parallel DNA strands.  
Both approaches yielded uniform, parallel DNA fibres that could be visualised, and length 
determined. These observations allow for the determination of DNA lengths using native and 
denatured DNA fibres. The major difference was with the quality of the imaging. Yoyo1 
staining was continuous, whereas antibody labelling was more patchy and non-continuous. 
However, this problem is present in most published DNA combing research (Scwob et al., 
2009). As the two methods were comparable, results between the two different methods 
could be compared with confidence.  
3.2.3. Combing YOYO1 Stained DNA from NIH 3T3  
All DNA combing experiments use DNA isolated from mouse fibroblast cell line NIH 3T3. This 
cell line was used because the cell free DNA replication assays utilise materials isolated from 
synchronised populations of cells (Section 2.5) that can be used to investigate the G1/S 
transition. In addition, most studies evaluating CIZ1 function have utilised murine cell 
fibroblasts of CIZ1 null mice. Consequently, using this cell line will ensure consistency 
between experimental approaches and as DNA is from the same source, the optimal binding 
and combing conditions should be the consistent in each approach.  
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The optimal pH for DNA combing typically lies between 5.1 and 5.8. To determine the 
optimal pH for murine fibroblasts, NIH 3T3 cells were grown to 80 % density and cells 
embedded in agarose. The purified DNA were resuspended in a MES buffer at a pH between 
pH 5.5 – 5.9 in 0.1 pH increments and labelled with Yoyo1. The DNA fibres were 
subsequently assessed for their degree of straightness and how parallel combed fibres are 





             5.6      5.7    5.8 
                     pH 
Figure 3.10-pH optimisation of DNA combing of NIH 3T3 DNA A) A schematic of the 
experimental design. B) Representative images of yoyo1 stained DNA at each of the pH 
values. C) Box and whisker plot of the straightness of the fibres from the 3 pH that 
successfully combed DNA.. The mean straightness of DNA  did not vary significantly 











At pH 5.5 and pH 5.9, DNA did not efficiently adhere to or align on the silanised coverslip. At 
pH 5.6-5.8, the DNA was efficiently combed and produced straight DNA molecules (Median S 
values > 0.097). Additionally, there were no significant differences between any of these 
three data sets. Together this data suggests that the optimal pH range for efficient combing 
of DNA from NIH 3T3 cells is between 5.6 and 5.8. All experiments shown hereafter use pH 
5.7 buffers.  
3.2.4. Optimisation of Dual Labelling with CldU and IdU in Cell Based Experiments 
To monitor DNA replication kinetics in NIH-3T3 cells, modified pyrimidine molecules IdU, 
CldU, and ethynyl-deoxyuridine (EdU) were used (Bianco et al., 2012). IdU and CldU require a 
denaturation step to reveal epitopes in double stranded DNA for immunofluorescence. IdU 
and CldU are fluorescently labelled using sandwiching of fluorescent antibody conjugates. In 
contrast, EdU does not require denaturation prior to labelling with azide-fluorophores using 
Click-It chemistry, which utilise the high energy C≡C bond to attach a fluorophore covalently 
to the nucleotide. As EdU does not require DNA denaturation to expose the binding epitope, 
EdU can be used to visualise both ssDNA, and dsDNA.  
To establish parameters for visualisation of nascent DNA replication, NIH 3T3 cells were 
grown to 80 % confluence and cells pulse labelled with one of the three nucleosides (IdU, 
CldU, or EdU) for 30 minutes. The direct comparison of each nucleotide and allowed the 




Figure 3.11 – Single labelling of combed DNA from NIH 3T3 cells A) Schematic for the 
design of the experiment B) Representative images of the combed labelled DNA. C) 
Replication fork rates from the single labelled fibres, for each nucleotide. Red diamonds 
on swarm plots indicate median values. The mean replication fork rate did not vary 
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To ensure that the nucleoside used was not affecting DNA replication fork progression rates, 
replication kinetics were determined for each pyrimidine analogue (Figure 3.11C). 
Importantly, the replication track length for each of the pyrimidine analogues was similar 
(IdU: 1.3 kb/min, CldU 1.4 kb/min EdU 1.7 kb/min) and showed no significant differences. 
Furthermore, the distribution of each of the different modified nucleotides, was comparable. 
Together, this data indicates that each of the nucleotides, at the concentration used, do not 
significantly affect replication rates, suggesting that comparison across experiments using 
different labelling techniques is appropriate.  
3.2.5. Dual labelling of nascent DNA using CldU and IdU. 
Having demonstrated that CldU and IdU can efficiently label nascent DNA, sequential 
labelling can be used to dual label nascent DNA to analyse DNA replication kinetics. With a 
single labelling of DNA replication, the firing of an origin, termination of DNA replication and 
replication fork stalling are impossible to distinguish. However, dual labelling of DNA with 
two individual modified nucleotides reveals initiation, elongation, fork stalling and 
termination events. 
In cell-based experiments, dual labelling of nascent DNA was performed using sequential 
labelling of IdU, followed by CldU (at a tenfold increase in concentration). This ensured that 
CldU was incorporated preferentially over IdU in the second labelling steps. Three plates of 
NIH 3T3 cells were labelled sequentially for 20 minutes with IdU and CldU. Cells were 










Figure 3.12-Dual labelling of DNA combed from NIH 3T3 cells. A) A schematic for the 
design of the experiment. B) Spectrally separated representative images of DNA from 
the experiment. C) Replication fork rates displayed as a beeswarm plot (N = 150). The 




Visual inspection of images found defined tracks for CldU and IdU which colocalised to 
ssDNA, confirming that they represent DNA synthesis. After addition of CldU, there was a 
low level IdU signal due to small amounts of IdU remaining in cells after media change, that 
was colocalised with CldU . This approach provided sufficient signal to noise ratio to 
discriminate between ssDNA, IdU, and CldU independently to make high fidelity 
measurements on single molecules of DNA. 
To determine replication fork velocity, 150 independent, dual labelled (IdU and CldU) 
replication tracks were measured and data plotted as a bee swarm plot (Figure 3.12C). This 
revealed the median replication fork velocity of 1.4 kbp/µm ± 0.4. Together, these data 
indicate that the IdU and CldU dual labelling method is appropriate for measuring replication 
kinetics from NIH 3T3 cells. The optimisation of the method enabled experiments could be 
performed to measure how loss of CIZ1 effects DNA replication dynamics in NIH 3T3 cells 
(Chapter 6).   
3.3. Establishing DNA combing of mammalian Cell free DNA replication assays.  
3.3.1. Validating Replication Competence of G1 Nuclei 
The cell cycle is regulated precisely by cyclin dependent kinases that establish the temporal 
regulation of the key transitions. Determination of the precise kinase activity that promotes 
the G1/S transition can be determined by careful titration of recombinant cyclin A-CDK2 into 
synchronous G1 cytosolic extracts and replication licensed late G1 nuclei (Chapter 5). This 
technique enables precise titration of proteins or small molecules and the impact on the 
initiation phase of DNA replication to be monitored (Copeland et al., 2010; Mariott et al., 
2015).  
Replication competent nuclei are defined as nuclei that have been synchronised in late G1 of 
the cell cycle and that enter S-phase in response to either an S-phase extract or addition of 
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recombinant cyclin A-CDK2 (Coverley et al., 2005; Copeland et al., 2010). Due to asynchrony 
that occurs during cell cycle re-entry from quiescence, there are nuclei that are already in S-
phase, typically 10 % of the population. The nuclei that can be stimulated to initiate DNA 
replication by addition of an S-phase HeLa cytosolic extract are referred to as the replication 
competent population. To determine the quality of the nuclei two parallel reactions were set 
up for each batch of nuclei. The nuclei were reacted in an NIH 3T3 G1 extract, and a HeLa S 
phase extract. The fraction of nuclei that were in S phase was calculated by fluorescent 
labelling of the biotin-16-dUTP nuclei with a streptavidin Alexa Fluor 555 conjugate (Figure 
3.13). 
 
Comparison of synchronised nuclei (Figure 3.13) showed the number replicating nuclei in a 
G1 extract is low (14.5 %). In contrast, addition of an S-phase extract that contains cyclin E-
CDK2 and cyclin A-CDK2 promotes initiation of DNA replication, increasing the percentage of 
S-phase nuclei to 46.8 %, an over 3 fold increase. However, nuclei batch 2 were not 
replication competent and could not initiate DNA replication with a similar number in S-
Figure 3.13- Quality control of nuclei isolated from NIH 3T3 cells. Nuclei were 
reacted in either G1 (dark grey) or S phase (light grey) extracts. The proportion of 
nuclei in S phase was calculated by measuring incorporation of biotin 16 dUTP. (N 
= 2)  
102 
 
phase as the G1 control (16.8% for G1 extract and 21.3 % in S-phase extract). These nuclei 
would not provide a significant signal to noise ratio so could not be used in future 
experiments. All isolated nuclei used here are validated this manner and nuclei that did not 
display a >2-fold increase in number of nuclei in S phase when comparing G1 reactions to S 
phase reactions were excluded from this analysis.  
3.3.2. Method Development for Improving DNA Combing of in vitro DNA replication assays  
Cell-free DNA replication assays enable titration of recombinant proteins to monitor 
chromatin binding or how factors affect DNA replication efficiency. In addition, cell free 
replication assays can also be used to identify mechanisms of action for novel inhibitors that 
are not able to cross the membranes of cells due to size or charge (Mariott et al., 2015). 
Hence, to gain greater resolution of the DNA replication process, this section aims to 
integrate the in vitro DNA replication system and DNA combing. However, this had proved 
unsuccessful due to fragmented strands of DNA produced during isolation or storage of 
nuclei. Isolated nuclei contained fragmented DNA and the short fibres are not long enough 
to accurately determine fork progression or to determine inter origin distance (IOD). 
Furthermore, replication fork velocity experiment results could be biased due to longer 
replication tracks being unable to be measured. The removal of fragmented DNA or 
modification to procedures to prevent formation of DNA fragments are required to 
investigate DNA replication kinetics and DNA replication stress in vitro.  
There are a number of steps in the procedure used to produce replication competent nuclei 
that have the potential to induce small amounts of DNA damage. Any small amount of DNA 
damage can cause dramatic increases in DNA fragments that coat the coverslip and obscure 
long DNA strands in a DNA combing experiment. Adjacent nicks in DNA during combing will 
cause fragmentation of DNA as the DNA is stretched in the combing procedure. The major 
steps in the isolation procedure that could cause mechanical or chemical stress to the DNA 
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were assessed to determine the stage that induced short DNA fragments. These stages were: 
dissociation of the cells by trypsinisation versus hypotonic buffer and cell scraping. This is 
followed by dounce homogenisation to isolate nuclei from cells and centrifugation to harvest 
nuclei, flash freezing in liquid nitrogen, or preparation of cell free DNA replication assays. 
As a first step, release of cells from the culture dish was performed using trypsinisation as 
this approach has been using in cell based DNA combing experiments without fragmentation 
of DNA. This could then be compared to the effects of mechanically scraping cells after 
hypotonic buffer incubation, followed by dounce homogenisation (Figure 3.14).  
Comparison of DNA fragmentation following harvesting by trypsinisation and mechanical 
scraping showed that both methods produced predominantly >4 kb DNA fragment and then 
Figure 3.14 – Degradation of DNA During Cell Isolation Comparison of DNA 
damage induced by trypsinisation and scrape harvesting. M is molecular 
marker. Lane 1 – 4 are loaded with a proteinase k digest of cells harvested by 
trypsinisation. Lane 5-8 are loaded with a proteinase k digest of cells harvested 
by swelling in hypotonic buffer and scraping. T = trypsinised, H = Hypotonic 
buffer 
DNA Size (kbp) 
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some evidence of smaller fragments at lower abundance. The trypsinised cells (Lane 1-4, 
Figure 3.18) had extensive low molecular weight DNA fragments <100bp and a band at 
approximately 300bp that were largely absent from the douced nuclei (Lanes 5-8). Although 
the amount of DNA was lower than that seen for trypsinised cells, it was mostly intact as it 
>4kbps in length above the highest marker. These results demonstrate that scrape 
harvesting in hypotonic buffer step does not cause an increase in DNA damage relative to 
control DNA. Therefore, DNA damage occurs during the nuclei isolation, not the harvesting 
of the cells. Next, synchronised nuclei were prepared by existing approaches and analysed 
after each step in their isolation by agarose gel electrophoresis (Figure 3.15).  
 
Analysis of DNA fragmentation at each step in the isolation of nuclei identified two steps as 
causing notable increases in the amount of smaller DNA fragments. These steps were (I) 
centrifugation and (ii) Snap freezing and thaw steps. This was characterised by a 
Figure 3.15 – Degradation of DNA During Nuclei Isolation  How different stages of nuclei 
isolation caused different levels of DNA damage. M is molecular marker. Lane 1, DNA from 
scrape harvested cells. Lane 2, DNA after dounce homogenisation of cells. Lane 3, purified 
nuclear DNA after centrifugation. Lane 4, DNA extracted after snap freezing and freeze 
thawing. Lane 5, DNA after incubation in an S-phase cytosolic extract.  
DNA Size (bp) 
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disappearance of long DNA (10 kbp). When preparing DNA for DNA combing, vibration is well 
known to increase shearing of DNA and movement is kept to as little as possible. Anecdotal 
evidence suggests that specialist labs do not keep samples on the same bench as an active 
centrifuge or take them in lifts. Consequently, these results were anticipated as 
centrifugation can cause excessive force to be enacted on the nuclei during isolation. In 
addition, freezing can induce mechanical stress as ice crystals form in the freezing process 
that rupture the phosphodiester backbone. Since these are vital steps for both preparation 
and storage of nuclei for in vitro replication material the procedure may need to be 
modified.  
To mitigate the damage to DNA caused by the physical stress of centrifugation, a number of 
modifications could be performed. For example, centrifuging nuclei onto sucrose cushions 
rather than the base of an Eppendorf tube may reduce impact and mechanical stress; this is 
a method that has been utilized to isolate nucleoli (Li & Lam, 2015). The increased density of 
the sucrose solution slows the separation of material during centrifugation, this may reduce 
the mechanical strain on DNA. 
Another method to mitigate the damage to DNA from centrifugation would be to reduce the 
speed of centrifugation. Slower speeds could result in a lower force acting on the DNA as it 
hits the base of the Eppendorf tubes. This could protect the integrity of the DNA making it 
more suitable for combing. To test the effects of different centrifuge speeds cells were 
grown, synchronised and 17.5 hours after release cells were swelled in hypotonic buffer, 
scrape harvested, and dounce homogenised. The dounce homogenised sample was split into 
3 equal sized volumes. Each sample was centrifuged at different rates ranging from 500 – 
12,000 x G, additionally one sample was vortexed to shear DNA to be used as a positive 
control. After centrifugation samples were digested overnight in proteinase K then prepared 






Figure 3.16 – Centrifuging Nuclei Effects DNA Integrity The effects of increasing centrifuge 
speed on DNA damage during isolation of nuclei for in vitro experiments. Lane 1 is loaded 
with a proteinase k digest of scrape harvested dounce homogenised cells. Lane 2 is a 
vortexed nuclei control to increase DNA shearing. Lanes 3-5 are harvested at 500, 6000, and 
12000 x G respectively. 
There was a little difference between the amount of small DNA fragments for samples 
centrifuged at speeds greater than 500 x G (Lane 4) and 12,000 x G (Lane 5) with these lanes 
showing band patterns similar to the vortexed DNA (Lane 2). Lane 3 was the 6000 x G 
samples which showed some signs of DNA damage but appeared to show an increased 
amount of longer DNA, and a pattern more similar to the negative control. The results 
suggest that centrifugation speeds of 6000 x g are sufficient to isolate nuclear materials and 
minimise DNA shearing. 
Freeze thawing nuclei appears to cause significant damage to DNA (Figure 3.10). The 
simplest way to avoid this damage is to perform in vitro experiments directly after harvesting 
of nuclei. To assess the effect of snap-freezing nuclei prior to use, 2 plates were 
synchronised, and nuclei were harvested at the 17.5 hour time point. Nuclei from 1 plate 
DNA Length (bp) 
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were frozen for use as a control and compared with fresh reagents after incubation with S-
phase extracts. Nuclei were embedded in low melting point agarose and DNA was purified as 




Figure 3.17-Freeze Thaw Effects DNA Integrity. Schematic for isolation of nuclei 
without freezing to test if they could be successfully combed. Samples were labelled 
with yoyo-1. Blue nuclei represent nuclei that have been thawed from liquid 
nitrogen storage. Orange nuclei represent nuclei that haven’t been frozen. B) 
Confocal fluorescence microscope image produced from nuclei that were freeze 
thawed prior to combing. C) displays an image of combed DNA from nuclei that 






The isolation of nuclei without snap freezing appears to increase the length of DNA as 
visualised by DNA combing, consistent with the shearing of the DNA during the freeze-thaw 
step. In addition, DNA combing of DNA from in vitro DNA replication assays is possible with 
modification of the procedures to isolate nuclei. However, omitting the freezing step 
prevents characterisation of the nuclei in cell free DNA replication experiments to identify 
batches that initiate DNA replication in vitro. Furthermore, repeat experiments using the 
same nuclei could not be performed. Additionally, isolating nuclei directly prior to DNA 
purification and combing adds significant time to an experiment as each will have to be 
preceded by days of cell synchrony and nuclei isolation. Whilst a simple solution had yielded 
better results, it was far from an ideal solution long term. 
To allow long-term storage of nuclei, the damage incurred by freeze thawing must be 
mitigated. Increased fragmentation of the DNA results in an increased concentration of short 
DNA, preventing quantitative analysis of DNA replication events. To overcome this issue, it 
may be feasible to remove the fragmented DNA by electrophoresis. As nuclei are 
encapsulated in agarose plugs, application of a current to the plugs containing DNA could 
remove the smaller DNA leaving a higher proportion of longer DNA preventing surface 
binding being outcompeted by the smaller DNA. 
To test this, cell free DNA replication reactions were prepared, nuclei were embedded in 
agarose and naked DNA produced by proteinase K digestion. Agarose plugs were placed in 
an electrophoresis tank and run at 100 V for 15 minutes. Agarose Plugs were retrieved, 





The application of a current to remove short DNA fragments allowed more efficient 
alignment and length of DNA during DNA combing (Figure 3.19b/c). This demonstrates that it 
is feasible to isolate and validate nuclei that have been snap frozen prior to analysis. It 
remains to be addressed whether DNA replication fork rates are consistent with an 
Figure 3.18 - Enriching Long DNA Fibres by Electrophoresis. Schematic for removing smaller 
DNA from agarose plugs using gel electrophoresis. DNA is purified as normal. However, prior 
to agarose digestion a 100 V current is applied to samples in TBE buffer for 15 minutes. DNA is 
then stained with Yoyo1 and combed. b) Confocal microscopy images of YoYo1 stained DNA 
fibres before electrophoresis. c) As b except for DNA fibres underwent electrophoresis at 100 V 






unperturbed, cell-based analysis of DNA replication rates. Having established techniques that 
can be used isolate DNA from in vitro cell free DNA replication assays, the 2 strategies will 
enable measurement of DNA replication fork dynamics in vitro. 
3.3.3. in vitro labelling methods  
The use of in vitro DNA replication assays provides an opportunity to use modified 
nucleotides as opposed to halogenated pyrimidine analogues (Marheineke et al., 2005; 
Bianco et al., 2012). Candidates include EdU, biotin-16-dUTP and digoxigenin 11 dUTP. Biotin 
16 UTP is used already in in vitro reactions (Chapter 5) and produces a sufficient signal to 
noise ratio on nuclei from in vitro reactions. However, biotin-dUTP has not yet been used to 
label nascent DNA by DNA combing. EdU has been shown to be labelled effectively in DNA 
combing experiments (Figure 3.11), however it has not been used for in vitro experiments. 
The third candidate is digoxigenin 11 dUTP. Digoxigenin has been used for combing 
previously (Marheineke et al., 2009). If the use of bulky modified nucleotides are not suitable 
the other option would use IdU and CldU as before for dual labelling. To test the viability for 
this BrdU was used. The viability of each nucleotide for labelling was verified in in vitro DNA 














Figure 3.19. Labelling of in vitro reactions with multiple nucleotides. A) A graphical 
schematic of the experiment. B) Representative images of positively labelled nuclei for 
each nucleotide used.  C) The mean proportion of nuclei in S phase did not vary 
significantly between conditions (one-way ANOVA P > 0.05, n = 3 for each condition, error 
bars represent standard deviation). D) Representative image of the positively labelled dual 
nucleotide labelled nuclei. 
Biotin-16-dUTP        EdU          Digoxigenin-11-dUTP        BrdU 















Fluorescence microscopy allowed discrimination between labelled, and unlabelled nuclei and 
there was a high signal to noise ratio for all nucleosides tested. Importantly, there was no 
significant difference in the percentage of S-phase nuclei, with Biotin 16 dUTP, EdU, and 
digoxigenin 11 dUTP showing 42%, 44% and 47 % of nuclei in S phase, respectively. This 
compares with 43% for BrdU. There were no significant differences to mean S phase entry 
between any of the nucleotides used. In addition, dual labelling with EdU and biotin-UTP 
showed strong colocalization of biotin 16 dUTP and EdU on the dual labelled nuclei, 
suggesting that this combination would be appropriate in DNA combing in vitro replication 
experiments. This suggests that modified nucleotides used here had no adverse effects on 
replication suggesting that they may be used to label DNA replication in DNA combing 
experiments.  
3.3.4. Labelling of Nucleotides of DNA from in vitro Replication Experiments  
Having successfully labelled nascent DNA replication in vitro, this approach was combined 
with DNA combing to determine the rate of DNA synthesis. The use of in vitro replication 
assays are a powerful tool for analysis of replication dynamics in multiple conditions. The 
addition of DNA combing to this approach would greatly enhance the quantitative analyses 
that could be performed beyond a binary G1 or S-phase score that is used currently. To 
determine if modified nucleotides provided sufficient sensitivity to label nascent DNA 
synthesis in DNA combing using an in vitro system, EdU, biotin -16-dUTP and digoxigenin-11-




The labelling of DNA with YoYo-1 and visualisation of nascent DNA replication was achieved 
using EdU (Figure 3.21A), biotin-16-dUTP (Figure 3.21B) and digoxigenin (Figure 3.21C) each 
of the nucleotides had a visible signal, and a sufficient signal to noise ratio to make accurate 
measurements. Signalling from antibody derived labelling methods (IdU, CldU, and 
digoxigenin 11 dUTP) resulted in non-contiguous (dotty) labelling. This same effect was 
observed in labelling of DNA from cell-based experiments. The non-contiguousness still 
allows for data analysis as clear labelling regions are shown. This result confirmed that these 
labelling methods were viable to perform experiments with modified nucleotides (Biotin or 
digoxigenin-dUTP) and EdU. Together these data suggest that any of these nucleotides could 





Figure 3.20-Labelling of Replication on Combed DNA From in vitro Replication 
Experiments.  Blue shows DNA, green shows the modified nucleotide (A: EdU, B: Biotin-
16-dUTP, C: Digioxigenin-11-dUTP) incorporated into DNA during replication. Scale bar 
shows 20 µm. 
A                                              B                                               C 
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3.4. Chapter Discussion  
This chapter establishes the use of DNA combing for analysis of DNA replication in cell based 
and cell free DNA replication analyses. The results from this chapter have verified the DNA 
combing technique to be used in later chapters (Chapter 6). Early experiments utilized 
labelling of DNA in both double stranded and single stranded states. dsDNA was labelled 
using DNA intercalating dye yoyo 1. ssDNA was labelled using  fluorescent antibody 
conjugated immune-labelling. Early experiment used viral (Lambda phage) DNA to confirm 
DNA aligning and DNA stretching factor. Together these results would verify the efficacy of 
the coverslip trimethoxy silane coating (Labit et al., 2008). 
Using λ DNA enabled verification of the basic parameters of DNA combing. The DNA fibres 
were shown to be both straight and parallel and observed DNA length was consistent with 
published values of 2kb/µm (Lebofsky & Bensimon, 2003). The average ratio between the 
length of fibres, and DNA fibre straightness was within expected parameters which is 
essential for accurate measurements of DNA replication. In addition, dual labelling 
experiments revealed that their antibodies could discriminate between IdU and CldU with 2 
separate tracks identified. Additionally, tracks could be identified that represented each of 




Resolution of all major replication patterns (Initiation, elongation, termination) was 
achieved. Additionally, the quality of imaging was comparable to previously published DNA 
combing and DNA fibre analysis (Bianco et al., 2012). Resolution of these patterns would 
allow measurements of changes in replication dynamics in experiments throughout this 
study. Additionally, to ensure that the nucleotides were not interfering with replication in 
these cells the replication rates needed to be measured. If this measurement were to reveal 
Figure 3.21. Patterns of DNA replication. Replication patterns derived from a sequential pulse 
labelling with IdU and CldU. Each of the replication patterns shown is characteristic of a 
specific replication event and timing. The replication event and timing for each observed 
pattern is described on the left. A scale bar is included.  
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that replication rates were largely different between published replication rates for other 
cell lines, then the nucleotides and concentrations used would have to be addressed.  
Measurements taken from a total of 150 replication events revealed that the median 
replication rate was 1.4 kbp/min. This rate was comparable to the rates identified for 
unstressed cells of a wide variety of different cell lines and species including DT40 cells, HeLa 
cells present with lower replication fork velocities than the cells used in this report, likely due 
to oncogenic mutations (Petermann et al., 2006; Petermann et al., 2008). Specifically, this 
replication fork rate was comparable to published rates from NIH 3T3 cells (Bhaskara et al., 
2013; Zhao et al., 2018).  The range of DNA replication fork rates displayed here showed a 
large variation from 0.4 kbp/min to 8 kbp/min. It has been observed in several published 
works from a variety of different cell lines and species, although typically between 0.4 
kbp/min – 5 kbp/min (Petermann et al., 2006; Petermann et al., 2008). This large range is 
likely due to the variation of DNA replication rates within a cell (Yurov et al., 1980; Rhind et 
al., 2013). Additionally, the length of individual combed fibres is a limit for large replication 
fork rates as breaks are more likely to occur in longer replication tracks (Kaykov et al., 2015).   
Analysis of DNA replication using synchronised nuclei has previously utilised mimosine to 
arrest cells in early S-phase (Marheineke et al., 2005). Here DNA combing has been achieved 
using the physiologically relevant synchronisation using G0 arrest for the first time. DNA 
combing experiments using mimosine synchronised nuclei labelled with digoxygenin dUTP 
and Biotin dUTP. These studies demonstrated that new replication origins fired bi-
directionally in these in vitro replication assays, and similarly to cell-based experiments fork 
rates in vitro were highly variable. Additionally, this study identified that replication forks 
from mimosine arrested nuclei proceeded less rapidly than from whole cells of the same cell 
type. This shows the advantage of DNA combing, which allows measurement of each 
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datapoint, whereas other methods of measuring fork progression rate measure averaged out 
data losing some fidelity (Nazari et al., 2013).  
This report marks the first example of late G1 nuclei promoted into S phase via incubation 
with an S phase extract being used for DNA combing. Additionally, this study has 
demonstrated that other nucleotides beyond digoxigenin dUTP and biotin 11 dUTP could be 
used for cell free DNA combing such as including BrdU, CldU, IdU and EdU. Successful BrdU 
labelling implies that IdU and CldU would be successful, which could allow a more direct 
comparison between cell based and cell free DNA combing experiments. The major 
advantage of using post quiescent nuclei is the reduced use of chemical synchrony which 
may have aberrant effects on results (Krude et al., 2006). Together the combination of these 
two techniques will allow for the high-fidelity measurement of replication kinetics in vitro. 
This will allow measurements of how individual molecular factors affect replication 
dynamics. For example, these techniques will be used to investigate the effect of CDK levels 
on DNA replication dynamics, how this is modulated by CIZ1, and the effect of replication 
inhibitors on DNA replication, as this is a cell free system, inclusion of these factors into cell 
cycle specific stage extracts is simple (Chapter 5). This bypasses complex genetic 
manipulation, or nonspecific chemical inhibition/activation allowing a more rapid 
measurement of DNA replication. When coupled with cell-based data this will provide 
deeper insight on a single event resolution into how replication initiation is controlled.  
The optimisation of DNA combing labelling methods for both cell based and cell free 
experiments has enabled this approach to be used to measure replication dynamics at 
altered levels of CIZ1 (Chapter 5 and 6) and altered levels of Cyclin/CDK signalling (Chapter 
5). CIZ1 has been shown to have a role in multiple cancers (Higgins et al., 2012; Chen et al. 
2019), and a specific role at co-ordinating CDK signalling around the nuclear matrix during 
the G1/S transition (Coverley et al., 2005; Copeland et al., 2010; Copeland et al., 2015). If 
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altered CIZ1 levels affect DNA replication dynamics, this could induce DRS which could drive 
















Chapter 4.                









4.1. Introduction  
4.1.1 Introduction to CRIPSR Cas9  
In this chapter, the potential role for CIZ1 in cell cycle regulation will be assessed. This will be 
achieved utilizing CRISPR Cas9 techniques to produce CIZ1 null fibroblasts to aid evaluation 
of its function in cell cycle regulation and begin to assess its potential role in tumourigenesis. 
Previous reports have demonstrated a role for CIZ1 in regulation of the G1/S transition and 
cooperative activity with cyclin A-CDK2 to promote replication initiation, an activity inhibited 
by CDK2 mediated phosphorylations (Copeland et al., 2010; Copeland et al., 2015), and in the 
DDR to HU (Nishibe et al., 2013). Experiments were performed to measure changes to cell 
cycle profile, and replication protein assembly, in this chapter the effect of loss of CIZ1 was 
determined. This provides a framework for future Chapters to investigate the specific 
changes that were observed in a targeted detailed manner.  
4.1.2. CRISPR Cas9 
To further investigate the role of the protein CIZ1 within the context of how its cellular levels 
effect cell cycle progression, DNA replication, and response to replicative stress, this section 
aims to produce a CIZ1 knockout cell line to aid functional analysis. Phenotypic analysis of 
CIZ1-/- cells may elucidate its role in a number of common cancers (Higgins et al., 2012) as 
well as its activity surround the G1/ S-phase transition (Copeland et al., 2010; Copeland et 
al., 2015; Pauzaite et al, 2017). CIZ1 is typically overexpressed in cancer (Rahman et al., 2010; 
Higgins et al., 2012, Swarts et al., 2018) but CIZ1 null mice have revealed that CIZ1 may have 
a tumour suppressor role that has not been characterised (Nishibe et al., 2013). To generate 
CIZ1 knockout NIH 3T3 cells, CRISPR Cas9 was used to produce a double strand break which, 
when incorrectly repaired by NHEJ promotes frameshifts that introduce stop codons in an 
early codon, effectively knocking out the CIZ1 gene.  
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The clustered regularly interspaced short palindromic repeats/CRISPR associated system 
(CRIPSR/CAS system) is a key component of the adaptive prokaryotic immune systems 
defence against viral infection (Barrangou, 2015). In bacterial DNA there are spacer 
sequences separated by palindromic repeat, these encode crisprRNA (crRNA) sequences, 
these crRNA bind to invading viral bacteriophage DNA targeting it for destruction by CAS 
endonucleases (Barrangou et al., 2007, Brouns et al., 2008, Marraffini & Sontheimer, 2008). 
Additionally, after viral infection bacteria incorporate new spacers in their CRISPR arrays to 
provide a memory response to provide resistance to viral infection (Barrangou et al., 2007).  
The ability to target specific sequences within DNA provides a useful tool for mammalian 
genome editing. The most commonly used CAS for genome editing is Cas9 which binds after 
a protospacer adjacent motif (PAM) with sequence 5’ – NGG – 3’. crRNAs can be generated 
with a 20 bp specific sequence, these coupled with a trans activating CRISPR RNA (tracrRNA) 
recruit the Cas9 to the PAM sequence which then cuts the DNA leaving blunt ends (Tsai et 
al., 2016). This is interpreted by eukaryotic cells as a double strand break (DSB), activating 
the DNA damage response (DDR). The DSB can be repaired by two mechanisms: non-
homologous end joining (NHEJ) or by homologous repair (Zaboikin et al., 2017). NHEJ is an 
imprecise method for repairing DNA prone to DNA insertions and deletions (Chang et al., 
2017). DNA insertion or deletion mutations mediated during NHEJ may produce a frame shift 
where the number is not divisible by 3 and therefore inserts a nonsense mutation 
terminating transcription. This effectively knocks out specific genes and this technique was 







For more precise genome editing the homologous recombination (HR) pathway is used.  
Briefly, HR utilizes homologous DNA as a template for DNA repair this limits repair by HR to 
G2/M making it a rarer event than NHEJ (approximately 25% of the time) (Mao et al., 2008). 
This repair pathway can be manipulated by concurrently transfecting cells with the tools for 
the CRISPR/Cas9 system along with a sequence of DNA containing the desired point 
mutation, insertion, or deletion flanked by regions of homologous DNA. HR uses this 
modified template to incorporate the desired gene manipulation into the genome. Since 
mammalian cells are diploid, both chromosomes must be edited, reducing the proportion of 
cells that are successfully modified (Figure 4.1).  
4.1.2. Chapter Aims 
• Generate 2 distinct CIZ1 KO NIH 3T3 clones (KO1 and KO2)  
• Generate CIZ1 add back cell lines that express GFP-CIZ1 (CIZ1AB) NIH 3T3 Cells. 
• Analyse and compare cell cycle profiles for parental WT fibroblasts and CIZ1 null 
fibroblast cell lines. 
• Determine cell cycle re-entry kinetics upon loss in WT and CIZ1 null fibroblasts 
• Evaluate the response to DNA Damage in CIZ1 null fibroblasts.  
Figure 4.1 – CRIPSR CAS9 mediated genome editing A) Schematic of the CRISPR Cas9 
mechanism used to edit eukaryotic genomes. crRNA binds complimentary sequence onto 
genomic DNA adjacent to a PAM sequence, together with tracrRNA this complex recruits the 
nuclease Cas9, which nicks the genomic DNA proximal to the PAM sequence. The DSB is then 
repaired by either NHEJ or HR. These repair pathways can be exploited to modify DNA either 
through truncations or by genome editing.  
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4.2. Generating CIZ1 Null Cells using CRISPR-Cas9 
To functionally knockout the CIZ1 gene, oligonucleotides were designed that would target 
the second exon of the mouse CIZ1 gene. The second exon was chosen because of 
differential splicing of the CIZ1 gene leads to 2 major transcripts that are developmentally 
regulated. The full length CIZ1 gene utilises Exon 1 and the embryonic CIZ1 (ECIZ1) splice 
variant does not express exon 1 (Higgins et al., 2012). Targeting of exon 2 would inactivate 
both splice variants. To ensure that the effects of targeting the CIZ1 gene with CRISPR-CAS9 
results in a phenotype associated with CIZ1 knockout, two different crRNA oligonucleotide 
templates were designed for distinct PAM sequences within the same exon. This approach 
was used as CRISPR-Cas9 may have significant off target effects (Cradick et al., 2013), 
although there is disagreement regarding how significant off target effects are (Cenci et al., 
2014). Production of two CIZ1 knockout cell lines through targeting of distinct sites enables 
comparison of any phenotype changes with independent clones. Consequently, a consistent 
phenotype in both CIZ1 knockout clones would suggest that it is related to the loss of CIZ1 
than from off-target effects.  
The complementary sequences for crRNA uses 20 nucleotides 5’ to a PAM sequence (Figure 
4.2). PAM sequences for Cas9 have a conserved sequence of 5’ – NGG – 3’. Two PAM 
sequences were identified: one at position 1137 with sequence 5’ – AGG – 3’, and one at 
position 1155 with sequence 5’ – TGG – 3’. Oligonucleotides for the guide RNA sequence 
were designed, inserted into the linearized gene art CD4 CRISPR plasmid (as described in 
Section 2). The oligonucleotides and structure of the dimerised oligonucleotides for PAM 




Cells were transfected with the CRISPR-Cas9 plasmid, enriched, and plated in a 96 well plate 
diluted to single cells and verified by microscopy. Clonal populations were expanded from 
single cells up to 6 well plates and screened for CIZ1 knockouts by western blotting using 
plate of wild type NIH 3T3 cells as positive control. CIZ1 knockouts were confirmed by the 
disappearance of the CIZ1 band for CIZ1 PAM 1116 (hereafter called CIZ1-KO1) and CIZ1 Pam 
1134, hereafter called CIZ1 KO2). Both clones were DNA sequenced to ensure the presence 
of a nonsense mutation in both chromosomes (Figure 4.3). Together, this data suggested 
that CIZ1 null cell lines had been successfully been generated utilizing both PAM sites. 
Due to non-specificity of the lab made polyclonal CIZ1 antibody bands were present on the 
CIZ1 KO western blot. To ensure that these bands were not due to alternative truncations of 
Figure 4.2 – crRNA Sequences targeting CIZ1 A) The target sequence for generating CIZ1 
knockouts at the KO1 site (A) and KO2 (B) showing the PAM site (red) and target sequence (green). 
The structure of the annealed oligonucleotide for inserting into plasmid GeneART plasmids to be 







CIZ1 a titration of CIZ1-N471 was added to blocking buffer. This did not promote 
disappearance of bands present exclusively in CIZ KO. The conclusion was bands were not 
from CIZ1 but were nonspecific bands. As the antibody is raised against CIZ1-N471 there was 
a possible of C-terminal only truncations, however these lack the important binding regions 
so would be unlikely to be functional. 
 
KO1 KO2 
Figure 4.3-Generation of CIZ1 null NIH 3T3 cells A/B) Western blots of successful CRISPR 
CAS9 mediated CIZ1 knockout cells. Both CIZ1 KO1 (A) and CIZ1 KO2 (B) PAM sites resulted in 
the knocking out of CIZ1. Lane 1 displays the candidate for KO, lane 2 displays untreated 
cells. Blots were probed with antibodies for CIZ1 and actin. C/D) Sequencing of the PAM sites 
of the successful CRISPR CAS9 mediated CIZ1 knockout cells. Both CIZ1 KO1 (C) and CIZ1 KO2 
(D) PAM sites resulted truncation of the CIZ1 gene prior to the PAM sites. The 2 KOS are 

















4.3. Characterisation of CIZ1 Null Cells  
4.3.1. Loss of CIZ1 Does Not Affect the Asynchronous Cell Cycle Profile of NIH 3T3 Cells  
Previous work has implicated a cell cycle role for CIZ1. CIZ1 levels accumulate as cells re-
enter the cell cycle from quiescence (Pauzaite et al., 2017). CIZ1 has additionally been shown 
to interact with the G1/S cyclins: Cyclin A-CDK2 and Cyclin E-CDK2 (Copeland et al., 2010). 
This work lead to the proposal that CIZ1 contributed to localisation of cyclin–CDK activity to 
putative replication origins suggesting that CIZ1 null cells may have altered cell cycle kinetics. 
However, no cell cycle or developmental defects in CIZ1 null mice have been identified 
(Nishibe et al., 2013; Ridings-Figueroa et al., 2017). To investigate the role of CIZ1 in cell cycle 
regulation and control of DNA replication timing, cell cycle characteristics of asynchronous 
cells were determined by EdU labelling and fluorescence microscopy, and EdU labelling and 
flow cytometry. Experiments were performed using WT NIH 3T3 cells, CIZ1 KO1, and CIZ1 
KO2(Figure 4.4).  
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There was no significant difference between the proportion of cells in S-phase, as 
determined by EdU labelling and fluorescence microscopy with 61 % of asynchronous WT 
cells were in S-phase compared to 62 % of CIZ1 KO1 cells, and 57 % of CIZ1 KO2 (Figure 4.4B). 
Further analysis of WT and CIZ1 KO1 cells using flow cytometry is consistent with 
fluorescence microscopy and show that between 50 % and 70 % of cells are in S-phase. 
Additionally, analysis of EdU positive cells by flow cytometry reveals similar proportions of 
WT and CIZ1 KO cells in early, mid and late S-phase (Figure 4.4C). This suggests that 
unperturbed asynchronous cells have no significant changes to cell cycle kinetics. 
Furthermore, analysis of the G1 and G2/M populations reveals similar proportions of cells in 






Figure 4.4 – Analysis of Cell Cycle Profiles of WT and CIZ1 KO Cell lines A) Schematic of the experimental 
design. B) The proportion of cells in S-phase (EdU +ve) measured using fluorescence microscopy (N = 3 ± 
S.D.). No significant differences in the proportion of S phase cells was observed across cell lines (One Way 
ANOVA, p > 0.05) C) Displays flow cytometry profiles of cells of WT,  and KO1, measuring nascent DNA 
synthesis (EdU incorporation) and total DNA content (PI). D) Flow cytometry profiles of WT and CIZ1 KO1 
cells. EdU negative cells are red (G1 or G2/M), EdU positive cells are blue ( S-phase). All data collected is 
displayed in green.  
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This data suggests that CIZ1 deletion does not grossly affect cell cycle progression in 
asynchronous mouse fibroblast cells. This observation is consistent with murine CIZ1 null 
mice that displayed no defects in cell cycle status, or cell growth (Nishibe et al., 2013; Riding-
Figueroa et al., 2017). Interestingly, loss of CIZ1 did cause increased aberrant cell cycle 
progression and DNA damage in aged mice (Khan et al., 2018), but this was not apparent in 
either CIZ1 KO cell line at low passage number. These results, together with previous work 
suggest that deletion of CIZ1 does not result in gross cell cycle defects in unstressed cycling 
cells.  
4.3.2. CIZ1 KO Cells display Altered Cell Cycle Profiles During Cell Cycle Re-entry Post 
Quiescence. 
Much of the work on CIZ1 suggests that it contributes to cell cycle progression in post-
quiescent cells (Coverley et al., 2005; Copeland et al., 2010). Cell free DNA replication assays 
that have evaluated CIZ1 function are isolated from post-quiescence nuclei and in this 
context CIZ1 cooperates with cyclin A-CDK2 to promote initiation of DNA replication. CIZ1 
accumulates as cells re-enter the cell cycle post-quiescence, and phosphorylation status is 
linked to activities of the G1/S cyclin CDK complexes (Copeland et al., 2015; Pauzaite et al., 
2017). To investigate whether CIZ1 has a role in controlling S-phase entry timing post-
quiescence WT, CIZ1 KO1, and CIZ1 KO2 cells were synchronised in G0 through contact 
inhibition and serum depletion (Section 2.4.5). Cell cycle kinetics and levels of DNA 
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replication factors MCM2, CDC6, and PCNA were assessed for WT and CIZ1 KO1 cell lines 
(Figure 4.5). 
Figure 4.5 – Cell Cycle re-entry Profiles of WT and CIZ1 null cells A) a Schematic of the 
experimental design. WT, CIZ1 KO1 and CIZ1 KO2 cells were synchronised in G0 and released into 
S-phase. Samples were harvested at 2 hourly time points. B) The proportion of cells in S-phase 
measured by EdU incorporation. The proportion of cells in S phase at each time point (n = 3 
repeats) for each cell line was compared using a two-way ANOVA with time and cell line as 
factors (P (time) < 0.01, P (cell line) < 0.01, P (interaction) < 0.01. Pairwise comparisons were 
made by simple main effects analysis: no significant differences were observed  between 
KO1/KO2 cells at any timepoint, or WT/KO1 and WT/KO2 cells at 12, 14, and 24  (P > 0.05 at each 
timepoint). Significant differences were observed between WT/KO1 and WT/KO2 cells at all 
remaining timepoints (P < 0.001 for all timepoints). Error bars in B = standard deviation. C) 




















To determine the effect on CIZ1 deletion on cells re-entering the cell cycle post-quiescence, 
the percentage of S-phase cells was determined for WT and CIZ1 KO1 and KO2 cell lines 
between 12-24 hours post-release from G0. The low percentage of cells in S-phase at 12 
hours and the rise in proportion of cells in S-phase after 16 hours is consistent with effective 
synchronisation and cell cycle re-entry for both WT and CIZ1 KO cell lines. However, there is 
a marked difference in G1 length as the CIZ1 KO cell lines entered S-phase 4 hours earlier 
than WT cells (Figure 4.5B). Both KO cell lines show an increase in S-phase cells at 16 hours, 
whereas the WT cell line enters S-phase later at ~20 hours post-release from quiescence. 
Between 16 – 20 hours significantly fewer WT cells are in S phase compared to both KO cell 
lines.  
A two way ANOVA revealed significant interaction between cell line and time after release 
from quiescence on the proportion of cells entering S phase. Simple mains effects analysis 
revealed that this difference was significant between WT and KO1, WT and KO2, but not KO1 
and KO2 cells between 16-22 hours post quiescence. 
 As CIZ1 KO cell lines showed differences in G1 length after release from quiescence, pre-RC 
proteins CDC6 and MCM2 and the replisome protein PCNA were monitored using western 
blotting of whole cell extracts (Figure 4.6). Western blots showed that there is an 
accumulation of PCNA and MCM2 in both WT And CIZ1 KO cell lines. Importantly, in WT cells 
increased MCM2 levels was observed between 12-14 hours that was not observed in CIZ1 
KO1 cells. Broadly, there are no gross changes in the protein accumulation for CDC6 or PCNA 
for WT and CIZ1 KO cells. As the protein levels are comparable, the accumulation of 
replication proteins as well as Cyclin A and Cyclin E was determined in a more 
comprehensive time course from 0-24 hours to capture potential differences in early G1 
phase (Figure 4.6).  
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Figure 4.6 – Loss of CIZ1 changed the timing of cell cycle re-entry A) A schematic of the 
experimental design. B) Cell cycle re-entry post quiescence showing proportion of cells in S-
phase at each time point for WT and CIZ1 KO cell lines. The proportion of cells in S phase at 
each time point ( n = 3 repeats) for each cell line was compared using a two-way ANOVA 
with time and cell line as factors (P (time) < 0.001, P (cell line) < 0.001, P (interaction) < 
0.001. Pairwise comparisons were made by simple main effects analysis: no significant 
differences were observed  between KO1/KO2 cells at any timepoint, or WT/KO1 and 
WT/KO2 cells at 0, 4, 8, 12 and 24  (P > 0.05 at each timepoint). Significant differences 
were observed between WT/KO1 and WT/KO2 cells at all remaining timepoints (20 Hours P 
< 0.05 for both comparisons, P < 0.001 for all remaining timepoints). Error bars in B = 
standard deviation D) Western blots showing the levels of MCM2, CDC6 cyclin A and Cyclin 
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Both WT and CIZ KO cell lines efficiently synchronised in G0 and re-entered the cell cycle. The 
very low S populations of S-phase cells are early timepoints and increasing S-population 
indicate that both WT and CIZ1 KO cells are effectively synchronised at G0 and effectively re-
enter the cell cycle. Between 0 to 12 hours, there are no differences in the percentage of 
WT, KO1 and KO2 cells in S-phase. However, CIZ1 KO cell lines entered S-phase more rapidly 
than WT cells. Both CIZ1 KO cell lines show an increase in S-phase cells at 16 hours, whereas 
the WT cell line enters S-phase later at 20 hours post-release from quiescence, consistent 
with Figure 4.5. 
A two way ANOVA revealed significant interaction between cell line and time after release 
from quiescence on the proportion of cells entering S phase. Simple main effect analysis 
revealed that this difference was significant between WT and KO1, WT and KO2, but not KO1 
and KO2 cells between 16-20 hours. 
As CIZ1 KO cell lines showed differences in G1 length after release from quiescence, pre-RC 
proteins CDC6 and MCM2 as well as the G1/S phase cyclins, Cyclin A and Cyclin E were 
determined (Figure 4.6C,D). Accumulation of CDC6 in WT cells was more apparent than in 
CIZ1 KO cells at late time points. Conversely, MCM2 levels were increased at early time 
points in CIZ1 KO cells compared to WT cells. Importantly, cyclin E and A are detectable at 
earlier time points for CIZ1 KO cell lines relative to WT 3T3 cells. This suggests that CIZ1 null 
cells may express Cyclins E and A earlier to overcome the loss of CIZ1 function that enhances 
their activity at the G1/S transition (Copeland et al., 2010) and suggests that CIZ1 contributes 
to the mechanisms that maintain cell cycle timing and progression at the G1/S transition in 





4.3.3. Analysis of cell cycle exit into quiescence in WT and CIZ1 KO murine fibroblasts  
The difference in G1 length observed in post quiescent WT NIH 3T3 and CIZ1 KO cells is 
accompanied by a change in G1 and S-phase cyclin levels. As cyclin expression is driven 
through mitogenic signals, changes in cyclin E and cyclin A accumulation in CIZ1 null cells 
may be due to a difference in the degree of synchrony achieved by contact inhibition or 
changes in the restriction point. The levels of cyclin expression also regulate G1 length after 
quiescence, as Cyclin E overexpression changes cell cycle re-entry kinetics post-quiescence 
(Macheret & Halozonetis, 2018). To validate that differences in results seen between WT, 
and CIZ1 KO cells re-entering the cell cycle effective synchrony at G0, exiting the cell cycle 
needed to be confirmed. To determine the effect of CIZ1 deletion on cells exiting the cell 
cycle ,the proportion of WT, CIZ1 KO1, and CIZ1 KO2 cells exiting the cell cycle was 
determined in confluent cells on day 0 (day of confluence), 24 hours after reaching 
















Figure 4.7 – CIZ1 KO cells exit cell cycle more rapidly than WT cells A/B) Representative images of WT and KO1 cells 
asynchronous, at quiescence, and each day after quiescence release. Blue represents DAPI, and red represents EdU. Scale 
bars represent 200 µm. C) The proportion of cells in S phase at each time point for each cell line. Measured by fluorescence 
microscopy of cells that incorporated EdU The proportion of cells in S phase at each time point (n = 3 repeats) for each cell 
line was compared using a two-way ANOVA with time and cell line as factors (P (time) < 0.001, P (cell line) < 0.001, P 
(interaction) < 0.001. Pairwise comparisons were made by simple main effects analysis, significance is highlighted on C. ns 








Analysis of asynchronous cell cultures between 60 -70 % of each cell line (WT, CIZ1 KO1, and 
CIZ1 KO2) were in S-phase, and no large differences were observed between the cell lines. 
However, at the day of 100 % confluence (day 0), fewer WT cells had exited the cell cycle 
than either of the CIZ1 KO cell lines, with 32 % of WT cells were in S-phase, compared to 12 
% and 10 % of CIZ1 KO1 and CIZ1 KO2 cell lines respectively. A two way ANOVA revealed 
significant interaction between time point and cell line. Simple main effects analysis revealed 
significant differences between WT cells, and both KO1 and KO2 cells on the day of 
confluence (day 0), no significant differences were observed between KO1 and KO2 cells at 
any timepoint. This suggested both KO cells lines exited the cell cycle faster than WT cells. 24 
hours after reaching confluence, all cell lines had fewer than 10 % of cells in S-phase and 2 
days after confluence all cell lines had <5% of cells in S-phase.  
The reduction in the proportion of cells in S-phase by two days after reaching confluence 
show that both WT, and CIZ1 KO cells are effectively synchronised at G0 by contact inhibition 
and serum starvation. This result confirms that differences observed in cell cycle re-entry 
were not due to an inefficiency in cell cycle exit caused by loss of CIZ1. The decrease in the 
number of both KO cells in S-phase at earlier time points suggest that CIZ1 KO cells exit the 
cell cycle faster than WT cells and that differences in cyclin E and A expression are not due to 
asynchrony in the CIZ1 KO cell lines. This data supports the potential for CIZ1 in regulation of 
the restriction point. The kinetics of cell cycle exit is linked to intracellular kinase levels 
carried over from the previous cell cycle (Moser et al., 2018). This is consistent with the 
CIZ1’s proposed role as a kinase sensor that regulates the G1/S transition through with Cyclin 
A and Cyclin E interactions (Copeland et al., 2015). These data further support observations 
that implicate CIZ1 as a kinase sensor and modulator of cyclin-CDK activity. These data 
suggest that CIZ1 affects the efficiency of cells exiting of the cell cycle at quiescence, and also 
influences cell cycle re-entry from quiescence.  
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4.3.4. Analysis of the timing for Restriction point in WT and CIZ1 null fibroblasts.  
Results up to this point have revealed that CIZ1 null cells have different cell cycle re-entry 
kinetics when compared to WT cells. There is some evidence indicating this result was due to 
changes in response to external growth signals. CIZ1 null cells display a more rapid cyclin 
expression profile and exit the cell cycle more rapidly when growth signals are depleted. If 
cells are responding differently to growth signals, a change in the timing of the restriction 
point may be observed. The restriction point describes the point in G1 at which cells no 
longer require mitogenic signal to complete the cell cycle. Post-restriction point cells are 
‘committed’  to completing the cell cycle and to dividing. 
To determine the timing of restriction point in WT and CIZ1 KO cell lines, synchronised cells 
were released and cultured in media with serum. Cells were synchronised in G0 released into 
fresh media and grown on coverslips for analysis of the proportion of cells at each time point 
in S-phase. Subsequently, at time points media was removed, cells washed and serum free 
media plus EdU added to define the time point where cells become independent of mitogens 






Figure 4.8-Loss of CIZ1 altered serum dependence A) A graphical schematic of the 
experimental design. B) The percentage of cells that were EdU positive, measured by 
fluorescence microscopy (N = 3 ± S.D.). C) Western blots of a number of replication 
factors at each time point for WT and CIZ1 KO1 cells. D) Quantification of MCM2 S40/41 








































To determine the effect of CIZ1 knockout on the timing of the restriction point after cells are 
synchronously released from G0, the percentage of S-phase cells was determined 24 hours 
after release. The removal of serum is indicated for each time point for WT and CIZ1 KO1. To 
establish if any changes observed were associated with differences in accumulation of 
replication licensing factors western blots of whole cell extracts were performed with DNA 
replication licensing factors and PCNA. 
In contrast to cell cycle re-entry in a complete medium, WT cells appear to be less 
dependent on serum for cell cycle re-entry than CIZ1 KO cells, pre-restriction point. For CIZ1 
KO1 cells, less than 10 % of cells enter S-phase before 14 hours but from the 16 hour time 
point onward between 45 – 55 % of cells had reached S-phase by 24 hours, comparable to 
the WT cells. As CIZ1 KO cell lines showed reduced numbers of cells in S-phase levels before 
the 16 hour time point, we monitored the Pre-RC proteins CDC6 and MCM2, pS40/41 MCM2 
and PCNA. The phosphospecific anti-MCM2 phosphoserine 40/41 monitor DDK and CDK 
mediated phosphorylation (Fei et al., 2018). Western blots showed a reduction in MCM2, 
and CDC6 in CIZ1 KO cells relative to WT controls at each time points. PCNA accumulation 
seemed less affected in CIZ1 KO1 cells, relative to controls PCNA levels increase from 16 
hours onwards was observed in WT cells. Reduced pre-RC (Cdc6, MCM2) protein levels are 
observed in CIZ1 null cells after the restriction point implying a deficiency in the cellular 
signalling that results in their accumulation. PCNA levels are largely unchanged implying that 
this deficiency is linked to replication licensing and initiation rather than replisome assembly. 
MCM2 phosphorylation was higher at all timepoints in WT cells. MCM2 Phosphorylation was 
unaffected by passing the restriction point in WT cells. In CIZ1 KO cells before the restriction 
point there was a large decrease in MCM2 s40/41 phosphorylation (4.8D). Together this 
indicates a greater reliance on growth signals in CIZ1 KO cells pre-restriction point. However, 
post restriction point replication is allowed to continue with reduced accumulation of 
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licensing and initiation factors. This could result in DRS due to under licensed DNA in 
conditions with low levels of growth signals.  
The rise in proportion of cells in S-phase for both WT, and CIZ1 KO1 cells from 16 hours post 
release suggests cells were effectively synchronised at G0, meaning differences were due to 
loss of serum. The increase in number of both WT, and CIZ1 KO1 cells in S-phase between 14 
hours and 16 hours indicates that the restriction is between 14 and 16 hours post release 
from quiescence. The reduced proportion of CIZ1 KO1 cells in S-phase prior to this implied 
restriction point suggests that before the restriction point, CIZ1 KO1 cells have an increased 
dependence on exterior signalling than WT cells. This coupled with increased cell cycle re-
entry rate suggesting a role for CIZ1 both before and after the restriction point.  
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4.3.5. Loss of CIZ1 Causes a Moderate Shift in the Restriction Point in Post Quiescence Cells 
To further investigate if there was any difference in the restriction point experiments from 
4.6. were repeated at hourly intervals surrounding 14-16 hours. The proportion of cells in S-
phase at 24 hours were determined from 15-17 hours (Figure 4.9). 
A low proportion of WT cells were in S-phase at 15 hours post-release, consistent with Figure 
4.8. However, there is an increase in the percentage of S-phase cells 15 hours post release 
from quiescence in CIZ1 KO cell lines. This was significantly difference from WT cells. The 
difference is short lived as at the 16 hour time point 40-50 % of both WT and CIZ1 KO cells 
are in S-phase, consistent with earlier results (Figure 4.8), no significant differences were 
observed between cell lines at either the 16 or 17 hour timepoints.  
The data presented here suggests that at early time points before 14 hours after release, WT 
cells are more likely to enter S-phase after removal of serum but that CIZ1 KO cell lines have 
A B 
Figure 4.9-Loss of CIZ1 altered the restriction point A) A graphical schematic of the experimental 
design. B) The proportion of cells that were EdU positive, measured by fluorescence microscopy. The 
proportion of cells in S phase at each time point (n = 3 repeats) for each cell line was compared using a 
two-way ANOVA with time and cell line as factors (P (time) < 0.001, P (cell line) < 0.01, P (interaction) < 
0.01). Pairwise comparisons were made by simple main effects analysis, significance is highlighted on 
C. ns = p > 0.05 * = p < 0.05, ** = p < 0.01, *** p< 0.001 Error bars in B= standard deviation 
 
***                ns       ns 
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an earlier restriction point. In WT cells the restriction point lies between 15-16 hours post 
release from quiescence, where as in CIZ1 KO1 cells it lies between 14- 15 hours post release 
from quiescence. Coupled with earlier data, this indicates that CIZ1 may contribute to the 
mechanisms that regulate the timing of restriction point.  
4.3.6. Loss of CIZ1 Results in a Prolonged DDR to Hydroxyurea 
In fibroblasts isolated from murine CIZ1 knockout models, CIZ1 null cells were sensitive to 
DNA damaging agent Hydroxyurea (HU) (Nishibe et al., 2013). Hydroxyurea is frequently 
used to increase DRS through the depletion of nucleotide pools leading to stalled DNA 
replication forks. To investigate the effect of HU treatment in CIZ1 KO cells, WT, CIZ1 KO1, 
and CIZ1 KO2 cells were treated with hydroxyurea for 2 hours, HU removed and cell 
incubated in fresh media. To investigate the impact on DNA replication the proportion of 
cells in S-phase was determined and activation of the DDR by phosphorylation of H2AX was 










Figure 4.10 – Loss of CIZ1 moderates the DDR to HU Cells were treated with HU and 
then HU was removed. A) A graphical schematic of the experimental design. B) The 
proportion of cells in S-phase at each time point for negative controls with no HU C) The 
proportion of cells in S-phase at each time point for experimental samples  (N = 3 ± S.D.) 
D) The levels of γH2aX phosphorylation at each time point for WT cells. E) The level of 

























For both WT, CIZ1 KO1, and CIZ1 KO2 cells there were small variations in the proportion of 
cells in S-phase at time points, however all remained between 50 – 70 %. This provides a 
base level of cells in S-phase, that is corroborated by earlier data. Treatment with HU 
resulted in no change in the percentage of S-phase cells 30 minutes after treatment. 
However, 2 hours after treatment with HU there was complete ablation of the S-phase 
population of cells for WT and CIZ1 KO cell lines. Controls were included in which media 
changes occurred, but no HU was included (Figure 4.10 b). After removal of HU WT and CIZ1 
KO1 and 2 cells rapidly entered the cell cycle within 2 hours (Figure 4.10C).  
CIZ1 KO cell lines showed no differences in cellular responses to HU and cell cycle re-entry at 
these time points, but previous reports had indicated loss of CIZ1 results in a disrupted DDR. 
Next the phosphorylation status of Histone H2 was monitored at each time point for WT, and 
CIZ1 KO1 cells. In untreated control samples, no H2AX phosphorylation was observed at any 
time point. For WT cells (Figure 4.10D), a H2AX response was observed 30 minutes after HU 
treatment, which was sustained for the length of HU treatment (2 hours), and 2 hours after 
removal of the HU challenge. 24 hours after HU treatment H2AX phosphorylation had 
returned to baseline levels.  
In CIZ1 KO1 cells (Figure 4.10E), there was a delay in H2AX phosphorylation relative to WT 
cells. There was a low H2AX phosphorylation signal, similar to those of negative controls 
after 30 minutes HU treatment.  However, the phosphorylation of H2AX increased after 2 
hours and this signal was maintained for 24 hours after treatment HU in CIZ1 KO1 cells. This 
prolonged intense H2AX signal suggests that CIZ1 null cells are deficient in fork restart or in 
the repair of damaged cells relative to WT cells (Figure 4.10D). 
The drop, and subsequent resumption of the proportion of cells in S-phase show in response 
to HU treatment and removal implies that both WT, and CIZ1 KO cells effectively halt and 
restart S-phase in response to HU challenge. HU depletes nucleotide pools causing a stalling 
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in DNA replication. Efficient fork restart following this HU challenge indicates that the DDR is 
functional in CIZ1 KO cells. H2AX signalling changes in CIZ1 KO1 cells implies that loss of CIZ1 
reduces the efficiency of the DDR, leading to prolonged phosphorylation of H2AX. This failure 
may cause increased DNA damage in response to DNA replication stress, leading to the 
prolonged H2AX response observed in CIZ1 KO1 cells. The prolonged response may also be 
due to a de-regulation of the DDR upon loss of CIZ1. This implicates CIZ1 as having a role in 
the efficiency of the DDR in response to replication stress. It has been proposed that CIZ1 
deregulation may lead to DRS, this may be linked to the alternative DDR observed in 
response to HU (Chapter 6.).  
4.4. Generating and Characterising CIZ1AB Cells 
4.4.1. Ectopic Expression of CIZ1 in CIZ1 KO1 NIH 3T3 Cells 
To ensure that differences in cell behaviour observed between WT and CIZ1 KO NIH 3T3 cells 
were due to loss of CIZ1 and not an off-target effect introduced during the CRISPR Cas9 
process, a GFP-CIZ1 addback cell line was produced. A GFP-CIZ1 construct was produced that 
contained a selection cassette to ensure stable transfection. CIZ1 KO1 cells were used to 
generate stably expressing GFP-CIZ1. The GFP-CIZ1 plasmid was linearized using ApaLI, and 
cells transfected with the linearized plasmid. After 24 hours 400 µg/ml geneticin (G-418) was 
added to the plate as a selection agent for 14 days, with media changes every 3 days. After 
selection, to validate that cells were expressing GFP-CIZ1, CIZ1 KO1 cell were harvested for 
western blot (Figure 4.11 e) and fluorescence microscopy analysis (Figure 4.11D). This stable 
transfection was performed in the CIZ1 KO1 cell line, which expressed the mouse WT ECIZ1 
gene fused to GFP and will be referred to CIZ1AB hereafter.  
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After 2 weeks of selection, fluorescence microscopy and western blotting were used to 
confirm GFP-CIZ1 expression. (Figure 4.11c/d/e). Fluorescence microscopy revealed a 
predominantly nuclear GFP fluorescence (Figure 4.11) demonstrating that selected cells 
expressed GFP-CIZ1. In addition, western blots showed the appearance of a GFP band at in 
transfected cells at the expected size (140 kDa), and CIZ1 was not present in untransfected 
CIZ1 KO1 cells. This data demonstrates successful stable expression of GFP-CIZ1 in the CIZ1AB 
cell line. This cell line was used to investigate if CIZ1AB cells would reverse the CIZ1 KO 
phenotypes observed in this chapter.  
A 
B 
Figure 4.11-Generation of stably transfected CIZ1AB Cell line A) Displays a Graphical 
Schematic of the process for generation of stably transfected GFP-CIZ1 expressing cells B)  
Displays representative images of cells expressing GFP-CIZ1 2 weeks after transfection 













4.4.2. Asynchronous Cell Cycle Profiles of GFP-CIZ1 Addback Cells  
Earlier experiments revealed that loss of CIZ1 caused no changes to the cell cycle profile of 
cells in S-phase (4.3.1). To validate the viability of CIZ1AB cells and ensure that the addition 
had no effect on the proportion of cells in S-phase these experiments were to be repeated 
with CIZ1AB cells. Again, asynchronous plates of WT, KO1, and CIZ1AB cells were EdU labelled, 
samples were analysed by flow cytometry and scoring of the proportion of cells in S-phase, 
protein samples from whole cell extracts were also taken for analysis by western blotting 
(Figure 4.12). 
Figure 4.12-Analysis of asynchronous CIZ1AB cell lines A) Displays a graphical schematic of 
the experimental design. B) Displays the proportion of each cell line in S-phase counted 
through fluorescence microscopy of positively Edu labelled cells. The mean proportion of cells 
in S phase did not vary significantly between conditions (one-way ANOVA P > 0.05, n = 3 for 
each condition), Error bars represent S.D.  C) Displays western blot analysis of whole cell 
extracts of asynchronous cultures of the 3 cell lines. 
 
To determine the viability of CIZ1AB cells the proportion of WT, CIZ1 KO1 and CIZ1AB cells was 
determined for asynchronous cell cultures. No significant differences were observed in the 
proportion of cells in S-phase for cells in WT, CIZ1 KO and CIZ1AB cell lines in asynchronous 
A) 
B)   
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culture (Figure 4.12b). For each cell line an average of ~60 % of cells were in S-phase any 
observed differences were insignificant.  
Western blots analysis of WT, CIZ1 KO and CIZ1AB cell lines for pre RC protein MCM2, 
replisome protein PCNA, G1 cyclin: Cyclin E, and S-phase cyclin: Cyclin A (Figure 4.12c). No 
differences in the levels of MCM2, PCNA or Cyclin E were observed across cell lines. No 
differences in proportion of cells in S-phase between WT, and CIZ1 KO cells corroborated 
earlier data (Figure 4.3). In addition, genetic add back of CIZ1 did not affect cell cycle 
progression in asynchronous cells.  
However, a reduction of Cyclin A levels was observed in CIZ1 KO1 cells compared to WT cells. 
This effect was reversed in CIZ1AB cells that showed Cyclin A levels comparable to WT cells. 
This provides a key link between Cyclin A, and CIZ1. Previous studies have shown that CIZ1 
interacts with Cyclin A at the nuclear matrix (Coverley et al., 2005; Copeland et al., 2010; 
Copeland et al., 2015), but no study has identified a link between CIZ1 and Cyclin A levels. 
This effect could be caused through disruption of the cellular signals that promote the 
expression of Cyclin A, or through disruption to the proteolytic pathways that result in the 
degradation of Cyclin A. The lower level of Cyclin A was not accompanied by a reduction in 
the proportion of cells in S-phase a direct link between CIZ1 and Cyclin A has interesting 
implications for its role in the G1/S transition (Chapter 5).  
4.4.3. CIZ1AB cells display WT cell cycle re-entry kinetics.  
CIZ1 KO cells displayed a more rapid entry to S-phase from G0 than WT cells (Figure 4.4-4.6). 
To provide additional support for the role of CIZ1 contributing to mechanisms that regulate 
the G1/S transition CIZ1AB cells were used to demonstrate that this effect was reversible. If 




To evaluate the effect of CIZ1 add back on cell-cycle re-entry kinetics post quiescence CIZ1AB 
cells were compared to WT cells. Cells were synchronised in quiescence, released and cells 
were harvested as indicated. Cells were analysed by EdU labelling and fluorescence 
microscopy (Figure 4.13).  
WT cells re-entered the cell cycle with increasing EdU incorporation from 20 hours and this 
was mirrored in CIZ1AB cells. Both cell lines had consistent percentages of cells in S-phase at 
all time points. These data were notably different from results from CIZ1 KO1 that showed 
an increase in EdU positive cells from 16 hours after release from quiescence (Figure 4.4, 
B) 
A) 
Figure 4.13. CIZ1AB cell cycle re-entry post-quiescence mirrors WT cells. A) An overview of the experimental design B) 
Cell cycle progression was determined by EdU incorporation in S-phase, showing the percentage of cells at each time 
point. KO1 data is superimposed from Figure 4.5. The proportion of cells in S phase at each time point ( n = 3 repeats) 
for each cell line was compared using a two-way ANOVA with time and cell line as factors (P (time) < 0.001, P (cell line) 
< 0.001, P (interaction) < 0.001. Pairwise comparisons were made by simple main effects analysis: no significant 
differences were observed  between WT/CIZ1AB cells at any timepoint, or WT/KO1 and KO1/CIZ1AB cells at 12, 14, and 
24  (P > 0.05 at each timepoint). Significant differences were observed between WT/KO1 and KO1/CIZ1AB cells at all 








data also shown in Figure 4.13). In contrast, there were no large differences between WT 
and CIZ1AB cell lines at any time point.  
A two way ANOVA with revealed significant interaction between cell line and time after 
release from quiescence on the proportion of cells entering S phase. Simple main effect 
analysis revealed that this difference was significant between 16-20 hours between WT and 
KO1, KO1 and CIZ1AB, but not WT and CIZ1AB cells. 
Earlier experiments revealed that the rapid entry of CIZ1 KO cells into the cell cycle after G0 
arrest occurred after 12 hours. To confirm this and validate the synchrony of CIZ1AB cells, 




Figure 4.14 – 24 hour monitoring of a release of CIZ1AB cells into S-phase A) Displays a graphical 
schematic of the experimental design B) The proportion of cells in S-phase for each time point measured by 
fluorescence microscopy of positively labelled cells. KO1 data is superimposed form Figure 4.6 . The 
proportion of cells in S phase at each time point (n = 3) for each cell line was compared using a two-way 
ANOVA with time and cell line as factors (P (time) < 0.001, P (cell line) < 0.001, P (interaction) < 0.001. 
Pairwise comparisons were made by simple main effects analysis: no significant differences were observed  
between WT/CIZ1AB cells at any timepoint, or WT/KO1 and KO1/CIZ1AB cells at 0, 4, 8, 12 and 24 hours  (P > 
0.05 at each timepoint). Significant differences were observed between WT/KO1 and KO1/CIZ1AB cells at all 
remaining timepoints (P < 0.01 for all comparisons). Error bars in B = standard deviation 








 Comparison of 0-24 time courses revealed that WT and CIZ1AB have similar re-entry kinetics 
that are not significantly different. This contrasts with CIZ1 KO1 that showed significant 
differences at time points 16-20 hours post release (Figure 4.6, data also shown in Figure 
4.14). These differences were reversed by in CIZ1AB cells.  
A two way ANOVA with revealed significant interaction between cell line and time after 
release from quiescence on the proportion of cells entering S phase. Simple main effects 
analysis revealed that this difference was significant between WT and KO1, KO1 and CIZ1AB, 
but not WT and CIZ1AB cells between 16-20 hours. This suggested ectopic CIZ1 expression 
reversed the increased quiescence rate phenotype observed in CIZ1 KO. 
As there were no significant differences between WT and CIZ1AB cells at any timepoint. This 
confirmed G0  synchrony of CIZ1AB cells and marked another observable difference upon loss 
of CIZ1 that was rescued by ectopic expression of the GFP-CIZ1 fusion protein. 
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4.4.4. Altered ‘Restriction Point’ of CIZ1 KO cells is rescued by Ectopic Expression of GFP 
CIZ1  
Earlier experiments revealed that loss of CIZ1 KO resulted in a shift in the timing of the 
restriction point by approximately 1 hour (Figure 4.9). This subtle, yet significant shift, may 
explain how CIZ1 null cells have altered cell cycle kinetics. Next to see if this effect was 
reversed in CIZ1AB cells, restriction point was determined by adding serum free media 
between 15-17 hours post quiescence, the percentage of cells in S-phase determined (Figure 
4.15). 
Removing serum at 15 hours showed 20 – 30 % of cells in S-phase for both cell lines. that 
increased for 16 hours to 40 – 50 % of cells were in S-phase, this is comparable to controls 
with no media change and suggests that the restriction point is between 15 and 16 hours for 
WT and CIZ1AB cell lines. Comparison with CIZ1 KO1 cell line (From Figure 4.9, also shown in 
Figure 4.15) shows that restriction point was before 15 hours, showing that the CIZ1AB cell 
line reversed differences in restriction point.  
A) 
Figure 4.15-Analysis of the restriction of the CIZ1AB cells. A) Displays a graphical schematic of the 
experimental design. B) Displays the proportion of cells in S-phase at 24 hours post release for each of the 
media change time points, measured through fluorescence microscopy of the positively EdU labelled cells. 
The proportion of cells in S phase at each time point (n = 3) for each cell line was compared using a two-
way ANOVA with time and cell line as factors (P (time) < 0.001, P (cell line) < 0.001, P (interaction) < 
0.001). Pairwise comparisons were made by simple main effects analysis, significance is highlighted on C. 
ns = p > 0.05 * = p < 0.05, ** = p < 0.01, *** p< 0.001 Error bars in B= standard deviation. KO1 data is 














A two way ANOVA revealed significant interaction between cell line and time after release 
from quiescence on the proportion of cells entering S phase. Simple main effects analysis 
revealed that this difference at the 15 hour timepoint was significant between WT and KO1, 
and KO1 and CIZ1AB, but not WT and CIZ1AB cells. This indicated that ectopic CIZ1 expression 
could rescue the altered restriction point phenotype. This data suggests that CIZ1 plays a role 
in establishing the timing of restriction point in murine fibroblasts.  
4.4.5. CIZ1AB cells reverse defects in cellular response to Hydroxyurea 
Earlier results demonstrated that loss of CIZ1 results in an altered DDR in response to DRS 
caused by HU. This was characterised by a delayed, yet prolonged phosphorylation of 
histone H2AX. To evaluate the effect of genetic add back of CIZ1, parallel experiments were 
performed to compare responses to HU in WT and CIZ1AB cells. Cells were treated with 1 mM 
HU for 2 hours. The experiment mirrored the experiment in Figure 4.10. Briefly, for 
experiential cells, media was replaced with media containing 1 mM HU, samples were 
harvested after 30 minute and 2 hours HU treatment. After 2 hours HU media was replaced 
with fresh media – HU. Control plates were harvested without addition of HU. At time points 




Figure 4.16-Response to HU treatment in CIZ1AB cells A) Displays a graphical schematic of the 
experimental design. B) Displays the proportion of cells in S-phase at each time point. Measured by 
counting the positively EdU labelled cells using fluorescence microscopy. The proportion of cells in S phase 
at each time point (n = 3) for each cell line was compared using a two-way ANOVA with time and cell line 
as factors (P (time) <0.05, P (cell line) > 0.05, P (interaction) > 0.05. C) Displays western blots of H2AX 
phosphorylation in CIZ1AB cells. D) Relative intensity of H2AX signal for each cell line (WT and KO1 data 
from Figure 4.10) Each sample is standardised to actin intensity and compared to the untreated control 





















For both WT, and CIZ1AB control cells no differences were seen in the proportion of cells in S-
phase at any time point. Both WT and CIZ1AB induced the same effect in the proportion of 
actively replicating cells, 2 hours after treatment a complete ablation of the population of S-
phase cells was observed, this was resolved 2 hours later, returning to control levels. This 
remained 24 hours after treatment. This confirmed that HU mediated replication stress 
resulted in the halting of the cell cycle. A Two way ANOVA confirmed there was no significant 
difference between cell lines.  
Western blots revealed that CIZ1AB cells responded similarly to WT cells from Figure 4.10. an 
increase in gamma H2AX was observed 30 minutes after HU treatment. This signal was 
maintained through the HU treatment, and 2 hours after removal. 24 hours after treatment 
the gamma H2AX levels had returned to untreated control levels (Figure 4.16C). Relative 
intensities of the blots presented here and in Figure 4.10, confirmed that ectopic CIZ1 
expression partially restored the WT phenotype of H2AX phosphorylation, although the 
initial response (0.5 hours) was lower in CIZ1AB cells (Figure 4.16d). Critically the sustained 
response observed in CIZ1 KO1 cells 24 hours after treatment with HU was lost in CIZ1AB cells. 
This implied that the defect in response to HU caused by loss of CIZ1 was rescued by 
returning GFP-CIZ1, CIZ1AB respond to HU more similarly to WT NIH 3T3 cells. Together this 
implies that ectopic expression of GFP-CIZ1 partially restores the altered DDR to HU 
observed in CIZ1 null cells.  
No differences in proportion of cells in S-phase between WT, and CIZ1AB cells implies that 
ectopic expression of GFP-CIZ1 didn’t result in gross changes in response to HU mediated 
DNA replication stress. Ablation of S-phase population confirmed that HU resulted in a 
stalling of the cell cycle through DDR activation. As the pattern of H2AX was more similar to 
WT cells than CIZ1 KO1 cells (Figure 4.10) this implied that ectopic expression of GFP-CIZ1 
was sufficient to reduce sensitivity to DNA replication stress. This further implies a role for 
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CIZ1 in modulating the DDR in response to replication stress. This will be further explored in 
Chapter 6.  
Critically, all of the subtle changes in cell cycle re-entry and response to DRS observed in CIZ1 
KO cells was either resolved or partially resolved by GFP-CIZ1 expression. Future Chapters 
will investigate the link between CDK networks and cell cycle re-entry (Chapter 5) and 
investigate the effect CIZ1 levels have on replication initiation, and DRS, using DNA combing 
(Chapter 6). 
4.5. Chapter Discussion 
Discovery of CRISPR Cas9 heralded a new age of rapid, cheap, efficient genome editing. The 
ability to simply modify the DNA sequence within cells had wide felt implications for 
research, and disease treatment. CRISPR CAS9 is being actively developed as a treatment for 
cystic fibrosis, mutation has been achieved in vitro in cultured cystic fibrosis epithelia cells 
(Maule et al., 2019). However, more recently problems have arisen for CRISPR Cas9 as a 
genome editing tool. Primarily this is focussed on the observed high frequency of off target 
mutation in cells that have been undergone the CRISPR CAS9 genome editing programme. 
Zhang et al. (2015) observed that there was a greater than 50 % rate of off target mutations. 
This could be problematic if mutations result in a phenotype change that incorrectly 
interpreted as being due to the loss of the target. In this study, this has been mitigated in 3 
ways. Firstly, a genome wide search of the complementary guide sequence revealed no 
repeats, this should prevent off target effects caused directly by a repeating PAM. Secondly, 
two neighbouring PAM sites in the CIZ1 sequence were targeted: CIZ1 KO1 and CIZ1 KO2. 
The use of 2 unique PAM sites should minimise the likelihood of common off target effects. 
Finally, the return of genetic addback CIZ1 to the KO1 cells to produce CIZ1AB cells reverses 
the phenotypes observed with respect to cell cycle regulation and responses to HU.  
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All phenotypes in CIZ1 KO clones 1 and 2 were consistent. In addition, the observed 
differences were consistently statistically significantly between WT and KO1 and KO2, 
whereas there were no significant differences between CIZ1 KO1 and KO2. Similarly, analysis 
of the CIZ1AB cell line showed a partial or full reversal to the WT phenotype. This was borne 
out in mean results returning to WT levels whilst remaining disparate from results observed 
in KO1 & KO2 cells. Using multiple levels of redundancy, the results observed in this Chapter 
& future Chapters are highly likely to be due to the deletion of CIZ1 in the cells. 
In this chapter, it has been demonstrated that CIZ1 directly plays a role on cell cycle. Loss of 
CIZ1 dysregulates timing of S-phase entry in cells exiting quiescence and alters the timing of 
restriction point. The timing of the G1 to S-phase transition is critical for maintenance of 
genome integrity through the fidelity of DNA replication. DNA replicated early can be “under 
licenced“ this would result in insufficient origins firing resulting in S-phase not concluding 
before the onset of mitosis (Limas & Cook, 2019). From the data presented here, it is unclear 
whether CIZ1 KO increases the potential for mitosis before completion of DNA synthesis. 
Whilst cell-cycle re-entry is accelerated it remains to be addressed whether the early entry 
into S-phase has an effect on DNA replication fidelity.  
Importantly, cell synchronisation revealed a difference in the expression pattern of the G1 
and S-phase cyclins between the WT and CIZ1 KO cells. Cells without CIZ1 appeared to show 
earlier expression of Cyclin A, although consistent Cyclin E. As the driving forces of cell cycle 
entry, more rapid cyclin expression would explain an early entry into S-phase. Previous 
reports have demonstrated that, during the G1/ S-phase transition CIZ1 anchors both Cyclin 
E/CDK2 and Cyclin A/CDK2 to the nuclear matrix (Copeland et al., 2010) promoting a switch 
between which cyclin is active during S-phase. Additionally, phosphorylation status of CIZ1 
drives the binding of cyclins to the nuclear matrix (Copeland et al., 2015). Localisation of 
both cyclin A and Cyclin E is key to their function; both are shuttled between the nucleus and 
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cytoplasm during the cell cycle depending on whether they are driving genome replication or 
cytoplasmic regulation (Jackman et al., 2002). Loss of CIZ1 may therefore cause a change in 
localisation of cyclins that could change their activity.  
Additionally, production of the G1/S cyclins occurs in a positive feedback loop. The initial 
signal is provided by the binding of exterior growth signals. These promote synthesis of 
Cyclin D. Cyclin D/CDK 4/6 phosphorylates tumour suppressor pRB which initiates a signal 
transduction pathway resulting in the activation of the E2F transcription factor which 
promotes production of Cyclins A and E (Lukas et al., 1997; Zarkowska et al., 1999). These 
cyclins dimerise with CDK2 promoting full phosphorylation of RB fully activating E2F resulting 
in the synthesis of more cyclin E, and cyclin A as well as a number of replication proteins 
including MCM2, CDC6, and PCNA.  
Changes in levels of replication factors can also partially be explained through increased 
cyclin E and cyclin A signalling. In cells, re-entering the cell cycle, CDK2 mediated 
phosphorylation of these replication factors regulate their stability and regulation by the 
UPS. For example, in G1 phosphorylation of CDC6 by Cyclin E/CDK2 protects if from 
proteolysis mediated by the APC/CCDH1, the major E3 ligase active from anaphase to early G1 
(Mailand & Diffley, 2005).  
Results in this Chapter predominantly stemmed from observing cells re-entering the cell 
cycle. A consistent, repeatable, average increase in the proportion of cells entering S-phase 
at earlier time points was observed in CIZ1 KO1 and KO2 cell lines. This result could be 
interpreted in multiple ways. The first is that CIZ1 null cells re-enter the cell cycle more 
rapidly than their WT counterparts. However, re-entry into the cell cycle is not homogenous, 
as a number of cells within the quiescent population will remain quiescent and will simply 
not enter the cell cycle (Wang et al., 2017). Because of this, a second interpretation of this 
result could be that simply, more CIZ1 null cells re-enter the cell cycle and S-phase following 
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quiescence. This seems less likely than the former option, as 24 hours after release from 
quiescence there are similar levels of WT and CIZ1 KO cells in S-phase. If simply more cells 
were entering S-phase, following the same ‘replication programme’ the expected result 
would be a greater proportion of cells in S-phase. Additionally, the shift in the restriction 
point observed in these experiments would not be expected.  
The data presented imply that CIZ1 contributes to regulation of G1 length specifically in cells 
re-entering the cell cycle from quiescence. This is of particular interest for genetic stability. It 
is long established that overexpression of oncogenic proteins Cyclin E and Cyclin D result in a 
shortened G1 in cells re-entering the cell cycle, Cyclin E also having this effect on cycling 
cells. Expression of these proteins also results in a delayed entry into quiescence phenotype 
(Resnitzky et al., 1994) It is not clear if this explains how altered CIZ1 expression effects this 
phenotype, Cyclin E is a known interacting partner (Coverley et al., 2005; Copeland et al., 
2010), although this has not been observed with Cyclin D. However, it is clear that shortened 
G1 phenotype results in increased DRS (Ahuja et al., 2016). 
G1 length and replication licensing is linked to genetic instability. Cells of different age, 
development and cell type present with varying length G1 phases (Matson et al., 2017). 
Additionally, the initial G1 phase after cell cycle re-entry is longer than in actively cycling 
cells. To ensure replication occurs unimpeded, cells with shorter G1 phase licence replication 
origins more rapidly than cells with slower G1 phases. Critically overexpression of Cyclin A or 
Cyclin E separates the G1 length from the replication licensing process resulting in early S 
phase and DRS, driving genome instability. CIZ1 has been shown to play a role in co-
ordinating the activity of Cyclin A and Cyclin E surrounding the G1/S transition (Copeland et 
al., 2010; Copeland et al., 2015). Interestingly, increasing the length of G1 following 
quiescence synchrony allows increased replication licensing to levels more comparable with 
cycling cells (Matson et al., 2019). Results in this chapter demonstrated that loss of CIZ1 
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resulted in a shorter G1 following quiescence perhaps due to changes in replication licensing 
through altered Cyclin levels. If this shortened G1 phase is coupled with decreased 
replication licensing, then this may act as a source of genome instability, potentially 
explaining the Tumour suppressor function of CIZ1 that has been reported (Nishibe et al., 
2013; Ridings-Figueroa et al., 2017). Future Chapters will investigate responses to 
Cyclin/CDKs in post-quiescent nuclei with and without CIZ1, as well as investigating if loss of 
CIZ1, and altered CDK levels results in a stressed phenotype. 
Other factors that regulate the G1 length include co-drivers of the cell cycle with the cyclin 
CDK networks. Cell cycle regulation is associated with temporally regulated activation of E3 
ligases that  degrade Cyclin subunits inactivating CDKs, resetting the cell cycle, and 
regulatory factors allowing cell cycle progression. CDH1 is a co-activator of APC, APCCDH1 is an 
E3 ligase active from anaphase to the onset of S-phase. One target of APCCDH1 is SKP2, SKP2 is 
a component of another cell cycle relevant E3 ligase SCFSKP2. SCFSKP2 is active from S-phase 
onset till degradation during mitosis by APCCDH1. Critically, SCFSKP2 degrades CDKi proteins p21 
and p27 (Rizzardi et al., 2012). P21 is a CIZ1 interacting partner (Mitsui et al., 1999). p21 and 
p27 inhibit CDK2 activity in G1, Depletion of CDH results in reduced levels of p21 and p27 in 
G1. Typically, CDK inhibition is overcome through CDK2 activity, allowing a molecular switch 
for cell cycle entry. In CDH1 deficient cells the positive feedback loop is weakened resulting 
in a lower CDK activity required to overcome p27 activity. This resulted in reduced G1 length 
(Yuan et al., 2014). CDH1 depletion leads to DRS, misregulated cyclin localisation, DNA 
damage and mitotic defects (Griel et al., 2016). CDH1, also promotes inhibition of origin 
firing after cells experience severe replication stress, this occurs in a p21 and p53 dependent 
manner. The effect of CIZ1 levels on the CDK activity level required for S-phase entry is 
investigated in Chapter 5.  
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Activation of oncogenes shorten G1 phase, resulting in the activation of replication origins 
independently of both constitutive origins, and dormant replication origins. These oncogene 
induced origins are localised in heavily transcribed genomic regions. These same origins are 
typically supressed by transcription, and reduced G1 length may result in firing of origins 
before the transcriptional suppression has taken effect. Replication from these oncogene 
induced origins results in transcriptional collision and DNA replication stress, resulting in an 
increase in DSBs near these origins (Macheret & Halozonetis, 2018). Critically, this chapter 
has uncovered 2 major phenotype changes, which could be explained through deregulated 
cyclin/CDK networks. 
This chapter has demonstrated subtle changes in cell cycle and DDR regulation in response 
to loss of CIZ1. Many of these effects may be attributed to a change in the expression 
patterns of the G1/S cyclins during cell cycle re-entry. This is summarised in Figure 4.17 
Future chapters will investigate further the effect of changes in cyclin signalling effects DNA 







Figure 4.17-A model for how loss of CIZ1 induces cellular changes Results in this 
Chapter have demonstrated that CIZ1 null cells display altered cell cycle re-entry 
kinetics. It can be hypothesised that this is linked to the observed tumour suppressor 
function of CIZ1. CIZ1 is involved in co-ordinating CDK2 activity during the G1/S 
transition. Changes in responses to CDK signalling could explain both altered cell cycle 
re-entry timing and altered response to stress. Both would result in DNA replication 
stress, which could drive a mutator phenotype in cells that have lost CIZ1 function. The 
interplay between CDK signalling and CIZ1 at the G1/S transition and replication 






Chapter 5.                
CIZ1 defines the CDK activity 
thresholds for the initiation of DNA 




5.1. Introduction to in vitro Replication Experiments 
Cell free in vitro replication systems recapitulate the events of DNA replication initiation and 
synthesis of nascent DNA outside the cell. Variations of these reactions have taken many 
forms and have been used to identify the regulatory mechanisms that control DNA 
replication for decades. These experiments have progressed in complexity, and precision 
from merging cell extracts, to the use of defined recombinant proteins that recapitulate  the 
events and stoichiometry of eukaryotic DNA replication. The cell free approaches used to 
study cell cycle regulation beginning with cell fusion experiments through to the latest in 
vitro systems will be evaluated here.  
5.1.1. Cell Fusion Experiments. 
The earliest in vitro experiments were performed by fusing cells. In a classical experiment, 
Rao & Johnson (1970) fused HeLa cells creating multinucleate cells. This approach 
established that soluble factors were able to induce mitosis (Maturation promoting factor, 
MPF), or induce DNA replication (S phase promoting factor, SPF). Critically, they found that 
DNA replication could be induced by fusing an S phase cells with G1 cells, however the same 
was not true when G2 multinucleate cells were fused with S phase cells. As well as 
demonstrating the unidirectional nature of the cell cycle, these experiments provided some 
of the earliest evidence for the quantitative model of CDK activity as the major regulator of 
the cell cycle (discussed in Chapter 1.8).  
5.1.2. Identification of Replication Origins and Fork Dynamics in vitro. 
The earliest in vitro replication systems were developed in yeast. In these experiments yeast 
plasmids (typically the yeast 2 µm plasmid), were initiated to replicate by crude enzyme 
extracts prepared from yeast cell extracts (Jazwinski & Edelman, 1979). This technique was 
modified to increase activity providing a useful tool for measuring eukaryotic DNA replication 
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(Kojo et al., 1981) . These experiments demonstrated that replication proceeded 
bidirectionally from the origin and recapitulated the order of replication events determined 
in in vivo experimentation. This system identified the autonomous replicating sequences 
(ARS), the specific sequences within the yeast genome that specify putative origins of 
replication through the recruitment of the origin recognition complex (ORC) (Celniker & 
Campbell, 1982). This highlighted how in vitro experiments could be used to learn about the 
in vivo process of DNA replication.  
5.1.3. Metazoan Cell Free DNA Replication Assays  
Following on from yeast experiments of the 1970s, the earliest animal in vitro replication 
experiments used eggs from the frog genus Xenopus, these experiments focussed largely on 
methods for isolating cell cycle competent S phase extracts. After roughly a decade of 
refinement of cell extract isolation, Blow & Laskey (1986) modified the extract isolation 
method developed by Lohka & Masui (1983, 1984, 1984). Using this new technique, they 
were able to demonstrate for the first time Xenopus DNA initiation in a cell free in vitro 
replication assay. These early experiments paved the way for the use of cell free DNA 
replication experiments using mammalian nuclei and extracts to probe the events of DNA 
replication initiation (Krude et al., 1997).  
In these experiments, isolated egg extracts promote DNA replication of sperm DNA. This 
methodology was used to identify many proteins involved in the DNA replication-licensing 
phase of replication initiation. These include the hexameric DNA helicase proteins of the 
MCM complex (Chong et al., 1995). Experiments performed using this system have also 
identified the activity of various cyclin/CDK proteins. Critically, the Xenopus system was used 
to demonstrate that Cyclin A/CDK2 and Cyclin E/CDK2 can both promote S phase entry 
(Strausfeld et al., 1996). These experiments implicated Cyclin E in the earliest events of DNA 
replication initiation; whereas Cyclin A would function later on.  
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More recently, xenopus in vitro replication systems have been used to demonstrate that the 
Chk1 response inhibits late firing origins, and that precise levels of Chk1 are required during 
stressed and normal S phase to maintain the DNA replication programme (Platel et al., 
2015). Additionally, Xenopus systems were used to demonstrate that MCM10, a replication 
factor, is not required for DNA replication initiation; however, reduction of MCM10 levels 
can result in reduced fork rate, a replication stress phenotype (Chadha et al., 2016).  
Mammalian in vitro replication assays were developed later than their frog and yeast 
counterparts. These experiments utilized the same nucleotide mix and energy regeneration 
system developed in frog in vitro replication assays (Blow & Laskey, 1986). As mammalian 
cells lack the ARS found in yeast, mammalian DNA replication systems utilised intact nuclei 
isolated in late G1 phase, supplemented by S-phase cytosolic extracts (Krude et al., 1997; 
Coverley 2002, Copeland 2015). To achieve this the cells needed to be efficiently 
synchronised. While this is achieved very efficiently with yeast, mammalian cells are more 
difficult to synchronise. The common methods used to generate the cell cycle stage specific 
cell extracts are: double thymidine block (S-phase cells), contact inhibition (Chapter 2) and 
serum starvation (G1 cells), and chemical synchronisation using mimosine (Late G1) (Krude 
et al., 1999).  
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Culturing cells in an excess of thymidine blocks the production of nucleotides by 
overwhelming ribonucleotide reductase that depletes the dNTP pool. This stalls DNA 
replication forks in early S-phase and dilution of thymidine allows fork restart and 
progression through S phase. By repeating thymidine incubations, a high proportion of cells 
can be arrested in early S-phase (Copeland et al., 2010; Copeland et al., 2015; Chen et al., 
2018). The other common method used for cell synchronisation for cell free experiments is 
mimosine arrest. Mimosine is a plant derived amino acid that halts cell cycle progression in 
G1 through inhibition of CTF4 binding to chromatin, release from this block allows nuclei to 
enter S phase (Park et al., 2012). A schematic displaying the two methods used for cell cycle 
synchronisation in this report displayed in Figure 5.1. 
 
Figure 5.1 - Overview of approaches used for mammalian cell cycle synchronisation A) 
Synchronous release of cells from quiescence into S phase using contact inhibition and serum 
starvation. B) Synchronous release of cells into S phase using inhibition of nucleotide synthesis 
by a double thymidine block. 
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The use of mammalian cell free DNA replication assays demonstrated that Cyclin A-CDK2 is 
sufficient to initiate mammalian DNA replication in vitro (Coverley et al., 2005) Mammalian 
cell free DNA replication assays identified that CIZ1 promotes DNA replication with cyclin A-
CDK2 (Coverley et al., 2005; Copeland et al., 2010) and that noncoding Y RNAs are required 
for efficient DNA replication initiation (Krude, 2000; Driedonks et al., 2018). Critically, when 
combined with DNA combing, they have demonstrated that depletion of these Y RNAs 
prevent the initiation of new replication forks, but not the elongation of ongoing replication 
forks (Krude et al., 2009). These results demonstrated a novel regulator of DNA replication, 
but also demonstrated the power of combining the two techniques of in vitro replication 
assays and DNA combing.  
More recently, in vitro replication assays were further developed from studies using cell 
cycle stage specific cell extracts and nuclei, to the recapitulation of DNA replication using 
entirely recombinant proteins to define the minimal replication machinery in yeast. Yeeles et 
al. (2015) identified the minimal protein toolkit required for recapitulation of origin 
specification, origin licensing and firing on DNA by the addition of 16 replication factors. 
Using this technique both the loading of preRC, conversion to preIC, and finally DNA 
replication were achieved (Yeeles et al., 2015). This technique was further developed to 
demonstrate that Mrc1 and Csm3/Tof1 are required to achieve optimal DNA replication 
rates in vitro. These experiments also revealed that DNA pol delta primarily used for lagging 
strand synthesis may be required for priming of leading strand synthesis to achieve optimal 
replication rate (Yeeles et al., 2017).  
This review demonstrates the power of in vitro replication assays to measure parameters 
about replication across multiple species. These experiments allow analysis of how individual 
factors can affect replication at both the assembly, and elongation level, which is difficult to 
isolate within a cell, due to downstream effects of genetic alteration, or non-specificity of 
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inhibitors. Cell free approaches allow analysis of the fundamental events that underpin DNA 
replication. Allowing identification of effectors of DNA replication and provide mechanistic 
insight if specific factors can alter replication and potentially drive tumorigenesis.  
5.1.4. Chapter Aims 
• Validate the replication competence of nuclei from post-quiescent WT, CIZ1 KO1 and 
CIZ1AB nuclei 
• Measure the replication initiation kinase thresholds in nuclei 
• Investigate how recombinant CIZ1 modulates kinase thresholds 
• Investigate the effect of CIZ1 and Cyclin A/CDK2 on replication kinetics 
5.2 Expression of Recombinant CIZ1 and Cyclin A-CDK2 for use in Cell Free DNA Replication 
Assays. 
Full length CIZ1 has proven to be challenging to purify in the past due to a natively 
disordered C terminal resulting in degradation. To overcome this issue, other fragments and 
splice variants have been used which are more stable including ECIZ1 an embryonic splice 
variant and ECIZ1 N471 a variant lacking the C terminus. (Copeland et al., 2010). Purified 
ECIZ1 N471 at a high concentration was already available in the lab from previous work 
(Tollitt, 2017).  
Purification of recombinant cyclin A/CDK2 is more challenging than expressing and purifying 
a single protein as the proteins need to be dimerised at stoichiometric levels. To achieve this 
the protein purification is staggered. A 3:1 culture ratio of cyclin A to CDK2 is used. GST-
cyclin A is purified, the GST tag removed by 3C cleavage. The purified cyclin A is added to 
GST-CDK2 that is immobilised on glutathione sepharose beads. The beads are washed to 
remove unbound cyclin A and stoichiometric cyclin A-CDK2 released by 3C cleavage of the 
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GST tag (Coverley et al., 2012). An SDS-PAGE gel showing each purification step is displayed 
in Figure 5.2.  
 
 
Lane 1 displays a strong band at roughly 70 kDa representing the Cyclin A-GST fusion protein 
(~25 kDa for GST and ~47 kDa cyclin A). Following 3c cleavage Lane 2 displays 2 strong bands 
at roughly 50 kDa (cyclin A)and 25 kDa (GST). These bands remain in Lane 3 which indicates 
not all cyclin A had been eluted. Lane 4 shows cyclin A at 50 kDa. In lane 5 the CDK2 GST 
fusion protein is shown at 50 kDa (both are ~25kDa). Lanes 6, 7 , and 8 show an intense band 
at 50 kDa representing both cyclin A and CDK2-GST during the binding and washing stages. 
Lane 9 shows intense bands at 50 kDa, 30 kDa, and 25 kDa representing Cyclin A, CDK2, and 
Figure 5.2 – Purification of Cyclin A-CDK2: Cyclin A-GST and CDK2-GST were expressed. 
Cyclin A was purified: Lane 1, Cyclin A Lysate on glutathione sepharose beads, Lane 2, Cyclin 
A bound glutathione sepharose beads after 3c cleavage, Lane 3, Glutathione sepharose 
beads after elution of cleaved protein. Lane 4, purified Cyclin A. Lane 5, CDK-GST bound to 
glutathione sepharose beads and incubated with Cyclin A (from lane 4) (Lane 6). Lane 7, 
shows beads bound protein after overnight digestion, and after washing (Lane 8). Samples 
were then digested overnight with 3C protease, Lane 9 shows all protein after digestion. Lane 
10 shows Glutathione sepharose beads after elution of non-bound protein after digestion. 
Lane 11 shows final eluted protein after overnight 3c digestion and purification. 
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GST respectively. Lane 10 shows bands at 25 kDa and 50 kDa representing GST and CDK2-
GST, potentially indicating incomplete 3c cleavage.  Following purification, the eluted protein 
bands for cyclin A (50 kDa) and CDK2 (30 kDa) (Lane 11) were of similar intensity suggesting a 
1:1 stoichiometry. The recombinant cyclin A-CDK2 complex was then functionally assessed 
using the cell free DNA replication assay to ensure quality of preparation. 
5.3 Using in vitro Reactions to Investigate Interplay Between CIZ1-N471 and Cyclin A/CDK2 
5.3.1 Cell Free Analysis of the Initiation Phase of DNA Replication. 
The initiation of DNA replication can be studied using replication licensed G1 nuclei that are 
stimulated by S-phase cell extracts or G1 extracts supplemented with cyclin A-CDK2 (Figure 
5.3). S phase extracts have the optimal amount of kinase activity to promote DNA replication 
initiation as they lie between the S phase threshold, and the S phase inhibitory threshold 
(Chapter 1.8). If CIZ1 plays a role in defining these thresholds, addition of recombinant CIZ1-
N471 may influence the concentration dependent activation of DNA replication. Cell free 
DNA replication assays with late G1 nuclei (From Chapter 3), and G1 cytosolic extracts 
supplemented with 0.1 ng/µl Cyclin A/CDK2 (From Figure 5.2), or an S phase extract (Figure 
5.3a/b). To determine the effect of increasing CIZ1 concentrations, cell free assays were 
prepared using 0.1 to 100 nM CIZ1 in S-phase extracts and G1 Extracts supplemented 0.1 ng/ 
µl cyclin A-CDK2 concentration (Figure 5.3c-f).  For both sets of reactions the proportion of 
nuclei in S-phase was determined.  
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Figure 5.3-High concentrations of CIZ1-N471 block DNA replication initiation. A) A schematic of 
the experimental design of simple in vitro reactions. B) Demonstration that 0.1 ng/µl Cyclin A/CDK2 
promotes replication initiation, but not to the level of an S-phase extract. The proportion of S-phase 
nuclei is shown after a 30 minute incubation in each extract. N=3 showing mean ± standard 
deviation. Significant differences were observed across the three conditions (One Way ANOVA, p < 
0.001) Pairwise comparisons were conducted by Tukey’s HSD test, significance is indicated on the 
graph: ns = p > 0.05 * = p < 0.05, ** = p < 0.01, *** p< 0.001. C) Schematic for titration of CIZ1-
N471 into S phase extract (result in E) D) Schematic for titration of CIZ1-N471 into a G1 extract 
supplemented with 0.1ng/µl Cyclin A/CDK2 (Result in F) E) The percentage of nuclei in S phase 
when different concentrations of CIZ1-N471were added to an S phase extract. F) The percentage of 
nuclei in S phase when different concentrations of CIZ1-N471were added to a G1 extract with 0.1 





A one way ANOVA revealed significant differences between the three conditions, and 
significant differences between each condition. Addition of Cyclin A/CDK2 promoted 
replication initiation twofold over a G1 extract alone from 13.1 % to 24.8 % of nuclei in S 
phase after S phase (Figure 5.3B). Addition of an S phase extracted resulted in an increase to 
45.1 %, approximately three-fold more nuclei in S phase after incubation when compared to 
a G1 extract and 1.8 times more nuclei in S phase than a G1 extract supplemented with 0.1 
ng/µl Cyclin A/CDK2. This data is consistent with results from Coverley et al. (2005) and 
demonstrated that Cyclin A/CDK2 alone promoted DNA replication initiation in vitro but not 
to the same level as an S phase extract. This indicated that Cyclin A/CDK2 could promote 
replication initiation in vitro.  
Addition of CIZ1-N471 to S-phase extracts (Figure 5.3E) initially has little effect on the 
percentage of nuclei in S phase. However, there is a slight concentration dependent 
reduction in the percentage of cells in S-phase at 0.01 ng/µl, 0.1 ng/µl, or 1 ng/µl of CIZ1-
N471, with an average of 51 %, 45 %, and 40 % of nuclei respectively. At 10 ng/µl of CIZ1-
N471 22% of nuclei were in S phase and at 100 ng/µl an average of 13 % of nuclei were in S 
phase. This was comparable to the G1 control. This indicated that high levels of CIZ1 inhibit 
replication initiation by an S-phase extract in vitro. 
The titration of CIZ1-N471 into a G1 extract with optimal cyclin A/CDK (Figure 5.3F), shows a 
concentration dependent increase in initiation of DNA replication. The most efficient 
initiation occurs at 0.1 nM CIZ1 and there is a general decrease in activity at higher 
concentrations At high concentrations of CIZ1-N471 (1 and 10 ng/µl) an average of between 
22 – 26 % of nuclei were in S phase, comparable to cyclin A-CDK2 alone. This suggests that 
the replication initiation promoting activity of CIZ1 is concentration dependent and is 




5.3.2 In vitro analysis of CIZ1 null fibroblasts during the initiation phase of DNA replication. 
The observation that CIZ1 is required for initiation of DNA replication in murine fibroblasts 
(Coverley et al., 2005, Copeland et al., 2010) suggested that CIZ1 may be an essential gene. 
However, murine knock out models demonstrated that this was not the case. Although, CIZ1 
may play a role in the maintenance of genomic stability as CIZ1 KO mice are predisposed to 
lymphoblastic tumours (Ridings-Figueroa et al., 2017) and viral oncogenic transformation 
(Nishibe et al., 2013). These observations suggest that CIZ1 knockout mice may have subtle 
defects in the regulation of DNA replication.  
Here the parental WT NIH 3T3 cell, the CIZ1 KO1 cell line and the CIZ1AB cell line to were used 
to evaluate if there are any phenotypic differences between wild type (WT) and CIZ1 KO cell 
lines. To begin to characterise the role of CIZ1 in the regulation of DNA replication in vitro 
DNA replication assays using replication competent nuclei were harvested from WT, CIZ1 
KO1 an CIZ1AB NIH 3T3 cells. The initiation kinetics and replication dynamics of these nuclei 
were determined in parallel reactions were set up comparing the effects of a G1 extract with 
an S phase extract. In addition, to probe changes in chromatin loading, nuclear fractionation 
was performed and analysed by western blot (Figure 5.4). 
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A two way ANOVA revealed no significant interaction between cell line and extract. All three 
nuclei batches prepared from WT, CIZ1 KO and CIZ1AB cell lines displayed a similarly low level 
of nuclei in S phase between 10 – 15 % (Figure 5.4b) and there were no significant 
differences in the level of S-phase nuclei in G1 extracts. The percentage of nuclei that 
initiated DNA replication when incubated in an S-phase extract was between 40-50 % for 
WT, CIZ1 KO and CIZ1AB nuclei. There were no significant differences in the number of 
replicating nuclei in S-phase extracts. Importantly, when comparing the increase in S-phase 
Figure 5.4 – Comparison of WT, CIZ1 KO and CIZ1AB Nuclei S Phase Entry in vitro A) A 
schematic of the experimental design. B) Bar chart showing the percentage of S-phase 
nuclei for WT, CIZ1 KO, & CIZAB in a G1 and S phase extracts. (N=3 ± S.D.) The proportion 
of nuclei in S phase in each extract (n = 3 repeats) for each cell line was compared using a 
two-way ANOVA with extract and cell line as factors (P (extract) < 0.0001, P (cell line) > 
0.05, P (interaction) >0.05 .  C/D) Total protein (C) and chromatin protein (D) fractions 
probed with G1/S cyclins: Cyclin A & Cyclin E, and Histone H3 as a load control.  
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nuclei after incubation with S-phase extracts all of the nuclei tested show a significant 
increase relative to G1 extracts. 
Western blot analysis revealed differences in the localisation of cyclin A. In total protein 
fractions there is a low level of cyclin A in G1 extracts for CIZ1 KO and AB, but less protein is 
detected in WT nuclei and extracts. However, isolation of the chromatin fraction showed 
similar levels of cyclin A on chromatin in the WT and CIZ1AB nuclei. However, there is a clear 
reduction in cyclin A in CIZ1 KO cells relative to WT and CIZAB nuclei. Loss of cyclin A 
chromatin localisation in KO nuclei, suggests that CIZ1 KO cells have impaired cyclin A 
localisation during the G1/S phase transition. Importantly, genetic addback of CIZ1 (CIZ1AB) 
reversed this effect. This further implicates CIZ1 in recruiting cyclin A to insoluble nuclear 
structures, as CIZ1 promotes chromatin association of Cyclin A and Cyclin E during the G1/S 
phase transition (Copeland et al., 2010).  
This reduction in cyclin A recruitment may be related to the observation that CIZ1 aids 
localisation of cyclin A to chromatin (Copeland et al., 2010) and that this facilitates initiation 
of DNA replication. The use of S-phase extracts that contain high levels of cyclin A-CDK2 from 
HeLa cells enabled efficient loading of cyclin A in all contexts. It should be noted that S-phase 
HeLa cytosolic extracts have CIZ1 protein that may be able to promote cyclin A binding in 
vitro. In G1 extracts, no differences were seen in chromatin localisation of cyclin E between 
WT, and CIZ1 KO nuclei. This suggests loss of CIZ1 does not affect the localisation of cyclin E 
in vitro (Figure 5.4d).  
5.3.3. CIZ1 is required for efficient Cyclin A chromatin association in vitro  
In G1 extracts prepared from CIZ1 KO cells, there is a cytosolic pool of cyclin A that fails to 
load onto chromatin (Figure 5.4C). The reduction in cyclin A chromatin binding in G1 phase in 
CIZ1 KO cells suggests that CIZ1 may act as a molecular scaffold, enabling efficient cyclin A 
recruitment. Titration of recombinant CIZ1 promotes cyclin A loading onto chromatin in DNA 
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replication assays in vitro (Copeland et al., 2010). To determine if biochemical add back of 
CIZ1 influences cyclin A localisation in CIZ1 KO cells, in vitro reactions were prepared with 
CIZ1 KO Nuclei, G1 cytosolic extracts and recombinant CIZ1-N471 concentrations were 
increased from 0 to 1 nM. This experiment was performed for two goals, firstly to investigate 
the effect recombinant CIZ1 had on the proportion of CIZ1 KO nuclei in a G1 extract. 
Secondly, to see if CIZ1 could promote chromatin localisation of Cyclin A that was lost when 
CIZ1 KO nuclei were incubated in a G1 extract.  (Figure 5.5) 
Addition of recombinant CIZ1-N471 had no effect on S phase entry KO nuclei, with 10 – 15 % 
of cells in S phase at all CIZ1 concentrations tested  (Figure 5.5B). Western blotting of the 
chromatin fraction showed that cyclin E chromatin loading is unaffected by addition of CIZ1-
N471. (Figure 5.5C). However, cyclin A chromatin localisation mirrored the increasing 
concentration of CIZ1-N471.  
C 
Figure 5.5. CIZ1 Titration promotes cyclin A loading onto CIZ1 KO nuclei in vitro. A) 
Experimental design. B) The proportion of nuclei in S phase for each of the 
concentrations (n = 3 ± standard deviation). No significant difference in S phase entry 
was observed across the range of CIZ1-N471 concentrations (One Way ANOVA, p 
>0.05).  c) Loading of G1/S cyclins onto chromatins at each of the CIZ1-N471 
concentrations.  



















Titration of CIZ1 alone into in vitro reactions using G1 nuclei and G1 cytosolic extracts did not 
promote initiation of DNA replication, demonstrating that CIZ1 alone is insufficient to trigger 
this signal in a G1 context. A one way ANOVA revealed no significant differences between 
means. This is consistent with a molecular scaffold, as it requires either S-phase extracts or 
recombinant cyclin A-CDK2 to enhance initiation of DNA replication (Coverley et al., 2005; 
Copeland et al., 2010; Copeland 2015). The biochemical add back of CIZ1 is consistent with 
results from the genetic addback of CIZ1 (CIZ1AB nuclei) (Figure 5.4c./5.5c and Figure 4.12) 
where chromatin recruitment of Cyclin A in a G1 extract lost upon loss of CIZ1 was restored. 
Taken together, these observations demonstrate that CIZ1 plays a role in the chromatin 
localisation of cyclin A in replication licensed nuclei, consistent with the cooperative activity 
of CIZ1 and cyclin A-CDK2 that promotes the G1/S transition (Copeland et al., 2010). 
5.2.4 Cyclin A/CDK2 promotes initiation of DNA replication in a narrow concentration 
range. 
The initiation of DNA replication occurs within a narrow concentration range (around 0.1 ng/ 
µl). This threshold is maintained by the opposing activities of cyclin dependent kinases and 
ubiquitin proteasome system that induces an unstable irreversible switch, key 
phosphorylations by CDKs promote degradation of replication licensing proteins by the UPS. 
(Rizzardi et al., 2012; Moser et al., 2018; Heldt et al., 2018). CIZ1 influences this threshold 
and enables initiation of DNA replication at a wide range of cyclin A-CDK2 activities 
(Copeland et al., 2010). The data presented here suggests that CIZ1 KO cells are inefficient 
for the recruitment of cyclin A-CDK2 to chromatin. Therefore, this suggested that CIZ1 KO 
nuclei may have altered cyclin A-CDK2 activity thresholds to promote initiation of DNA 
replication as a consequence of the reduction in cyclin A-CDK2 chromatin recruitment.  
To determine the optimal cyclin A-CDK2 activity to promote initiation of DNA replication, cell 
free DNA replication assays were prepared with replication licensed nuclei prepared from 
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WT, CIZ1 KO and CIZ1AB cell lines. Recombinant cyclin A/CDK2 was titrated from 0 to 1 ng/µl 
and the percentage S-phase nuclei determined for each concentration (Figure 5.6).  
 
Figure 5.6 – Titration of Cyclin A into G1 extracts promotes replication initiation at a 
narrow range of concentrations A) A schematic design of the experiment. B) mean  
proportion of nuclei in S phase at each concentration (n  = 3 ± standard deviation). The 
proportion of nuclei in S phase at each Cyclin A/CDK2 concentration for each cell line was 
compared using a two-way ANOVA with cyclin A/CDK2 concentration and cell line as factors 
(Cyclin A/CDK2 concentration) < 0.05, P (cell line) < 0.05, P (interaction) < 0.05). Pairwise 
comparisons were made by simple main effects analysis WT and CIZ1AB nuclei were not 
significantly different at any Cyclin A/CDK2 concentration (p > 0.05). CIZ1 KO nuclei were 
significantly different from WT and CIZ1AB nuclei at 0.1 and 0.25 ng/µl Cyclin A/CDK2 (p < 
0.05 for all comparisons). CIZ1 KO nuclei were not significantly different from WT or CIZ1 
nuclei at any other concentrations. Error bars in B = standard deviation. 
This cell free DNA replication system allows precise titration Cyclin A-CDK2 activity. This 
allows precise control of CDK activity and provides a useful tool to study the quantitative 








threshold and the S phase inhibitory threshold (Chapter 1). This approach showed that cyclin 
A-CDK2 promotes initiation of DNA replication at 0.1 ng/µl and is consistent in several 
studies (Coverley et al., 2002; Copeland et al., 2010). As expected for WT nuclei, cyclin A-
CDK2 promotes initiation of DNA replication in a concentration dependent manner peaking 
at 0.1 ng/µl (Figure 5.6B). Significantly, CIZ1 KO nuclei do not initiate at 0.1 ng/µl and 
required a 2 fold increase in cyclin A-CDK2 to initiate DNA replication (Figure 5.5). The 
optimal cyclin A-CDK2 shifted to a higher concentration, suggesting that CIZ1 can influence 
the threshold of kinase activity that is required for initiation of DNA replication.  
A two-way ANOVA was conducted which identified significant differences across cell line and 
Cyclin A/CDK2 levels. Simple main effects analysis tests showed that WT and CIZ1AB nuclei did 
not respond differently. Whereas CIZ1 KO nuclei responded significantly differently to both, 
and CIZ1AB nuclei.  The shift in peak initiating concentration of Cyclin A/CDK upon CIZ1 KO 
was significant, and rescuable through ectopic expression of GFP-CIZ1. 
These results lead to two main conclusions. Firstly, cyclin A/CDK2 can initiate DNA replication 
in a G1 nuclei at a specific concentration. At low cyclin A-CDK2 levels this signal is insufficient 
to initiate replication, peaking at a characteristic concentration and above this DNA 
replication initiation is blocked. Secondly, the cyclin A-CDK2 threshold required to optimally 
initiate DNA is determined in part by CIZ1. Deletion of the CIZ1 gene (CIZ1 KO) reveals that 
the kinase activity threshold is increased ~2-fold and this effect can be reversed by CIZ1AB.  
5.3.5. Recombinant CIZ1 can promote WT like DNA replication initiation kinetics in CIZ1 
null nuclei.  
The previous experiment identified that loss of CIZ1 promoted a change in the activating 
concentration of CDK2 signal and that the optimal concentration for initiation of DNA 
replication could be restored through genetic addback of GFP-CIZ1. To investigate whether a 
biochemical add back of CIZ1 could influence the kinase threshold that regulates initiation of 
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DNA replication, recombinant CIZ1- N471 was added to WT and CIZ1 KO nuclei in cell free 
DNA replication assays (Figure 5.7).  
Figure 5.7 – Recombinant CIZ1 rescues CIZ1 KO nuclei, and restores optimal CDK thresholds 
in vitro A) Experimental overview. WT, and CIZ1 KO nuclei were incubated in G1 extracts with 
or without CIZ1-N471 and Cyclin A/CDK2. B) Bar chart showing the percentage (where N = 3, 
showing mean ± standard deviation) of WT (Black) and CIZ1 KO1 (White) nuclei in S phase. 
The proportion of nuclei in S phase in each extract (n = 3 repeats) for each cell line was 
compared using a two-way ANOVA with extract and cell line as factors (P (extract) <.01, P 
(cell line) < 0.05, P (interaction) < 0.05).  Pairwise comparisons were made by simple main 
effects analysis, significance is highlighted on C. ns = p > 0.05 * = p < 0.05, ** = p < 0.01, *** 
p< 0.001 
To determine if the CDK threshold that promoted DNA replication in vitro could be restored 
to WT levels in CIZ1 KO nuclei, nuclei were incubated in G1 extracts, G1 extracts 
supplemented with 0.1 ng/µl Cyclin A CDK2, and G1 extracts supplemented with 0.1 ng/µl 
Cyclin A CDK2 and 0.05 nM CIZ1 N471 (Figure 5.7a). This is around half the level of CIZ1 to 





replication initiation the proportion of nuclei were in S phase was determined by measuring 
incorporation of Biotin-11-dUTP by fluorescence microscopy.  
A two way ANOVA revealed significant interaction between cell line and extract. In G1 
extracts, WT and CIZ1 KO nuclei displayed similar levels of nuclei in S-phase (WT: 14.7 %, 
CIZ1 KO: 14.3) that were not significantly different. When incubated in G1 extracts 
supplement with 0.1 ng/µl Cyclin A/CDK2, there is an increase in S-phase nuclei to 24 % that 
is absent for CIZ1 KO nuclei (13.7%), that showed a significant difference in the percentage of 
S phase nuclei. However, the addition of 0.05 nM CIZ1-N471 with 0.1 ng/µl Cyclin A/CDK2 
the percentage of S-phase nuclei was increased to a similar level in both WT and CIZ1KO, 
that were not significantly different, yet significantly different from both G1 extract control 
sample and G1 extracts supplemented with Cyclin A/CDK2 samples. Results here reiterated 
earlier results that in the absence of CIZ1 the CDK threshold required to promote initiation of 
DNA replication is increased. This result demonstrated that recombinant CIZ1-N471 
recapitulates the lower Cyclin A/CDK2 threshold replication in CIZ1 KO nuclei and phenocopy 
wild type nuclei. These data support the hypothesis that CIZ1 contributes to mechanisms 
that establish the kinase thresholds that regulate the G1/S phase transition and DNA 
replication initiation in vitro.  
5.3.6. CIZ1 Expands the range of concentrations of Cyclin A/CDK2 that promote DNA 
replication initiation.  
Previous experiments have demonstrated that the interplay between CIZ1 and Cyclin A/CDK2 
alter when nuclei enter S phase in vitro. The cyclin A-CDK2 activity required to promote 
initiation altered upon loss of CIZ1. This can be restored through addback of CIZ1 through 
either biochemical or genetic means (Figure 5.7). Next, experiments were designed to 
investigate how CIZ1 affects the range of concentrations of cyclin A/CDK2 that promote DNA 
replication initiation.  
183 
 
Cell free DNA reactions were prepared WT, CIZ1 KO and CIZ1AB nuclei, with a mid G1 extract. 
The concentration of Cyclin A/CDK2 was titrated between 0.01 and 1 ng/µl in parallel 
reactions with 0.1 nM CIZ1-N471 and the percentage of nuclei in S-phase determined (Figure 
5.8).  
Figure 5.8. CIZ1-N471 Expands concentrations of Cyclin A/CDK2 that can promote DNA 
replication initiation A) Schematic diagram of the experimental design. B) mean proportion 
of nuclei in S phase for each reaction (n  = 3 ± standard deviation). The proportion of nuclei in 
S phase at each Cyclin A/CDK2 concentration for each cell line was compared using a two-
way ANOVA with cyclin A/CDK2 concentration and cell line as factors P (Cyclin A/CDK2 
concentration) < 0.05, P (cell line) > 0.05, P (interaction) > 0.05).  
A two way ANOVA revealed there were no significant interaction between the three cell lines 
and Cyclin A-CDK2 concentration in the presence of 0.1 nM CIZ1-N471. For WT, CIZ1 KO and 
CIZ1AB nuclei, addition of 0.1 nM CIZ1-N471 expanded the range of concentrations of Cyclin 
A/CDK2 that could promote DNA replication initiation in vitro. Addition of CIZ1-N471 
promoted DNA replication at concentrations 10-fold higher than reactions without 








For the majority of concentrations of Cyclin A/CDK2 added there were no significant 
differences between the proportion of nuclei in S phase across nuclei, and each nuclei type 
displayed significantly more nuclei in S-phase upon addition of CIZ1-N471 (when compared 
to data from Figure 5.6). Notably at low concentrations of Cyclin A/CDK2 (0.03ng/µl), WT and 
CIZ1AB nuclei displayed a proportion of nuclei in S phase that was not different from the 
same concentration in the absence of CIZ1 (data from Figure 5.6). However, at the same 
concentration, KO nuclei showed a significant increase in the proportion of nuclei in S phase 
from 14.5 % to 30.6 % upon addition of CIZ1-N471. Next, the replication kinetics of each of 
the nuclei was determined. 
5.3.7. Recombinant CIZ1 can enhances activity of Cyclin A/CDK2 in vitro.  
The data are consistent with CIZ1 contributing to mechanisms that establish the cyclin 
A/CDK2 activity threshold that triggers DNA replication initiation in vitro. To investigate 
whether addition of recombinant CIZ1 can alters the optimal concentration of cyclin A/CDK2 
for initiation of DNA replication, cell free DNA replication assays were performed. The assays 
used G1 extracts containing the optimal concentration of cyclin A/CDK2 and increasing CIZ1-
N471 concentrations. from 0.03 to 1 nM. The effect was determined in WT, CIZ1 KO and 
CIZ1AB nuclei and the percentage of S-phase nuclei determined (Figure 5.9).  
Additionally, reactions for CIZ1 KO nuclei were performed at both 0.1 ng/µl and 0.2 ng/µl 
cyclin A/CDK2. This was to determine if the WT Cyclin A/CDK2 replication initiation activating 
concentration could be restored through chemical addback of recombinant CIZ1-N471. As 
well as observing the effects of recombinant CIZ1-N471 at CIZ1 KO nuclei activating 




Figure 5.9 – CIZ1-N471 increases the activity of cyclin A-CDK2 and enhances initiation of 
DNA replication. A) Experimental overview. B) The mean percentage of nuclei in S phase at 
each CIZ1-N471 concentration in G1 extracts, with 0.1 ng/µl (n  = 3 ± standard deviation).  
This experiment was performed to investigate how CIZ1 levels affect DNA replication at the 
optimal level of Cyclin A/CDK2 for WT, and CIZ1AB nuclei. The aim was to identify if CIZ1 
levels altered the ability of recombinant Cyclin A/CDK2 to promote replication. Without 
addition of recombinant CIZ1-N471, 0.1 ng/µl Cyclin A/CDK2 promoted and increase in 
initiation of DNA replication by a factor of 2 for the WT, CIZ1 KO and GFP CIZ1 nuclei. The 
increase in initiation of DNA replication was comparable between the nuclei, any observed 
differences were non-significant.  
Addition of CIZ1-N471 at low concentrations (<0.1 nM) did not promote any change in rates 
of DNA replication initiation compared to the cyclin A/CDK2 alone in WT, CIZ1 KO and CIZ1AB 









concentrations >0.1 nM in WT, CIZ1 KO, and GFP-CIZ1 KO nuclei. Comparison of the WT and 
CIZ1 KO nuclei revealed a 2-fold increase in cyclin A-CDK2 levels to reach peak activity.  This 
may reflect the difference in CIZ1 levels in CIZ1 KO cells relative to WT and CIZKI cells. 
Interestingly at 0.2 nM CIZ1-N471, more CIZ1 KO  nuclei were in S phase: 44.2 % of CIZ1 KO 
nuclei were in S phase compared to 28.1 % of WT nuclei, and 25.3 % of CIZ1AB. This could be 
due to loss of endogenous CIZ1 in CIZ1 KO nuclei, resulting in a greater requirement of CIZ1-
N471 to promote optimal replication initiation. This effect was reversed in CIZ1AB nuclei, that 
peaked at 0.1 nM CIZ1-N471.  
The data presented in Figure 5.9 utilise the optimal cyclin A-CDK2 concentration for WT 
nuclei. However, the optimal concentration for CIZ1 KO cells is 0.2 ng/µl. This change in 
cyclin A-CDK2 activity may affect the concentration of CIZ1 that is optimal for initiation of 
DNA replication. To investigate how this effects replication initiation a CIZ1 titration in CIZ1 
KO nuclei supplemented with 0.2 ng/µl cyclin A-CDK2, cell free DNA replication assays were 





Figure 5.10 – Increased cyclin A-CDK2 concentration changes optimal CIZ1 levels for CIZ1 
KO Nuclei A) Experimental overview. B) mean roportion of nuclei in S phase at each 
concentration superimposed over data at 0.1 ng/µl from Figure 5.9 (n  = 3 ± standard 
deviation).   
 
The data show that there is a concentration dependent initiation of DNA replication, with a 
peak at 0.1 nM CIZ1. There are 2 phases of activity at concentrations less than 0.1 nM 
increasing CIZ1 enhances initiation of DNA replication, and above 0.1 nM the activity of CIZ1 
does not promote such an increase in replication initiation. This is consistent with earlier 
results showing that there is both an activating and inhibitory effect when increasing CIZ1 
concentrations (Figure 5.2). The data presented here shows that the optimal CIZ1 
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assays. At low cyclin A-CDK2 (0.1 ng/µl) CIZ1 KO nuclei require additional CIZ1 (0.25nM) for 
optimal activity (Figure 5.10). Increasing the concentration of Cyclin A-CDK2 to 0.2 ng/µl 
reduces the requirement for CIZ1 and shifts the optimal peak to 0.1 nM CIZ1-N471.  
Additionally, increasing Cyclin A/CDK2 concentrations reduces the increase in nuclei in S 
phase at 0.03 nM CIZ1-N471, indicating an importance on the ratio of Cyclin A-CDK2:Ciz1 
levels in promoting replication initiation. Critically, using optimal Cyclin A/CDK2 levels 
returned the observed peak to a distribution more similar to WT, and CIZ1AB nuclei. 
Taken with the other data presented here, there is a cooperativity between cyclin A-CDK2 
activity and the levels of CIZ1 that contribute to the kinase activity threshold that regulates 
the initiation phase of DNA replication. Changing the concentration of either factors affects 
the optimal concentrations required for efficient initiation of DNA replication. This adds to 
data that indicates that CIZ1 could be acting as a kinase sensor. Levels of CIZ1, alter the 
concentration at which Cyclin CDK networks promote the onset of S phase. Genetic loss of 
CIZ1 increases the amount of signal required to promote S phase initiation. CIZ1 addback, 
through both genetic and chemical methods, can restore the concentration at which cyclin 
A/CDK2 can promote replication initiation.  
5.4. DNA combing of Cell free DNA replication assays in vitro 
5.4.1. Replication fork velocities are reduced in CIZ1 KO nuclei in cell free DNA replication 
assays  
In vitro DNA replication assays revealed that CIZ1-N471 modulates the response to 
increasing cyclin A-CDK signalling in vitro. To test how changes in CIZ1 levels and cyclin A-
CDK2 activity alter the DNA replication programme, DNA replication fork velocities were 
determined using DNA combing in cell free DNA replication assays.  
Firstly, differences in fork progression rates were estimated in WT, CIZ1 KO and CIZ1AB nuclei.  
A measure of this would be achieved through the single labelling technique developed in 
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Chapter 3. Reactions were performed using replication competent WT, CIZ1 KO and CIZ1AB 
nuclei incubated in an S phase extract for 30 minutes and nascent DNA labelled with EdU. 
The nuclei were harvested, DNA was purified, combed and the EdU labelled. A measure of 
replication rate was determined using the length of EdU tracks (Figure 5.11).  
Figure 5.11- Measuring Replication Kinetics in in vitro reactions. A) Displays a schematic of 
the experimental design. B) Representative confocal fluorescence microscopy images of 
positively labelled DNA. C) Displays swarm plots of replication track lengths for DNA from 
nuclei of each cell line: WT (Blue), CIZ1 KO1 (Red), CIZ1AB (Green) (n = 150). Red dots 
represent the median for each dataset. D) Displays box and whisker charts displaying the 
distribution of replication track lengths for each cell line: WT (White), CIZ1 KO1 (Light grey), 
CIZ1AB (Dark grey). The crosses represent the mean value for each dataset (N =  150). 
Significant differences between the replication track lengths were observed across the three 
cell line (One Way ANOVA, p < 0.0001). Pairwise comparisons were conducted by Tukey’s HSD 
test, significance is indicated on the graph: ns = p > 0.05 * = p < 0.05, ** = p < 0.01, *** = p< 
0.001, **** = p < 0.0001 
 










A one way ANOVA was conducted that indicated there were significant differences in mean 
replication track lengths across the three nuclei types. Analysis of the DNA replication track 
length showed that WT nuclei had higher replication track lengths than CIZ1 KO nuclei, and 
that was reversed by CIZ1AB (median track length of 14 kbp, 10.6 kbp and 15 kbp 
respectively). Furthermore, the drop in replication track length between WT and CIZ1 KO and 
also CIZ1 KO and CIZ1AB were found to be statistically significant. The CIZ1AB nuclei had a 
median track length of 15.01 kbp and comparison with WT nuclei (14 kbp) showed they were 
not statistically significantly different. This implied that CIZ1 KO caused an alteration in the 
replication programme, if this is consistent in cell based experiments this may indicate a DRS 
phenotype, this is further explored in Chapter 6 through determination of replication kinetics 
in WT, CIZ1 KO and CIZ1AB cells. 
5.4.2. Cyclin A and CDK2 Co-operate to Promote Optimal DNA Replication in vitro  
Earlier experiments have demonstrated that loss of CIZ1 in nuclei resulted in reduced fork 
rate, a phenotype that is consistent with DNA replication stress. This data demonstrated that 
CIZ1 plays a role in maintaining DNA replication.  With the tools at disposal this could not be 
uncovered in cell-based experiments. Fortunately using the in vitro replication experiments 
an in vitro model of this could be developed. 
Earlier experiments demonstrated (for WT nuclei) an optimal concentration at which cyclin 
A/CDK2 initiated DNA replication (0.1 ng/µl), above and below this level DNA replication was 
not initiated at a level above baseline. Secondly, addition of an optimal concentration of 
recombinant CIZ1-N471 (0.1 nM for WT cells) resulted in an increase in the proportion of 
cells in S phase, as well as a widening of the concentrations of Cyclin A/CDK2 that allowed a 
significant increase in the proportion of nuclei entering S phase. These levels shifted with 
genetic loss of CIZ1 but could be returned by addback of recombinant CIZ1-N471. 
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Experiments were designed to analyse the effects of increased CIZ1 levels on DNA replication 
initiation. Four Reactions were set up, all reactions were performed in a G1 extract. For the 
first, a final concentration of 0.1 ng/µl recombinant cyclin A/CDK2 was added to the reaction. 
For the second, 0.1 nM CIZ1-N471, and 0.1 ng Cyclin A/CDK2 was added (This represented 
optimal replication). For the third, 0.02 ng/µl and 0.1 nM CIZ1-N471 was added to the 
reaction (This represented replication that at a low CDK level only permissible upon addition 
of CIZ1-N471). For the fourth and final reaction 0.1 nM CIZ1-N471 and 1 ng/µl of cyclin 
A/CDK2 was added to the reaction (This represented replication that at a high CDK level only 
permissible upon addition of CIZ1-N471). After, incubation the nuclei were isolated, DNA 





Figure 5.12. The effect of adding recombinant CIZ1 to a range of cyclin A/CDK2 
concentrations in vitro A) Displays a graphical schematic of the design of the experiment. 
Using data from Chapter 5 an optimal (0.1 ng/µl), high (1 ng/µl) and low (0.02 ng/µl) cyclin 
A/CDK2 concentration was assigned, and optimal CIZ1 concentration (0.1 nM). B) displays box 
and whisker plots showing the distribution of fork rates from nuclei in each experimental 
condition (n =150). (1=optimal Cyclin A/CDK2, 2=Optimal Cyclin A/CDK2 and optimal CIZ1-
N471, 3=Low Cyclin A/CDK2 and optimal CIZ1, 4=High Cyclin A/CDK2 and optimal CIZ1-N471). 
Significant differences in fork rate were observed between the conditions (One Way ANOVA, p 
< 0.0001). Pairwise comparisons were conducted by Tukey’s HSD test, significance is indicated 
on the graph: ns = p > 0.05 * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 C) 
displays a swarm plot of fork rates of each of the experimental conditions (green = 1, blue = 2, 
red = 3, purple = 4). Red diamonds represent median values (n =150).  
C 
A B 1           2           3            4 
1                2               3                4 
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Figure 5.12b and 5.12c displays the replication fork rate of each of the reactions. 
Interestingly, all observed replication fork velocities were lower than what was observed in 
cell based experiments (Chapter 3). A one way ANOVA was conducted that indicated there 
were significant differences in mean fork rate across the four samples. For reaction 1 (0.1 
ng/µl Cyclin A/CDK2) a median replication fork rate of 0.51 kbp/min was observed. This was 
lower than the observed rate when nuclei were stimulated with an S phase extract (0.83 
kbp/min, Figure 5.11). This is unsurprising, experiments in Chapter 6 revealed that S phase 
entry was less efficient with addition of cyclin A/CDK2 in a G1 extract compared to an S 
phase extract.  
The second reaction (0.1 ng/µl cyclin A/CDK2 and 0.1 nM CIZ1-N471) Displayed a median 
replication rate of 0.75 kbp/min. This was higher than in reaction 1, and additionally, the 
difference between the two was significant. This indicated that addition of CIZ1-N471 at 
optimal concentrations prompted a change in replication dynamics. The fork rate was lower 
than in an S phase extract, representing an intermediate value.  
Reaction 3 (low Cyclin A/CDK2 and 0.1 nM CIZ1-N471) displayed a median replication fork 
velocity of 0.52 kbp/min. This replication fork rate was comparable to the rate seen in 
reaction 1. The difference between the two values was not significant. The value was 
significantly different from reaction 2. This indicated that low CIZ1 levels allow replication to 
occur, but the replication programme is altered.  
Reaction 4 (High Cyclin A/CDK2 and 0.1 nM CIZ1-N471) displayed a median replication fork 
velocity of 0.72 kbp/min. This value was comparable to reaction 2. The 2 datasets were not 
significantly different. The value was significantly higher than reaction 1, and reaction 3, and 
lower than an S phase extract. This indicates that high levels of CIZ1 results in a comparable 




A number of implications can be inferred from this data. Firstly, in vitro, replication initiated 
in a G1 extract is inefficient, and results in a reduced replication fork rate compared to S 
phase extracts. This could be due to a number of reasons; many replication factors present in 
S phase extracts will not be present. This replicates the effect of replicating DNA early, due to 
oncogenic activation, which can result in mitotic issues. Critically, addition of CIZ1-N471 
allows replication to occur at lower cyclin A/CDK2 concentrations. This resulted in a reduced 
replication fork velocity. This could indicate that increased CIZ1 allows DNA replication to 
occur at lower cyclin A/CDK2 levels, and critically replication that occurs results in a stressed 
phenotype.  
At optimal kinases levels for replication, addition of CIZ1 results in promoting replication 
kinetics more similar to those seen by addition of an S phase extract (although remaining 
significantly lower). This could indicate that CIZ1 at optimal levels promotes a healthier 
replication programme in these in vitro conditions. This could indicate that CIZ1 is one of the 
factors missing from the G1 extract that results in reduced replication efficiency. At high 
cyclin A/CDK2 concentrations a similar phenotype was observed, an intermediate phenotype 
between no CIZ1 and an S phase extract. Again, indicating that increased CIZ1 levels may 
promote a healthy replication programme at higher CDK levels.  
5.5. Chapter Discussion 
5.5.1. CIZ1 Shifting Kinase Thresholds May Induce DRS 
The results presented here provide evidence that CIZ1 contributes to mechanisms that 
control the kinase thresholds that underpin both S phase entry and prevent re-replication of 
chromosomes. Cancer cells have disrupted Cyclin/CDK signalling networks through 
mutations and disruption of these networks leads to DNA replication stress (Gailard et al., 
2015). There are a number of ways that the cell cycle and CDK activity can be perturbed 
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including oncogenic signalling, TSG inactivation obfuscating the requirement of external 
growth signals (Hanahan and Weinberg, 2000).  
Firstly, there is clear evidence that loss of CIZ1 caused a change in the concentration of cyclin 
A/CDK2 that promotes DNA replication initiation. The data presented in this chapter show 
that there is cooperativity between CIZ1 and cyclin A-CDK2 activity and here for the first time 
evidence suggests an interdependence for their activity. The data has demonstrated that the 
concentration of cyclin A-CDK2 that promotes initiation of DNA replication can be modulated 
by CIZ1 levels, and conversely, loading of Cyclin A to DNA in a G1 extract can be modulated 
by CIZ1 levels (Figure 5.5/5.5). The deletion of CIZ1 and cell free DNA replication assays have 
revealed that loss of endogenous CIZ1 increases the concentration of cyclin A-CDK2 that is 
required to promote initiation of DNA replication (Figure 5.6). This effect is reversible by 
either addition of recombinant CIZ1 or by genetic add back of GFP-CIZ1 in CIZ1AB nuclei.   
Significantly, addition of exogenous CIZ1 increases the range of cyclin A-CDK2 activity that 
can promote initiation of DNA replication in vitro.  However, this effect is concentration 
dependent as that addition of CIZ1 to cell free replication assays at very high concentrations 
can block DNA replication initiation in vitro. This observation was observed in cell free assays 
using both an S phase extract, or G1 extracted supplemented with the optimal concentration 
of Cyclin A/CDK2 to promote initiation.  
Data from this chapter can be applied to the quantitative cell cycle model (Discussed in detail 
in Section 1.8).  Briefly, this model attributes cell cycle progression to oscillating kinase levels 
driven by increasing levels of Cyclin proteins as cells progress from G1 through to Mitosis. 
The kinase level is “reset” during anaphase due to the activity of the APC/C (Uhlmann et al., 
2011; Swaffer et al., 2016; Alfieri et al., 2017). Surrounding S phase there are two kinase 
thresholds: a lower kinase activity which must be passed to allow DNA replication initiation 
(Ts), and a higher kinase activity above which replication licensing, and initiation is prevented 
196 
 
(iTs). These two thresholds can be directly observed in cell free DNA replication assays using 
cyclin A-CDK2 titrations (Figure 5.6). 
Data in this chapter has demonstrated that the addition of recombinant CIZ1 can allow 
replication at kinase levels that are either below or above the thresholds that typically allow 
DNA synthesis (TS and iTS). This narrow range of CDK activity that facilitates initiation of DNA 
replication is termed the permissive CDK activity range. A proposed model for the effect of 
CIZ1 levels on kinase thresholds is summarised in Figure 5.13. 
Loss or gain of CIZ1 altered Ts, additional of recombinant CIZ1-N471 promoted DNA 
replication initiation at lower kinase levels, accompanied by a chromatin localisation of Cyclin 
A (Figure 5.13b). Genetic loss of CIZ1 (CIZ1 KO) shifted Ts to higher Cyclin A/CDK2 
concentrations than observed in WT nuclei (Figure 5.13c). Loss of control of the Ts through 
loss or gain of CIZ1 may result in replication occurring earlier than in healthy cells. Often, 
oncogenic activation results in a shortening of G1, which results in DNA replication stress, 
and increased replication/transcription machinery collisions (Macheret & Halazonetis, 2015; 
Macheret & Halazonetis, 2018). Loss of control over the Ts will result in an erosion of 
genome, and regulation integrity  (Técher et al., 2017). 
Experiments in this chapter demonstrated that loss of CIZ1 alters iTs, addition of 
recombinant CIZ1 promoted replication initiation at previously non permissible kinase level 
(Figure 5.13b) and genetic loss of CIZ1 (CIZ1 KO) shifted Ts above the iTs observed in WT 
nuclei (Figure 5.13c). Deregulation of the iTs in these manners could result in re-replication 
promoting genome amplification, aneuploidy and aberrant chromosomal structures (Hook et 
al., 2007). Re-replication is observed in tumour cells (Melixetian et al., 2004). Furthermore, 
as well as inducing chromosome level alterations DNA re-replication leads to mutation. In 
yeast, re-replication can induce 30 fold increases in frameshift rates, as well as inducing base 
substitutions (Bui & Li, 2019). Clearly, the iTs is important for maintenance of genome, and 
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replication integrity. Critically, if dysregulation of CIZ1 results in erosion of control of S-phase 
thresholds this has implications for the role that CIZ1 may play in cancers (Higgins et al., 
2012; Nishibe et al., 2013; Xhou et al., 2018). 
Figure 5.13 – Model for the effect of CIZ1 levels and thresholds for initiation of DNA 
replication  A) Displays the kinase thresholds for normal cells. B) Displays a proposed model 
wherein CIZ1 expands kinase thresholds resulting in mistimed replication, this may be 
measurable by inducing DNA replication stress.  C) Displays a proposed model wherein loss of 
CIZ1 shifts kinase thresholds resulting in mistimed replication, again this may be measurable 
by inducing DNA replication stress. 
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5.5.2. CIZ1 Disruption of Kinase Thresholds may be Linked to its Role in Cancers 
Together these data provide a model for how CIZ1 could be involved in tumorigenesis; both 
with its apparent oncogenic and tumorigenesis activity (Higgins et al., 2012; Nishibe et al., 
2013; Riding-Figueroa et al., 2017). Altered responses to CDK signalling at the G1/S transition 
could promote mistimed replication, this could induce replication stress, driving genome 
instability and promoting a mutator phenotype promoting tumourigenesis. Uncoupling of 
kinase activity and replication initiation control has been shown to induce DNA replication 
stress. (Matson et al., 2019). Oncogenic mutations that promote increased kinase activities 
have also demonstrated replication stress (Srinivasan et al., 2013; Llobet et al., 2019). CIZ1 
disruption of kinase thresholds may induce DRS 
 Loss of CIZ1 increases the S phase kinase threshold, this would promote S phase occurring 
later than appropriate timing. Intriguingly this was not observed in cells in Chapter 4. 
Conversely, S phase occurred more rapidly in cell re-entering the cell cycle. Although, CIZ1 
null cells did more rapidly exit the cell cycle upon contact inhibition and serum starvation. 
This could perhaps be explained by a more rapid increase in Cyclin A accumulation following 
quiescence in CIZ1 null cells (Figure 4.6), which may compensate for the increased CDK2 
threshold required to initiate DNA replication that was observed in vitro. Additionally, CIZ1 
levels accumulate as cells re-enter the cell cycle from quiescence (Pauzaite et al., 2017), the 
levels of CIZ1 may be low enough during cell-cycle re-entry that the threshold manipulation 
of CIZ1 observed in this Chapter may not the major effector on G1 length stemming from 
CIZ1 loss observed in cells (Chapter 4).  
Some evidence of replication stress was provided in DNA combing results from this Chapter 
In vitro data provides evidence for what happens to cells when they gain excess CIZ1. This is 
important as it could explain CIZ1’s dual role as both a tumour suppressor and as an 
oncogene (Higgins et al., 2012; Nishibe et al., 2013). In this chapter, it was revealed in Figure 
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5.12. that addition of CIZ1-N471 to low cyclin A/CDK2 concentrations allows replication. 
However, this replication is inefficient, characterised by a low replication fork velocity. This is 
consistent with DRS, that could result in genome instability (Figure 6.13). At higher cyclin 
A/CDK2 concentrations addition of CIZ1 promotes a replication dynamic more similar to S 
phase cells. This indicates healthy replication could occur at these levels. This could provide 
another clue as to why overexpressed CIZ1 is observed in cancers. This provides a model 
where cells with higher CIZ1 levels can replicate more readily, due to the expanded 
permissible kinase window. This model is summarised in Figure 5.14. 
A second hypothesis can be derived from these results. The overexpression of CIZ1 increases 
the permissive range of cyclin A-CDK2 activities that can promote DNA replication. This may 
provide a growth advantage in cancers with a peturbed cell cycle or persistent oncogenic 
signalling. Cancer cells often have oncogenic mutations that promote increased kinase 
activity and deranged replication dynamics, many of these are proposed cancer therapeutic 
targets (Chen et al., 2018; Caruso et al., 2018).  A potential role for CIZ1 is that it may be 
overproduced to allow cancerous cells to grow in non-favourable conditions, such as where 
there is deregulation of cyclin-CDK activity as a result of oncogenic activation. 
Figure-5.14- Model for the effect of increased CIZ1- Summary of a potential 
model for why high CIZ1 levels are observed in certain cancers. In this model 
genome instability is triggered by replication stress caused by CIZ1 allowing 
DNA replication to occur at lower CDK2 activity levels than ‘healthy cells’. 
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In this role, CIZ1 may be a subject of “non oncogene gene addiction”, this phenomenon 
describes how cancer cells become dependent on a non-oncogenic (or oncogenic) gene as a 
result of phenotypes derived from cancerous mutations. An example of this is Heat shock 
factor 1 (HSF1), a heat shock protein involved in protein refolding. Loss of HSF1 results in a 
decrease in viability of numerous human tumour cells, whilst having no effect on non-
cancerous cells. It is hypothesised that HSF1 relieves the stress present in cancer cells (Dai et 
al., 2007; Solimini et al., 2007). Targeting gene addiction has been proposed as a novel 
cancer therapeutic strategy (Torti & Trusolino, 2011). Future research should focus on the 
dependence of various cancer on CIZ1 to observe whether CIZ1 becomes a gene addiction 
and identify the efficacy of targeting CIZ1 as a personalised cancer therapeutic.  
5.5.3. Analysis of Cell Free DNA Replication Kinetics  
Interestingly, Marheineke et al. (2005) have performed DNA combing experiments on nuclei 
synchronised through mimosine arrest. Using this method human bladder carcinoma EJ30 
cells were used. These cells are treated for 24 hours with mimosine which halts their cell 
cycle progression at late G1. These can be signalled to enter S phase by addition of a 
cytosolic extract from asynchronous cells. S phase nuclei in this report were generated using 
thymidine inhibition. In this report nuclei displayed lower replication rates than would be 
expected from similar cell-based experiments. 0.3 kb/min, similar to the 0.5 kb/min 
displayed in this report. Intriguingly comparable replication rates in these nuclei were found 
from G1 to S phase nuclei, increases in replication were due to an increase replication origin 
firing characterised by an increase in replication density.  
The observed reduction in replication fork rate for in vitro DNA replication assays relative to 
cell-based experiments suggests that there are limiting factors that reduce fork progression. 
For example, addition of CIZ1 and Cyclin A/CDK2 can modulate replication rates in vitro. For 
the nuclei in this report, nuclei may be under additional stress, Replication origins, after cell 
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cycle restart, are under licensed in the first S phase this would lead to a hypersensitivity to 
DNA replication stress (Matson et al., 2019). It is unclear if mimosine mediated cell cycle 
arrest would have a similar effect, there are no published reports measuring the efficiency of 
replication licensing in S phase following mimosine arrest. It is unlikely that the 
synchronisation method used would have this effect on DNA fork rate, as both methods 
(Mimosine/Contact inhibition + serum starvation) produced the similar fork rates compared 
to cell-based experiments. 
The effect that was observed in this report could be similar to what is observed when 
generating the minimal toolkit required to promote DNA replication in vitro. In these 
experiments the minimum proteins required for DNA replication were generated. Nascent 
DNA could be synthesised simply using a mixture of eukaryotic proteins from yeast. 
Replication could be achieved with a minimum of 16 replication factors including replication 
licensing, replication initiation and DNA polymerase proteins (Yeeles et al., 2015). However, 
this minimal toolkit achieved replication but at a lower than in vivo replication rate. Further 
replication factors were required to be added to achieve optimal replication rates. These 
included mrc1, Csm3/Tof1, PCNA and DNA Pol δ. As these replication factors were added 
replication fork rates steadily increased to optimal levels (Yeeles et al., 2017). This is 
strikingly similar to the effect of adding CIZ1 to G1 extracts containing Cyclin A/CDK2. 
Perhaps, CIZ1 promotes optimal DNA replication through co-ordination of CDK signalling. In a 
cancer context. This may provide a growth advantage to cells with deranged CDK networks.  
These methods were used to identify yeast origin dynamics showing that yeast leading 
strand occurs adjacent to the origin, originating from a lagging strand primer (removing the 
need to prime leading strand synthesis) then replicating through the origin (Aria & Yeeles, 
2019). These effects were observed using yeast proteins on yeast DNA, it would be difficult 
to incorporate CIZ1 in these experiments as there is no Yeast CIZ1 homolog. The minimal 
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toolkit for mammalian DNA replication would have to be identified to utilize CIZ1 in this type 
of experiment, a significant challenge. Future experiments should use in vitro techniques 
from this report to establish other factors required for optimal DNA replication in a G1 
extract. 
Perhaps, the reduced fork rate observed in the in vitro experiments in this report, and earlier 
reports is due to a similar effect. CIZ1 can increase the fork rate (in the presence of Cyclin A-
CDK2). From this result there are 2 major possibilities. 1: CIZ1 is a replication factor lacking 
from G1 extracts that is required to achieve efficient replication in vitro. 2: If the effect 
observed here is not similar to the effect from Yeeles et al. (2017), then CIZ1 actively 
promotes DNA replication fork rate increase (to S phase like levels) in the presence of Cyclin 
A/CDK2. Both implicate CIZ1 strongly in the link between CDK signalling and replication 
initiation and could explain how deregulation of CIZ1 can lead to deregulation of replication 
initiation.  
Experiments in this Chapter showed that CIZ1 can promote more optimal replication kinetics 
when added in conjunction with Cyclin A-CDK2. This implies that CIZ1 may play a role at the 
replication fork. Future experiments should aim to identify the role of CIZ1 in the replisome. 
Previous studies have demonstrated that CIZ1 co-localizes to both nascent DNA and 
replication factor PCNA (Coverley et al., 2005). However how CDK activity effects this is 
unclear. Using iPOND techniques to identify replisome proteins could shed light on the role 
CIZ1 plays in DNA replication, and identify any post translational modifications on CIZ1 
(Dungrawala & Cortez, 2016). 
This chapter has built on data from Chapter 4, in that chapter CIZ1 KO caused altered cell 
cycle re-entry kinetics that were accompanied by altered Cyclin accumulation. This chapter 
has demonstrated that CIZ1 KO alters how post quiescent nuclei respond to CDK signalling. 
Additionally, data in this Chapter highlighted that CIZ1 KO nuclei may have an altered 
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replication programme to WT nuclei. Next, the tumour suppressor function of CIZ1 can be 
assessed using CIZ1 KO cell lines to evaluate DNA replication stress in vivo. DNA combing will 
be used to determine the effects of CIZ1 KO on DNA replication kinetics that could underpin 










Chapter 6      
Analysis of DNA Replication 





6.1. Introduction  
CIZ1 has been implicated to have both a tumour suppressor (Nishibe et al., 2013), and 
oncogenic activity (Chen et al., 2019; Higgins et al., 2012; Wang et al., 2014; Yu et al., 2014). 
Increased CIZ1 expression promotes tumour growth and tumorigenicity in lung, colon, 
prostate, breast and bladder cancers (Chen et al., 2019; Higgins et al., 2012; Wang et al., 
2014; Yu et al., 2014; Den Hollander 2006). However, in CIZ1 knock out mice, there is an 
increased sensitivity to DNA damage, and these mice develop lymphoproliferative disorders 
(Nishibe et al., 2013: Ridings-Figueroa et al., 2017). As yet, there are no mechanisms that 
could explain both phenotypes. CIZ1 is proposed to influence the epigenetic landscape and 
contribute to mechanisms that control DNA replication initiation. In addition, CIZ1 has also 
been implicated in regulation of transcriptional responses in oestrogen responsive (Den 
Hollander 2006) and YAP/TAZ regulated genes (Lei et al., 2016). Defects in epigenetics, 
transcription and DNA replication regulation are all associated with DNA replication stress 
(DRS). This phenomenon could potentially provide a mechanism for the tumorigenic 
transformation of cells with deregulated CIZ1 levels. 
Oncogene activation or inactivation of tumour suppressors promote DRS, which is 
characterised by reduced DNA replication forks rates and fork stalling during S phase (Gailard 
et al., 2015). Prolonged DNA replication stress results in genome instability, a traditional 
cancer hallmark (Hanahan & Weinberg, 2000). Replication stress itself has been proposed as 
an additional hallmark of cancer (Macheret & Halazonetis, 2015). Other sources of 
replication stress include bulky DNA lesions introduced by UV irradiation, collisions with the 
transcription machinery, and premature S phase entry (Ahuja et al., 2016; Gottipati et al., 
2008; Yajima et al., 2009). Importantly, premature S phase entry was observed in CIZ1 null 
cells re-entering the cell cycle (Chapter 4), and this may be a cause of DRS in CIZ1 null mice.  
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Stalling or slowing replication forks introduces a disparity between the rate that DNA 
polymerases and DNA helicases progress along DNA, this unwinding of DNA exposes long 
stretches of single stranded DNA (ssDNA) (Byun et al., 2005). This decoupling primarily 
occurs on leading strand synthesis upon the stalling of DNA pol δ or DNA pol ε (Taylor & 
Yeeles, 2019). RPA binds to and stabilises exposed ssDNA and accumulation of RPA can 
activate the DNA damage response (DDR). Prolonged accumulation of RPA results in 
activation of p53, halting of the cell cycle, and cells are either repaired, enter senescence, or 
in cases of serious damage become apoptotic (Maréchal & Zou, 2015). In most cases 
activation of the DDR and halting of the cell cycle acts as a tumorigenesis barrier (Prieur & 
Peeper, 2008). Suppression of RPA in ATR deficient cells results in increased rates of 
replication fork stalling (Toledo et al., 2013). 
In cases of severe replication stress, replication forks stall because of collision with bulky 
DNA damage (UV), or the transcription machinery (Gottipati et al., 2008). In this situation, 
cells usually restart replication forks through activation of the ATR and Chk1 pathway 
(Mazouzi et al, 2014). If cells are deficient in this pathway it can lead to replication fork 
collapse, where proteins dissociate from the DNA and DSB can occur which if not repaired 
can lead to under replicated DNA and chromosome abnormalities following mitosis (Burrell 
et al., 2013; Gaillard et al., 2015). Secondly, collision with transcription machinery induces 
replication stress. Collisions with DNA:RNA hybrid loops induce replication fork stalling, 
occurring primarily in highly transcriptionally active common fragile sites (Kotsantis et al., 
2018). Head on collisions are resolved less easily that co-directional collisions. DNA damage 
induced by transcriptional machinery has been recorded across all domains of life (Gómez-
González et al., 2019). Transcription is upregulated in cancer cells, due to the requirements 
of accelerated cell growth, further exacerbating this increase in genomic instability. As such, 
inhibition of transcription has been proposed as a novel way to treat cancers (Laham-Karam 
et al., 2020). Clinical trials demonstrated in humans (phase 1) that treatment with CX-5461, 
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an RNA Polymerase I Transcription Inhibitor, had some anticancer effect, although strong 
side effects (Khot et al., 2019). Nevertheless, this validates targeting these pathways in 
cancer  
Additionally, DNA methylation is linked to replication stress (Prado & Aguilera, 2005). 
Recently it was demonstrated that methylation of DNA in active transcription zones slows 
DNA replication to prevent collisions between replication and transcription machinery 
(Chong et al., 2018). This could be of particular interest here, as CIZ1 has been shown to play 
a role in X chromosome activation through colocalization with Xist RNA (Ridings-Figueroa et 
al., 2017; Sunwoo et al., 2017).  
Figure 6.1 - Sources of DNA Replication Stress Replication stress can be induced through 
changes in DNA replication dynamics, and transcriptional collisions. These changes can be 
resolved by either the slowing or stalling of DNA replication forks. The factors that induces 
these changes are briefly summarised in this Figure. Oncogene Activation, and changes in 
DNA methylation often induce a shortening of fork rate. PARPi and p21 can result in a fork 
rate acceleration replication stress phenotype. Head on, and head to tail collisions between 




This chapter will use the tools developed here to investigate the role of CIZ1 in establishing 
DNA replication kinetics in parental and CIZ1 KO cell lines. In addition, the CIZAB cell line will 
be used to investigate if effects are reversible through genetic add back. In addition, the 
effect of increased DRS using hydroxyurea will be determined in parental, CIZ1 KO and CIZ1AB 
cell lines. In this chapter DNA combing is used to:  
• Observe changes in DNA replication kinetics in CIZ1 null cells 
• Evaluate the changes in response to HU at the single replication event level 
• Assess how observed changes can be linked to the tumour suppressor function of 
CIZ1 
6.2. Results  
6.2.1. Using DNA Combing to Measure Changes in DNA Replication Dynamics.  
Data from this report suggests that aberrant CIZ1 expression could induce replication stress 
via perturbations in the activating threshold of CDK activity required to initiate DNA 
replication. Deregulation of CDK activity by over-expression of cyclin D, or E can reduce G1 
length and promote oncogenesis (Lange et al., 2010; Dong et al., 2018). This suggests that 
CIZ1 may contribute to genome stability through contributing to the mechanisms that 
control timely activation of replication origins. 
In Chapter 5, the activating concentration of cyclin A-CDK2 to promote initiation of DNA 
replication was altered depending on the level of CIZ1 expression. In CIZ1 KO nuclei, 2-fold 
higher levels of cyclin A-CDK2 were required to promote initiation of DNA replication than in 
WT nuclei (Figure 5.6). In addition, cell free DNA replication assays with additional 
recombinant CIZ1, which may be consistent with CIZ1 overexpression in vivo, showed that 
cells could initiate DNA replication at both aberrantly high and low CDK levels. The CDK 
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thresholds that regulate the G1/S transitions are precisely controlled and the data show that 
CIZ1 levels can influence the permissive CDK activity range at the G1/S transition. 
Perturbations to CIZ1 levels may lead to replication stress, which promotes a mutator 
phenotype that underpins both the tumour suppressor and oncogenic effects observed in 
CIZ1 knockout cells and overexpressing cells. 
Analysis of the timing of restriction point and the G1/S transition using parental WT, CIZ1 KO 
and CIZ1AB cell lines (Chapter 4) demonstrated that CIZ1 deficiency can change the timing of 
the cell cycle, specifically in G1 phase. Following synchronisation and release from 
quiescence, CIZ1 KO cells entered S phase more rapidly than both WT and CIZ1AB cells. 
Additionally, in CIZ1 KO cells loss of CIZ1 changed the timing at which cells relied on the 
presence of exterior growth signals to enter the S phase. These experiments also revealed a 
defect in the DDR in response to agents that promote the stalling of DNA replication forks, 
characterised by prolonged H2AX phosphorylation. Together this data demonstrated that 
changes in CIZ1 levels caused changes to cell cycle control. It is not yet clear if this results in 
alterations in replication dynamics which could help to explain why CIZ1 is linked to cancer 
development.  
First to ensure that changes in DNA replication dynamics could be measured using DNA 
combing CDK/DDK inhibitor drugs PHA-767491 (PHA) and XL-413 hydrochloride (XL) were 
used. Published reports on PHA and XL have demonstrated that they both inhibit Dbf4 
dependent kinase (Dbf4-Cdc7, DDK) signalling through inhibition of CDC7 kinase. However, 
PHA has demonstrated off target signalling, specifically for CDK2 (Montagnoli et al.,2008) 
Due to the different off target effects for PHA and XL they inhibit entry into S phase by 
different mechanisms which effects DNA replication fork progression, this may result in a 
change in the effect on DNA replication dynamics. To measure the effects on DNA replication 




























Figure 6.2. Replication dynamics of cell treated with CDC7 inhibitors PHA-767491 or XL-413. A) 
DNA combing analysis of DNA replication kinetics showing ssDNA (Blue), IdU (Green) and CldU 
(Red) B) Displays replication event density for untreated and XL-413 treated cells. C) Displays the 
proportion of DNA co-labelled with either IdU or CldU, this forms a measure of the proportion of 
total DNA replicating for untreated and XL-413 treated cells. D) Replication fork velocities for 
untreated (Blue) and XL-413 treated (Black) cells. Red spots show the median value for each 
dataset (N =150). E) Replication fork velocities for untreated (white) and XL-413 treated (grey) 
cells. Displaying the quartile values from the data. X represents the mean value. The mean fork 
rate of XL treated nuclei was significantly lower than control (T test P < 0.001, n=150 for each 





XL. Control cells were compared with DDK inhibitor treated cells after sequential pulse 
labelled with IdU and CldU (Chapter 3). Cells were harvested, combed and labelled for 
analysis by fluorescence microscopy. Parameters measured from imaged fibres were fork 
rate, replication density and the proportion of total measured DNA in S phase (Figure 6.2).  
Cells that were treated with PHA displayed so few replication forks that it was not possible to 
acquire sufficient events to measure replication kinetics, due to potent inhibition of DNA 
replication. Comparison of control cells and XL413 treated cells revealed a significant 
difference in fork velocities for untreated cells and with median replication fork rates of 1.14 
kbp/min and had a 0.96 kb/min, respectively (Figure 6.2D,E). The significant reduction in 
replication fork velocity in cells treated with XL 413 was accompanied by a reduction in 
replication event density by a factor of 2 (Figure 6.2B) identifying a reduction in the number 
of replication origins firing in the XL-413 treated cells. Additionally, a drop in the proportion 
of DNA replicating was observed, a reduction by ~ 40% after 24 hours treatment with XL-413 
(Figure 6.2c).  
Together, this data reveals that the DDK inhibitors, PHA-767491 and XL 413, cause 2 distinct 
phenotypes. PHA causes a complete block into S phase entry, this has been previously 
observed (Pauzaite, 2019). Whereas, XL 413 reduces efficiency of replication origin activation 
and reduces replication fork efficiency during S phase. This indicates that XL 413 may have a 
more selective effect than PHA, potentially due to off target inhibition of CDK2 eliciting a 
more potent response. This result also demonstrates that XL-413 mediated inhibition of DDK 
signalling at the G1/S transition induces a replication stress like phenotype. This was 
characterised by a global reduction in the amount of DNA being replicated caused by a 
reduction in both replication fork rate and the number of replication origins that fired. This 
data has verified that the DNA combing technique optimised in Chapter 3 can be used to 
measure changes in replication kinetics.  
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6.2.2. CIZ1 KO Induces a DNA Replication Stress Phenotype 
Cells under constitutive replication stress show a reduced replication fork rate, and 
decreased IOD due to activation of cryptic origin sites. To determine the effects of CIZ1 KO 
on DNA replication kinetics, CIZ1 KO1 and CIZ1 KO2 cell lines were compared to parental WT 
cells. Asynchronous cultures of WT NIH 3T3 cells, CIZ1 KO1 cells, and CIZ1 KO2 cells were 
sequentially pulse labelled (20 minutes) with IdU and CldU , cellular DNA harvested, combed 
and imaged   
Figure 6.3-Replication dynamics of parental WT NIH 3T3 and CIZ1 KO Cells Cells were 
labelled for DNA combing analysis by sequential 20 minutes IdU and CldU labelling. A) 
Representative DNA combing tracks B) Bar chart of WT and CIZ1 KO cell lines displaying mean 
percentage of dual labelled tracks for WT, KO1 and KO2 cell lines (n = 150). C) Swarm plot 
showing replication fork velocities for WT, KO1 and KO2 cell lines. The red dot represents the 
median of each dataset. (N = 150), no significant differences were observed across cell lines 
(One Way ANOVA, P > 0.05).  D) Box and whisker plots showing the distribution of replication 
fork velocities for WT, and CIZ1 KO cell lines. Cross represents the mean value. Significant 
differences are indicated by significance bars. There was a significant difference in fork rates 
across cell lines (One Way ANOVA, P < 0.001, N = 150). Pairwise comparisons were conducted 
by Tukey’s HSD test, significance is indicated on the graph: ns = p > 0.05 * = p < 0.05, ** = p < 
0.01, *** = p < 0.001, **** = p < 0.0001 C  
100 µm 
A 
B C D ns 
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Firstly, the proportion of dual labelled replication tracks was calculated. Changes in the 
number of dual labelled tracks could indicate increased fork stalling, origin firing, and 
termination events. There were no significant differences in the mean proportion of dual 
labelled replication tracks from Wild type parental cell line (WT), and 2 independent CIZ1 
clones CIZ1 KO1 and KO2.  
Next dual labelled replication tracks were selected and lengths of the second track (CldU) 
were measured to determine fork progression rates and single track kinetics displayed in 
swarm plots and box and whisker charts. For WT cells the median velocity was 1.4 kb/min, 
this value is comparable to published rates from NIH 3T3 cells (between 1.25 – 1.5 kbp/min) 
(Bhaskara et al., 2013). This indicates that WT cells are efficiently progressing through S 
phase. Both KO cells displayed decreased replication fork velocities at approximately 1.1 
kb/min. Significant differences were observed between the mean rates across the 3 samples, 
specifically between the WT and KO cell lines. There was no significant difference between 
the two KO cell lines. This observation suggests that CIZ1 KO is responsible for the reduction 
in fork rate, as the  KO cell lines used independent PAM sites within the  CIZ1 sequence. This 
data suggests that CIZ1 KO alters the DNA replication programme, reducing fork velocities 
consistent with DNA replication stress.  
6.2.3. CIZ1AB reverses the DNA replication stress phenotype observed in CIZ1 KO Cells.  
Changes in replication fork dynamics were observed between WT and CIZ1 KO cells. To 
evaluate the reversibility of the DRS in CIZ1 KO cell lines, replication fork dynamics were 
monitored using DNA combing (Figure 6.3). WT cells, CIZ1 KO1 and CIZ1AB cells were grown 
to 80 % density, treated sequentially for 20 minutes with IdU, and CldU. Cells were 









       WT               CIZ1 KO1             CIZ1AB 
  WT      CIZ1 KO1      CIZ1AB 
Figure 6.4. CIZ1AB reverses the DRS phenotype in CIZ1KO cells Cells were labelled for DNA combing 
analysis by sequential 20 minutes IdU and CldU labelling. A) Displays a representative image of combed 
DNA from each of the samples. B Displays a Graphical schematic of the experimental design. C) displays 
the mean proportion of each cell that is dual labelled (n = 150), no significant differences were observed 
across cell lines (One Way ANOVA, P > 0.05).  D) Displays replication fork rate of each of the samples. Red 
dots represent the median value for each data set. E) Displays box and whisker charts displaying the 
distribution of fork rates for WT, CIZ1 KO1, and CIZ1AB cell lines. The cross represents the mean for each 
data set. There was a significant difference in fork rates across cell lines (One Way ANOVA, P < 0.01, N = 
150) Pairwise comparisons were conducted by Tukey’s HSD test, significance is indicated of the graph: ns 





For WT cells, 76 % of counted replication tracks were dual labelled. CIZ1 KO1 cells and CIZ1AB 
cells showed no significant differences relative to parental cell lines with 73% and 75% of 
scored replication forks dual labelled (Figure 6.4C). Together this data confirms consistent 
replication dynamics between experiments and between the cell lines.  
The median replication fork velocity was 1.4 kbp/minute for WT cells, consistent with earlier 
data (1.4 kbp/min, Figure 6.3). In contrast, the median fork rate for CIZ1 KO cells was 1 
kbp/min, consistent with earlier data for CIZ1 KO1 and 2 (1.1 kbp/min vs 1 kbp/min). 
Significantly, the reduced median fork progression rate was reversed in CIZ1AB cells, which 
had a median replication fork velocity of 1.45 kbp/minute. A one way ANOVA revealed that 
there were significant differences between the means across the 3 cell lines. Critically, 
Tukey’s HSD tests showed the difference in fork rate was statistically significant between WT 
and CIZ1 KO1 cells, and between KO1 and CIZ1AB. However, the WT and CIZ1AB fork rates 
were not significantly different. Together, these data demonstrated CIZ1 KO cells have 
reduced fork rates, an effect that can be rescued by CIZ1AB, reversing the replication stress 
like phenotype observed in CIZ1 KO cells. These data suggest that CIZ1 contributes to 
mechanisms that prevent DNA replication stress and promote efficient DNA replication. 
6.2.4. CIZ1 KO Results in Increased Origin Activation, consistent with DRS. 
When cells are put under replication stress (e.g. chemically, or physically) the replication fork 
velocities slow. To compensate this reduced replication rate, cells activate ‘cryptic origins’ to 
ensure that DNA replication is completed within a suitable time frame (McIntosh & Blow, 
2012). This is seen as a decrease in inter-origin distance (IOD), that is revealed by an increase 
in replication origin firing events per micrometre of DNA. To test if there are changes in 
origin activation in CIZ1 KO cells, the number of replication events were determined using 
EdU. The use of a single label allows 2 variables to be determined (i) the proportion of 
labelled DNA as a ratio with total DNA provides an estimate for the global amount of DNA 
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synthesis, and (ii) The number of replication events per micron provides an estimate of origin 
activation (Figure 6.5). 
Figure 6.5. CIZ1 KO increases activation of cryptic replication origins A) A schematic of the 
experimental design. Cells were treated with EdU for 30 minutes before harvesting for DNA 
combing. B) Displays the replication event density (replication events per kbp DNA).  There 
was a significant difference in replication density across cell lines (One Way ANOVA, P < 0.01, 
N = 3), Tukey’s HSD test demonstrated KO1 and KO2 results were significantly different from 
WT cells (WT:KO1, P < 0.05, WT:KO2 P < 0.01) but KO1 and KO2 cells did not have 
significantly different replication densities (p > 0.05). C) Displays the proportion of DNA 
replicating (percentage of DNA positively labelled). There was a significant difference in 
proportion of replicating DNA across cell lines (One Way ANOVA, P < 0.0001, N = 3). Pairwise 
comparisons were conducted by Tukey’s HSD test, significance is indicated of the graph: ns = 






WT NIH 3T3 cells have 0.023 events/kbp, which translated to one replication event every 43 
kbp of DNA. For CIZ1 KO1 and CIZ1 KO2, there was a significant increase in replication events  
by a factor of 1.98 And 2.6 respectively relative to WT. The difference between KO1 and KO2 
cells was not significant. 
For WT NIH 3T3 cells, an average of 8 % of DNA was being replicated during the 30 minute 
EdU incubation, this was comparable to results observed in an enriched S phase nuclei 
population (Marheineke et al., 2005). For both CIZ1 KO cells an increase in the proportion of 
DNA that was being replicated during the 30 minute EdU incubation increased by a factor of 
1.9 and 1.85 respectively compared to WT cells. A one way ANOVA revealed that there were 
significant differences between the means across the 3 cell lines. A Tukey’s HSD post hoc test 
revealed that the averages were significantly different from WT cells. The average values for 
KO1 and KO2 cells was not significantly different.  This indicated that upon loss of CIZ1 there 
is an increase in the proportion of DNA actively replicated, consistent with an increase in 
origin usage to compensate for reduced fork rate. This represents a further difference in the 
DNA replication programmed in NIH 3T3 cells upon genetic ablation of CIZ1. The data show 
that CIZ1 KO NIH 3T3 cells have an altered replication programme compared to WT NIH 3T3 
cells, with increased origin firing, a higher percentage of DNA undergoing replication but 
with reduced replication fork velocity.  
To determine if the activation of cryptic origins was as a consequence of CIZ1 KO, the origin 
density was determined for WT, CIZ1 KO1 and CIZ1AB (Figure 6.6). A one way ANOVA 
revealed significant differences between the means across the three cell lines. CIZ1 KO cells 
displayed an increase in replication event density by a factor of 2.3 compared to WT cells. 
Importantly, this effect is reversed in CIZ1AB cells, which displayed an increase by a factor of 
1.1 compared to WT cells. The CIZ1 KO was significantly higher than WT cells, but not CIZ1AB 
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cells (P = 0.063) suggesting ectopic CIZ1 addback could only partially rescue the CIZ1 KO 
phenotype. 
 
Figure 6.6. CIZ1AB reverses the activation of cryptic replication origins in CIZ1 KO cells. A) 
Displays the replication event density (replication events per kbp) (showing mean ±S.D.). 
There was a significant difference in replication density across cell lines (One Way ANOVA, P 
< 0.01, N = 3), Tukey’s HSD test demonstrated WT replication densities were significantly 
different from KO1 cells (P < 0.05) but there were no significant differences between WT and 
CIZ1AB  (p > 0.05), or KO1 and CIZ1AB cells (P > 0.05) B) Displays the proportion of DNA 
replicating (percentage of DNA positively labelled) (showing mean ±S.D.). There was a 
significant difference in the proportion of replicating DNA across cell lines (One Way ANOVA, 
P < 0.05, N = 3). Pairwise comparisons were conducted by Tukey’s HSD test, significance is 
indicated of the graph: ns = p > 0.05 * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001. 
 
In addition, there is an increase in the percentage of nascent DNA in CIZ1 KO cells with 
respect to WT NIH 3T3 cells. A one way ANOVA revealed significant differences between the 
means across the three cell lines. For WT cell lines, an average of 8 % of DNA was undergoing 
DNA replication, compared to 18% for CIZ1 KO NIH 3T3 cells. In contrast, in CIZ1AB cells 
showed similar level of nascent DNA compared to WT cells, to 8.8 %. There was no significant 
difference between CIZ1 KO and CIZ1AB cell lines. This demonstrates that the increased origin 
A B 
WT      CIZ1 KO1    CIZ1AB 




activation seen in CIZ1 KO cell lines is only partially reversed by genetic add back of CIZ1 
(CIZ1AB). Together these results indicate that CIZ1 KO induces DNA replication stress, and 
that this effect can be partially rescued by CIZ1AB.  
6.2.5. Evaluation of the role of CIZ1 in cellular responses to increased DRS. 
In Chapter 4, experiments revealed that loss of CIZ1 altered the response to replication 
stress inducing agents HU. This was characterised by prolonged H2AX phosphorylation after 
HU treatment in CIZ1 KO cells relative to WT cells (Figure 4.10). However, the proportion of 
cells in S phase remained consistent between WT, CIZ1 KO and CIZ1AB cell lines. As a 
difference in DDR was observed, the phosphorylation status of H2AX will be monitored to 
detect dsDNA breaks. In addition, DNA combing or DNA fibre analysis are commonly used 
tools to detect how cells change their response to replication stress or DNA damage.  
Cells with chronic DNA replication stress often display increased sensitivity to agents that 
induce DRS and have defects in replication fork restart. Fork restart efficiency can be 
determined by sequential incubations in IdU, HU and then restart determined with a second 
incubation with CldU (Nieminuszczy et al., 2016). In this context, fork restart is efficiently 
determined by the presence of both labels. This contrasts with stalled forks that cannot 
efficiently restart and are labelled with IdU only. Similarly, origins that fire after HU 
treatment will be labelled solely with a CldU track. This allows discrimination of both events 
and aids their exclusion from analyses. Termination events during the 1st pulse labelling 
stage will also be labelled as a single IdU track, however these should form such a minority 
that they can be ignored. 
To measure changes in fork restart rates upon loss of CIZ1: WT, KO1, KO2, and CIZ1AB were 
labelled with IdU for 2 hours, treated with HU for 2 hours, then released from HU block into 
fresh media supplemented with CldU for 30 minutes and control cells were left in media 
supplemented with CldU and HU for 30 minutes (Figure 6.7).  
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Figure 6.7. CIZ1 KO cells have impaired ability to restart forks after replication challenge with HU. WT, 
CIZ1 KO1, CIZ1 KO2, and CIZ1AB were treated sequentially with IdU (2 hours, HU 2 hours, and CldU for 30 
minutes, control cells were co-incubated with HU and CldU. A) Displays a schematic of the design of the 
experiment. B) displays the proportion of replication tracks labelled with both IdU and CldU for both the HU 
treated (black) and control (white cells). This is a measure of fork restart efficiency. The proportion of 
replication forks dual labelled in each condition (n = 3) for each cell line was compared using a two-way 
ANOVA with treatment and cell line as factors (P (treatment) < 0.0001, P (cell line) < 0.01, P (interaction) < 
0.01. Pairwise comparisons were made by simple main effects analysis. No significant differences were 
observed for cells not released from HU (p > 0.05 for all comparisons). No significant differences were 
observed between WT/CIZ1AB cells or KO1/KO2 cells released from HU (P > 0.05 for all comparisons). 
Significant differences were observed between either KO cell line and WT or CIZ1AB cells (p< 0.01 for all 
comparisons.) C) Displays box and whisker charts showing the distribution of fork rates of restarted forks for 
experimental samples for each cell line. (WT: White, CIZ1 KO1: Dark grey, CIZ1 KO2: light grey, CIZ1AB: 
Black). There was significant differences in rates of restarted fork rates across cell lines (One Way ANOVA, P 
< 0.0001, n 150) Pairwise comparisons were conducted by Tukey’s HSD test, significance is indicated of the 
graph: ns = p > 0.05 * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.  D) displays swarm plots 
of the fork rates of restarted forks for experimental cells (n =150) (WT: Purple, CIZ1 KO1: red, CIZ1 KO2: 










Firstly, WT cells in a HU block an average of 9 % of replication tracks were dual labelled. 
Similar results were observed in both KO cell lines with an average of 11% and 13 % for KO1 
and KO2 respectively. Unsurprisingly, CIZ1AB cells also displayed a low proportion of tracks 
dual labelled: 10.3 %. There were no significant differences between cell lines for controls. 
This indicated that H2AX  phosphorylation efficiently stalled replication regardless of CIZ1 
levels. For each cell line, a minority of replication forks were able to continue. This could be 
due to cell to cell variation in responses to hydroxyurea. 
However, significant differences were observed in the proportion of replication forks that 
were able to restart after HU challenge. In WT cells, released from the HU block, an average 
of 72 % of replication tracks were dual labelled, an increase of 61 % from controls. For the 
CIZ1 KO1 and KO2 cell lines there was a reduction in fork restart with only 53% and 42% dual 
labelled respectively (Figure 6.7C). The reduced capacity to restart DNA replication after HU 
treatment was reversed in CIZ1AB cells, that showed an average of 77 % of dual labelled 
replication tracks. Critically, the proportion of forks that restarted for WT and CIZ1AB cells 
were both significantly different from both CIZ1 KO cell lines. The proportion of restarted 
forks was not significantly different when comparing WT and CIZ1AB or KO1 and KO2 cell 
lines. 
Interestingly, for WT and CIZ1AB cell lines, the proportion of dual labelled restarted forks was 
comparable to untreated cells where 69 % and 70 % of replication forks  were dual labelled 
for WT and CIZ1AB cells respectively (Figure 6.4). This indicates that recovery from HU 
challenge in these cells was a result of restarting stalled forks, rather than an increase in 
replication origin firing from dormant origins. For CIZ1 KO cell lines a decrease in the 
proportion of dual labelled fork was observed, compared to untreated cells (Figure 6.4). This 
indicates that CIZ1 null cells may be deficient in restarting forks in response to HU challenge 
and did not compensate by firing dormant origins. This data coupled with data from 4.10 
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indicated that loss of CIZ1 promotes a deficient recovery from HU mediated replication 
stress.  
All cell lines showed reduced fork rates after HU treatment compared to unchallenged cells 
(Figure 6.7D, E and Figures 6.3/6.4). A one way ANOVA revealed significant differences 
between the means across the 4 cell lines. Both CIZ1 KO cell lines showed an increased fork 
rate after withdrawal of HU compared to WT and CIZ1AB cells. For WT cells, the median 
replication fork velocity was 0.4 kbp/min after release from HU. CIZ1 KO1 cells displayed a 
median replication fork velocity of 0.55 kbp/min and KO2 cells showed a median replication 
fork rate of 0.7 kb/min. The fork rates were significantly higher than WT . Comparison with 
unperturbed fork rates in KO1 and KO2 cells showed an approximate 2-fold reduction, lower 
than the observed drop in WT cells. This increase in median fork rate for CIZ1 KO1 cells was 
reversed in CIZ1AB cells. The median fork rate of the restarted replication forks in CIZ1AB cells 
was 0.45 kbp/min. This was lower than unstalled forks in CIZ1AB cells by a factor of 3 (Figure 
6.4). This dataset was not significantly different from rates of restarted forks observed in WT 
cells. However, this data was significantly different from restarted fork rates for both KO1 
and KO2 cells lines.  
Together these results indicate that CIZ1 may contribute to mechanisms that regulate fork 
restart following DRS induced by a HU block. This manifests as an observed higher replication 
fork rate in CIZ1 KO cell lines relative to WT and CIZ1AB cell lines. This could be due to either 
faster fork rates, or a more rapid restart after release from the HU replication challenge. The 
increase in fork rate observed may be compensation for the reduced proportion of restarted 
forks that was observed. This could be linked to the phenotype observed in Chapter 4, in 
which a delayed H2AX activation was observed that resulted in a prolonged response 24 
hours after treatment. Perhaps, an inefficient response to HU results in an accumulation of 
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damage that results in the prolonged H2AX activation. This change in response at the DNA 
has implications for the fidelity of DNA replication following replication challenge.  
6.2.6 CIZ1 KO cell lines show defective origin activation 24 Hours after HU Treatment. 
Analysis of DNA replication kinetics after an acute period after HU treatment revealed 
evidence of defects around fork restart in CIZ1 KO cells. Previously, CIZ1 KO cells displayed 
prolonged H2AX gamma phosphorylation 24 hours post release from HU block, where WT 
cells did not. However, there was no significant difference in the proportion of cells in S-
phase at the 24 hour time point in WT, CIZ1 KO and CIZ1AB cells. To investigate if there is a 
difference in fork rates after HU treatment after 24 hours DNA combing was used.  WT, CIZ1 
KO1, and CIZ1AB cells were each treated for 2 hours with 2 mM HU and released for 24 hours. 
Fork rates were determined as well as the proportion of replication forks that were dual 
















Figure 6.8 Measuring Replication Dynamics 24 hours after HU Mediated Replication Stress. A) Representative images of combed 
fibres displaying ssDNA (Blue), IdU (Red), CldU (Green). B) A schematic of the design of the experiment.  C) Replication Event 
densities of the three cell lines used. Calculated by measuring replication events (non-contiguous replication tracks) as a proportion 
of total length of DNA measured. There were significant differences in replication density  across cell lines (One Way ANOVA, P < 
0.05). Pairwise comparisons were conducted by Tukey’s HSD test, significance is indicated of the graph: ns = p > 0.05 * = p < 0.05, ** 
= p < 0.01, *** = p < 0.001, **** = p < 0.0001. D) Box and whisker chart showing the distribution of fork rates for each cell line: WT 
(White, CIZ1 KO1 (Light grey), CIZ1AB (Dark Grey). The cross represents the mean value. There were significant differences in fork rate 
across cell lines (One Way ANOVA, P < 0.0001, n =150). Pairwise comparisons were conducted by Tukey’s HSD test, significance is 
indicated of the graph: ns = p > 0.05 * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. E) Swarm plots displaying the 
replication fork rates for each cell line: WT (Blue), CIZ1 KO1 (Red), and CIZ1AB (Green). Red point represents the median for each data 
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In contrast to DNA replication rates 2 hours after release from HU (Figure 6.7), median fork 
progression rates for WT and CIZ1AB were consistent with unperturbed rates (Figure 6.4). WT 
cells displayed an average replication fork rate of 1.5 kbp/min, and  CIZ1AB  cells 1.6 kbp/min  
consistent with fork rates in unperturbed cells (Figure 6.3/6.4). CIZ1 KO cells had a median 
fork rate of 0.9 kb/min, lower than in unperturbed CIZ1 KO cells (Figure 6.3/6.4). This 
suggested after increased DRS CIZ1 KO developed increased DRS. A one way ANOVA 
revealed significant differences across the means for the 3 cell lines. Importantly, the mean 
fork rates for WT and CIZ1 KO were significantly different, an effect that was reversed in 
CIZ1AB cells  (Figure 6.8 D,E).  
When comparing replication fork density, a measure of the origin activation, there is a 
significant difference in replication origin usage. A one way ANOVA revealed significant 
differences between the means across the 3 cell lines. Parental WT cells have more active 
DNA replication origins per kb of DNA and this is reduced in CIZ1 KO cells (0.05 and 0.002 
origins/kb DNA) consistent with a reduction in origin firing in CIZ1 KO cells. This effect is 
mostly reversed in CIZ1AB cells (0.04 origins/kb) suggesting that expression of CIZ1 is required 
for efficient origin activation after increased DRS. CIZ1 KO replication density was 
significantly different from both WT, and CIZ1AB cells; whereas, mean values for WT and 
CIZ1AB samples were not significantly different  from each other (Figure 6.8 C). This indicated 
ectopic CIZ1 could rescue the DRS phenotype.  
This effect is distinct from the typical response to origin activation, where cryptic origins are 
activated to ensure timely completion of S-phase and the precise mechanism that underpins 
this response has yet to be identified. However, this experiment revealed that after 24 hours 
release from a HU mediated replication block CIZ1 KO1 cells display a significantly lower fork 
progression rate and a reduction in origin activation than untreated WT and CIZ1AB cells. This 
data shows that CIZ1 KO cells have a reduced ability to recover from a HU mediated 
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replication block, compared to WT cells, and this can be rescued by the genetic addback of 
GFP-CIZ1.  
6.3. Chapter Discussion 
Together, data from this chapter has linked CIZ1 function and regulation of DNA replication 
dynamics. Loss of CIZ1 induces a change in replication dynamics that is consistent with DNA 
replication stress. Together with data from previous chapters, this has demonstrated the link 
between CIZ1 levels and replication fidelity. In addition, the data demonstrates that the loss 
of CIZ1 results in a DRS phenotype and a hypersensitivity to further replication stress such as 
HU treatments.  Taken together the data suggest that CIZ1 potentially plays a tumour 
suppressor role by acting to regulate fork dynamics and reduce potential for DRS. These 
observations will be discussed with implications for the potential mechanisms that promote 
genetic instability and tumour formation in the absence of CIZ1.  
6.3.1. CIZ1 Null cells undergo DRS and have increased sensitivity to DRS inducing agents 
Comparison of WT and CIZ1 KO cell lines has revealed that CIZ1 cells have a DRS phenotype. 
Typically, replication stress results in an increased origin activation and decreased replication 
fork. (Zhong et al., 2013). CIZ1 KO cell lines show typical DRS characteristics with a drop in 
DNA replication fork rates (Figure 6.3) and an increase in active replication origins (Figure 
6.5). This result was consistent with synchronised nuclei in in vitro DNA replication assays 
(Chapter 5.4.). The results presented in this chapter demonstrated that loss of CIZ1 results in 
an impaired DDR, both in regards to replication fork restart (fewer forks restarted 2 hours 
after HU treatment), and replication kinetics 24 hours after exposure to the DNA replication 
stress agent HU (Fork progression was impaired 24 hours after HU exclusively in CIZ1 null 
cells). Erosion of an effective DDR coupled with induction of replication stress may help 
provide CIZ1 null cells the ability to bypass the tumourigenesis barrier.  
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In CIZ1 KO cells, when cells were further stressed by HU treatment a reduction in both fork 
velocity and origin usage was observed (Figure 6.8). A similar phenotype is observed upon 
MCM depletion, reduced origin firing and fork progression due to a reduced ability to fire 
dormant origins (Ge et al., 2007). These cells were unable to respond to increased damage as 
a result of HU treatment. A similar result was observed in pancreatic cancer cells treated 
with MEK inhibitor GSK212, this blocked both HR and NHEJ repair, these cells displayed 
delayed resolution of DSBs from radiotherapy resulting in a prolonged H2AX response. This 
was used to radio-sensitise the pancreatic cancer cells (Estrada-Bernal et al., 2015). 
This could implicate a role for CIZ1 in the replisome during fork restart, and this is supported 
by results from Chapter 4 showing that CIZ1 KO cells experienced a sustained H2AX response 
after treatment with HU. If CIZ1 null cells are deficient in fork restart this may result in an 
inability to repair DNA introducing more complex damage resulting in a sustained DDR 
(Huang et al., 2020).  
6.3.2 A potential model for the role of DRS in tumourigenesis in CIZ1 KO mice 
Replication stress is crucially important at the early stages of tumorigenesis. Pre-cancerous 
and early tumour cells have stressed replication, resulting in incomplete or low fidelity 
replication. This erodes the stability of the genome, expediting the mismatches, and 
mutations. When these occur in key tumour suppressor and oncogenic genes pre-cancerous 
cells can become cancerous, or cancerous cells can become more aggressively proliferative 
(Macheret & Halazonetis, 2015).  
Severe replication stress will result in the exposure of ssDNA promoting a DDR. ssDNA is 
protected by RPA coating, which activates ATR triggering the DDR. The DDR provides a 
‘tumourigenesis barrier’ that functions in 2 ways. Firstly, the cell cycle can be stalled at the S 
phase checkpoint allowing resolution of stalled forks, DNA damage repair to allow S phase to 
reach completion before the cell divides at mitosis. After this stage, mutations will become 
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permanent and increase the likelihood of mutations within proto-oncogenes or tumour 
suppressors that underpin cancer development. Secondly, in cases of severe DNA damage or 
irretrievable DNA replication blockage the DDR can inhibit cell cycle progression and division, 
safeguarding from mutation (Turgeon et al., 2018). This can occur through committing the 
cell into an irreversible cell cycle exit known as senescence, a major barrier to tumorigenesis. 
The other option, in severe cases is apoptosis (Bartkova et al., 2006). Apoptosis is 
programmed safe cell death. This removes any dangerously damaged cells preventing 
mutations. If this barrier fails to function, mutation rate will increase, and cancer could 
develop (Childs et al., 2014). 
Cancers have multiple mechanisms to bypass the tumorigenesis barrier. The most common 
method to bypass this barrier is to erode the S phase checkpoint by weakening the DDR. One 
of the most common mutations found in cancer is the ‘guardian of the genome’ p53 encoded 
for by gene TP53. p53 is the most frequently mutated gene in cancers (Shajani-Yi et al., 
2018). p53 has a range of functions that allow it to function as a tumour suppressor, most 
inactivate the protein (Rivlin et al., 2011). Some mutations allow the p53 protein to gain an 
oncogenic function (Brosh & Rotter, 2009; Oren & Rotter, 2010). 
The inactivation of CIZ1 promotes lymphoblastic tumours suggesting that it may function as 
a tumour suppressor (Nishibe et al., 2013). One model that could be constructed from data 
presented here is that loss of CIZ1 induces DNA replication stress that underpins tumour 
formation in CIZ1 null mice (Figure 6.9).  
Changes in the DNA replication programme may cause constitutive replication stress and 
drive a mutator phenotype. A reduction in replication fork progression rate is typical with a 
replication stress phenotype. This suggests that cells with reduced CIZ1 are under a 
replication stress like phenotype. As CIZ1 is known to act as a tumour suppressor gene this 
could help explain that role (Nishibe et al., 2013). It is likely that increased CIZ1 expression 
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also causes a change in replication dynamics, which was observed in Chapter 5. This forms a 
model in which CIZ1 levels are required to be precisely controlled. Cell free DNA replication 
assays have revealed that modulation of CIZ1 levels can cause a change in response to 
cyclin/CDK networks and alter the kinase thresholds that regulate the initiation phase of DNA 
replication. In addition, DNA combing experiments have revealed that CIZ1 KO changes 
replication dynamics and responses to hydroxyurea induced replication stress.  
Taken together the data demonstrated the importance of CIZ1 in maintaining genomic 
stability. The CIZ1 KO and CIZKI cell lines have demonstrated that CIZ1 contributes to 
regulation of DNA replication fork rates, replication origin usage and fork restart following 
HU induced DRS. These observations support a role for CIZ1 at the replisome, where it 
maintains replication fork integrity. Significantly, the deletion of CIZ1 promotes DRS, and this 
perturbation to the DNA replication program is proposed to induce a mutator phenotype 






Figure 6.9 A Model for the Tumour Suppressor Function of CIZ1. Summary of phenotypes 


















7.1. Summary of Results  
Through a combination of cell free DNA replication assays, cell cycle analysis and DNA 
combing, this work has demonstrated a role for CIZ1 in genome stability. CIZ1 null fibroblasts 
have identified key phenotypes, including a shortened G1 phase, an alteration in restriction 
point timing and sensitivity to growth signals present in serum following quiescence. 
Intriguingly, these experiments also identified reduced Cyclin A chromatin loading, which has 
previously been found to be an important step in the initiation process (Copeland et al., 
2010) could link to each observed phenotypic change. 
Cell free replication assays demonstrated an interdependence between CIZ1 and Cyclin 
A/CDK2, where CIZ1 levels modulated the Cyclin A/CDK2 concentration that promoted 
initiation of DNA replication. In a G1 context, cyclin A recruitment to chromatin was reduced 
in CIZ1 KO cells and this effect was reversed by titration of increasing concentrations of 
exogenous CIZ1-N471. Significantly, the interdependence between CIZ1 and cyclin A-CDK2 
activity was associated with a reduced fork rate and increase origin activation in CIZ1 KO 
cells, consistent with DRS. Importantly, the stoichiometry of CIZ1 and cyclin A-CDK2 
appeared to be a crucial factor. Addition of CIZ1 with low cyclin A-CDK2 levels induced a DRS 
like effect on fork rate and origin usage, yet at optimal or high cyclin A-CDK2 levels, CIZ1 
facilitated replication fork rates more typical of a complete S-phase extract. These results 
suggest that CIZ1 and cyclin A-CDK2 cooperate to ensure that fork progression is optimal, 
and that activation of replication origins is maintained at sufficient levels for duplication of 
the genome in a timely manner. 
Consistent with data from cell free experiments, data generated using CIZ1 null fibroblasts 
displayed a DRS phenotype: reduced fork rate, and increased origin usage. This phenotype 
was specific to the loss of CIZ1, as two independent PAM sites were used and generated 
similar replication kinetics. In addition, this phenotype was rescued by ectopic expression of 
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GFP-CIZ1 (CIZ1AB). Finally, results demonstrated that CIZ1 null cells display an aberrant DDR 
to HU, this was characterised by a delayed, and sustained H2AX response. At a cellular level 
no changes in fork stalling/restart rate were observed. However, DNA combing revealed that 
fork restart after removal of HU CIZ1 KO cells occurred at fewer forks, and that restarted 
replication forks proceeded more rapidly than in WT, and CIZKI cells. Yet at 24 hours after HU 
treatment, CIZ1 null cells had significantly slower replication forks, and reduced origin usage. 
This implied an inability to recover from heightened DRS. These data collectively support a 
role for CIZ1 in recovery from DRS, an effect that requires further mechanistic analysis. 
Results presented in this report have not fully identified the role that CIZ1 plays during DNA 
replication initiation. However, the novel findings presented here have provided clues that 
can direct future research to answer these questions. As the majority of the results observed 
in this report have implications for genome stability, this Chapter will focus on findings in this 
report and previous studies identifying how results here can be explained and enrich 
previous work in that context.  Additionally, proposals will be made to direct future research 
to elucidate the role of CIZ1. 
7.2. Loss of CIZ1 Alters the kinetics of cell cycle re-entry from Quiescence  
The initial findings presented in this report demonstrated no significant cell cycle profile 
deviations in asynchronous fibroblasts (Figure 4.4). Interestingly, later findings revealed that 
DNA replication dynamics were altered in these cells (Chapter 6). However, numerous 
changes were observed in cells entering, and exiting quiescence, additionally, a change in 
sensitivity to serum, and the restriction point was observed. The main CIZ1 interacting 
partners that play a role in controlling quiescence entry and exit are: Cyclin E, Cyclin A, and 
p21.  
The link between p21CIP1/Waf1 is long established. The initial discovery of CIZ1 reported that 
CIZ1 was a p21 binding partner. Thus, CIZ1 was named p21Cip1 interacting zinc finger protein 
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1.  This paper reported competition of the CDK binding site on p21, between CIZ1 and CDK2, 
with a preference for binding CDK2. Co-expression of CIZ1 increased p21 levels suggesting 
CIZ1 may have a protective effect of p21 levels. The conclusion of the report was that when 
expressed alone, both CIZ1 and p21 localised to the nucleus. However, co-expression of CIZ1 
and p21 promoted cytoplasmic localisation (Mitsui et al., 1999).    
Little has been reported exploring the interaction of p21 and CIZ1. Coverley et al. (2005) 
demonstrated that the replication initiation promoting activity of CIZ1 was independent of 
p21, remaining functional in a p21 null background. The conclusion made here was that CIZ1 
did not promote replication initiation through alleviation of the p21 mediated CDKi, instead 
acting directly promoting the activity of the replisome.  Since then the link between p21 and 
CIZ1 has largely been unexplored. Zhou et al. (2017) identified increased CIZ1 levels in SLCC 
cells compared to normal tissue, correlating with the cancer stage. In the same tumour 
samples the opposite was seen in P21 levels, P21 levels were lower in cancer cells compared 
to normal cells (Li et al., 1994; Rodriguez & Meuth, 2006; Georgakilas et al., 2017).  
The restriction point marks the point where CDK activity overcomes CDK inhibition from 
p27/p21 (Zetterberg et al., 1995). p21 plays a role in setting the restriction point in cycling 
cells. Cells with low CDK2 (due to high p21) enter a pre-restriction point stage, not entering 
the cell cycle until triggered. Whereas cells with higher CDK2activity (due to low p21 in G2 
and M phase) continue replicating entering the cell cycle in a hyperphosphorylated RB state 
(Moser et al., 2018). Since CIZ1 binds p21 (Mitsui et al., 1999) it may be bringing p21 to the 
nuclear matrix, increasing the local concentration and potentially reducing its CDK inhibitory 
activity. Loss of CIZ1 may therefore result in lower interactions between Cyclin- CDK 
complexes and p21 which could explain the increased cell cycle re-entry observed here and 
may also have implications for the altered CDK threshold that promotes initiation of DNA 
replication in CIZ1 KO cells.  
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Alternatively, the altered quiescence phenotype could be due to a compensatory 
mechanism. Cyclin A levels on chromatin in CIZ1 KO1 cells were reduced, additionally in vitro 
data suggested that higher kinase activities were required to promote S-phase onset. Taken 
together these data would imply that CIZ1 null cells should require more time to re-enter the 
cell cycle. However, data from Chapter 4 implied that Cyclin E and Cyclin A levels 
accumulated faster in CIZ1 KO1 cells re-entering the cell cycle and previous reports show 
that suppression of Cyclin E during cell cycle re-entry results in delayed S phase entry (Léger 
et al., 2016).  An unknown compensatory mechanism may be active in CIZ1 null cells 
compensating for reduced chromatin Cyclin A. As both Cyclin A and Cyclin E are E2F 
regulated proteins (Dimova et al., 2005), the regulation of the E2F pathways, and RB 
phosphorylation should be assessed in CIZ1 null fibroblasts re-entering the cell cycle.  
Critically, the timing of G1 in cells re-entering the cell cycle has implications for genome 
stability. Shortening of G1 in cycling cells results in DRS (Macheret & Halazonetis, 2018). 
Replication origins in the first cell cycle are under licensed, with reduced MCM levels 
compared to cycling cells and become hypersensitive to replication stress due to a reduced 
ability to activate cryptic origins, a similar effect to Cyclin E overexpression. Interestingly 
lengthening the first G1 phase after quiescence through p21 accumulation, promoted 
increased origin licensing, which reduced the inherent instability of cell cycle re-entry. 
(Matson et al., 2018). Loss of CIZ1 reduced the length of the first G1 after cell cycle re-entry 
through an unknown mechanism (Chapter 4). This could result in an erosion of genome 
stability. Future work should analyse DNA replication licensing in CIZ1 null cells re-entering 
the cell cycle from quiescence.  
7.3. Loss of CIZ1 Alters Replication Dynamics which Could Result in Genome Instability  
Loss of CIZ1 induced a change in replication programme characteristic of DRS. DRS can be 
caused through DNA lesions blocking replication, or oncogenic activation promoting 
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mistimed DNA replication, resulting in an increase in collisions between replication and 
transcriptional machinery. This results in increased DRS in certain cancers, and DRS is a 
proposed therapeutic target in triple negative breast cancer (Jones et al., 2013; Fragkos et 
al., 2015; Llobet et al., 2020). The effect of replication stress by oncogene activation is an 
erosion in genome integrity, increased p53 mutations, aneuploidy, and increases tumour size 
are all observed in Cyclin E overexpressing cancers  (Lindahl et al., 2004).  
Linking CIZ1 levels to genome stability has clear links to its role in cancers (Higgins et al., 
2012; Chen et al., 2019). However, the effect of increased CIZ1 levels on replication remains 
unclear. In vitro experiments demonstrated that addition of increased CIZ1-N471 at low 
(typically non permissible) Cyclin A/CDK2 concentrations promoted replication initiation with 
increased DRS to an S phase extract. Whereas adding CIZ1 to optimal and high (typically non 
permissible) concentrations of Cyclin A/CDK2 promoted replication more comparable to an S 
phase extract (Figure 5.12). If this is extrapolated to a cell based system, then increased CIZ1 
could promote early replication at low CDK2 activities with increased DRS reducing genome 
stability. This effect could support a potential mechanism where overexpression of CIZ1 
promotes genome stability as a precursor to tumour formation. Further work is required to 
confirm this.  
There are indications that the increase in DRS has been observed elsewhere. CIZ1 null MEFs 
exposed to γ irradiation displayed increased DNA breaks, and sustained phosphorylation of 
γ-H2AX (Khan et al., 2019). These results could indicate a sensitivity due to a decrease in 
genome stability from the increased DRS phenotype. Alternatively, this result could be as a 
result of a defect in activating the DDR as upregulated DDR due to constitutive replication 
stress results in radioresistance in glioblastoma cells (Carruthers et al., 2018). 
236 
 
7.4. Loss of CIZ1 Promotes an altered DDR 
Data from this report has expanded on work from Nishibe et al. (2013) regarding CIZ1 null 
cells sensitivity to HU. CIZ1 KO resulted in a delayed H2AX response, leading a prolonged 
activation of DDR (Chapter 4). This Response manifested as reduced fork restart within 2 
hours of removal of HU, and faster replication from the reduced restarted replication forks. 
24 hours after removal of HU a collapse in replication dynamics was observed in CIZ1 KO1 
cells, whereas WT and CIZ1AB cells displayed a return (or partial return) to replication kinetics 
comparable with untreated cells. These results identified another scenario where removal of 
CIZ1 resulted in a reduction in genome stability.  
It remains unclear what role CIZ1 performs in response to DRS induced by HU, but 
predictions can be made. Firstly, CIZ1 KO promoted a prolonged DRS. An ineffective initial 
response to HU in CIZ1 null cells may result in more complex DNA damage, hence the 
prolonged H2AX phosphorylation and deranged replication kinetics. The delayed H2AX 
phosphorylation could indicate a delayed DDR. In response to ionising radiation a delayed 
DDR can result in complex DNA damage that cells cannot repair (Eccles et al., 2011).  
A second hypothesis is that CIZ1 plays a direct role in the replisome during fork stalling and 
fork restart as well as the G1/S transition. CIZ1 co-ordinates the localisation of Cyclin A/CDK2 
to Cyclin E rich regions of the nuclear matrix during the G1/S transition in a CDK2 
phosphorylation regulated manner (Copeland et al., 2010; Copeland et al., 2015). Perhaps 
CIZ1 plays a similar role during replication fork stalling and restart. Reduction of Cyclin E 
degradation results in a delay in the onset of S-phase (Bi et al., 2015). Blocking of replication 
fork progression through treatment with mitomycin C results in in a stabilisation of Cyclin 
E/CDK2 through inhibition of its degradation by the UPS. This is thought to inhibit S phase 
progression by blocking Cyclin A associating with CDK2 impairing its ability to promote origin 
firing (Lu et al., 2009). Additionally, prevention of inhibitory phosphorylation of CDK2 after 
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HU treatment prevents cyclin E accumulation, promotes p21 accumulation, increases DNA 
damage, and results in defects restarting S phase (Hughes et al., 2013). Therefore, CIZ1 KO 
may alter the phosphorylation or localisation of Cyclin E following heightened DRS.  
CIZ1 overexpressing cancers have displayed altered DDR, or sensitivity to DNA damage. 
Removal of exon 5 of CIZ1 in mice resulted in sensitivity to gamma irradiation (Khan et al., 
2018). Knockdown of CIZ1 in bladder cancer cells induced tumour apoptosis and 
upregulation of p21, p53 and caspase 3 This implied CIZ1 was supressing the DDR, potentially 
adapting cells to growth in cancer conditions (Chen et al., 2019). Critically, some cancers 
become dependent on an intact DDR, that can be exploited through therapeutic approaches 
to induce synthetic lethality (Beijersbergen et al., 2017). This has provided a platform for 
development of new therapeutics that exploit this weakness to selectively treat specific 
cancers, most famously, PARPi in BRCA1/2 mutant cancers (Yi et al., 2019). Future work 
should endeavour to assess the feasibility of targeting the DDR in CIZ1 overexpressing 
cancers. 
An aberrant DDR (observed in this report) may be linked to other conditions associated with 
CIZ1. DDR defects result in neurodevelopment disorders, such as Xeroderma Pigmentosum, 
and age-related neurodegenerative disorders such as Alzheimer’s disease (Madabhushi et 
al., 2017). CIZ1 null mice display developmental abnormalities, as CIZ1 null mice age motor 
defects become more pronounced: increased DNA damage, and oxidative stress. (Khan et al., 
2018; Xiao et al., 2018). Mirroring the role of the DDR in neurodegenerative disorders. This 
may suggest a physiologically relevant role for CIZ1 in the DDR. Future work should identify 
whether CIZ1 plays a direct role during fork restart. Additionally, the physiological relevance 
of the DDR role in CIZ1 overexpressing cancers should be assessed. This could help elucidate 
the activity of CIZ1 during increased DRS, as well as provide therapeutic targets in cancers 
with altered CIZ1 expression.  
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7.5. The Quantitative Model: CIZ1 as a Kinase Sensor at G1/S Phase Transition  
The quantitative model of the cell cycle was discussed in detail in Chapters 1 and 5. Briefly, 
this model simplifies control of cell cycle progression to oscillating kinase gradients. Critical 
cell cycle events (S phase, and Mitosis) are regulated by kinase thresholds, driven through 
differentially phosphorylated populations of proteins (Spencer et al., 2013; Gutierrez-
Escribano & Nurse, 2015; Swaffer et all., 2016; Moser et al., 2019; Ord et al., 2019) .  
There is compelling evidence presented in this report that suggests that CIZ1 may play a role 
in ‘setting’ the kinase levels at which the Ts and the iTs are found. Increasing CIZ1 levels 
altered the kinase levels required to promote S phase entry in vitro. Importantly, the 
modulation of CIZ1 levels, either through CIZ1 KO, or addition of recombinant CIZ1-N471, 
promoted initiation of DNA replication above the iTs and below the Ts, as determined in WT 
cells without the addition of CIZ1.  
The mechanism by which CIZ1 alters thresholds is unclear. This contrasts cell-based 
experiments where loss of CIZ1 promoted more rapid S-phase entry following quiescence. 
However, the more rapid cell cycle re-entry in CIZ1 null cells was accompanied by a more 
rapid accumulation of Cyclin A (Chapter 4). It may be in a cellular context, that the more 
rapid restriction point required for S phase entry is compensated for by the earlier restriction 
point. The mechanism of restriction point bypass could be through altered p21 activity, or 
reduced degradation of Cyclin A in early G1 by the UPS. In a DDR context, Cyclin E 
accumulation competes with Cyclin A delaying S-phase onset (Bi et al., 2015).  
One mechanism by which CIZ1 may play this role is by acting as a kinase sensor. Evidence for 
this was suggested by Copeland et al. (2015). This paper revealed that CIZ1 had different 
activities dependent on its phosphorylation state. At low CDK2 levels CIZ1 promotes pre-RC 
assembly through interactions with CDC6 on the nuclear matrix. As Cyclin A/CDK2 levels 
increase it binds CIZ1 promoting preIC assembly through phosphorylation of preRC proteins,  
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Loss of CIZ1 increased concentration of CDK2 required to initiation. CIZ1 localises Cyclin 
A/CDK2 to the nuclear matrix, this could create a local increase in Cyclin A concentration at 
preRCs. This may increase the replication promoting effect of Cyclin A-CDK2, by localising 
activity, it may also sequester Cyclin A from inhibitory phosphorylation similar to how Cyclin 
D-CDK4/6 sequesters p21 and p27 from Cyclin E-CDK2 (Planas-Silva & Weinberg, 1997), 
increasing CDK activity. CIZ1 KO may create an environment where increased cyclin A-CDK2 
is required to promote equivalent kinase activity without CIZ1 mediated localisation to 
replication origins.   
7.6. CIZ1’s Links to Tumorigenesis 
Results observed in this report have clear links between CIZ1 and genome stability, which 
has clear links to cancer development. However, to elucidate CIZ1’s DNA replication activity 
these results have focussed on loss of CIZ1. The tumour suppressor function of CIZ1 has been 
observed only in engineered CIZ1 null cell lines (Nishibe et al., 2013; Khan et al., 2019). CIZ1 
overexpression and splice variation have commonly been associated with a range of 
common cancer types (Table 7.1) (Higgins et al., 2012; Zhang et al., 2014; Liu et al., 2015; 
Chen et al., 2019). Surveying published data to unpick the various alterations reported in 
cancers with altered CIZ1 levels can contextualise the data from this report.  
Observed CIZ1 Alteration Cancer Type  Reference 
Overexpression Colorectal Cancer Yin et al., 2013 
Prostate Cancer Liu et al., 2015 
Breast Cancer Li et al., 2020 
Lung Cancer Zhou et al., 2017 
Splice Variation  Lung Cancer  Higgins et al., 2012 
Colon Cancer Swarts et al., 2018 
Breast Cancer 
Table 7.1 – CIZ1 alterations observed in cancers.  Adapted from Pauzaite et al., 2017 
Splice variation of CIZ1 has been associated with cancers. Two splice variants of CIZ1:  CIZ1-B 
and CIZ1-F have both been found to be expressed in tumour samples. Both variants lack the 
nuclear matrix attachment domain of CIZ1. This CIZ1 variant was found to lack the C terminal 
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nuclear matrix anchor domain. In mice xenograft experiments loss of the CIZ1-B in tumours 
resulted in a suppression of tumour growth (Higgins et al., 2012). Interestingly CIZ1-F 
transcription is supressed during cell cycle re-entry after quiescence until multiple cycles 
after cell cycle re-entry. CIZ1-F transcription was also supressed after treatment with DNA 
replication inhibitor aphidicolin (Swarts et al., 2018). These are of note due to the role CIZ1 
plays during quiescence, and response to DNA replication inhibitor HU that were observed in 
this report. 
In other cancers, CIZ1 expression levels change. Haemangioma of the tongue, bladder 
cancer, prostate carcinoma, and colon cancer have all been found overexpressing CIZ1. In 
each of these examples, suppression of CIZ1 reduces cellular proliferation (Chen et al., 2019; 
Liu et al., 2015; Wang et al., 2019, Yin et al., 2013). This implies a direct role for CIZ1 for 
maintaining tumorigenicity and proliferation in cancer.  This aligns with observations in this 
report that CIZ1 may adapt tumour cells to altered internal conditions.  
Despite the observed TS function of CIZ1 in vitro (Nishibe et al., 2013; Khan et al., 2019) no 
clinical samples have yet been identified. However, in recent years useful tools have been 
developed that analyse the genomes of multiple cancer types allowing the identification of 
specific mutations, and copy number variations (CNVs) of thousands of genes. The cancer 
genome atlas (TCGA), has surveyed genomes across over 30 different cancer types 
(Weinstein et al., 2014). This allows analysis of mutations in CIZ1 across cancers.  Multiple 
mutations in CIZ1 were identified inserting a stop codon relatively early in the sequence of 





Additionally, CIZ1 copy number variation (CNV) changes were identified in a number of 
cancers. CNV is the number of amplifying or decreasing >1kbp DNA segments in the genome. 
TCGA allows analysis of CNV changes in response to specific genes in cancers. CNV is 
positively correlated with the mRNA expression levels of the gene (Shao et al., 2019). A 
search for CIZ1 reveals the presence of both loss and gain of CNV (Figure 7.1B). Certain 
cancer types such as ovarian have predominantly reduced copies of the CIZ1 gene. This 
suggests that there may be a clinical relevance to the TS function of CIZ1. Future studies 
should analyse multiple cancer cell lines that have a reduced CIZ1 copy number to 
investigate the clinical relevance, if any, of CIZ1 acting as a TS.  Data from this report implies 
A) 
Figure 7.1 – Surveying CIZ1 alterations in cancers in the cancer genome atlas A) The 
presence of stop codon gained and frameshift mutations in cancers.. Notably there are 
several loss of function mutations early in the CIZ1 sequence. B) The incidence of CNV 
changes in CIZ1 in cancers studied in the cancer genome atlas. Red represents gain of CNV, 
and Blue represents Loss. CNV strongly correlates with mRNA expression. Cancers with CIZ1 
mostly present with gain although there are a striking number of cancers with losses. This 
particularly striking in ovarian cancers, testicular germ cell cancers, sarcomas, and Diffuse 
Large B-cell Lymphoma. The results shown here are in whole or part based upon data 





a genome stability role for CIZ1, which could be linked to cancer phenotypes. In vitro data 
from this report implies a model whereby overexpression of CIZ1 could allow replication to 
occur in the altered environment cancerous cell.  Future work should identify the clinical 
relevance of the tumour suppressor function of CIZ1 and identify strategies for targeting CIZ1 
activity in CIZ1 dependent tumours. 
7.7. Phenotypes Observed upon Loss of CIZ1 Consistently have Links to Epigenetics  
There may be an epigenetic role for CIZ1, linked to the phenotypes observed in CIZ1 null 
cells. CIZ1 is involved in the localisation of Xi. CIZ1 is recruited by Xist, this is accompanied by 
methylation and ubiquitylation of Xi histones. Loss of CIZ1 results in a reduction in the 
methylation (H3K27me3) and ubiquitylation (H2AK119UB1) of Xi histones. (Ridings-Figueroa 
et al., 2017; Stewart et al., 2019). The link between CIZ1 and epigenetics is unexplored in the 
context of DNA replication.  
The epigenetic landscape of DNA has links to the key observations of this report: Quiescence, 
replication dynamics, and the DDR. Histone methylation is also altered in quiescent cells. The 
histone methyltransferase proteins EZH1 and EZH2 that trimethylate histone 3 lysine 27 
(H3K27me3) during quiescence in stem cells (Yao, 2014). Quiescent stem cells have reduced 
H3K27 methylation, until stem cell activation when H3K27 methylation increases (Liu et al., 
2014). CIZ1 KO may cause altered H3K27 methylation in quiescence which may explain the 
altered quiescence kinetics in CIZ1 KO. 
H3K27me3 is linked to replication fidelity, and H3K27 methylation is important for protecting 
against DRS (Yi et al., 2009; Khurana & Oberdoerffer, 2015).  In the ciliate Tetrahymena 
thermophila, H3K27 methylation deficiency promotes DRS (Gao et al., 2015). In Drosophila 
Stwl depletion decreased H3K27 methylation increasing HU sensitivity (Yi et al., 2009). There 
are parallels between these results and CIZ1 KO. However, links between H3K27 methylation 
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and DNA replication are not understood in mammalian cells. Additionally, limited research 
has been performed investigating how CIZ1 effects histone methylation of somatic 
chromosomes.  
The link between CIZ1 and epigenetic maintenance remains unclear. No published CIZ1 
binding partner plays a direct role in histone methylation. However, CIZ1 interacts with 
Cyclin E and Cyclin A, both of which activate CDK2 (Coverley et al., 2005; Copeland et al., 
2010). Loss of CIZ1 promotes a change in EZH2 solubility (Stewart et al., 2019). EZH2 
phosphorylation by CDK1 and CDK2 promotes methylation of H3K27 on nascent DNA, 
ensuring epigenetic marks are transferred through generations (Zeng et al., 2011). It is 
feasible that CIZ1 may influence EZH phosphorylation, and CDK2 mediated phosphorylation 
of EZH2 promoted tumour development in mice (Nie et al., 2019).  
7.8. Future Work 
There are several areas for future research that have been developed during this project. 
Firstly, data presented here strengthened the link CIZ1 and replication initiation (Coverley et 
al., 2005; Copeland et al., 2010; Copeland et al., 2015) However, the full role of CIZ1 during 
initiation remains unclear. Secondly, CIZ1 has implications for genome stability, loss of CIZ1 
promoted DRS, altered replication timing, and HU sensitivity. Thirdly, the physiological 
relevance of CIZ1 in cancer, and feasibility of using it as therapeutic target, or to inform 
treatment decisions. And finally, the further elucidation of the role CIZ1 plays in epigenetic 
maintenance. 
Future work should endeavour to identify if kinase thresholds are altered in whole cell 
context, crucially this should be expanded to cancer cell lines shown to be dependent on 
CIZ1 for proliferation. One way to achieve this would be the use of fluorescent kinase 
sensors. Spencer et al. (2013) developed a fluorescent kinase sensor that as it is 
phosphorylated moves from nuclear to cytosol localisation, the ratio of cytosol: nuclear 
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fluorescence was used to measured CDK activity. This demonstrated cells bifurcate into low 
and high CDK activity following mitosis, determining the rate the next cell cycle begins. If 
changes observed in this report in vitro regarding sensitivity to CDK activity are true in cells 
then introducing this sensor into CIZ1 null cells should show differences in CDK patterns.  
Results from this report have identified a potential role for CIZ1 within the replisome as well 
as during replication initiation. CIZ1 stabilised replication kinetics in vitro at both optimal and 
high CDK concentration’s (Chapter 5). Additionally, loss of CIZ1 promoted a reduction in 
replication fork rate in both cycling cells (Chapter 6), and nuclei re-entering the cell cycle 
from quiescence (Chapter 5). It is unclear whether this is a by-product of altered origin firing, 
or a direct role CIZ1 plays during in the replisome during replication elongation.  
One technique that could be used to establish this is iPOND (isolation of proteins on nascent 
DNA). In this technique, nascent DNA is labelled with EdU, A biotin tag is attached to nascent 
DNA, then proteins bound to nascent DNA are isolated through streptavidin pulldown 
(Dungrawala & Cortez, 2016). This technique could be used to confirm a role for CIZ1 at the 
replisome, additionally, other proteins CIZ1 may have an effect on, such as 
methyltransferases, would be identified which may help elucidate CIZ1 activity. Critically, if 
CIZ1 does not play a role directly on the replisome, this technique could identify changes to 
replisome proteins in CIZ1 null cells. 
CIZ1 is overexpressed, or alternatively spliced in a number of cancer cell lines and tumour 
samples, these reports have been low throughput investigating one specific cancer or cell 
line (Higgins et al., 2012; Swarts et al., 2018; Chen et al., 2019). The prevalence of CIZ1 
overexpression, and dependence should be determined across a wide range of cancers. 
Cancer biobanks are a tool that is important for developing personalised cancer therapeutics 
through the ability to screen multiple cancer types (Patil et al., 2018). Cancer biobank 
samples should be used to measure CIZ1 expression, and mutation. Samples that display 
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increased or altered CIZ1 should be used to measure replication dynamics before and after 
depletion of CIZ1. This would identify the efficacy of potentially targeting CIZ1 cancers 
(either directly or through a separate mechanism), additionally, this approach may identify if 
there is a physiological relevance to the TS function of CIZ1 (Nishibe et al., 2013).  
Finally, changes in epigenetics upon loss of CIZ1 should be measured.  Techniques have been 
developed that allow measurements of histone modifications. Immunoprecipitation of 
chromatin proteins, immunostaining, next generation sequencing and RT PCR allows for 
measurements of all major histone methylation (Zhao et al., 2016). Utilizing similar 
techniques to compare WT, and CIZ1 null cells will allow assessment of the effect of loss of 
CIZ1 on the epigenome. If an effect is seen this could be measured in CIZ1 dependent 
cancers before and after suppression of CIZ1. The activity of histone methyltransferases 
(such as EZH2) by chemical inhibition could be measured in these cancers to investigate any 
effect on histone methylation, tumour growth and DNA replication (Duan et al., 2020).   
7.9. Concluding remarks   
Data from this report has implicated CIZ1 in maintenance of genome stability. Loss of CIZ1 
results in changes in replication timing, DRS, and hypersensitivity to DRS. These observations 
can be used to inform the role that CIZ1 plays in cancer. For the oncogenic function CIZ1 
overexpression may provide a growth advantage to cells in cancerous conditions. The TS 
function can be explained by a reduction in genome stability.  
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Using data from this report, a hypothesis surrounding this can be built around the role CIZ1 
plays (Figure 7.3). Firstly, maintenance of G0, loss of CIZ1 resulted in aberrant cell-cycle re-
entry, the expected result of this would be heightened genome instability. Secondly CIZ1 
may function to determine the CDK activity that will promote replication initiation and 
inhibition. Disruption of this could result in under licensed replication and DRS, or provide a 
growth advantage for cells with disrupted CDK networks. Thirdly, this report identified a role 
for CIZ1 in maintaining the replisome in cell free and cell based experiments. CIZ1 null cells 
displayed reduced fork rates, and increased origin usage, a phenotype consistent with DRS. 
Critically, this resulted in a hypersensitivity to increased DRS.  
Figure 7.2-A Model for how CIZ1 Loss Reduces Genome Stability. Each of the major 
phenotypes observed in this report result in a reduction in genome stability. Altered 
responses to CDK signalling and cell cycle re-entry timing promote DRS. Increased DRS, or 
another unknown mechanism lead to an altered DDR and hypersensitivity to replication 
challenge. All these phenotypes lead to a reduction in genome stability.  
In conclusion, this report has demonstrated a potential important role for CIZ1 in 
maintaining genome stability through control over DNA replication. Data presented here has 
opened may questions as to how CIZ1 is involved in the phenotypes observed, and the 
physiological relevance of this. Data from this report has informed previous research and 
provided new avenues to explore in CIZ1 biology. This could provide research avenues for 





Abbas, T. and Dutta, A., 2009. p21 in cancer: intricate networks and multiple activities. 
Nature Reviews Cancer, 9(6), pp.400-414. 
 
Abbastabar, M., Kheyrollah, M., Azizian, K., Bagherlou, N., Tehrani, S.S., Maniati, M. and 
Karimian, A., 2018. Multiple functions of p27 in cell cycle, apoptosis, epigenetic modification 
and transcriptional regulation for the control of cell growth: A double-edged sword protein. 
DNA repair, 69, pp.63-72. 
 
Abbotts, R. and Wilson III, D.M., 2017. Coordination of DNA single strand break repair. Free 
Radical Biology and Medicine, 107, pp.228-244. 
 
Acevedo, J., Yan, S. and Michael, W.M., 2016. Direct binding to replication protein A (RPA)-
coated single-stranded DNA allows recruitment of the ATR activator TopBP1 to sites of DNA 
damage. Journal of Biological Chemistry, 291(25), pp.13124-13131. 
 
Ahuja, A.K., Jodkowska, K., Teloni, F., Bizard, A.H., Zellweger, R., Herrador, R., Ortega, S., 
Hickson, I.D., Altmeyer, M., Mendez, J. and Lopes, M., 2016. A short G1 phase imposes 
constitutive replication stress and fork remodelling in mouse embryonic stem cells. Nature 
communications, 7(1), pp.1-11. 
 
Aldossary, S.A., 2019. Review on pharmacology of cisplatin: clinical use, toxicity and 
mechanism of resistance of cisplatin. Biomedical and Pharmacology Journal, 12(1), pp.7-15. 
 
Alfieri, C., Zhang, S. and Barford, D., 2017. Visualizing the complex functions and mechanisms 
of the anaphase promoting complex/cyclosome (APC/C). Open biology, 7(11), p.170204. 
 
Altieri, P., Spallarossa, P., Barisione, C., Garibaldi, S., Garuti, A., Fabbi, P., Ghigliotti, G. and 
Brunelli, C., 2012. Inhibition of doxorubicin-induced senescence by PPARδ activation agonists 
in cardiac muscle cells: cooperation between PPARδ and Bcl6. PLoS One, 7(9), p.e46126. 
 
Al-Zain, A., Schroeder, L., Sheglov, A. and Ikui, A.E., 2015. Cdc6 degradation requires 
phosphodegron created by GSK-3 and Cdk1 for SCFCdc4 recognition in Saccharomyces 
cerevisiae. Molecular biology of the cell, 26(14), pp.2609-2619. 
 
Aria, V. and Yeeles, J.T., 2019. Mechanism of bidirectional leading-strand synthesis 
establishment at eukaryotic DNA replication origins. Molecular cell, 73(2), pp.199-211. 
 
Bageghni, S.A., Frentzou, G.A., Drinkhill, M.J., Mansfield, W., Coverley, D. and Ainscough, J.F., 
2017. Cardiomyocyte-specific expression of the nuclear matrix protein, CIZ1, stimulates 
production of mono-nucleated cells with an extended window of proliferation in the 
postnatal mouse heart. Biology open, 6(1), pp.92-99. 
 
Barr, A.R., Cooper, S., Heldt, F.S., Butera, F., Stoy, H., Mansfeld, J., Novák, B. and Bakal, C., 
2017. DNA damage during S-phase mediates the proliferation-quiescence decision in the 
subsequent G1 via p21 expression. Nature communications, 8(1), pp.1-17. 
 
Barrangou, R., 2015. Diversity of CRISPR-Cas immune systems and molecular machines. 




Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D.A. 
and Horvath, P., 2007. CRISPR provides acquired resistance against viruses in prokaryotes. 
Science, 315(5819), pp.1709-1712. 
 
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.V.F., 
Kolettas, E., Niforou, K., Zoumpourlis, V.C. and Takaoka, M., 2006. Oncogene-induced 
senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. 
Nature, 444(7119), pp.633-637. 
 
Beijersbergen, R.L., Wessels, L.F. and Bernards, R., 2017. Synthetic lethality in cancer 
therapeutics. Annual Review of Cancer Biology, 1, pp.141-161. 
 
Bensimon, A., Simon, A., Chiffaudel, A., Croquette, V., Heslot, F. and Bensimon, D., 1994. 
Alignment and sensitive detection of DNA by a moving interface. Science, 265(5181), 
pp.2096-2098. 
Bensimon, D., Simon, A.J., Croquette, V. and Bensimon, A., 1995. Stretching DNA with a 
receding meniscus: experiments and models. Physical review letters, 74(23), p.4754. 
 
Bétous, R., de Rugy, T.G., Pelegrini, A.L., Queille, S., de Villartay, J.P. and Hoffmann, J.S., 
2018. DNA replication stress triggers rapid DNA replication fork breakage by Artemis and 
XPF. PLoS genetics, 14(7), p.e1007541. 
 
Bhaskara, S., Jacques, V., Rusche, J.R., Olson, E.N., Cairns, B.R. and Chandrasekharan, M.B., 
2013. Histone deacetylases 1 and 2 maintain S-phase chromatin and DNA replication fork 
progression. Epigenetics & chromatin, 6(1), p.27. 
 
Bi, H., Li, S., Qu, X., Wang, M., Bai, X., Xu, Z., Ao, X., Jia, Z., Jiang, X., Yang, Y. and Wu, H., 
2015. DEC1 regulates breast cancer cell proliferation by stabilizing cyclin E protein and delays 
the progression of cell cycle S phase. Cell death & disease, 6(9), pp.e1891-e1891. 
 
Bian, X. and Lin, W., 2019. Targeting DNA replication stress and DNA double-strand break 
repair for optimizing SCLC Treatment. Cancers, 11(9), p.1289. 
 
Bianco, J.N., Poli, J., Saksouk, J., Bacal, J., Silva, M.J., Yoshida, K., Lin, Y.L., Tourrière, H., 
Lengronne, A. and Pasero, P., 2012. Analysis of DNA replication profiles in budding yeast and 
mammalian cells using DNA combing. Methods, 57(2), pp.149-157. 
 
Biertümpfel, C., Zhao, Y., Kondo, Y., Ramón-Maiques, S., Gregory, M., Lee, J.Y., Masutani, C., 
Lehmann, A.R., Hanaoka, F. and Yang, W., 2010. Structure and mechanism of human DNA 
polymerase η. Nature, 465(7301), pp.1044-1048. 
 
Bishop, A.J. and Schiestl, R.H., 2002. Homologous recombination and its role in 
carcinogenesis. Journal of Biomedicine and Biotechnology, 2(2), p.75. 
 
Black, J.O., 2016. Xeroderma pigmentosum. Head and neck pathology, 10(2), pp.139-144. 
 
Bleichert, F., Botchan, M.R. and Berger, J.M., 2017. Mechanisms for initiating cellular DNA 
replication. Science, 355(6327). 
Blow, J.J. and Laskey, R.A., 1986. Initiation of DNA replication in nuclei and purified DNA by a 
cell-free extract of Xenopus eggs. Cell, 47(4), pp.577-587.  
249 
 
Boehm, E.M., Gildenberg, M.S. and Washington, M.T., 2016. The many roles of PCNA in 
eukaryotic DNA replication. In The Enzymes (Vol. 39, pp. 231-254). Academic Press. 
 
Boopathy, G.T. and Hong, W., 2019. Role of Hippo pathway-YAP/TAZ signaling in 
angiogenesis. Frontiers in cell and developmental biology, 7, p.49. 
 
Bose, S., Yap, L.F., Fung, M., Starzcynski, J., Saleh, A., Morgan, S., Dawson, C., Chukwuma, 
M.B., Maina, E., Buettner, M. and Wei, W., 2009. The ATM tumour suppressor gene is down‐
regulated in EBV‐associated nasopharyngeal carcinoma. The Journal of Pathology: A Journal 
of the Pathological Society of Great Britain and Ireland, 217(3), pp.345-352. 
 
Botezatu, A., Iancu, I.V., Plesa, A., Manda, D., Popa, O., Bostan, M., Mihaila, M., Albulescu, A., 
Fudulu, A., Vladoiu, S.V. and Huica, I., 2019. Methylation of tumour suppressor genes 
associated with thyroid cancer. Cancer Biomarkers, 25(1), pp.53-65. 
 
Brambati, A., Zardoni, L., Achar, Y.J., Piccini, D., Galanti, L., Colosio, A., Foiani, M. and Liberi, 
G., 2018. Dormant origins and fork protection mechanisms rescue sister forks arrested by 
transcription. Nucleic acids research, 46(3), pp.1227-1239. 
 
Broderick, R. and Nasheuer, H.P., 2009. Regulation of Cdc45 in the cell cycle and after DNA 
damage. 
Brosh, R. and Rotter, V., 2009. When mutants gain new powers: news from the mutant p53 
field. Nature reviews cancer, 9(10), pp.701-713.  
Brouns, S.J., Jore, M.M., Lundgren, M., Westra, E.R., Slijkhuis, R.J., Snijders, A.P., Dickman, 
M.J., Makarova, K.S., Koonin, E.V. and Van Der Oost, J., 2008. Small CRISPR RNAs guide 
antiviral defense in prokaryotes. Science, 321(5891), pp.960-964. 
Bui, D.T. and Li, J.J., 2019. DNA rereplication is susceptible to nucleotide-level mutagenesis. 
Genetics, 212(2), pp.445-460.  
Burrell, R.A., McClelland, S.E., Endesfelder, D., Groth, P., Weller, M.C., Shaikh, N., Domingo, 
E., Kanu, N., Dewhurst, S.M., Gronroos, E. and Chew, S.K., 2013. Replication stress links 
structural and numerical cancer chromosomal instability. Nature, 494(7438), p.492.  
Buscemi, G., Ricci, C., Zannini, L., Fontanella, E., Plevani, P. and Delia, D., 2014. Bimodal 
regulation of p21waf1 protein as function of DNA damage levels. Cell cycle, 13(18), pp.2901-
2912. 
Byun, T.S., Pacek, M., Yee, M.C., Walter, J.C. and Cimprich, K.A., 2005. Functional uncoupling 
of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. 
Genes & development, 19(9), pp.1040-1052.  
Cancer Research UK, 2020, A trial looking at AZD6738 with radiotherapy for advanced solid 







Carruthers, R.D., Ahmed, S.U., Ramachandran, S., Strathdee, K., Kurian, K.M., Hedley, A., 
Gomez-Roman, N., Kalna, G., Neilson, M., Gilmour, L. and Stevenson, K.H., 2018. Replication 
stress drives constitutive activation of the DNA damage response and radioresistance in 
glioblastoma stem-like cells. Cancer research, 78(17), pp.5060-5071. 
 
Caruso, J.A., Duong, M.T., Carey, J.P., Hunt, K.K. and Keyomarsi, K., 2018. Low-molecular-
weight cyclin E in human Cancer: cellular consequences and opportunities for targeted 
therapies. Cancer research, 78(19), pp.5481-5491. 
 
Cascales, H.S., Burdova, K., Müllers, E., Stoy, H., von Morgen, P., Macurek, L. and Lindqvist, 
A., 2017. Cyclin A2 localises in the cytoplasm at the S/G2 transition to activate Plk1. bioRxiv, 
p.191437. 
 
Ceccaldi, R., Sarangi, P. and D'Andrea, A.D., 2016. The Fanconi anaemia pathway: new 
players and new functions. Nature reviews Molecular cell biology, 17(6), p.337. 
Celniker, S.E. and Campbell, J.L., 1982. Yeast DNA replication in vitro: initiation and 
elongation events mimic in vivo processes. Cell, 31(1), pp.201-213.  
Chadha, G.S., Gambus, A., Gillespie, P.J. and Blow, J.J., 2016. Xenopus Mcm10 is a CDK-
substrate required for replication fork stability. Cell Cycle, 15(16), pp.2183-2195.  
Chang, H.H., Pannunzio, N.R., Adachi, N. and Lieber, M.R., 2017. Non-homologous DNA end 
joining and alternative pathways to double-strand break repair. Nature reviews Molecular 
cell biology, 18(8), p.495. 
 
Chao, H.X., Poovey, C.E., Privette, A.A., Grant, G.D., Cook, J.G. and Purvis, J.E., 2017. DNA 
damage checkpoint dynamics drive cell cycle phase transitions. BioRxiv, p.137307. 
 
Chatterjee, N. and Walker, G.C., 2017. Mechanisms of DNA damage, repair, and 
mutagenesis. Environmental and molecular mutagenesis, 58(5), pp.235-263. 
 
Chen, G. and Deng, X., 2018. Cell synchronization by double thymidine block. Bio-protocol, 
8(17). 
 
Chen, H., Liu, H. and Qing, G., 2018. Targeting oncogenic Myc as a strategy for cancer 
treatment. Signal transduction and targeted therapy, 3(1), pp.1-7. 
 
Chen, S. and Parmigiani, G., 2007. Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of 
clinical oncology: official journal of the American Society of Clinical Oncology, 25(11), p.1329. 
 
Chen, S., Chen, X., Gui'e Xie, Y.H., Yan, D., Zheng, D., Li, S., Fu, X., Li, Y., Pang, X., Hu, Z. and Li, 
H., 2016. Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in 
bladder cancer cells. Oncotarget, 7(26), p.40362. 
 
Chen, Q., Zhang, X., Jiang, Q., Clarke, P.R. and Zhang, C., 2008. Cyclin B1 is localized to 
unattached kinetochores and contributes to efficient microtubule attachment and proper 
chromosome alignment during mitosis. Cell research, 18(2), pp.268-280. 
 
Chen, X., Wang, P., Wang, S., Li, J., Ou, T. and Zeng, X., 2019. CIZ1 knockdown suppresses the 




Cheung, T.H. and Rando, T.A., 2013. Molecular regulation of stem cell quiescence. Nature 
reviews Molecular cell biology, 14(6), pp.329-340. 
 
Child, E.S. and Mann, D.J., 2006. The intricacies of p21 phosphorylation: protein/protein 
interactions, subcellular localization and stability. Cell cycle, 5(12), pp.1313-1319. 
 
Childs, B.G., Baker, D.J., Kirkland, J.L., Campisi, J. and Van Deursen, J.M., 2014. Senescence 
and apoptosis: dueling or complementary cell fates?. EMBO reports, 15(11), pp.1139-1153. 
Chong, J.P., Mahbubani, H.M., Khoo, C.Y. and Blow, J.J., 1995. Purification of an MCM-
containing complex as a component of the DNA replication licensing system. Nature, 
375(6530), pp.418-421.  
Chong, S.Y., Cutler, S., Lin, J.J., Tsai, C.H., Tsai, H.K., Biggins, S., Tsukiyama, T., Lo, Y.C. and 
Kao, C.F., 2020. H3K4 methylation at active genes mitigates transcription-replication conflicts 
during replication stress. Nature communications, 11(1), pp.1-16.  
Ciccia, A. and Elledge, S.J., 2010. The DNA damage response: making it safe to play with 
knives. Molecular cell, 40(2), pp.179-204. 
Cicenas, J., Kalyan, K., Sorokinas, A., Stankunas, E., Levy, J., Meskinyte, I., Stankevicius, V., 
Kaupinis, A. and Valius, M., 2015. Roscovitine in cancer and other diseases. Annals of 
translational medicine, 3(10). 
 
Coelho, L.M., Cursino-Santos, J.R., Persinoti, G.F., Rossi, A. and Martinez-Rossi, N.M., 2013. 
The Microsporum canis genome is organized into five chromosomes based on evidence from 
electrophoretic karyotyping and chromosome end mapping. Medical mycology, 51(2), 
pp.208-2013. 
 
Copeland, N.A., Sercombe, H.E., Ainscough, J.F. and Coverley, D., 2010. CIZ1 cooperates with 
cyclin-A–CDK2 to activate mammalian DNA replication in vitro. Journal of cell science, 123(7), 
pp.1108-1115. 
 
Copeland, N.A., Sercombe, H.E., Wilson, R.H. and Coverley, D., 2015. Cyclin‐A–CDK2‐
mediated phosphorylation of CIZ1 blocks replisome formation and initiation of mammalian 
DNA replication. Journal of Cell Science, 128(8), pp.1518-1527. 
 
Coudreuse, D. and Nurse, P., 2010. Driving the cell cycle with a minimal CDK control network. 
Nature, 468(7327), pp.1074-1079. 
De Falco, M., Ferrari, E., De Felice, M., Rossi, M., Hübscher, U. and Pisani, F.M., 2007. The 
human GINS complex binds to and specifically stimulates human DNA polymerase α‐primase. 
EMBO reports, 8(1), pp.99-103. 
 
Courtot, L., Hoffmann, J.S. and Bergoglio, V., 2018. The protective role of dormant origins in 
response to replicative stress. International journal of molecular sciences, 19(11), p.3569. 
 
Coverley, D., Marr, J. and Ainscough, J., 2005. CIZ1 promotes mammalian DNA replication. 
Journal of cell science, 118(1), pp.101-112. 
 
Cradick, T.J., Fine, E.J., Antico, C.J. and Bao, G., 2013. CRISPR/Cas9 systems targeting β-globin 





Dahmcke, C.M., Büchmann-Møller, S., Jensen, N.A. and Mitchelmore, C., 2008. Altered 
splicing in exon 8 of the DNA replication factor CIZ1 affects subnuclear distribution and is 
associated with Alzheimer's disease. Molecular and Cellular Neuroscience, 38(4), pp.589-594. 
 
Dai, C., Whitesell, L., Rogers, A.B. and Lindquist, S., 2007. Heat shock factor 1 is a powerful 
multifaceted modifier of carcinogenesis. Cell, 130(6), pp.1005-1018. 
 
Davidson, M.B., Katou, Y., Keszthelyi, A., Sing, T.L., Xia, T., Ou, J., Vaisica, J.A., Thevakumaran, 
N., Marjavaara, L., Myers, C.L. and Chabes, A., 2012. Endogenous DNA replication stress 
results in expansion of dNTP pools and a mutator phenotype. The EMBO journal, 31(4), 
pp.895-907. 
 
Davis, P.K., Ho, A. and Dowdy, S.F., 2001. Biological methods for cell-cycle synchronization of 
mammalian cells. Biotechniques, 30(6), pp.1322-1331. 
 
de Renty, C., DePamphilis, M.L. and Ullah, Z., 2014. Cytoplasmic localization of p21 protects 
trophoblast giant cells from DNA damage induced apoptosis. PloS one, 9(5), p.e97434. 
 
Delk, Nikki A., Kelly K. Hunt, and Khandan Keyomarsi. "Altered subcellular localization of 
tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and 
proteasomal regulation." Cancer research 69, no. 7 (2009): 2817-2825. 
 
Den Hollander, P., Rayala, S.K., Coverley, D. and Kumar, R., 2006. CIZ1, a novel DNA-binding 
coactivator of the estrogen receptor α, confers hypersensitivity to estrogen action. Cancer 
Research, 66(22), pp.11021-11029. 
 
Deng, T., Yan, G., Song, X., Xie, L., Zhou, Y., Li, J., Hu, X., Li, Z., Hu, J., Zhang, Y. and Zhang, H., 
2018. Deubiquitylation and stabilization of p21 by USP11 is critical for cell-cycle progression 
and DNA damage responses. Proceedings of the National Academy of Sciences, 115(18), 
pp.4678-4683. 
 
Dhar, M.K., Sehgal, S. and Kaul, S., 2012. Structure, replication efficiency and fragility of yeast 
ARS elements. Research in microbiology, 163(4), pp.243-253. 
 
Dillon, M.T., Barker, H.E., Pedersen, M., Hafsi, H., Bhide, S.A., Newbold, K.L., Nutting, C.M., 
McLaughlin, M. and Harrington, K.J., 2017. Radiosensitization by the ATR inhibitor AZD6738 
through generation of acentric micronuclei. Molecular cancer therapeutics, 16(1), pp.25-34. 
 
Dong, P., Zhang, C., Parker, B.T., You, L. and Mathey-Prevot, B., 2018. Cyclin D/CDK4/6 
activity controls G1 length in mammalian cells. PloS one, 13(1), p.e0185637. 
 
Dimova, D.K. and Dyson, N.J., 2005. The E2F transcriptional network: old acquaintances with 
new faces. Oncogene, 24(17), pp.2810-2826. 
 
Driedonks, T.A., 2019. Circulating Y-RNAs in extracellular vesicles and ribonucleoprotein 
complexes; implications for the immune system. Frontiers in immunology, 9, p.3164. 
 
Drury, L.S., Perkins, G. and Diffley, J.F., 1997. The Cdc4/34/53 pathway targets Cdc6p for 
proteolysis in budding yeast. The EMBO journal, 16(19), pp.5966-5976. 
  
Duan, R., Du, W. and Guo, W., 2020. EZH2: a novel target for cancer treatment. Journal of 




Dufke, C., Hauser, A.K., Sturm, M., Fluhr, S., Wächter, T., Leube, B., Auburger, G., Ott, T., 
Bauer, P., Gasser, T. and Grundmann, K., 2015. Mutations in CIZ1 are not a major cause for 
dystonia in Germany. Movement Disorders, 30(5), pp.740-743Duncker, B.P., 2017. 
Mechanisms governing DDK regulation of the initiation of DNA replication. Genes, 8(1), p.3. 
 
Dungrawala, H. and Cortez, D., 2015. Purification of proteins on newly synthesized DNA using 
iPOND. In The Nucleus (pp. 123-131). Humana Press, New York, NY. 
 
Edgell, D.R. and Doolittle, W.F., 1997. Archaea and the origin (s) of DNA replication proteins. 
Cell, 89(7), pp.995-998. 
 
El-Maouche, D., Merke, D.P., Vogiatzi, M.G., Chang, A.Y., Turcu, A.F., Joyal, E.G., Lin, V.H., 
Weintraub, L., Plaunt, M.R., Mohideen, P. and Auchus, R.J., 2020. A Phase 2, Multicenter 
Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia. The Journal of 
Clinical Endocrinology & Metabolism, 105(8), p.dgaa381. 
 
Engel, S.R., Dietrich, F.S., Fisk, D.G., Binkley, G., Balakrishnan, R., Costanzo, M.C., Dwight, S.S., 
Hitz, B.C., Karra, K., Nash, R.S. and Weng, S., 2014. The reference genome sequence of 
Saccharomyces cerevisiae: then and now. G3: Genes, Genomes, Genetics, 4(3), pp.389-398. 
 
Estefanía, M.M., Ganier, O., Hernández, P., Schvartzman, J.B., Mechali, M. and Krimer, D.B., 
2012. DNA replication fading as proliferating cells advance in their commitment to terminal 
differentiation. Scientific Reports, 2, p.279. 
 
Estrada-Bernal, A., Chatterjee, M., Haque, S.J., Yang, L., Morgan, M.A., Kotian, S., Morrell, D., 
Chakravarti, A. and Williams, T.M., 2015. MEK inhibitor GSK1120212-mediated 
radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break 
repair pathways. Cell Cycle, 14(23), pp.3713-3724. 
 
Fei, L. and Xu, H., 2018. Role of MCM2–7 protein phosphorylation in human cancer cells. Cell 
& bioscience, 8(1), p.43. 
 
Forment, J.V. and O’Connor, M.J., 2018. Targeting the replication stress response in cancer. 
Pharmacology & therapeutics, 188, pp.155-167. 
 
Frampton, J.E., 2015. Olaparib: a review of its use as maintenance therapy in patients with 
ovarian cancer. BioDrugs, 29(2), pp.143-150. 
 
Francica, P. and Rottenberg, S., 2018. Mechanisms of PARP inhibitor resistance in cancer and 
insights into the DNA damage response. Genome medicine, 10(1), pp.1-3. 
 
Gaillard, H., García-Muse, T. and Aguilera, A., 2015. Replication stress and cancer. Nature 
Reviews Cancer, 15(5), pp.276-289. 
 
Gandara, D.R., Hammerman, P.S., Sos, M.L., Lara, P.N. and Hirsch, F.R., 2015. Squamous cell 
lung cancer: from tumor genomics to cancer therapeutics. 
 
Ganier, O., Prorok, P., Akerman, I. and Méchali, M., 2019. Metazoan DNA replication origins. 




Gao, S., Xiong, J., Zhang, C., Berquist, B.R., Yang, R., Zhao, M., Molascon, A.J., Kwiatkowski, 
S.Y., Yuan, D., Qin, Z. and Wen, J., 2013. Impaired replication elongation in Tetrahymena 
mutants deficient in histone H3 Lys 27 monomethylation. Genes & Development, 27(15), 
pp.1662-1679. 
 
Gao, F., 2015. Bacteria may have multiple replication origins. Frontiers in microbiology, 6, 
p.324. 
 
Ge, X.Q., Jackson, D.A. and Blow, J.J., 2007. Dormant origins licensed by excess Mcm2–7 are 
required for human cells to survive replicative stress. Genes & development, 21(24), pp.3331-
3341. 
 
Georgakilas, A.G., Martin, O.A. and Bonner, W.M., 2017. p21: a two-faced genome guardian. 
Trends in molecular medicine, 23(4), pp.310-319. 
 
Ghosh, S., Vassilev, A.P., Zhang, J., Zhao, Y. and DePamphilis, M.L., 2011. Assembly of the 
human origin recognition complex occurs through independent nuclear localization of its 
components. Journal of Biological Chemistry, 286(27), pp.23831-23841. 
 
Gibson, B., Wilson, D.J., Feil, E. and Eyre-Walker, A., 2018. The distribution of bacterial 
doubling times in the wild. Proceedings of the Royal Society B: Biological Sciences, 285(1880), 
p.20180789. 
 
Gladden, A.B. and Diehl, J.A., 2005. Location, location, location: the role of cyclin D1 nuclear 
localization in cancer. Journal of cellular biochemistry, 96(5), pp.906-913. 
 
Glanzer, J.G., Liu, S., Wang, L., Mosel, A., Peng, A. and Oakley, G.G., 2014. RPA inhibition 
increases replication stress and suppresses tumor growth. Cancer research, 74(18), pp.5165-
5172. 
 
Glover, T.W., Wilson, T.E. and Arlt, M.F., 2017. Fragile sites in cancer: more than meets the 
eye. Nature Reviews Cancer, 17(8), p.489. 
 
Gómez-González, B. and Aguilera, A., 2019. Transcription-mediated replication hindrance: a 
major driver of genome instability. Genes & development, 33(15-16), pp.1008-1026. 
 
Gopinathan, L., Tan, S.L.W., Padmakumar, V.C., Coppola, V., Tessarollo, L. and Kaldis, P., 
2014. Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis. Cancer 
research, 74(14), pp.3870-3879. 
Gottipati, P., Cassel, T.N., Savolainen, L. and Helleday, T., 2008. Transcription-associated 
recombination is dependent on replication in Mammalian cells. Molecular and cellular 
biology, 28(1), pp.154-164.  
Greaves, E.A., Copeland, N.A., Coverley, D. and Ainscough, J.F., 2012. Cancer-associated 
variant expression and interaction of CIZ1 with cyclin A1 in differentiating male germ cells. 
Journal of cell science, 125(10), pp.2466-2477. 
 
Greil, C., Krohs, J., Schnerch, D., Follo, M., Felthaus, J., Engelhardt, M. and Wäsch, R., 2016. 





Guo, H., Tian, T., Nan, K. and Wang, W., 2010. p57: A multifunctional protein in cancer. 
International journal of oncology, 36(6), pp.1321-1329. 
 
Gutiérrez-Escribano, P. and Nurse, P., 2015. A single cyclin–CDK complex is sufficient for both 
mitotic and meiotic progression in fission yeast. Nature communications, 6(1), pp.1-13. 
Hanahan, D. and Weinberg, R.A., 2000. The hallmarks of cancer. cell, 100(1), pp.57-70.  
Hégarat, N., Crncec, A., Suarez Peredo Rodriguez, M.F., Echegaray Iturra, F., Gu, Y., Busby, O., 
Lang, P.F., Barr, A.R., Bakal, C., Kanemaki, M.T. and Lamond, A.I., 2020. Cyclin A triggers 
Mitosis either via the Greatwall kinase pathway or Cyclin B. The EMBO journal, p.e104419. 
 
Heldt, F.S., Barr, A.R., Cooper, S., Bakal, C. and Novák, B., 2018. A comprehensive model for 
the proliferation–quiescence decision in response to endogenous DNA damage in human 
cells. Proceedings of the National Academy of Sciences, 115(10), pp.2532-2537. 
Higgins, G., Roper, K.M., Watson, I.J., Blackhall, F.H., Rom, W.N., Pass, H.I., Ainscough, J.F. 
and Coverley, D., 2012. Variant CIZ1 is a circulating biomarker for early-stage lung cancer. 
Proceedings of the National Academy of Sciences, 109(45), pp.E3128-E3135.  
Hinz, N. and Jücker, M., 2019. Distinct functions of AKT isoforms in breast cancer: a 
comprehensive review. Cell Communication and Signaling, 17(1), p.154. 
 
Hiraga, S.I., Monerawela, C., Katou, Y., Shaw, S., Clark, K.R., Shirahige, K. and Donaldson, 
A.D., 2018. Budding yeast Rif1 binds to replication origins and protects DNA at blocked 
replication forks. EMBO reports, 19(9), p.e46222. 
 
Hirao, A., Cheung, A., Duncan, G., Girard, P.M., Elia, A.J., Wakeham, A., Okada, H., Sarkissian, 
T., Wong, J.A., Sakai, T. and De Stanchina, E., 2002. Chk2 is a tumor suppressor that regulates 
apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-
independent manner. Molecular and cellular biology, 22(18), pp.6521-6532. 
 
Hoege, C., Pfander, B., Moldovan, G.L., Pyrowolakis, G. and Jentsch, S., 2002. RAD6-
dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature, 
419(6903), pp.135-141. 
Hook, S.S., Lin, J.J. and Dutta, A., 2007. Mechanisms to control rereplication and implications 
for cancer. Current opinion in cell biology, 19(6), pp.663-671.  
Hopkins, T.A., Ainsworth, W.B., Ellis, P.A., Donawho, C.K., DiGiammarino, E.L., Panchal, S.C., 
Abraham, V.C., Algire, M.A., Shi, Y., Olson, A.M. and Johnson, E.F., 2019. PARP1 trapping by 
PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow. Molecular 
Cancer Research, 17(2), pp.409-419. 
 
Huang, R.X. and Zhou, P.K., 2020. DNA damage response signaling pathways and targets for 
radiotherapy sensitization in cancer. Signal Transduction and Targeted Therapy, 5(1), pp.1-
27. 
 
Hughes, B.T., Sidorova, J., Swanger, J., Monnat, R.J. and Clurman, B.E., 2013. Essential role 
for Cdk2 inhibitory phosphorylation during replication stress revealed by a human Cdk2 





Jackman, M., Kubota, Y., Den Elzen, N., Hagting, A. and Pines, J., 2002. Cyclin A-and cyclin E-
Cdk complexes shuttle between the nucleus and the cytoplasm. Molecular biology of the cell, 
13(3), pp.1030-1045. 
 
Jackson, D.A. and Pombo, A., 1998. Replicon clusters are stable units of chromosome 
structure: evidence that nuclear organization contributes to the efficient activation and 
propagation of S phase in human cells. The Journal of cell biology, 140(6), pp.1285-1295. 
 
Jang, S.W., Jung, J.K. and Kim, J.M., 2016. Replication Protein A (RPA) deficiency activates the 
Fanconi anemia DNA repair pathway. Cell Cycle, 15(17), pp.2336-2345. 
 
Japaridze, A., Gogou, C., Kerssemakers, J.W., Nguyen, H.M. and Dekker, C., 2020. Direct 
observation of independently moving replisomes in Escherichia coli. Nature communications, 
11(1), pp.1-10. 
Jazwinski, S.M. and Edelman, G.M., 1979. Replication in vitro of the 2-micrometer DNA 
plasmid of yeast. Proceedings of the National Academy of Sciences, 76(3), pp.1223-1227.  
Jones, R.M., Mortusewicz, O., Afzal, I., Lorvellec, M., Garcia, P., Helleday, T. and Petermann, 
E., 2013. Increased replication initiation and conflicts with transcription underlie Cyclin E-
induced replication stress. Oncogene, 32(32), pp.3744-3753. 
 
Kalaszczynska, I., Geng, Y., Iino, T., Mizuno, S.I., Choi, Y., Kondratiuk, I., Silver, D.P., 
Wolgemuth, D.J., Akashi, K. and Sicinski, P., 2009. Cyclin A is redundant in fibroblasts but 
essential in hematopoietic and embryonic stem cells. Cell, 138(2), pp.352-365. 
 
Kawakami, H., Ohashi, E., Kanamoto, S., Tsurimoto, T. and Katayama, T., 2015. Specific 
binding of eukaryotic ORC to DNA replication origins depends on highly conserved basic 
residues. Scientific reports, 5, p.14929. 
 
Kaykov, A., Taillefumier, T., Bensimon, A. and Nurse, P., 2016. Molecular combing of single 
DNA molecules on the 10 megabase scale. Scientific reports, 6(1), pp.1-9. 
 
Keck, J.M., Summers, M.K., Tedesco, D., Ekholm-Reed, S., Chuang, L.C., Jackson, P.K. and 
Reed, S.I., 2007. Cyclin E overexpression impairs progression through mitosis by inhibiting 
APCCdh1. The Journal of cell biology, 178(3), pp.371-385. 
 
Kelly, T. and Callegari, A.J., 2019. Dynamics of DNA replication in a eukaryotic cell. 
Proceedings of the National Academy of Sciences, 116(11), pp.4973-4982. 
 
Kelman, L.M. and Kelman, Z., 2018. Do archaea need an origin of replication?. Trends in 
microbiology, 26(3), pp.172-174. 
 
Khan, M.M., Xiao, J., Patel, D. and LeDoux, M.S., 2018. DNA damage and neurodegenerative 
phenotypes in aged CIZ1 null mice. Neurobiology of aging, 62, pp.180-190. 
 
Khot, A., Brajanovski, N., Cameron, D.P., Hein, N., Maclachlan, K.H., Sanij, E., Lim, J., Soong, 
J., Link, E., Blombery, P. and Thompson, E.R., 2019. First-in-human RNA polymerase I 
transcription inhibitor CX-5461 in patients with advanced hematologic cancers: Results of a 




Khurana, S. and Oberdoerffer, P., 2015. Replication stress: a lifetime of epigenetic change. 
Genes, 6(3), pp.858-877. 
Kojo, H., Greenberg, B.D. and Sugino, A., 1981. Yeast 2-micrometer plasmid DNA replication 
in vitro: origin and direction. Proceedings of the National Academy of Sciences, 78(12), 
pp.7261-7265.  
Kotsantis, P., Silva, L.M., Irmscher, S., Jones, R.M., Folkes, L., Gromak, N. and Petermann, E., 
2016. Increased global transcription activity as a mechanism of replication stress in cancer. 
Nature communications, 7(1), pp.1-13. 
 
Krude, T., Jackman, M., Pines, J. and Laskey, R.A., 1997. Cyclin/Cdk-dependent initiation of 
DNA replication in a human cell-free system. Cell, 88(1), pp.109-119. 
 
Krude, T., 1999. Mimosine arrests proliferating human cells before onset of DNA replication 
in a dose-dependent manner. Experimental cell research, 247(1), pp.148-159. 
Krude, T., 2000. Initiation of human DNA replication in vitro using nuclei from cells arrested 
at an initiation-competent state. Journal of Biological Chemistry, 275(18), pp.13699-13707.  
Krude, T., Christov, C.P., Hyrien, O. and Marheineke, K., 2009. Y RNA functions at the 
initiation step of mammalian chromosomal DNA replication. Journal of cell science, 122(16), 
pp.2836-2845.  
Kumar, R., Nagpal, G., Kumar, V., Usmani, S.S., Agrawal, P. and Raghava, G.P., 2019. HumCFS: 
a database of fragile sites in human chromosomes. BMC genomics, 19(9), p.985. 
 
Kushwaha, P.P., Rapalli, K.C. and Kumar, S., 2016. Geminin a multi task protein involved in 
cancer pathophysiology and developmental process: A review. Biochimie, 131, pp.115-127. 
 
Labit, H., Goldar, A., Guilbaud, G., Douarche, C., Hyrien, O. and Marheineke, K., 2008. A 
simple and optimized method of producing silanized surfaces for FISH and replication 
mapping on combed DNA fibers. Biotechniques, 45(6), pp.649-658. 
 
Laham-Karam, N., Pinto, G.P., Poso, A. and Kokkonen, P., 2020. Transcription and Translation 
Inhibitors in Cancer Treatment. Frontiers in Chemistry, 8. 
Lange, C. and Calegari, F., 2010. Cdks and cyclins link G1 length and differentiation of 
embryonic, neural and hematopoietic stem cells. Cell cycle, 9(10), pp.1893-1900. 
 
Laptenko, O., Beckerman, R., Freulich, E. and Prives, C., 2011. p53 binding to nucleosomes 
within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation. 
Proceedings of the National Academy of Sciences, 108(26), pp.10385-10390. 
 
Laugesen, A., Højfeldt, J.W. and Helin, K., 2016. Role of the polycomb repressive complex 2 
(PRC2) in transcriptional regulation and cancer. Cold Spring Harbor perspectives in medicine, 
6(9), p.a026575. 
 
Lavado, A., Park, J.Y., Paré, J., Finkelstein, D., Pan, H., Xu, B., Fan, Y., Kumar, R.P., Neale, G., 
Kwak, Y.D. and McKinnon, P.J., 2018. The Hippo pathway prevents YAP/TAZ-driven 
258 
 
hypertranscription and controls neural progenitor number. Developmental cell, 47(5), 
pp.576-591. 
 
Le Beau, M.M., Rassool, F.V., Neilly, M.E., Espinosa III, R., Glover, T.W., Smith, D.I. and 
McKeithan, T.W., 1998. Replication of a common fragile site, FRA3B, occurs late in S phase 
and is delayed further upon induction: implications for the mechanism of fragile site 
induction. Human molecular genetics, 7(4), pp.755-761. 
 
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C.L., 
Meier, W., Shapira-Frommer, R., Safra, T. and Matei, D., 2014. Olaparib maintenance therapy 
in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned 
retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The lancet 
oncology, 15(8), pp.852-861. 
 
Lee, M.J., Byun, M.R., Furutani-Seiki, M., Hong, J.H. and Jung, H.S., 2014. YAP and TAZ 
regulate skin wound healing. Journal of Investigative Dermatology, 134(2), pp.518-525. 
 
Lee, M.Y., Wang, X., Zhang, S., Zhang, Z. and Lee, E.Y., 2017. Regulation and modulation of 
human DNA polymerase δ activity and function. Genes, 8(7), p.190. 
 
Léger, K., Hopp, A.K., Fey, M. and Hottiger, M.O., 2016. ARTD1 regulates cyclin E expression 
and consequently cell-cycle re-entry and G1/S progression in T24 bladder carcinoma cells. 
Cell Cycle, 15(15), pp.2042-2052. 
 
Lei, L., Wu, J., Gu, D., Liu, H. and Wang, S., 2016. CIZ1 interacts with YAP and activates its 
transcriptional activity in hepatocellular carcinoma cells. Tumor Biology, 37(8), pp.11073-
11079. 
 
Leonard, A.C. and Méchali, M., 2013. DNA replication origins. Cold Spring Harbor 
perspectives in biology, 5(10), p.a010116. 
 
Leslie, M., 2006. Cyclin localization controls activity. The Journal of Cell Biology, 172(7), 
pp.961-961. 
 
Li, R., Waga, S., Hannon, G.J., Beach, D. and Stillman, B., 1994. Differential effects by the p21 
CDK inhibitor on PCNA-dependent DNA replication and repair. Nature, 371(6497), pp.534-
537. 
 
Li, J., Meyer, A.N. and Donoghue, D.J., 1997. Nuclear localization of cyclin B1 mediates its 
biological activity and is regulated by phosphorylation. Proceedings of the National Academy 
of Sciences, 94(2), pp.502-507. 
 
Li, Z., Zhao, B., Wang, P., Chen, F., Dong, Z., Yang, H., Guan, K.L. and Xu, Y., 2010. Structural 
insights into the YAP and TEAD complex. Genes & development, 24(3), pp.235-240. 
 
Li, J., Deng, M., Wei, Q., Liu, T., Tong, X. and Ye, X., 2011. Phosphorylation of MCM3 protein 
by cyclin E/cyclin-dependent kinase 2 (Cdk2) regulates its function in cell cycle. Journal of 
Biological Chemistry, 286(46), pp.39776-39785. 
 
Li, Z.F. and Lam, Y.W., 2015. A new rapid method for isolating nucleoli. In The Nucleus (pp. 




Li, H. and O'Donnell, M.E., 2018. The eukaryotic CMG helicase at the replication fork: 
emerging architecture reveals an unexpected mechanism. Bioessays, 40(3), p.1700208. 
 
Li, Z., Pinch, B.J., Olson, C.M., Donovan, K.A., Nowak, R.P., Mills, C.E., Scott, D.A., Doctor, 
Z.M., Eleuteri, N.A., Chung, M. and Sorger, P.K., 2020. Development and characterization of a 
Wee1 kinase degrader. Cell chemical biology, 27(1), pp.57-65. 
 
Li, Y., Zhou, X., Liu, J., Gao, N., Yang, R., Wang, Q., Ji, J., Ma, L. and He, Q., 2020. 
Dihydroartemisinin inhibits the tumorigenesis and metastasis of breast cancer via 
downregulating CIZ1 expression associated with TGF-β1 signaling. Life Sciences, 248, 
p.117454. 
 
Limas, J.C. and Cook, J.G., 2019. Preparation for DNA replication: the key to a successful S 
phase. FEBS letters, 593(20), pp.2853-2867. 
 
Lindahl, T., Landberg, G., Ahlgren, J., Nordgren, H., Norberg, T., Klaar, S., Holmberg, L. and 
Bergh, J., 2004. Overexpression of cyclin E protein is associated with specific mutation types 
in the p53 gene and poor survival in human breast cancer. Carcinogenesis, 25(3), pp.375-380. 
 
Lindqvist, A., 2010. Cyclin B–Cdk1 activates its own pump to get into the nucleus. Journal of 
Cell Biology, 189(2), pp.197-199. 
 
Liu, P., Barkley, L.R., Day, T., Bi, X., Slater, D.M., Alexandrow, M.G., Nasheuer, H.P. and Vaziri, 
C., 2006. The Chk1-mediated S-phase checkpoint targets initiation factor Cdc45 via a 
Cdc25A/Cdk2-independent mechanism. Journal of Biological Chemistry, 281(41), pp.30631-
30644. 
 
Liu, T., Ren, X., Li, L., Yin, L., Liang, K., Yu, H., Ren, H., Zhou, W., Jing, H. and Kong, C., 2015. 
CIZ1 promotes tumorigenicity of prostate carcinoma cells. Frontiers in bioscience (Landmark 
edition), 20, pp.705-715. 
 
Liu, Q., Niu, N., Wada, Y. and Liu, J., 2016. The role of Cdkn1A-interacting zinc finger protein 
1 (CIZ1) in DNA replication and pathophysiology. International journal of molecular sciences, 
17(2), p.212. 
 
Liu JC, Granieri L, Shrestha M, Wang DY, Vorobieva I, Rubie EA, Jones R, Ju Y, Pellecchia G, 
Jiang Z, Palmerini CA. Identification of CDC25 as a common therapeutic target for triple-
negative breast cancer. Cell reports. 2018 Apr 3;23(1):112-26. 
 
Liu, J.Y., Souroullas, G.P., Diekman, B.O., Krishnamurthy, J., Hall, B.M., Sorrentino, J.A., 
Parker, J.S., Sessions, G.A., Gudkov, A.V. and Sharpless, N.E., 2019. Cells exhibiting strong 
p16INK4a promoter activation in vivo display features of senescence. Proceedings of the 
National Academy of Sciences, 116(7), pp.2603-2611. 
 
Llobet, S.G., van der Vegt, B., Jongeneel, E., Bense, R.D., Schröder, C.P., Everts, M., de Bock, 
G.H. and van Vugt, M.A., 2019. Cyclin E expression is associated with high levels of 
replication stress in triple-negative breast cancer. bioRxiv, p.532283. 
Lohka, M.J. and Masui, Y., 1983. Formation in vitro of sperm pronuclei and mitotic 




Lohka, M.J. and Masui, Y., 1984. Effects of Ca2+ ions on the formation of metaphase 
chromosomes and sperm pronuclei in cell-free preparations from unactivated Rana pipiens 
eggs. Developmental biology, 103(2), pp.434-442.  
Lohka, M.J. and Masui, Y., 1984. Roles of cytosol and cytoplasmic particles in nuclear 
envelope assembly and sperm pronuclear formation in cell-free preparations from 
amphibian eggs. The Journal of cell biology, 98(4), pp.1222-1230.  
Lopez, P., Philippe, H., Myllykallio, H. and Forterre, P., 1999. Identification of putative 
chromosomal origins of replication in Archaea. Molecular microbiology, 32(4), pp.883-886. 
 
Lu, X., Liu, J. and Legerski, R.J., 2009. Cyclin E is stabilized in response to replication fork 
barriers leading to prolonged S phase arrest. Journal of Biological Chemistry, 284(51), 
pp.35325-35337. 
 
Lukas, J., Herzinger, T., Hansen, K., Moroni, M.C., Resnitzky, D., Helin, K., Reed, S.I. and 
Bartek, J., 1997. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes 
& Development, 11(11), pp.1479-1492. 
 
Luo, H. and Gao, F., 2019. DoriC 10.0: an updated database of replication origins in 
prokaryotic genomes including chromosomes and plasmids. Nucleic acids research, 47(D1), 
pp.D74-D77. 
 
Luo, X., Huang, Y. and Sheikh, M.S., 2003. Cloning and characterization of a novel gene PDRG 
that is differentially regulated by p53 and ultraviolet radiation. Oncogene, 22(46), pp.7247-
7257. 
 
Ma, Y., McKay, D.J. and Buttitta, L., 2018. The coordination of terminal differentiation and 
cell cycle exit is mediated through the regulation of chromatin accessibility. bioRxiv, 
p.488387. 
 
Macheret, M. and Halazonetis, T.D., 2015. DNA replication stress as a hallmark of cancer. 
Annual Review of Pathology: Mechanisms of Disease, 10, pp.425-448. 
 
Macheret, M. and Halazonetis, T.D., 2018. Intragenic origins due to short G1 phases underlie 
oncogene-induced DNA replication stress. Nature, 555(7694), pp.112-116. 
 
Macip, S., Igarashi, M., Fang, L., Chen, A., Pan, Z.Q., Lee, S.W. and Aaronson, S.A., 2002. 
Inhibition of p21‐mediated ROS accumulation can rescue p21‐induced senescence. The 
EMBO journal, 21(9), pp.2180-2188. 
 
Mackiewicz, P., Zakrzewska-Czerwińska, J., Zawilak, A., Dudek, M.R. and Cebrat, S., 2004. 
Where does bacterial replication start? Rules for predicting the oriC region. Nucleic acids 
research, 32(13), pp.3781-3791. 
 
Madabhushi, R., Pan, L. and Tsai, L.H., 2014. DNA damage and its links to neurodegeneration. 
Neuron, 83(2), pp.266-282. 
 
Mailand, N. and Diffley, J.F., 2005. CDKs promote DNA replication origin licensing in human 




Marraffini, L.A. and Sontheimer, E.J., 2008. CRISPR interference limits horizontal gene 
transfer in staphylococci by targeting DNA. science, 322(5909), pp.1843-1845. 
 
Maugeri-Saccà, M., Bartucci, M. and De Maria, R., 2013. Checkpoint kinase 1 inhibitors for 
potentiating systemic anticancer therapy. Cancer treatment reviews, 39(5), pp.525-533. 
 
Mahadevappa, R., Neves, H., Yuen, S.M., Bai, Y., McCrudden, C.M., Yuen, H.F., Wen, Q., 
Zhang, S.D. and Kwok, H.F., 2017. The prognostic significance of Cdc6 and Cdt1 in breast 
cancer. Scientific reports, 7(1), pp.1-11. 
 
Mailand, N., Gibbs-Seymour, I. and Bekker-Jensen, S., 2013. Regulation of PCNA–protein 
interactions for genome stability. Nature reviews Molecular cell biology, 14(5), pp.269-282. 
 
Mao, Z., Bozzella, M., Seluanov, A. and Gorbunova, V., 2008. Comparison of nonhomologous 
end joining and homologous recombination in human cells. DNA repair, 7(10), pp.1765-1771. 
 
Marcel, V., Catez, F. and Diaz, J.J., 2015. p53, a translational regulator: contribution to its 
tumour-suppressor activity. Oncogene, 34(44), pp.5513-5523. 
Maréchal, A. and Zou, L., 2015. RPA-coated single-stranded DNA as a platform for post-
translational modifications in the DNA damage response. Cell research, 25(1), pp.9-23.  
Marheineke, K., Hyrien, O. and Krude, T., 2005. Visualization of bidirectional initiation of 
chromosomal DNA replication in a human cell free system. Nucleic acids research, 33(21), 
pp.6931-6941. 
 
Marheineke, K., Goldar, A., Krude, T. and Hyrien, O., 2009. Use of DNA Combing to Study 
DNA Replicationin Xenopus and Human Cell-Free Systems. In DNA Replication (pp. 575-603). 
Humana Press. 
  
Marriott, A.S., Copeland, N.A., Cunningham, R., Wilkinson, M.C., McLennan, A.G. and Jones, 
N.J., 2015. Diadenosine 5′, 5′′′-P1, P4-tetraphosphate (Ap4A) is synthesized in response to 
DNA damage and inhibits the initiation of DNA replication. DNA repair, 33, pp.90-100. 
 
Martín-Caballero, J., Flores, J.M., García-Palencia, P. and Serrano, M., 2001. Tumor 
susceptibility of p21Waf1/Cip1-deficient mice. Cancer research, 61(16), pp.6234-6238.  
 
Matson, J.P., Dumitru, R., Coryell, P., Baxley, R.M., Chen, W., Twaroski, K., Webber, B.R., 
Tolar, J., Bielinsky, A.K., Purvis, J.E. and Cook, J.G., 2017. Rapid DNA replication origin 
licensing protects stem cell pluripotency. Elife, 6, p.e30473. 
 
Matson, J.P., House, A.M., Grant, G.D., Wu, H., Perez, J. and Cook, J.G., 2019. Intrinsic 
checkpoint deficiency during cell cycle re-entry from quiescence. Journal of Cell Biology, 
218(7), pp.2169-2184. 
 
Maule, G., Casini, A., Montagna, C., Ramalho, A.S., De Boeck, K., Debyser, Z., Carlon, M.S., 
Petris, G. and Cereseto, A., 2019. Allele specific repair of splicing mutations in cystic fibrosis 
through AsCas12a genome editing. Nature communications, 10(1), pp.1-11. 
 
Maya-Mendoza, A., Ostrakova, J., Kosar, M., Hall, A., Duskova, P., Mistrik, M., Merchut-Maya, 
J.M., Hodny, Z., Bartkova, J., Christensen, C. and Bartek, J., 2015. Myc and Ras oncogenes 
262 
 
engage different energy metabolism programs and evoke distinct patterns of oxidative and 
DNA replication stress. Molecular oncology, 9(3), pp.601-616. 
  
Mazouzi, A., Velimezi, G. and Loizou, J.I., 2014. DNA replication stress: causes, resolution and 
disease. Experimental cell research, 329(1), pp.85-93.  
McCulloch, S.D. and Kunkel, T.A., 2008. The fidelity of DNA synthesis by eukaryotic 
replicative and translesion synthesis polymerases. Cell research, 18(1), pp.148-161. 
 
McDermott, N., Buechelmaier, E.S. and Powell, S.N., 2019. Capitalizing on Cancer Replication 
Stress by Preventing PAR Chain Turnover: A New Type of Synthetic Lethality. Cancer cell, 
35(3), pp.344-346. 
 
McIntosh, D. and Blow, J.J., 2012. Dormant origins, the licensing checkpoint, and the 
response to replicative stresses. Cold Spring Harbor perspectives in biology, 4(10), 
p.a012955. 
 
Méchali, M., 2010. Eukaryotic DNA replication origins: many choices for appropriate 
answers. Nature reviews Molecular cell biology, 11(10), pp.728-738. 
Melixetian, M., Ballabeni, A., Masiero, L., Gasparini, P., Zamponi, R., Bartek, J., Lukas, J. and 
Helin, K., 2004. Loss of Geminin induces rereplication in the presence of functional p53. The 
Journal of cell biology, 165(4), pp.473-482.  
Merrick, C.J., Jackson, D. and Diffley, J.F., 2004. Visualization of altered replication dynamics 
after DNA damage in human cells. Journal of Biological Chemistry, 279(19), pp.20067-20075. 
 
Michalet, X., Ekong, R., Fougerousse, F., Rousseaux, S., Schurra, C., Hornigold, N., Van 
Slegtenhorst, M., Wolfe, J., Povey, S., Beckmann, J.S. and Bensimon, A., 1997. Dynamic 
molecular combing: stretching the whole human genome for high-resolution studies. 
Science, 277(5331), pp.1518-1523. 
 
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harshman, K., Tavtigian, S., Liu, Q., 
Cochran, C., Bennett, L.M. and Ding, W., 1994. A strong candidate for the breast and ovarian 
cancer susceptibility gene BRCA1. Science, 266(5182), pp.66-71. 
 
Miller, M.S. and Miller, L.D., 2012. RAS mutations and oncogenesis: not all RAS mutations are 
created equally. Frontiers in genetics, 2, p.100. 
 
Mitsui, K., Matsumoto, A., Ohtsuka, S., Ohtsubo, M. and Yoshimura, A., 1999. Cloning and 
characterization of a novel p21cip1/waf1-interacting zinc finger protein, CIZ1. Biochemical 
and biophysical research communications, 264(2), pp.457-464. 
 
Mohanta, T.K. and Bae, H., 2015. The diversity of fungal genome. Biological procedures 
online, 17(1), p.8. 
 
Moiseeva, T.N., Qian, C., Sugitani, N., Osmanbeyoglu, H.U. and Bakkenist, C.J., 2019. WEE1 
kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1-
and S-phase cells. Proceedings of the National Academy of Sciences, 116(48), pp.23891-
23893. 
 
Moiseeva, T.N., Yin, Y., Calderon, M.J., Qian, C., Schamus-Haynes, S., Sugitani, N., 
Osmanbeyoglu, H.U., Rothenberg, E., Watkins, S.C. and Bakkenist, C.J., 2019. An ATR and 
263 
 
CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA 
replication. Proceedings of the National Academy of Sciences, 116(27), pp.13374-13383. 
 
Mol, P.R. and Balan, A., 2013. Oncogenes as Therapeutic Targets in Cancer: A Review. IOSR J. 
Dent. Med. Sci, 5, pp.46-56. 
 
Montagnoli, A., Valsasina, B., Croci, V., Menichincheri, M., Rainoldi, S., Marchesi, V., Tibolla, 
M., Tenca, P., Brotherton, D., Albanese, C. and Patton, V., 2008. A Cdc7 kinase inhibitor 
restricts initiation of DNA replication and has antitumor activity. Nature chemical biology, 
4(6), pp.357-365. 
 
Morales, J., Li, L., Fattah, F.J., Dong, Y., Bey, E.A., Patel, M., Gao, J. and Boothman, D.A., 2014. 
Review  
of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in 
cancer and other diseases. Critical Reviews™ in Eukaryotic Gene Expression, 24(1). 
 
Moritani, M. and Ishimi, Y., 2013. Inhibition of DNA binding of MCM2-7 complex by 
phosphorylation with cyclin-dependent kinases. The Journal of Biochemistry, 154(4), pp.363-
372. 
 
Moroishi, T., Hansen, C.G. and Guan, K.L., 2015. The emerging roles of YAP and TAZ in 
cancer. Nature Reviews Cancer, 15(2), pp.73-79. 
 
Moser, J., Miller, I., Carter, D. and Spencer, S.L., 2018. Control of the Restriction Point by Rb 
and p21. Proceedings of the National Academy of Sciences, 115(35), pp.E8219-E8227. 
 
Murga, M., Campaner, S., Lopez-Contreras, A.J., Toledo, L.I., Soria, R., Montaña, M.F., 
D'artista, L., Schleker, T., Guerra, C., Garcia, E. and Barbacid, M., 2011. Exploiting oncogene-
induced replicative stress for the selective killing of Myc-driven tumors. Nature structural & 
molecular biology, 18(12), p.1331. 
 
Müller, C.A., Hawkins, M., Retkute, R., Malla, S., Wilson, R., Blythe, M.J., Nakato, R., Komata, 
M., Shirahige, K., de Moura, A.P. and Nieduszynski, C.A., 2014. The dynamics of genome 
replication using deep sequencing. Nucleic Acids Research, 42(1), pp.e3-e3. 
 
Munkley, J., Copeland, N.A., Moignard, V., Knight, J.R., Greaves, E., Ramsbottom, S.A., 
Pownall, M.E., Southgate, J., Ainscough, J.F.X. and Coverley, D., 2011. Cyclin E is recruited to 
the nuclear matrix during differentiation, but is not recruited in cancer cells. Nucleic acids 
research, 39(7), pp.2671-2677. 
 
Muñoz, S., Búa, S., Rodríguez-Acebes, S., Megías, D., Ortega, S., de Martino, A. and Méndez, 
J., 2017. In Vivo DNA Re-replication elicits lethal tissue dysplasias. Cell reports, 19(5), pp.928-
938. 
 
National Institute of Health1, 2020, Phase II Trial of AZD6738 Alone and in Combination With 
Olaparib, National Institute of Health, view 20 May 2020, 
https://clinicaltrials.gov/ct2/show/NCT03682289> 
 
National Institute of Health2, 2020, Trial of M4344 and Niraparib in Patients With Poly (ADP-
ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer (PARP), National Institute of 




National Institute of Health3, 2020, ATRi Transition Rollover Study, National Institute of 
Health, view 20 May 2020, <https://clinicaltrials.gov/ct2/show/NCT03309150> 
 
Nazareth, D., Jones, M.J. and Gabrielli, B., 2019. Everything in Moderation: Lessons Learned 
by Exploiting Moderate Replication Stress in Cancer. Cancers, 11(9), p.1320. 
 
Nazari, Z.E. and Gurevich, L., 2013. Molecular Combing of DNA: Methods and Applications. 
Journal of Self-assembly and Molecular Electronics (same), 1(1), pp.125-148. 
 
NICE1 2020, Cytarabine, Nice, viewed 1 July 2020, 
<https://bnf.nice.org.uk/drug/cytarabine.html> 
 
NICE2 2020, Cisplatin, Nice, viewed 1 July 2020, <https://bnf.nice.org.uk/drug/cisplatin.html> 
 
NICE3 2020, Doxorubicin Hydrochloride, Nice, viewed 1 July 2020, 
<https://bnf.nice.org.uk/drug/doxorubicin-hydrochloride.html> 
 
Nickerson, J.A., Krockmalnic, G., Wan, K.M. and Penman, S., 1997. The nuclear matrix 
revealed by eluting chromatin from a cross-linked nucleus. Proceedings of the 
National Academy of Sciences, 94(9), pp.4446-4450. 
 
Nie, L., Wei, Y., Zhang, F., Hsu, Y.H., Chan, L.C., Xia, W., Ke, B., Zhu, C., Deng, R., Tang, J. and 
Yao, J., 2019. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains 
triple-negative breast cancer. Nature communications, 10(1), pp.1-15. 
 
Nieminuszczy, J., Schwab, R.A. and Niedzwiedz, W., 2016. The DNA fibre technique–tracking 
helicases at work. Methods, 108, pp.92-98. 
 
Nishibe, R., Watanabe, W., Ueda, T., Yamasaki, N., Koller, R., Wolff, L., Honda, Z.I., Ohtsubo, 
M. and Honda, H., 2013. CIZ1, a p21Cip1/Waf1‐interacting protein, functions as a tumor 
suppressor in vivo. FEBS letters, 587(10), pp.1529-1535. 
 
Nitiss, J.L., 2009. Targeting DNA topoisomerase II in cancer chemotherapy. Nature Reviews 
Cancer, 9(5), pp.338-350. 
 
Nombela, P., Lozano, R., Aytes, A., Mateo, J., Olmos, D. and Castro, E., 2019. BRCA2 and 
other DDR genes in prostate cancer. Cancers, 11(3), p.352. 
 
Noordermeer, S.M. and van Attikum, H., 2019. PARP inhibitor resistance: a tug-of-war in 
BRCA-mutated cells. Trends in cell biology, 29(10), pp.820-834. 
 
Oehlmann, M., Score, A.J. and Blow, J.J., 2004. The role of Cdc6 in ensuring complete 
genome licensing and S phase checkpoint activation. The Journal of cell biology, 165(2), 
pp.181-190. 
 
Ohkoshi, S., Yano, M. and Matsuda, Y., 2015. Oncogenic role of p21 in hepatocarcinogenesis 
suggests a new treatment strategy. World journal of gastroenterology, 21(42), p.12150. 
 
Olivier, M., Hollstein, M. and Hainaut, P., 2010. TP53 mutations in human cancers: origins, 




O'Neil, N.J., Bailey, M.L. and Hieter, P., 2017. Synthetic lethality and cancer. Nature Reviews 
Genetics, 18(10), pp.613-623. 
 
Örd, M., Möll, K., Agerova, A., Kivi, R., Faustova, I., Venta, R., Valk, E. and Loog, M., 2019. 
Multisite phosphorylation code of CDK. Nature structural & molecular biology, 26(7), pp.649-
658. 
Oren, M. and Rotter, V., 2010. Mutant p53 gain-of-function in cancer. Cold Spring Harbor 
perspectives in biology, 2(2), p.a001107.  
Papouli, E., Chen, S., Davies, A.A., Huttner, D., Krejci, L., Sung, P. and Ulrich, H.D., 2005. 
Crosstalk between SUMO and ubiquitin on PCNA is mediated by recruitment of the helicase 
Srs2p. Molecular cell, 19(1), pp.123-133. 
Park, S.Y., Im, J.S., Park, S.R., Kim, S.E., Wang, H.J. and Lee, J.K., 2012. Mimosine arrests the 
cell cycle prior to the onset of DNA replication by preventing the binding of human Ctf4/And-
1 to chromatin via Hif-1α activation in HeLa cells. Cell Cycle, 11(4), pp.761-766.  
Parra, I. and Windle, B., 1993. High resolution visual mapping of stretched DNA by 
fluorescent hybridization. Nature genetics, 5(1), pp.17-21. 
 
Pateras, I.S., Apostolopoulou, K., Niforou, K., Kotsinas, A. and Gorgoulis, V.G., 2009. 
p57KIP2:“Kip” ing the cell under control. Molecular Cancer Research, 7(12), pp.1902-1919. 
 
Patil, S., Majumdar, B., Awan, K.H., Sarode, G.S., Sarode, S.C., Gadbail, A.R. and Gondivkar, S., 
2018. Cancer oriented biobanks: A comprehensive review. Oncology reviews, 12(1). 
 
Pauzaite, T., Thacker, U., Tollitt, J. and Copeland, N.A., 2017. Emerging roles for CIZ1 in cell 
cycle regulation and as a driver of tumorigenesis. Biomolecules, 7(1), p.1. 
 
Pernas, S., Tolaney, S.M., Winer, E.P. and Goel, S., 2018. CDK4/6 inhibition in breast cancer: 
current practice and future directions. Therapeutic advances in medical oncology, 10,  
p.1758835918786451. 
 
Petermann, E., Maya-Mendoza, A., Zachos, G., Gillespie, D.A., Jackson, D.A. and Caldecott, 
K.W., 2006. Chk1 requirement for high global rates of replication fork progression during 
normal vertebrate S phase. Molecular and cellular biology, 26(8), pp.3319-3326. 
 
Petermann, E., Helleday, T. and Caldecott, K.W., 2008. Claspin promotes normal replication 
fork rates in human cells. Molecular biology of the cell, 19(6), pp.2373-2378. 
 
Petropoulos, M., Tsaniras, S.C., Taraviras, S. and Lygerou, Z., 2019. Replication licensing 
aberrations, replication stress, and genomic instability. Trends in biochemical sciences, 44(9), 
pp.752-764. 
 
Piovesan, A., Pelleri, M.C., Antonaros, F., Strippoli, P., Caracausi, M. and Vitale, L., 2019. On 
the length, weight and GC content of the human genome. BMC research notes, 12(1), p.106. 
 
Piunti, A., Rossi, A., Cerutti, A., Albert, M., Jammula, S., Scelfo, A., Cedrone, L., Fragola, G., 
Olsson, L., Koseki, H. and Testa, G., 2014. Polycomb proteins control proliferation and 
266 
 
transformation independently of cell cycle checkpoints by regulating DNA replication. Nature 
communications, 5(1), pp.1-14. 
 
Planas-Silva, M.D. and Weinberg, R.A., 1997. Estrogen-dependent cyclin E-cdk2 activation 
through p21 redistribution. Molecular and Cellular Biology, 17(7), pp.4059-4069. 
Platel, M., Goldar, A., Wiggins, J.M., Barbosa, P., Libeau, P., Priam, P., Narassimprakash, H., 
Grodzenski, X. and Marheineke, K., 2015. Tight Chk1 levels control replication cluster 
activation in Xenopus. PloS one, 10(6).  
Pond, K.W., de Renty, C., Yagle, M.K. and Ellis, N.A., 2019. Rescue of collapsed replication 
forks is dependent on NSMCE2 to prevent mitotic DNA damage. PLoS genetics, 15(2), 
p.e1007942. 
Prado, F. and Aguilera, A., 2005. Impairment of replication fork progression mediates RNA 
polII transcription‐associated recombination. The EMBO journal, 24(6), pp.1267-1276.  
Prieur, A. and Peeper, D.S., 2008. Cellular senescence in vivo: a barrier to tumorigenesis. 
Current opinion in cell biology, 20(2), pp.150-155.  
Primo, L.M. and Teixeira, L.K., 2020. DNA replication stress: oncogenes in the spotlight. 
Genetics and Molecular Biology, 43(1). 
 
Qian, Y. and Chen, X., 2013. Senescence regulation by the p53 protein family. In Cell 
Senescence (pp. 37-61). Humana Press, Totowa, NJ. 
 
Qie, S. and Diehl, J.A., 2016. Cyclin D1, cancer progression, and opportunities in cancer 
treatment. Journal of Molecular Medicine, 94(12), pp.1313-1326. 
 
Qie, S. and Diehl, J.A., 2020, January. Cyclin D degradation by E3 ligases in cancer progression 
and treatment. In Seminars in Cancer Biology. Academic Press. 
 
Quinet, A., Lemaçon, D. and Vindigni, A., 2017. Replication fork reversal: players and 
guardians. Molecular cell, 68(5), pp.830-833. 
 
Quintás-Cardama, A. and Cortes, J., 2009. Molecular biology of bcr-abl1–positive chronic  
myeloid leukemia. Blood, 113(8), pp.1619-1630. 
 
Rahman, F.A., Aziz, N. and Coverley, D., 2010. Differential detection of alternatively spliced 
variants of CIZ1 in normal and cancer cells using a custom exon-junction microarray. BMC 
cancer, 10(1), p.482. 
Rao, P.N. and Johnson, R.T., 1970. Mammalian cell fusion: studies on the regulation of DNA 
synthesis and mitosis. Nature, 225(5228), pp.159-164.  
Ren, B., Cam, H., Takahashi, Y., Volkert, T., Terragni, J., Young, R.A. and Dynlacht, B.D., 2002. 
E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. 
Genes & development, 16(2), pp.245-256. 
 
Resnitzky, D., Gossen, M., Bujard, H. and Reed, S.I., 1994. Acceleration of the G1/ 
267 
 
S phase transition by expression of cyclins D1 and E with an inducible system. Molecular and 
cellular biology, 14(3), pp.1669-1679. 
 
Rhind, N. and Gilbert, D.M., 2013. DNA replication timing. Cold Spring Harbor perspectives in 
biology, 5(8), p.a010132. 
 
Ribeyre, C., Lebdy, R., Patouillard, J., Larroque, M., Abou-Merhi, R., Larroque, C. and 
Constantinou, A., 2020. The isolation of proteins on nascent DNA (iPOND) reveals a role for 
RIF1 in the organization of replication factories. bioRxiv, p.669234. 
 
Richmond, C.A., Shah, M.S., Carlone, D.L. and Breault, D.T., 2016. An enduring role for 
quiescent stem cells. Developmental Dynamics, 245(7), pp.718-726. 
Ridings-Figueroa, R., Stewart, E.R., Nesterova, T.B., Coker, H., Pintacuda, G., Godwin, J., 
Wilson, R., Haslam, A., Lilley, F., Ruigrok, R. and Bageghni, S.A., 2017. The nuclear matrix 
protein CIZ1 facilitates localization of Xist RNA to the inactive X-chromosome territory. Genes 
& development, 31(9), pp.876-888.  
Rivera-Mulia, J.C., Dimond, A., Vera, D., Trevilla-Garcia, C., Sasaki, T., Zimmerman, J., Dupont, 
C., Gribnau, J., Fraser, P. and Gilbert, D.M., 2018. Allele-specific control of replication timing 
and genome organization during development. Genome research, 28(6), pp.800-811. 
 
Rivin, C.J. and Fangman, W.L., 1980. Replication fork rate and origin activation during the S 
phase of Saccharomyces cerevisiae. The Journal of cell biology, 85(1), pp.108-115. 
Rivlin, N., Brosh, R., Oren, M. and Rotter, V., 2011. Mutations in the p53 tumor suppressor 
gene: important milestones at the various steps of tumorigenesis. Genes & cancer, 2(4), 
pp.466-474.  
Rizzardi, L.F. and Cook, J.G., 2012. Flipping the switch from g1 to s phase with e3 ubiquitin 
ligases. Genes & Cancer, 3(11-12), pp.634-648. 
 
Robinson, N.P. and Bell, S.D., 2005. Origins of DNA replication in the three domains of life. 
The FEBS journal, 272(15), pp.3757-3766. 
 
Rodriguez, R. and Meuth, M., 2006. Chk1 and p21 cooperate to prevent apoptosis during 
DNA replication fork stress. Molecular biology of the cell, 17(1), pp.402-412. 
 
Rodriguez-Acebes, S., Mourón, S. and Méndez, J., 2018. Uncoupling fork speed and origin 
activity to identify the primary cause of replicative stress phenotypes. Journal of Biological 
Chemistry, 293(33), pp.12855-12861. 
 
Rossari, F., Minutolo, F. and Orciuolo, E., 2018. Past, present, and future of Bcr-Abl inhibitors: 
from chemical development to clinical efficacy. Journal of hematology & oncology, 11(1), 
p.84. 
 
Rossbach, D. and Sclafani, R.A., 2016. Role of DDK in replication initiation. In The Initiation of 
DNA Replication in Eukaryotes (pp. 279-296). Springer, Cham. 
 
Roy, R., Chun, J. and Powell, S.N., 2012. BRCA1 and BRCA2: different roles in a common 
pathway of genome protection. Nature Reviews Cancer, 12(1), pp.68-78. 
268 
 
Rynearson, A.L. and Sussman, C.R., 2011. Nuclear structure, organization, and 
oncogenesis. Journal of gastrointestinal cancer, 42(2), pp.112-117. 
 
Sale, J.E., 2013. Translesion DNA synthesis and mutagenesis in eukaryotes. Cold Spring 
Harbor perspectives in biology, 5(3), p.a012708. 
 
Santocanale, C., Sharma, K. and Diffley, J.F., 1999. Activation of dormant origins of DNA 
replication in budding yeast. Genes & development, 13(18), pp.2360-2364. 
Scully, R. and Livingston, D.M., 2000. In search of the tumour-suppressor functions of BRCA1 
and BRCA2. Nature, 408(6811), pp.429-432.  
Semmler, L., Reiter-Brennan, C. and Klein, A., 2019. BRCA1 and breast cancer: a review of the 
underlying mechanisms resulting in the tissue-specific tumorigenesis in mutation carriers. 
Journal of breast cancer, 22(1), pp.1-14. 
 
Semple, J.W., Da‐Silva, L.F., Jervis, E.J., Ah‐Kee, J., Al‐Attar, H., Kummer, L., Heikkila, J.J., 
Pasero, P. and Duncker, B.P., 2006. An essential role for Orc6 in DNA replication through 
maintenance of pre‐replicative complexes. The EMBO journal, 25(21), pp.5150-5158. 
 
Sen, T., Tong, P., Diao, L., Li, L., Fan, Y., Hoff, J., Heymach, J.V., Wang, J. and Byers, L.A., 2017. 
Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 
inhibition in small-cell lung cancer. Clinical Cancer Research, 23(20), pp.6239-6253. 
Shajani-Yi, Z., de Abreu, F.B., Peterson, J.D. and Tsongalis, G.J., 2018. Frequency of Somatic 
TP53 Mutations in Combination with Known Pathogenic Mutations in Colon 
Adenocarcinoma, Non–Small Cell Lung Carcinoma, and Gliomas as Identified by Next-
Generation Sequencing. Neoplasia, 20(3), pp.256-262.  
Sheu, Y.J. and Stillman, B., 2006. Cdc7-Dbf4 phosphorylates MCM proteins via a docking site-
mediated mechanism to promote S phase progression. Molecular cell, 24(1), pp.101-113. 
 
Sishc, B.J. and Davis, A.J., 2017. The role of the core non-homologous end joining factors in 
carcinogenesis and cancer. Cancers, 9(7), p.81. 
 
Sideridou, M., Zakopoulou, R., Evangelou, K., Liontos, M., Kotsinas, A., Rampakakis, E., Gagos, 
S., Kahata, K., Grabusic, K., Gkouskou, K. and Trougakos, I.P., 2011. Cdc6 expression 
represses E-cadherin transcription and activates adjacent replication origins. Journal of Cell 
Biology, 195(7), pp.1123-1140. 
 
Simon, A.C., Sannino, V., Costanzo, V. and Pellegrini, L., 2016. Structure of human Cdc45 and 
implications for CMG helicase function. Nature communications, 7, p.11638. 
 
Solimini, N.L., Luo, J. and Elledge, S.J., 2007. Non-oncogene addiction and the stress 
phenotype of cancer cells. Cell, 130(6), pp.986-988. 
 
Spencer, S.L., Cappell, S.D., Tsai, F.C., Overton, K.W., Wang, C.L. and Meyer, T., 2013. The 
proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic 




Speck, C. and Messer, W., 2001. Mechanism of origin unwinding: sequential binding of DnaA 
to double‐and single‐stranded DNA. The EMBO journal, 20(6), pp.1469-1476. 
 
Srinivasan, S.V., Dominguez-Sola, D., Wang, L.C., Hyrien, O. and Gautier, J., 2013. Cdc45 is a 
critical effector of myc-dependent DNA replication stress. Cell reports, 3(5), pp.1629-1639. 
 
Stepankiw, N., Kaidow, A., Boye, E. and Bates, D., 2009. The right half of the Escherichia coli 
replication origin is not essential for viability, but facilitates multi‐forked replication. 
Molecular microbiology, 74(2), pp.467-479. 
 
Stern, B. and Nurse, P., 1996. A quantitative model for the cdc2 control of S phase and 
mitosis in fission yeast. Trends in Genetics, 12(9), pp.345-350. 
Strausfeld, U.P., Howell, M., Descombes, P., Chevalier, S., Rempel, R.E., Adamczewski, J., 
Maller, J.L., Hunt, T. and Blow, J.J., 1996. Both cyclin A and cyclin E have S-phase promoting 
(SPF) activity in Xenopus egg extracts. Journal of cell science, 109(6), pp.1555-1563.  
Stern, B. and Nurse, P., 1996. A quantitative model for the cdc2 control of S phase and 
mitosis in fission yeast. Trends in Genetics, 12(9), pp.345-350. 
Sunwoo, H., Colognori, D., Froberg, J.E., Jeon, Y. and Lee, J.T., 2017. Repeat E anchors Xist 
RNA to the inactive X chromosomal compartment through CDKN1A-interacting protein 
(CIZ1). Proceedings of the National Academy of Sciences, 114(40), pp.10654-10659.  
Suryadinata, R., Sadowski, M. and Sarcevic, B., 2010. Control of cell cycle progression by 
phosphorylation of cyclin-dependent kinase (CDK) substrates. Bioscience reports, 30(4), 
pp.243-255. 
 
Swaffer, M.P., Jones, A.W., Flynn, H.R., Snijders, A.P. and Nurse, P., 2016. CDK substrate 
phosphorylation and ordering the cell cycle. Cell, 167(7), pp.1750-1761. 
 
Swarts, D.R., Stewart, E.R., Higgins, G.S. and Coverley, D., 2018. CIZ1-F, an alternatively 
spliced variant of the DNA replication protein CIZ1 with distinct expression and localisation, 
is overrepresented in early stage common solid tumours. Cell Cycle, 17(18), pp.2268-2283. 
 
Tallet, A., Nault, J.C., Renier, A., Hysi, I., Galateau-Salle, F., Cazes, A., Copin, M.C., Hofman, P., 
Andujar, P., Le Pimpec-Barthes, F. and Zucman-Rossi, J., 2014. Overexpression and promoter 
mutation of the TERT gene in malignant pleural mesothelioma. Oncogene, 33(28), pp.3748-
3752. 
 
Taylor, M.R. and Yeeles, J.T., 2019. Dynamics of replication fork progression following 
helicase–polymerase uncoupling in eukaryotes. Journal of molecular biology, 431(10), 
pp.2040-2049. 
 
Técher, H., Koundrioukoff, S., Nicolas, A. and Debatisse, M., 2017. The impact of replication 
stress on replication dynamics and DNA damage in vertebrate cells. Nature Reviews Genetics, 
18(9), pp.535-550. 
 
Thome, K.C., Dhar, S.K., Quintana, D.G., Delmolino, L., Shahsafaei, A. and Dutta, A., 2000. 
Subsets of human origin recognition complex (ORC) subunits are expressed in non-
270 
 
proliferating cells and associate with non-ORC proteins. Journal of Biological Chemistry, 
275(45), pp.35233-35241. 
 
Thwaites, M.J., Cecchini, M.J., Passos, D.T., Zakirova, K. and Dick, F.A., 2019. Context 
dependent roles for RB-E2F transcriptional regulation in tumor suppression. Plos one, 14(1), 
p.e0203577. 
 
Toledo, L.I., Altmeyer, M., Rask, M.B., Lukas, C., Larsen, D.H., Povlsen, L.K., Bekker-Jensen, S., 
Mailand, N., Bartek, J. and Lukas, J., 2013. ATR prohibits replication catastrophe by 
preventing global exhaustion of RPA. Cell, 155(5), pp.1088-1103. 
 
Toren, P. and Zoubeidi, A., 2014. Targeting the PI3K/Akt pathway in prostate cancer: 
challenges and opportunities. International journal of oncology, 45(5), pp.1793-1801. 
 
Tourrière, H., Saksouk, J., Lengronne, A. and Pasero, P., 2017. Single-molecule analysis of 
DNA replication dynamics in budding yeast and human cells by DNA combing. Bio-protocol, 
7(11), p.e2305. 
 
Trinkle-Mulcahy, L., 2019. Recent advances in proximity-based labeling methods for 
interactome mapping. F1000Research, 8. 
 
Tuduri, S., Crabbé, L., Conti, C., Tourrière, H., Holtgreve-Grez, H., Jauch, A., Pantesco, V., De 
Vos, J., Thomas, A., Theillet, C. and Pommier, Y., 2009. Topoisomerase I suppresses genomic 
instability by preventing interference between replication and transcription. Nature cell 
biology, 11(11), pp.1315-1324. 
 
Tudzarova, S., Mulholland, P., Dey, A., Stoeber, K., Okorokov, A.L. and Williams, G.H., 2016. 
p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress. Cell Cycle, 
15(21), pp.2958-2972. 
 
Turgeon, M.O., Perry, N.J. and Poulogiannis, G., 2018. DNA damage, repair, and cancer 
metabolism. Frontiers in oncology, 8, p.15. 
 
Ubhi, T. and Brown, G.W., 2019. Exploiting DNA replication stress for cancer treatment. 
Cancer research, 79(8), pp.1730-1739. 
 
Uhlmann, F., Bouchoux, C. and Lopez-Avilés, S., 2011. A quantitative model for cyclin-
dependent kinase control of the cell cycle: revisited. Philosophical Transactions of the Royal 
Society B: Biological Sciences, 366(1584), pp.3572-3583. 
 
van den Bosch, M., Bree, R.T. and Lowndes, N.F., 2003. The MRN complex: coordinating and 
mediating the response to broken chromosomes. EMBO reports, 4(9), pp.844-849. 
 
Voitenleitner C, Rehfuess C, Hilmes M, O’Rear L, Liao PC, Gage DA, Ott R, Nasheuer HP, 
Fanning E. Cell cycle-dependent regulation of human DNA polymerase α-primase activity by 
phosphorylation. Molecular and cellular biology. 1999 Jan 1;19(1):646-56. 
 
Wang, D.Q., Wang, K., Yan, D.W., Liu, J., Wang, B., Li, M.X., Wang, X.W., Liu, J., Peng, Z.H., Li, 
G.X. and Yu, Z.H., 2014. CIZ1 is a novel predictor of survival in human colon cancer. 




Wang, D. and Gao, F., 2019. Comprehensive analysis of replication origins in Saccharomyces 
cerevisiae genomes. Frontiers in microbiology, 10, p.2122. 
 
Wang, S.C., Nakajima, Y., Yu, Y.L., Xia, W., Chen, C.T., Yang, C.C., McIntush, E.W., Li, L.Y., 
Hawke, D.H., Kobayashi, R. and Hung, M.C., 2006. Tyrosine phosphorylation controls PCNA 
function through protein stability. Nature cell biology, 8(12), pp.1359-1368. 
 
Wang, X., Fujimaki, K., Mitchell, G.C., Kwon, J.S., Della Croce, K., Langsdorf, C., Zhang, H.H. 
and Yao, G., 2017. Exit from quiescence displays a memory of cell growth and division. 
Nature communications, 8(1), pp.1-11. 
 
Wang, Y., Li, X., Zhang, J., Liu, Q., Gao, P., Li, D., Zhang, S. and Liu, J., 2019. CIZ1 Expression Is 
Upregulated in Hemangioma of the Tongue. Pathology & Oncology Research, 25(4), pp.1653-
1658. 
 
Wasąg, P. and Lenartowski, R., 2016. Nuclear matrix-structure, function and 
pathogenesis. Postepy higieny i medycyny doswiadczalnej (Online), 70, pp.1206-1219. 
 
Watanabe, K., Tateishi, S., Kawasuji, M., Tsurimoto, T., Inoue, H. and Yamaizumi, M., 2004. 
Rad18 guides polη to replication stalling sites through physical interaction and PCNA 
monoubiquitination. The EMBO journal, 23(19), pp.3886-3896. 
 
Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R.M., Ozenberger, B.A., Ellrott, K., 
Shmulevich, I., Sander, C., Stuart, J.M. and Cancer Genome Atlas Research Network, 2013. 
The cancer genome atlas pan-cancer analysis project. Nature genetics, 45(10), p.1113. 
 
Wawrzyniak, P., Płucienniczak, G. and Bartosik, D., 2017. The different faces of rolling-circle 
replication and its multifunctional initiator proteins. Frontiers in Microbiology, 8, p.2353. 
 
Wilson, R.H. and Coverley, D., 2013. Relationship between DNA replication and the nuclear 
matrix. Genes to Cells, 18(1), pp.17-31. 
 
Wilson, R.H., Hesketh, E.L. and Coverley, D., 2016. The nuclear matrix: fractionation 
techniques and analysis. Cold Spring Harbor Protocols, 2016(1), pp.pdb-top074518. 
 
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., 
Gumbs, C., Micklem, G. and Barfoot, R., 1995. Identification of the breast cancer 
susceptibility gene BRCA2. Nature, 378(6559), pp.789-792. 
 
Wu, Z., Liu, J., Yang, H. and Xiang, H., 2014. DNA replication origins in archaea. Frontiers in 
microbiology, 5, p.179. 
 
Wu, J., Lei, L., Gu, D., Liu, H. and Wang, S., 2016. CIZ1 is upregulated in hepatocellular 
carcinoma and promotes the growth and migration of the cancer cells. Tumor Biology, 37(4), 
pp.4735-4742. 
 
Wu, D., Duan, C., Chen, L. and Chen, S., 2017. Efficacy and safety of different doses of 
cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network 




Xiao, J., Uitti, R.J., Zhao, Y., Vemula, S.R., Perlmutter, J.S., Wszolek, Z.K., Maraganore, D.M., 
Auburger, G., Leube, B., Lehnhoff, K. and LeDoux, M.S., 2012. Mutations in CIZ1 cause adult 
onset primary cervical dystonia. Annals of neurology, 71(4), pp.458-469. 
Yajima, H., Lee, K.J., Zhang, S., Kobayashi, J. and Chen, B.P., 2009. DNA double-strand break 
formation upon UV-induced replication stress activates ATM and DNA-PKcs kinases. Journal 
of molecular biology, 385(3), pp.800-810.  
Yan, Z., DeGregori, J., Shohet, R., Leone, G., Stillman, B., Nevins, J.R. and Williams, R.S., 1998. 
Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proceedings 
of the National Academy of Sciences, 95(7), pp.3603-3608. 
 
Yao, G., 2014. Modelling mammalian cellular quiescence. Interface focus, 4(3), p.20130074. 
 
Ye, X., Nalepa, G., Welcker, M., Kessler, B.M., Spooner, E., Qin, J., Elledge, S.J., Clurman, B.E. 
and Harper, J.W., 2004. Recognition of phosphodegron motifs in human cyclin E by the 
SCFFbw7 ubiquitin ligase. Journal of Biological Chemistry, 279(48), pp.50110-50119. 
 
Yeeles, J.T., Deegan, T.D., Janska, A., Early, A. and Diffley, J.F., 2015. Regulated eukaryotic 
DNA replication origin firing with purified proteins. Nature, 519(7544), pp.431-435. 
 
Yeeles, J.T., Janska, A., Early, A. and Diffley, J.F., 2017. How the eukaryotic replisome 
achieves rapid and efficient DNA replication. Molecular cell, 65(1), pp.105-116. 
 
Yi, X., de Vries, H.I., Siudeja, K., Rana, A., Lemstra, W., Brunsting, J.F., Kok, R.M., Smulders, 
Y.M., Schaefer, M., Dijk, F. and Shang, Y., 2009. Stwl modifies chromatin compaction and is 
required to maintain DNA integrity in the presence of perturbed DNA replication. Molecular 
biology of the cell, 20(3), pp.983-994. 
 
Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K. and Luo, S., 2019. Advances and perspectives of 
PARP inhibitors. Experimental Hematology & Oncology, 8(1), p.29. 
 
Yin, Y., Shen, Q., Tao, R., Chang, W., Li, R., Xie, G., Liu, W., Zhang, P. and Tao, K., 2018. Wee1 
inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to 
the anticancer effect of irinotecan. Molecular medicine reports, 17(2), pp.3344-3349. 
 
Young, C.P., Hillyer, C., Hokamp, K., Fitzpatrick, D.J., Konstantinov, N.K., Welty, J.S., Ness, 
S.A., Werner-Washburne, M., Fleming, A.B. and Osley, M.A., 2017. Distinct histone 
methylation and transcription profiles are established during the development of cellular 
quiescence in yeast. BMC genomics, 18(1), p.107. 
 
Yousefi, R. and Rowicka, M., 2019. Stochasticity of replication forks’ speeds plays a key role 
in the dynamics of DNA replication. PLoS computational biology, 15(12), p.e1007519. 
 
Yu, Y., Cai, J.P., Tu, B., Wu, L., Zhao, Y., Liu, X., Li, L., McNutt, M.A., Feng, J., He, Q. and Yang, 
Y., 2009. Proliferating cell nuclear antigen is protected from degradation by forming a 
complex with MutT Homolog2. Journal of Biological Chemistry, 284(29), pp.19310-19320. 
 
Yuan, J. and Chen, J., 2010. MRE11-RAD50-NBS1 complex dictates DNA repair independent 




Yuan, X., Srividhya, J., De Luca, T., Lee, J.H.E. and Pomerening, J.R., 2014. Uncovering the role 
of APC-Cdh1 in generating the dynamics of S-phase onset. Molecular biology of the cell, 
25(4), pp.441-456. 
 
Yuan, Z., Georgescu, R., Bai, L., Zhang, D., Li, H. and O’Donnell, M.E., 2020. DNA unwinding 
mechanism of a eukaryotic replicative CMG helicase. Nature communications, 11(1), pp.1-10. 
 
Yurov, Y.B., 1980. Rate of DNA replication fork movement within a single mammalian cell. 
Journal of molecular biology, 136(3), pp.339-342. 
 
Zaboikin, M., Zaboikina, T., Freter, C. and Srinivasakumar, N., 2017. Non-homologous end 
joining and homology directed DNA repair frequency of double-stranded breaks introduced 
by genome editing reagents. PloS one, 12(1), p.e0169931. 
 
Zafar, M.K. and Eoff, R.L., 2017. Translesion DNA synthesis in cancer: molecular mechanisms 
and therapeutic opportunities. Chemical research in toxicology, 30(11), pp.1942-1955. 
 
Zarkowska, T.A., 1999. Phosphorylation of the retinoblastoma protein, pRB, by CDK4-cyclin 
D1 (Doctoral dissertation, Institute of Cancer Research (University Of London)). 
 
Zeman, M.K. and Cimprich, K.A., 2014. Causes and consequences of replication stress. Nature 
cell biology, 16(1), pp.2-9. 
 
Zeng, X., Chen, S. and Huang, H., 2011. Phosphorylation of EZH2 by CDK1 and CDK2: a 
possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through 
cell divisions. Cell cycle, 10(4), pp.579-583. 
 
Zetterberg, A., Larsson, O. and Wiman, K.G., 1995. What is the restriction point?. Current 
opinion in cell biology, 7(6), pp.835-842. 
 
Zhan, T., Rindtorff, N. and Boutros, M., 2017. Wnt signaling in cancer. Oncogene, 36(11), 
pp.1461-1473. 
 
Zhang, D., Wang, Y., Dai, Y., Wang, J., Suo, T., Pan, H., Liu, H., Shen, S. and Liu, H., 2015. CIZ1 
promoted the growth and migration of gallbladder cancer cells. Tumor Biology, 36(4), 
pp.2583-2591. 
 
Zhang, H. and Freudenreich, C.H., 2007. An AT-rich sequence in human common fragile site 
FRA16D causes fork stalling and chromosome breakage in S. cerevisiae. Molecular cell, 27(3), 
pp.367-379. 
 
Zhang, J., Si, J., Gan, L., Di, C., Xie, Y., Sun, C., Li, H., Guo, M. and Zhang, H., 2019. Research 
progress on therapeutic targeting of quiescent cancer cells. Artificial cells, nanomedicine, and 
biotechnology, 47(1), pp.2810-2819. 
 
Zhang, S., Zhou, Y., Trusa, S., Meng, X., Lee, E.Y. and Lee, M.Y., 2007. A Novel DNA Damage 
Response RAPID DEGRADATION OF THE p12 SUBUNIT OF DNA POLYMERASE δ. Journal of 
Biological Chemistry, 282(21), pp.15330-15340. 
 
Zhang, W., Nandakumar, N., Shi, Y., Manzano, M., Smith, A., Graham, G., Gupta, S., Vietsch, 
E.E., Laughlin, S.Z., Wadhwa, M. and Chetram, M., 2014. Downstream of mutant KRAS, the 
274 
 
transcription regulator YAP is essential for neoplastic progression to pancreatic ductal 
adenocarcinoma. Science signaling, 7(324), pp.ra42-ra42. 
 
Zhang, X.H., Tee, L.Y., Wang, X.G., Huang, Q.S. and Yang, S.H., 2015. Off-target effects in 
CRISPR/Cas9-mediated genome engineering. Molecular Therapy-Nucleic Acids, 4, p.e264. 
 
Zhao, Q.Y., Lei, P.J., Zhang, X., Zheng, J.Y., Wang, H.Y., Zhao, J., Li, Y.M., Ye, M., Li, L., Wei, G. 
and Wu, M., 2016. Global histone modification profiling reveals the epigenomic dynamics 
during malignant transformation in a four-stage breast cancer model. Clinical epigenetics, 
8(1), pp.1-15. 
 
Zhou, J.C., Janska, A., Goswami, P., Renault, L., Ali, F.A., Kotecha, A., Diffley, J.F. and Costa, A., 
2017. CMG–Pol epsilon dynamics suggests a mechanism for the establishment of leading-
strand synthesis in the eukaryotic replisome. Proceedings of the National Academy of 
Sciences, 114(16), pp.4141-4146. 
 
Zhou, X., Liu, Q., Wada, Y., Liao, L. and Liu, J., 2018. CDKN1A-interacting zinc finger protein 1 
is a novel biomarker for lung squamous cell carcinoma. Oncology letters, 15(1), pp.183-188. 
 
Zhou, Y., Pozo, P.N., Oh, S., Stone, H.M. and Cook, J.G., 2020. Distinct and sequential re-
replication barriers ensure precise genome duplication. bioRxiv, p.366666. 
  
Zimmerman, K.M., Jones, R.M., Petermann, E. and Jeggo, P.A., 2013. Diminished origin-
licensing capacity specifically sensitizes tumor cells to replication stress. Molecular Cancer 
Research, 11(4), pp.370-380. 
 
Zlotorynski, E., Rahat, A., Skaug, J., Ben-Porat, N., Ozeri, E., Hershberg, R., Levi, A., Scherer, 
S.W., Margalit, H. and Kerem, B., 2003. Molecular basis for expression of common and rare 
fragile sites. Molecular and cellular biology, 23(20), pp.7143-7151. 
 
 
 
